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A variety of structural abnormalities are consistent findings in schizophrenia.
These include enlargement of the lateral and third ventricles and reduced volume of
the frontal lobes, medial temporal lobes and thalami. These abnormalities are present
in first episode subjects and may be detectable before the onset of clinical disorder.
There is accruing evidence that substance misuse may contribute to an
individual's risk of developing schizophrenia. Substance misuse is associated with
similar brain abnormalities to those seen in schizophrenia and is often well established
at the time of first presentation. This makes it difficult to ascertain if any of the
structural abnormalities seen when individuals first present with psychosis are
attributable to substance misuse. An understanding of the relationship between
substance misuse and structural imaging abnormalities in people who are well but at
high risk of schizophrenia is thus of great importance. It has the potential to yield
important insights in to: (1) the role substance misuse may play in the development of
structural brain abnormalities; and (2) how substance use may influence risk of
developing the condition.
A prospective cohort study with nested case-controlled comparison design was
employed to examine the relationship between substance misuse, brain imaging
abnormalities and the subsequent development of schizophrenia. Substance misuse
history, imaging data, and clinical information were collected on 147 subjects at high
risk of schizophrenia and 36 controls at point of entry to the study. Regions exhibiting
a significant relationship between level of use of alcohol, cannabis or tobacco and
structure volume were identified, this relationship being elucidated through the use of
both volumetric and voxel-based morphometric image analysis techniques.
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Additionally, we established whether substance misuse up to the point of recruitment
was associated with later risk of schizophrenia.
In addition to the baseline scan, the first 57 high risk subjects recruited to the
study also had a follow-up scan after approximately 18 months. As substance use
between scanning points was known, this enabled longitudinal comparison of brain
structural changes in high risk subjects who did and did not use the aforementioned
drugs of abuse. This comparison was made using both volumetric and tensor-based
morphometric image analysis techniques.
In the baseline analysis, increased ventricular volume was associated with
alcohol and cannabis use in a dose-dependent manner. Alcohol consumption was
associated with reduced frontal lobe volume. Multiple regression analyses found both
alcohol and cannabis were significant predictors of these abnormalities when
simultaneously entered into the statistical model. The longitudinal analysis
demonstrated that cannabis use between scanning points was associated with both
bilateral thalamic and right anterior hippocampal volume loss. Alcohol and cannabis
misuse by point of entry in to the study were associated with an increased subsequent
risk of schizophrenia.
This study provides prospective evidence that use of cannabis or alcohol by
people at high genetic risk of schizophrenia is associated with brain abnormalities and
later risk of psychosis. A family history of schizophrenia may render the brain
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Chapter 1
Substance misuse and the human condition
1
1.1 The rise of substance use in the West
Evidence of psychoactive substance use dates to the beginnings of recorded
history, and centres on the use of alcohol and plants with psychoactive properties.
Once established, use of these substances tends to spread by a process of global
diffusion, the pattern this takes reflecting contact and trade between different
populations. The process by which the commonly consumed drugs of abuse became
established in Western Europe, with a particular emphasis on how this influenced
patterns of use in Scotland, will be discussed below. A class of drugs that will not be
discussed in this section is opiates. This is not because opiates do not represent a
major problem in Scotland (they do); rather, use of these substances was not expected
to be prominent in the people who are the focus of this study. In contrast, cocaine will
be considered in this section. Though use of this drug is also not expected to have
been commonplace in the group under study, the strong association between
stimulants and psychosis does necessitate consideration of the history of this
substance.
1.1.1 Alcohol
Alcohol is the favoured drug ofmuch of the world's population. It was
probably discovered following experimental fermentation, and archaeological
investigations suggest that beer was being habitually consumed earlier than 6000BC.1
Similarly viticulture, the selective cultivation of grape varieties for making wine,
probably originated where Armenia is now located, sometime between 6000 and
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4000BC.2 The spread of viticulture exemplifies the manner in which patterns of drug
use have been heavily influenced by both land-based and ocean-going commerce.
After being established in Europe the wine vine was successfully transported to the
Americas, Southern Africa and Australia; this spread of viticulture shadowing the
expanding empires of various European nations.
The technology of distilling, the process by which a concentrated,
imperishable alcohol product is produced from fermented liquids, was known to the
Greeks and Romans and preserved and advanced by the Arabs. It re-entered Europe
via Salerno in the eleventh century, but widespread knowledge of the technique was
not achieved until printed books began appearing in the late fifteenth century. It then
assumed increasing economic importance, with improved copper stills making the
mass production of liquor possible.2 By the mid-seventeenth century the industry was
widespread throughout Europe, with the product being profitably exported around the
world. Mass-produced spirits were a cheap source of intoxication, and this led to a
huge increase in intoxication and alcoholism both in European and non-European
societies. In Britain the problem was compounded by positive incentives to produce
cheap gin being given to promote agriculture, and by 1736 consumption of spirits was
approximately one gallon a head per annum.3 Consequently drunkenness was
commonplace and widespread, and adverse social consequences inevitable. These
have been captured for posterity in William Hogarth's famous engraving 'Gin Lane',




Hogarth's 1751 engraving 'Gin Lane'
Gradually, by means of licensing and taxation, alcohol consumption was
successfully reduced. This was not to be a sustained trend however and in the 19th
century, likely as a consequence of social changes accompanying the industrial
revolution, consumption began to rise again.4 It was in this period that the Scots
acquired their particular reputation for heavy drinking, with reports of scenes such as
the following being reported in the London press:
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"The drunk and incapable on a New Year's Day are not stray eccentrics who
take a drop too much and steal home as silently as they may, but are really
almost as numerous as the wounded in a general engagement; they succumb in
ranks and platoons and need a special ambulance service to get them to the
rear."
Daily Telegraph, December 1877
In his consideration of the Scottish experience of alcohol, Daniel Paton concludes that
this reputation was probably justified.4 As he describes, industrial society had given
rise to the combination of an increase in disposable income and the loss of constraints
provided by the social controls of traditional society; this, when drinking was
occurring in towns with high population densities, resulted in 'brutal drunkenness on
an unprecedented scale'. Inevitably the backlash followed, with the rise of the
temperance movement and the assembly of a formidable anti-drink coalition.
Legislation was passed, and by the early 20th century the Scottish licensing system
became the most restrictive in Britain. Consumption fell once more and continued to
fall, this being encouraged by the harsh economic climate of the 1930s. Alcohol
ceased to be a major social concern, which meant that when consumption began to
rise again in the 1950s there was no culture of abstinence and no organised political
opposition to campaign against it.
The recent history of alcohol consumption in Scotland from the 1950s
onwards has been one of ever-increasing consumption. By the 1970s the vast majority
of Scots were drinkers and alcohol had regained an almost universal acceptance not
known in the country for a century.4 The rise continued, and consumption levels are
now more than double what they were in the 1950s.4 Indeed, recent survey data have
reported that 60% of Scottish men and women aged 16-24 'binge drink' (i.e.
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consume more than 6 units (women) and 8 units (men) in a single drinking session) on
a weekly basis, and 38% of Scottish men aged 45-54 exceed 21 units of alcohol a
week.3 Reflecting the particular severity of this problem in Scotland, alcohol-related
death rates for males and females here are around double those for the UK as a
whole.6 It is thus the case once again that alcohol consumption is a major public
health preoccupation in Scotland.
1.1.2 Tobacco
Europeans first learned of tobacco in 1492, when two members of Columbus's
party observed Tainos Indians smoking leaves rolled in large cigars.2 Widespread
cultivation began in the late 16th century, and by the mid 17th century the cost of the
product had fallen to the extent that widespread consumption was possible. The habit
was rapidly acquired, and was quickly spread through Europe by sailors and soldiers.
Consumption was further boosted by the development of the cigarette in the 19th
century, and by the early 20th century this was the dominant method of nicotine
administration. By the 1950s world tobacco production of tobacco was over 8.4
billion pounds annually, and the plant was a cash crop on all continents save
Antarctica. With growing awareness of the health concerns associated with use of the
product consumption levelled off in Western nations during the 1960s and 1970s, but
use continued to expand in developing nations; indeed, by the mid-1990s a third of the
world's population were believed to be smokers.
The prevalence of smoking in Scotland is approximately 27% in those aged 16
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years or over. This exceeds the UK adult prevalence of 21%. Twenty four percent of
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all deaths in Scotland in 2004 were attributable to smoking.8 It is clearly a major
public health concern, and a number of initiatives (such as the smoking ban, operating
in Scotland since 2006) have been introduced to try and address it.
1.1.3 Cannabis
Cannabis originated in central Asia and was first extensively cultivated in
China 6,000 years ago. It was a valuable, multipurpose crop, yielding a potent drug as
well as cooking oil, edible seeds, animal fodder and hempen fibres.2 Cannabis also
has a long history in India, early Indian texts dating from 2000-1400 BC referring to
its psychoactive properties. Indian cannabis use apparently peaked during the Mogul
era (1526-1856), when cultivation and preparation of various cannabis drugs
flourished in all parts of the subcontinent. By this time cannabis had spread through
the Islamic world, down the East coast of Africa and in to Europe.
Both Indian and Chinese cultures promoted the medicinal use of cannabis, and
there was periodic interest in applying cannabis products for this purpose in Britain
from at least the 18lh century.9 Before the 1950s however the general population had
little knowledge of the intoxicating properties of cannabis and it was little used as a
recreational drug. Nevertheless, it had been illegal in Britain since 1928, when the
1925 Dangerous Drugs Act came in to force.10 The profde of cannabis in the UK
began to be raised in the late 1950s, when a drug subculture seemed to emerge in the
West End of London linked to bohemian and jazz cultures.1 This gained momentum
in the 1960s, particularly in the context of the 'hippie' movement, and cannabis is
now well established as the most commonly used illicit drug in the UK.
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The high prevalence of cannabis use in Britain is supported by findings from
surveys of drug use. The British Crime Survey for example reported that in 2008-
2009 18.7% of people aged 16-18 had used cannabis in the last year, and 10.4% in the
last month.11 These figures do represent a decline from earlier years of the
millennium, but clearly cannabis use remains very widespread among young people.
Given such widespread use, any health risks related to use of the drug would clearly
be of great concern. The data supporting a relationship between cannabis and
psychosis will be discussed in subsequent chapters.
1.1.4 Cocaine
Evidence of the chewing of coca leaves, the raw material from which cocaine
is derived, date back to 3000BC.2 It was however not until 1860 that Albert Niemann,
a graduate student at Gottingen, described the isolation of cocaine in his dissertation.12
He did not profit from this advance. By contrast however, a number of entrepreneurs
who marketed foodstuffs utilising coca extract did, Coca-Cola being among the glut
of coca-based products to achieve international success from 1863 onwards. In the
1880s, promoted by figures such as Sigmund Freud, interest in the drug escalated
further, the resulting shortages of coca supply from Peru precipitating global
cultivation. The Dutch established Java as a rival producer, transporting the product to
Europe for the extraction of cocaine. Increased supply resulted in lowered prices, and
this prompted a global epidemic of cocaine use that lasted from the 1890s to the
1920s.
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The manner in which different countries experienced the 'cocaine epidemic'
varied substantially, but the British experience was of some interest. It is described by
Mark Kohn in Paul Gottenberg's global history of cocaine.12 It was essentially
restricted to the West End of London, and regarded as associated with the women who
worked there as actresses, nightclub dancers, and prostitutes. The West End was a
fertile habitat for an underground drug scene at the time, being small, crowded, and a
centre of hedonism. With the outbreak of the First World War efforts were made to
control the consumption of alcohol, and restrictions placed on pub opening hours.
This represented a boom for underground clubs in the West End, potentially bringing
more people in contact with cocaine-using groups. In this context all it took was for a
number of stories to appear in the press of servicemen being sold cocaine for a moral
panic to ensue. Newspapers talked of cocaine use 'spreading like wildfire' and women
'preying on soldiers'. As is so often the case with drugs policy, this period of moral
panic on a background of grumbling concerns resulted in immediate legislation, and
cocaine possession was made a criminal offence.
In the late 1920s cocaine use subsided, and world exports began a sustained
decline. Indeed, there was little interest in cocaine for almost half a century, and little
further research undertaken with the drug. This, of course, was all to change in the
1970s, when cocaine returned to mass consumption in North America.2 This
continued in to the 1980s, when the drug also made its way back to the UK, being the
favoured drug of high-earning professionals in the City. Subsequently prices have
fallen, and crack (a pure and smokeable form of the drug with a more intense high)
has also arrived. Now cocaine is widely available to all socioeconomic classes, and
has firmly re-established itself in the UK.
9
Cocaine exposure has progressively risen in the UK over the last decade.
Whereas 3.8% of people aged 16 to 59 had ever used cocaine in 1998, this figure was
9.4% in 2008/2009.11 Comparable changes have occurred in those aged 16-24; 7.1%
had ever used the drug in 1998, rising to 12.4% in 2008/2009. Use in the last month,
predominantly representing regular users, has risen from 0.6% to 3.7% in the same
age group over the same period.
1.1.5 Other illicit drugs
The other drugs expected to have a reasonable prevalence of use in the group
under study are amphetamines, LSD and ecstasy. These three substances are synthetic
products, and each was initially developed in the hope they may have medical utility.
In each case initial promise gave way to disappointment, and as the problems
associated with the substance became apparent use shifted from medical to popular
consumption. The history of amphetamine is archetypal of this process, recognition of
its propensity to cause dependence and induce psychotic symptoms resulting in
restrictions being placed on its availability.2 As the history of amphetamine use is
intertwined with early conceptualisations of the dopamine hypothesis of
schizophrenia, the history of this drug will be considered in greater detail in the
relevant subsequent section; the history of the other two substances will be discussed
below.
The Swiss chemist Albert Hoffman first synthesized LSD in 1938 while
studying derivatives of the fungus ergot for use as potential medicines. It was set aside
for five years, but in 1943 he decided to re-examine it. When he accidentally absorbed
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some LSD during a laboratory session there followed an intense experience of
perceptual and emotional effects.13 By the late 1940s psychiatrists were beginning to
experiment with LSD; this work included exploration of the possibility that
psychedelics might be used as 'psychotomimetics', to mimic the mental states of
patients with schizophrenia, and that it could be used as an adjunct to
psychotherapy.14 It was in this context that Timothy Leary, then a research
psychologist at Harvard University, first had exposure to the drug. He promoted
widespread use of the substance, coining the catchphrase 'tune in, turn on, drop out'
and advocating youth to utilise the drug for self-discovery. With such promotion LSD
leaked from the scientific community to a wider audience, and by 1966 LSD use had
become regarded as a problem in the USA and its use made illegal.14 Nonetheless, use
of the drug continued to rise, intimately associated with the hippy movement. A
similar escalation was seen in Britain, this being associated particularly with the 1967
summer of love.15 Inevitably media hysteria followed, this predicting mass violence
and chromosomal abnormalities in children.16'17
Despite the decline in popularity of the 'hippy' culture, use of LSD remained
fairly prevalent in the UK through the 1980s and 1990s. The most recent British
Crime Survey reports that 5.5% ofpeople aged 16-59 have ever used the drug, a
figure which has changed little since the mid-1990s. Since 1996 however, use of LSD
in those aged 16 to 24 has actually fallen dramatically; whereas 13.1% had ever used
the drug in 1996, this had fallen to 2.5% by 2008/2009.11
MDMA (or ecstasy) was patented in 1913 by the German company Merck.
They did not market the drug however, and no uses are mentioned in the patent. The
drug re-emerged in the 1970s. The American biochemist Alexander Shulgin
synthesised the drug, and being impressed by the effects it had began to promote it as
11
a tool in psychotherapy.18 By 1984 the drug was still legal in the USA, but had seeped
in to popular use, predominantly among college students. The escalation in use
combined with concerns about its safety led to pressure for the drug to be made
illegal, this occurring in 1985.19
Interestingly, MDMA had actually been illegal in the UK since 1977, under
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legislation banning a number of psychedelic amphetamines. Nonetheless, use of the
drug became rapidly established in Britain in the late 1980s; it quickly became the
drug of choice at the all-night dancing parties (raves), which came to dominate the
youth scene of the time. The sub-culture associated with raves, the affordability of the
drug and its highly desirable behavioural effects (with apparently few side effects) all
90
contributed to an explosion of recreational ecstasy use. In recent years, although the
popularity of raves has declined, the use of ecstasy has shifted to nightclubs and
discos, where it remains a highly popular recreational drug. Ecstasy is thought to be
21 •the second most commonly used controlled drug (after cannabis) in Europe, and it is
22estimated that 12-24 million people worldwide have taken ecstasy.
In the UK it is estimated that 8.6% of the population of 16 to 59 year olds has
ever used ecstasy, with 0.6% having used the drug in the last month.11 A total of 9.9%
of 16 to 24 year olds have ever used the drug, a slight decline since the 1990s. Of
these 1.5% have used the drug in the last month; the majority of these individuals are
likely to constitute a regularly using population.
12
1.2 General effects of drugs on brain
Drug dependence is a phenomenon which, while deeply embedded within a
social context, is increasingly appreciated to be underpinned by neuropathological
abnormalities. As the current study will focus on the brain structural abnormalities
existing at the interface between drug use/dependence and risk for schizophrenia, it is
important that the neuropathology underpinning addiction is appreciated. In this
section I will thus briefly discuss the most important pathways and neurotransmitters
believed to be central to the development of dependence. It is important to note at the
outset that, despite the diversity of pharamacological effects exhibited by drugs of
abuse, there is believed to be a 'core' addiction syndrome. This is illustrated by the
fact that the diagnostic criteria for the dependence syndrome are the same regardless
of the drug under discussion (see Table 1.1, outlining the Diagnostic and Statistical
Manual of Mental Disorders, (DSM), criteria). This review will thus focus on the
circuitry underpinning this core syndrome; when warranted the specific
pharmacological effects of particular drugs of abuse will be discussed in subsequent
sections.
13
A maladaptive pattern of substance use, leading to clinically significant impairment or distress, as
manifest by three (or more) of the following, occurring at any time in the same 12-month period:
(1) Tolerance as defined by either of the following:
(a) a need for markedly increased amounts of the substance to achieve intoxication or desired
effect
(b) markedly diminished effect with continued use of the same amount of the substance
(2) Withdrawal, as manifested by either of the following:
(a) the characteristic withdrawal syndrome for the substance
(b) the same (or closely related) substance is taken to relieve or avoid withdrawal symptoms
(3) The substance is often taken in larger amounts or over a longer period than was intended
(4) There is a persistent desire or unsuccessful efforts to cut down or control substance use
(5) A great deal of time is spent in activities necessary to obtain the substance, use the substance, or
recover from its effects
(6) Important social, occupational, or recreational activities are given up or reduced because of
substance use
(7) The substance use is continued despite knowledge of having a persistent or recurrent physical or
psychological problem that is likely to have been caused or exacerbated by the substance
Table 1.1
The DSM-IV dependence syndrome.23
Addiction to drugs and alcohol is now understood to be based on pathological
changes in brain function produced by repeated pharmacological insult to the brain
circuitry underpinning motivation. In their normal state the function of these brain
circuits is to learn about and behaviourally adapt to important environmental stimuli,
whether these be how to best approach rewards such as food or sex, or to avoid
dangerous situations.24 By interacting with and changing this motivational circuitry,
addictive drugs impair the development of behavioural strategies towards biological
stimuli in favour ofprogressively greater orientation of behaviour towards drug-
9 S •
seeking and drug-taking strategies. These changes are long-lasting and not readily
reversed, resulting in an individual's life being increasingly dominated by the seeking
and consumption of drugs of abuse. Most disturbingly, even if abstinence is achieved,
this recurring desire to take drugs can persist for many years or even a lifetime.
Consequently, an individual remains at risk of relapse even after many years of
abstinence.
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If an impaired ability to regulate the drive to use substances is at the core of addiction,
then it is understandable that abnormalities ofmotivational circuitry are implicated in
these conditions. The most significant structures constituting this motivational
circuitry are outlined in Figure 1.2. Within these circuits the mesolimbic
dopaminergic pathway is regarded as central. All drugs of abuse, albeit through
different molecular mechanisms of action, (and with the exception of
benzodiazepines), increasing dopamine here.26 This release has two related
consequences; it results in the experience of pleasure (reward), and it imbues the
prevailing circumstances with salience (so promoting memory).27 There is nothing
innately pathological about this circuit; indeed, as discussed above, it is essential in
providing the drive to undertake and continue the activities essential for life. The
power of drugs of abuse derives from their ability to directly activate this circuit,
doing so to a degree both of greater amplitude and duration than can be achieved
through biological mechanisms. Thus, when an individual consumes a particular drug
they both experience pleasure, and the memory of this experience and the
circumstances surrounding it are promoted.27 Given that networks so central to
conferring salience are being directly stimulated, this memory promotion is much
more effective than that associated with most other stimuli, which become of
increasingly secondary importance. Conversely, with repeated exposures drug-related
associations become further strengthened, and stimuli associated with substance use
precipitate craving, (an intense urge to use the substance). The process of the




The primary constituent structures underpinning motivation and drug dependence
(reproduced from Ferrer et a/.).28
Though preserved in its basic form, in recent years our understanding of the
processes outlined above has been further refined. This understanding is summarised
by Kalivas et al. in two recent reviews, these attempting to integrate understanding of
neurotransmission in the circuits involved in motivation and salience with advances in
the understanding of neuroplasticity.25'27 In their model the importance of repeated
drug intake resulting in repeated release of dopamine from cells in the ventral-
tegmental area (VTA) into the prefrontal cortex (PFC), striatal complex (including the
nucleus accumbens, NA), and amygdala remains central. As discussed above, this
imbues an event with salience, creating an internal sense that this is a relatively
7Q
important event requiring the development of a behavioural response. As use
continues, so enduring changes in neuronal physiology occur. This occurs through
mechanisms such as excitatory synaptic plasticity driven by glutamate-associated long
term potentiation, and results in ever-increasing associations being made between the
drug and life events.27 In time the drug comes to dominate an individual's life, the
primacy given to drug use manifesting as maladaptive drug-seeking behaviours and
16
occurring at the expense of biologically important stimuli such as seeking food and
avoidance of harm.
In characterising the processes underpinning learning and behaviour, Kalivas
et al. further distinguish between those which are important in promoting new
behaviour (i.e. establishment of a drug use problem) and those involved in
maintaining an existing problem (relatively stable changes promoting ongoing
vulnerability to relapse).27 Kalivas et al. argue that in establishing a drug problem
dopaminergic afferents to the amygdala, nucleus accumbens and prefrontal cortex are
indeed central. Even at this early stage however, corticofugal glutamate projections
are also involved (predominantly from the PFC and amygdala into the NA), these
resulting in greater efficiency of memory retrieval in response to drug-related cues. At
this stage however, drug use does still occur as a consequence of a conscious choice,
the glutamatergic projections simply facillitating the retrieval and integration of drug-
associated memories. As the behaviour is repeatedly executed however, this network
becomes less important in favour of glutamate projecting from sensory motor cortical
-jrv • • •
areas to the dorsal striatum. In this way, they argue, behaviour evolves from being a
declarative process involving prefrontal executive functions into a habitual behaviour
utilizing working memory circuitry.31 It is all too easy to see the implications of this
for drug dependence. As this transition from prefrontal circuitry to habit motor
circuitry occurs, so drug use becomes less of a conscious decision, and an individual's
ability to control their intake is further diminished. Indeed, this is inkeeping with
findings from neuroimaging studies, hypofrontality having been identified as a strong
indicator of reduced ability to regulate drug-seeking.27 In individuals so affected, it
seems, drug-seeking is now permitted to occur free of conscious intervention.
17
It is thus the case, as the above summary illustrates, that a substantial body of
research now points to enduring changes in mesocorticolimbic circuitry in the
established dependence syndrome. These data provide a neurocircuitry template for
the primary features of addiction, and yield a neurobiological explanation for why a
dependent individual experiences an excessive, uncontrolled responding for drug-
related cues (clinically described as craving), but conversely experiences poor or
inappropriate responding for more appropriate and biologically important stimuli
(clinically manifest as neglect of alternative pleasures and interests). Consequently, an
individual finds it very difficult to change damaging behaviours, and their substance
misuse problem is perpetuated. I will now examine if it is indeed the case that people
with schizophrenia are particularly susceptible to substance misuse problems.
18
Chapter 2
The extent of the problem of comorbidity and how an association between
substance use and schizophrenia first came to be recognised
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2.1 Prevalence of substance misuse in schizophrenia
It is generally regarded as an accepted truth in psychiatry that rates of
substance misuse are particularly elevated among people with schizophrenia. In the
ECA study, for example, it was estimated that 47% of patients with schizophrenia also
. . .
had a lifetime diagnosis of substance abuse disorder. As always with such accepted
truths however, it is both prudent to be cautious in accepting its veracity and if
genuinely present to question why such an association should exist. It is thus
important to establish (1) if other studies also support the claim that there is an
increased prevalence of substance misuse in schizophrenia, (2) if this increase exists
independent of any potential bias that may be inherent in sampling methods, (3) if this
increased propensity to use substances is not simply a general feature of major mental
illness (rather than specific to schizophrenia itself), and (4) if this increased propensity
to use substances arises not as a direct consequence of schizophrenia but as a
consequence of other factors associated with the condition (i.e. the association exists
as a consequence of confounding). Confounders which could be very relevant to the
association between substance misuse and schizophrenia are factors such as poverty
and long term unemployment. Ofparticular importance in investigating this
association will be data from disparate cultures; if substance use is indeed a central
feature of schizophrenia, then it would be expected to be observed across cultures.
With these considerations in mind, I will consider the prevalence data for each of
main groups of substances of interest in turn. Given the high profile that cannabis use
in schizophrenia has received, it will be considered first in this section.
Prior to considering the data relating to the prevalence of substance misuse in
schizophrenia an important issue of classification needs to be clarified. In much of the
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data relating to this area of research both the specific diagnosis of schizophrenia and
the less specific term 'psychosis' are frequently used. Often, as well as encompassing
schizophrenia, the latter term also includes other schizophrenia spectrum psychoses
and also the affective psychoses. In this report, when research refers specifically to
schizophrenia then this term will be used; when the term 'psychoses' is used this
means that the work being referred to relates to the broader concept.
2.1.1 Cannabis
Systematic reviews of the prevalence of cannabis use disorder in people with
schizophrenia were published in 1990 and 2001 by Muesner and Cantor-Graae
respectively.33'34 Both reviews noted that the studies included were markedly
heterogeneous, and that this hindered interpretation. Nevertheless, they both drew
some conclusions. Mueser concluded that a history of cannabis abuse was related to
fewer symptoms of schizophrenia and fewer hospitalizations, suggesting more
socially competent schizophrenia patients were more prone to cannabis use. On the
basis of six reports, in addition to their own data, this study estimated that people with
schizophrenia were no more likely to use cannabis than other psychiatric patients.
According to Cantor-Graae et al., alcohol was generally the most frequently used
substance among schizophrenia patients, with cannabis use frequent among younger
patients. Seventeen studies were reported as specifically ascertaining the proportion of
patients with a (generally lifetime) history of cannabis abuse or dependence, the vast
majority of these studies originating from the USA. Rates varied from 13.0% in a first
admission German sample to 42% in an American inpatient sample. No comparison is
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made with prevalence rates in either other psychiatric populations or the general
population.
The first meta-analysis of this topic was published in April 2009 by Koskinen
et al35 It focused on studies published from 1996 to January 2009. Only studies that
ascertained the presence of cannabis abuse or dependence (fulfilling either
International Classification of Diseases (ICD) or DSM criteria and collectively
deemed cannabis use disorders, CUD) were included, with 'schizophrenia' being
regarded as one of the DSM schizophrenia-spectrum diagnoses (schizophrenia,
schizophreniform disorder, schizoaffective disorder, delusional disorder). At least
80% of the subjects in the study had to have a schizophrenia spectrum disorder
diagnosis for the study to be included in the meta-analysis. Thirty-five studies met the
inclusion criteria; as before the majority were from America or Europe, though a
study from Turkey and one from Lebanon were also identified. The total number of
cases was 5540. The total median rate of CUDs in schizophrenia was 27.0% (range =
0.0-65.6, 35 studies). The median rate of lifetime CUDs was 27.1% (IQR = 12.2-
38.5, 28 studies) and that of current CUDs was 16.0% (IQR = 8.6-28.6, 10 studies).
CUDs were more common in younger (<30 years) than older (>30 years) patient
samples. Additionally this study compared CUD rates between first-episode and long-
term schizophrenia patient samples. In samples other than first-episode patients, the
minimum reported average duration of illness was 9 years, and all these studies were
categorized as having long-term patient samples. In studies presenting results from
first-episode samples, the median CUD rate was higher for these patients than for
those with chronic illness (28.6% vs 22.0% for current and 44.4% vs 12.2% for
lifetime diagnoses).
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Some general features of CUDs were notable. Firstly, as well as being more
common in younger and first-episode patient samples, they were also more common
in samples with a high proportion of males. The CUD rate was however not affected
by the study location (only Europe vs. North America was considered), classification
system used (DSM-III-R vs. DSM-IV vs. ICD-10), or patient type (inpatient vs.
outpatient). On the basis of a small subset of studies, schizophrenia patients with
CUDs were reported to have more positive symptoms and fewer negative symptoms.
A weakness of this meta-analysis is that it did not consider rates of cannabis use in
comparison populations. Indeed, this was not practicable as most studies did not
include a comparison group of appropriately matched controls from either the general
population or other psychiatric patient groups. Instead, the authors compared
prevalence rates reported in schizophrenia to those reported by the United Nations in
the respective countries from which the samples arose (these mainly being in the age
Tf\
range 16-65 years). Perhaps surprisingly, in these comparisons no consistent pattern
emerges; in some samples of patients with schizophrenia prevalence of CUD is
greater than the general population, while in others it is less. It is the case however
that the UN and patient samples differ substantially in factors such as age and gender
distribution. This makes such comparisons challenging, and (as the authors state),
they should be interpreted with caution.
Update ofsystematic review
To augment the above reviews, a further literature search was undertaken with
the aim of identifying relevant papers published after the period included in the
review of Koshkinen et al. Comparably to that meta-analysis, the search terms
included were "schizophrenia," "psychosis," "psychoses," and "psychotic" to
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locate studies on schizophrenic psychoses, as well as "cannabis," "drug abuse"
"substance abuse," and "dual diagnosis". Searches were conducted in Psychlnfo,
Medline and EMBASE, with both free text and expanded subject headings being
used. Only studies focusing on subjects over 16 years of age in which at least 80% of
subjects had diagnoses of schizophrenia spectrum disorders (i.e. schizophrenia,
schizoaffective disorder or delusional disorder) were included. Specific rates of use of
cannabis had to be given, rather than simply rates of generic 'substance misuse'.
Given that the meta-analysis of Koshkinen et al. included studies published up to the
beginning of January 2009, the search was limited to reports published after this date.
The above methodology identified 489 studies. On examination of abstracts 13 were
potentially relevant and attempts made to obtain the full text report. A number of
37
studies had to be excluded either because the subjects included were too young, or
the study included substantial numbers (>20%) of subjects with conditions other than
schizophrenia spectrum disorders.38"41 Four studies yielded useable additional data, of
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Studies reporting prevalence of cannabis use or abuse/dependence in people with
schizophrenia spectrum disorders published after 2008.
SZ: schizophrenia; SA: schizo-affective disorder; BPAD: bipolar affective disorder; SD: significant
difference; NSD: no significant difference
A number of findings from these studies are notable. Firstly, rates of cannabis use in
the Croatian study are rather lower than in most other reports, with only 8.7%
reporting active cannabis abuse at the point of admission to hospital.43 Conversely, a
Northern Irish first episode study reported rates of cannabis abuse or dependence over
the year preceding their presentation as 26.2% in those people diagnosed with
schizophrenia.45 This rate, together with that reported by Ongur et al,,44 is broadly
comparable with rates reported in the meta-analysis of Koshkinen et al. As Galderisi
et al. reported on cannabis use rather than abuse/dependence their data are not directly
comparable to Koshkinen et al. 's meta-analysis.42
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Interpreting the data ascertaining rates ofcannabis use in people with schizophrenia
In reviewing the studies outlined above, it is of course important to consider
the potential implications of how the patient samples were derived. In these studies,
(both the review of Koshkinen et al. and my supplementary review), the
schizophrenia populations in which prevalence of cannabis use was ascertained were
all patients in contact with services. It is possible that the prevalence of cannabis use
in patients in contact with services differs from those who are not, and thus these
estimates are not representative of the population with schizophrenia as a whole. If
this were the case, more representative data would be expected to be obtained from
population studies.
To address the above question Green et al. reviewed data from community
population studies, comparing cannabis use and misuse prevalence estimates among
individuals with and without psychosis.46 They identified 6 such studies published
between 1990 and 2002, a haul I was unable to supplement, being unable to identify
any relevant studies published after this date. All of these studies showed higher odds
of cannabis use or misuse for people with psychosis. Rates of use in the last twelve
months in the psychosis groups ranged from 6.9 - 69.4%, while in the non-psychosis
comparison groups were 2.5 - 50.6%. Rates of lifetime use ranged from 17.7 - 34.5%
in the former group and 9.4 - 21.9% in the latter. In the discussion accompanying this
report Green et al. underline the importance of demonstrating a higher prevalence of
cannabis use in people with schizophrenia in population studies as well as treatment
cohorts. Such findings increase confidence that the reports of elevated rates of
cannabis use in treatment cohorts do not simply represent a sampling artefact; i.e. they
demonstrate that the increased prevalence of cannabis use observed in psychosis is not
26
restricted to those in contact with services and thus available for study. An obvious
proviso to these epidemiological studies is of course whether or not the relationships
observed are simply a consequence of sociodemographic confounders. A number of
the studies have controlled for these factors however. The findings of Degenhardt et
al., for example, (which admittedly did focus on level of psychotic symptoms rather
than diagnoses of schizophrenia), were robust to the inclusion of demographic
characteristics, personality and other mental health problems in the regression
analysis.47 It does thus seem to be the case that rates of cannabis use in psychosis are
genuinely elevated over those in the general population, and that this increased risk is
related to the mental illness itself.
Of fundamental importance in establishing if the increased risk of substance
misuse is a feature specific to schizophrenia/psychosis, are studies comparing the
prevalence of substance misuse in the condition to that in other major psychiatric
disorders. Unfortunately, only a handful of studies have done this. Muesser et al.
compared patients with schizophrenia, bipolar affective disorder or depression. They
reported that diagnosis was not clearly related to type of substance misuse, with
demographic variables such as gender, age and race being stronger predictors.48
Patients with schizophrenia and bipolar affective disorder had similar rates of lifetime
cannabis use disorder, a rate approximately double that seen in people with
depression. Similarly, in a more recent study comparing bipolar affective disorder and
schizophrenia, rates of cannabis use were similar in the two conditions.49 Lifetime
rates of cannabis abuse or dependence were also reported as similar in the two
conditions by Ongur et al.44 Conversely, a Lebanese study reported that cannabis use




As is clear from the above, a large number of studies have examined the
prevalence of cannabis use in schizophrenia, generally finding it substantially elevated
compared to rates in the general population. Given this, it is perhaps surprising that so
few studies have formally compared rates in those with schizophrenia to a comparable
population with other major psychiatric conditions. The few studies that have
attempted this have generally compared rates to bipolar affective disorder; generally
rates have been similar in the two conditions. This is perhaps not surprising, bipolar
affective disorder itself being generally recognised as having a strong association with
substance misuse.51 Studies compared rates of cannabis use/abuse in schizophrenia
with rates in psychiatric conditions other than bipolar affective disorder are even rarer,
but the limited data available does suggest rates are elevated in comparison to
depression.50
In summary, it does seem to be the case that rates of cannabis use in
schizophrenia are indeed elevated compared to the general population. This
association has now been demonstrated in many different nations, though most studies
have been undertaken in Western Europe or North America. Though this is at times
regarded as a problem specific to schizophrenia however, it is also a prominent
feature of bipolar affective disorder. Surprisingly, despite the large number of studies
investigating the prevalence of cannabis use in schizophrenia, studies comparing this
with the prevalence in what is likely the most appropriate comparator group (i.e.
individuals with another major mental illness) are actually rather rare.
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2.1.2 Alcohol
Koshkinen et al., the group who undertook the meta-analysis addressing the
prevalence of cannabis use/abuse in schizophrenia, also applied this methodology to
ascertain the prevalence of alcohol use disorders in the condition. As with the
cannabis meta-analysis, this built on the two earlier systematic reviews undertaken by
Muesser et al. and Cantor-Graae et al. which had focused on the use of various
substances by people with schizophrenia.33,34 The nine relevant studies identified by
Muesser et al. reported lifetime rates of alcohol abuse or dependence rates ranging
from 8.8 to 47%. Their interpretation of these data is that people with schizophrenia
were no more likely to abuse alcohol than patients with other psychiatric disorders or
general population controls. The more recent review of Cantor-Graae et al. identifies
25 relevant studies. They report that abuse rates are greater for alcohol than any other
substance (tobacco is not considered), and report lifetime abuse rates ranging from 6.7
to 50.7%. When considered together with their own data, they believe rates of alcohol
abuse to be elevated in schizophrenia compared to the general population.
The methodology of the Koshkinen et al. meta-analysis was essentially the
same as the cannabis review. The only significant alteration was that cannabis-
specific terms were altered to their alcohol-specific equivalents; e.g. 'cannabis abuse'
changed to 'alcohol abuse'. As with the cannabis review it included studies published
from 1996-2008.
Sixty studies met inclusion criteria for the meta-analysis. On the basis of these
studies the median prevalence of alcohol use disorder (AUD, essentially fulfilling
ICD or DSM diagnostic criteria for alcohol harmful use/abuse or dependence) either
at any point in lifetime or currently was determined. The median of lifetime AUD
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prevalence was 20.6% (IQR 12.0-34.5, 47 studies) while that of current AUD
prevalence 9.4% (IQR 4.6-19.0, 18 studies). As was the case with the cannabis meta¬
analysis, there was a paucity of studies comparing the prevalence of alcohol
abuse/dependence in people with schizophrenia to matched controls derived either
from the general population or people with other psychiatric conditions. Indeed this
was done in only one of the studies they identified, which reported that rates ofboth
current alcohol abuse and dependence were approximately doubled in those with
schizophrenia compared to the general population. In lieu of these data, AUD
prevalence in schizophrenia was compared with alcohol consumption in the countries
•j z:
in question as reported by WHO. In general, in studies presenting results from
countries with high consumption of alcohol, the prevalence of AUD in patients with
schizophrenia was also higher than in studies from countries with lower alcohol
consumption. Direct contrasts between AUD prevalence in people with schizophrenia
and either the general population or those with other psychiatric disorders were not
made.
Update ofsystematic review
As was the case with cannabis, the above reviews were augmented by a
supplementary literature search, aimed of identifying relevant papers published after
the period reviewed by Koshkinen et al. The search undertaken was identical to that
for cannabis, with the exception that 'alcohol' was substituted for 'cannabis' in the
search terms.
On examination of abstracts yielded by the above search, 12 potentially
relevant studies were identified and the full text papers obtained. As previously, a
number of studies had to be excluded either because the subjects included were too
30
young,37 or prevalence figures included substantial numbers of subjects with
conditions other than schizophrenia spectrum disorders.39"41 Three of the four studies
which augmented the cannabis review yielded useable additional data; details of these
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Studies reporting prevalence of alcohol use or abuse/dependence in people with
schizophrenia spectrum disorders published after 2008.
SZ: schizophrenia; SA: schizo-affective disorder; BPAD: bipolar affective disorder
Overall studies identified with this supplementary search report rates of AUDs
in schizophrenia which exceed those reported by Koshkinen et al.. This is particularly
so in the Northern Irish study.45
Interpreting the data ascertaining rates ofalcohol abuse/dependence use in people
with schizophrenia
In their discussion Koshkinen el al. compared the rates of AUDs in
schizophrenia in more recent studies to those observed in the earlier reviews. Overall
their impression was that though AUDs in patients with schizophrenia remained
31
common, there may be a descending trend. The findings of my supplementary search
do not however seem to support this.
Interestingly, when Koshkinen et al. compared findings from the cannabis and
alcohol meta-analyses, rates of cannabis use disorders appear to be higher than
alcohol use disorders. Specifically, median current and lifetime rates of the former are
16.0% and 27.1%, while that of the latter are 9.4% and 20.6%.33 On considering this
finding however, it does seem likely that the relative prevalence of the two conditions
will be substantially affected by geographical location. In countries such as Scotland,
for example, where alcohol problems are so common in the general population, it
seems likely this will be reflected in particularly high rates of use of this drug by
people with schizophrenia. Evaluation of specific studies does in fact provide support
for this supposition. In countries with generally high rates of alcohol consumption
(such as Northern Ireland or Scotland), the rates of alcohol abuse/dependence exceed
that of cannabis use disorders.45'52 In populations in which alcohol use is generally
less prevalent however the converse is true.50'53 These observations clearly underline
the fact that substance misuse by people with schizophrenia does not occur in
isolation from the prevailing patterns of substance misuse in a particular population.
As was the case with cannabis use, studies comparing rates of alcohol
abuse/dependence in schizophrenia to that in other psychiatric conditions are
particularly rare. Mueser reported similar rates of lifetime diagnoses of alcohol use
33disorder in schizophrenia, bipolar affective disorder and major depression. A small
number of studies have directly compared rates of alcohol abuse/dependence in
schizophrenia and bipolar affective disorder; though rates are reported as greater in
the latter condition, any difference is non-significant.44'49 Again, as was the case with
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cannabis, this underlines that though rates of alcohol problems may be elevated in
people with schizophrenia, this problem is not necessarily specific to this diagnosis.
2.1.3 Tobacco
Clinicians have long observed that people with schizophrenia are markedly
prone to smoke tobacco, but prevalence estimates have varied widely. To facilitate
accurate estimation of the prevalence of cigarette smoking in schizophrenia, de Leon
et al. undertook a meta-analysis in 2005.54 A primary aim of this meta-analysis was to
enable comparison of prevalence rates across countries and cultures; thus the
methodology aimed to include all possible studies from all over the world, with
inclusion not being restricted to studies published in English.
A major strength of this review is that in each included study smoking rates in
schizophrenia were incorporated into the meta-analysis as an odds ratio; the odds of
smoking in schizophrenia relative to that in the general population (and, where data
were available, relative to the odds in other major psychiatric conditions). As some
articles provided smoking data from schizophrenia patients but did not provide
comparable data from the general population, in these cases comparable data were
obtained from independent (usually government) surveys. This means that the output
from the meta-analysis is an odds ratio of worldwide smoking rates in schizophrenia
relative to that in population controls (or, alternatively, non-schizophrenic people with
a major mental illness). This odds ratio is more meaningful than a simple estimation
of prevalence.
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The review process identified 42 samples from 20 different nations,
investigating a total of 7593 schizophrenia patients (62% of whom were current
smokers). The weighted average of the ORs comparing prevalences for schizophrenia
patients versus the general population was 5.3 (CI, 4.9-5.7). This suggests that the
odds that patients with schizophrenia are current smokers are 5.3 times higher than
people from the worldwide general population. The association between
schizophrenia and current smoking remained after using severe mentally ill controls
(18 studies across 9 countries, weighted average OR was 1.9, CI 1.7-2.1). The
severely ill control group was heterogeneous and varied between studies, but patients
with affective disorders generally made up the largest single component of it.
I updated the study discussed above by searching for studies investigating the
prevalence of smoking in schizophrenia published after 2004 (and thus not included in
the above meta-analysis). The methodology employed was comparable to the
approach taken for the searches supplementing the cannabis and alcohol meta¬
analyses, with the substitution of the search terms 'cigarette', 'tobacco smoking' OR
'smoking' for those substances.
The above approach yielded 924 potentially relevant studies, ofwhich on
examination of abstracts 34 were potentially relevant, and attempts were made to
retrieve full text articles. One of these was unobtainable,55 the main reason for
exclusion of the others was that the recruitment methods meant that the sample may
be unrepresentative of the population with schizophrenia as a whole e.g.56'57 Nine
studies provided additional usable information which could potentially augment the
de Leon et al. meta-analysis. These are detailed in Table 2.2 below. Data from these
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Table 2.2
Studies investigating the prevalence of smoking in schizophrenia published after the
de Leon et al. review.
Unless the control group is specifically described studies were uncontrolled.
Period during which data were collected is included if this is reported in study
Interpreting the data ascertaining rates of tobacco use in people with schizophrenia
An important outcome of the meta-analysis of de Leon et al. was to yield a
global odds ratio, quantifying the strength of the association between smoking and
schizophrenia when these individuals are compared to general population controls.
This was convincingly achieved, people with schizophrenia being demonstrated to be
at a hugely elevated risk of smoking. This strong association between schizophrenia
and smoking is further illustrated by the additional studies detailed in Table 2.2; on
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considering these supplementary data, only in Turkey did the smoking rate in people
with schizophrenia not exceed that in the general population.65
It is the case however that a specific objective of the meta-analysis, (and my
subsequent review), was also to compare data from across cultures. As discussed by
de Leon et al., by this means the hypothesis that the association between
schizophrenia and tobacco smoking is relatively independent of sociocultural factors
could be further explored. This being the case, even in the context of generally
consistent findings overall, any notably anomalous studies do need to be examined a
little more carefully. While these may of course simply represent chance findings,
they may potentially offer important insights in to the relationship between smoking
and schizophrenia in particular social contexts.
Firstly the potential explanations for the anomalous negative Turkish result,
which demonstrated no increase in the prevalence of smoking in people with
schizophrenia when compared to the general population, must be considered. It may
indeed represent a chance finding, or be consequent to a ceiling effect arising from the
very high rate of smoking in the population in general in Turkey, or reflect anomalous
features of the control group (drawn as they were from the relatives of neurology
outpatients).
A number of other studies included in de Leon et al. 's meta-analysis also
reported negative findings however, and these must also be considered. Specifically,
three Columbian (in contrast to the Columbian study of Campo-Arias et al., above, in
which the difference was smaller in magnitude than in other studies but still
significant60) and one Indian study included in the meta-analysis also reported that
rates of smoking were not increased in those with schizophrenia compared to the
general population. In contrast to the Turkish study, these non-significant findings are
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in the context of populations which have a very low prevalence of tobacco use.
Clearly the explanation of a ceiling effect does not apply here, and nor did the
comparator groups have any obviously unusual characteristic. The explanation for
these apparent anomalous results seems different, and likely stems from the fact that
the degree of drug accessibility will have a major influence on smoking prevalence.
Thus, even if the association between schizophrenia and smoking were entirely
biologically (rather than socio-culturally) determined, restriction in access to tobacco
would still impact on the manifestation of this association in some countries and/or
societies. As an example, if a society is very poor then very few people will be able to
afford to buy cigarettes, and consequently very few people will ever be exposed to
tobacco. If they never try tobacco they can never become a smokers, and thus the
association between schizophrenia and tobacco use cannot become manifest in that
society. Similarly, if it is not socially acceptable for women to smoke then they will
be unlikely to ever be exposed to the drug, and thus the association between
schizophrenia and smoking will not be observed in that subset of the population. The
lack of smoking by people with schizophrenia in these circumstances does not refute
the association between schizophrenia and tobacco smoking; it only proves
economical and social factors may be a major deterrent to nicotine use initiation and
consequent addiction. Thus, on considering these issues, the Columbian and Indian
reports are in fact not inconsistent with there being a strong association between
schizophrenia and tobacco smoking.
A further observation made in the meta-analysis is that, (though the increase is
substantially less than when compared to the general population), smoking rates in
schizophrenia are elevated relative to that seen in people with other severe mental
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disorders. Specifically, 14 of the 18 studies included in the meta-analysis that make
this comparison report an elevated rate of smoking in the former group.54 People with
other major mental illness share many of the potential confounding factors exhibited
by people with schizophrenia (e.g. institutionalisation, high levels of unemployment),
so these data are particularly important in making the case that an elevated
vulnerability to smoking is a characteristic directly attributable to this condition. It has
also been argued however that the association between schizophrenia and smoking
may be a specific consequence of antipsychotic treatment, an exposure which would
be expected to be greater in people with schizophrenia even than in those with other
major mental illnesses. It is the case however that in the small number of studies
controlling for this (and other potential confounders such as race, use of other
substances etc), the association between schizophrenia and smoking did remain (3
studies, adjusted ORs ranged 2-3).66-68
Some of the studies in which differences in prevalence of tobacco use between
schizophrenia and controls are least apparent are those in which the latter group is
made up of people with bipolar affective disorder.59'65'69 Thus, though it is clear that
smoking rates in schizophrenia are elevated above those in the general population, and
likely also in the generality ofpeople with major psychiatric disorders, any elevation
above that in bipolar affective disorder is likely considerably more modest, if indeed it
is present at all. Clearly exploration of the reasons why bipolar affective disorder may
have a strong association with tobacco use is an important topic, but beyond the scope
of this review. I will however further explore the potential reasons for an association
between schizophrenia and tobacco use in Section 3.2.1.3.
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2.1.4 Other drugs
Process by which stimulants were recognised as having a relationship with psychosis
The other class of drugs which have been long associated with psychosis are
stimulants. Though this group is now loosely regarded as containing amphetamine,
cocaine and MDMA, it was with amphetamine that this association was initially
observed. This drug was first synthesised by Lazar Edeleanu in Berlin in 18 8 7.70 By
the 1930s it was being marketed as a treatment for narcolepsy and a decongestant, but
as well as addressing these conditions was also noted to result in general
psychological stimulation, increased confidence and a degree of euphoria.71 A
potential for abuse was also noted, as was a tendency for it to worsen the somatic
features of anxiety. Nevertheless, it was widely promoted as an antidepressant in the
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USA in the 1930s and 40s. Additionally, it and methamphetamine, (a related drug
synthesised in Japan in 1918), were widely used by British, German and Japanese
troops during the Second World War to combat fatigue. It was during this period of
military application that reports of amphetamine/methamphetamine induced delusions
began to emerge.73 Indeed, such reports together with increasing concerns about
addictive potential prompted the Germans to limit availability of the drug. Further
cases of stimulant associated psychosis subsequently arose, culminating in Philip
Conned's 1958 monograph in which he reviewed cases of stimulant psychosis, noting
that they tended to resolve rapidly on discontinuation of the drug.74 He also observed
that the psychopathology of this psychosis closely resembled paranoid schizophrenia,
an observation soon confirmed by other researchers.75'76
Given the apparent psychotomimetic effect of this drug class, their use by
people with schizophrenia would be expected to have detrimental consequences.
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Clearly this makes ascertainment of the extent of use of these drugs by people with
the condition important to ascertain. Thus, though other issues such as how stimulant
use can give rise to psychosis, and the consequences of stimulant use for prognosis of
schizophrenia are clearly important, I will first try to clarify the extent of their use by
people with schizophrenia.
Prevalence ofuse ofamphetamines and other substances in schizophrenia
In 1995, LeDuc and Mittelman undertook a systematic review of the
prevalence of stimulant use in schizophrenia. It covered articles published between
1975 and 1994, and focused on amphetamine and cocaine (including crack cocaine).77
They included studies which ascertained rate of use of either amphetamine or cocaine,
or the combined rate of use of either drug. Only studies that classified patients'
psychosis according to diagnostic criteria in the DSM-III, DSM-III-R, or RDC,
including only patients diagnosed within the schizophrenia spectrum (i.e.,
schizophrenia, schizoaffective disorder, schizophreniform disorder, or schizotypal
personality disorder) were included. As was the case in the reviews of Koshkinen et
ah, studies of subjects selected on the basis of being substance misusers were
excluded. The definition of substance misuse itself varied between studies. While in a
substantial proportion it was a requirement to fulfil DSM criteria for abuse or
dependence, in others criteria were more variable; in some instances it was regarded
as, for example, two consecutive weeks of use or positive urinalysis.
The review of LeDuc and Mittelman identified 20 studies fulfilling their
inclusion criteria, yielding a total of 1512 patients. They all originated from North
America, with 19 of the 20 studies arising from the USA. Thirteen of these studies
focussed on 'stimulants' in general, six on cocaine, and one on amphetamines. The
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rate of psychostimulant abuse in these identified studies averaged 26.5 %; as
described above, the term 'abuse' had a rather broad interpretation. It is
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acknowledged that age is a significant factor influencing drug abuse, and the
average age of the subjects with schizophrenia included in this review was 33. Rates
of psychostimulant abuse in schizophrenics were thus compared to rates reported in
American subjects over 26 years of age in The National Household Survey on Drug
Abuse (NIDA 1991);79 at the time of the study this had last been conducted in 1990.
This indicated that the incidence of psychostimulant abuse in schizophrenics was 2-5
times higher than that of the American general public. The researchers also compared
rates of stimulant use in people with schizophrenia spectrum disorders to those with
affective disorders. Rates of recent stimulant use in patients with schizophrenia
spectrum disorders were significantly elevated when compared to rates in the 160
identified patients with a primary diagnosis of affective disorders (in whom the rate of
recent use was 20%, P < .01).
The researchers also examined trends in levels of stimulant use with increasing
age. They noted that unlike the decline in use that was being seen with increasing age
in adults in the American general population, high rates of abuse appear to be
maintained in older schizophrenics.
Update ofsystematic review
Though in recent years North America has experienced an epidemic of
amphetamine use (in the particularly potent form of methamphetamine),80 this review
has not been updated since initial publication. Given the close relationship between
amphetamine and psychosis, such an update is clearly important. Not least, it is
essential in providing a context from which to consider the potential significance of
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any brain structural abnormalities that may be associated with use of amphetamine in
the study population. It is also the case however, that since the review of LeDuc and
Mittelman cocaine use has also become more widespread in Europe, and use of a new
o 1
drug with stimulant properties, MDMA (or ecstasy), has also become commonplace.
Thus, in addition to amphetamine and cocaine, the following review will also identify
studies which consider the prevalence of use of ecstasy by people with schizophrenia.
In order to maximise identification of articles reporting the prevalence of
amphetamine and/or cocaine use (or the use disorders of abuse or dependence) in
patients with schizophrenia published in 1994-2010, we conducted a search using
three electronic databases (PsycINFO, Medline and EMBASE). The keywords used
were schizophrenia OR psychosis to find studies on schizophrenic psychoses,
combined with amphetamine, stimulants OR cocaine. At the same time a similar
search was performed substituting the latter search terms for MDMA or ecstasy.
The searches outlined above were augmented by a further search employing
more general terms (substance use OR dual diagnosis combined with schizophrenia
OR psychosis), this methodology being comparable to that employed in the searches
undertaken for alcohol and cannabis.
The inclusion criteria for studies were comparable to those employed by
Koshkinen et al. in their recent meta-analyses of alcohol and cannabis use in
schizophrenia. These were that: the study reported information on the prevalence of
substance of interest (i.e. amphetamine, cocaine, or MDMA) use or abuse/
dependence; the sample consisted (at least 80%) of individuals with schizophrenia
spectrum diagnosis (schizophrenia, schizophreniform disorder, schizoaffective
disorder and delusional disorder) or articles reported the prevalence rates by
diagnostic group (in samples that were less than 80% schizophrenia spectrum); the
42
subjects were older than 16 years of age; and that the study sample was larger than 15.
Only articles reporting schizophrenia spectrum disorders and specifying that they
were either diagnosing substance abuse or dependence according to DSM or ICD
diagnostic system criteria or simply reporting that they determined rates of exposure
were included. We excluded studies with samples that might have biased the
presented prevalence of substance use in the study, e.g. samples recruited from
prisons, forensic psychiatry units or shelters for the homeless, or studies including
only subjects on depot preparations (as substance misuse is so strongly associated
with non-compliance). Trials and intervention studies were also excluded. Where the
same sample of subjects appears to have been included in more than one publication,
only data from the publication with the largest sample size was included. Only articles
written in English were included.
On applying the above methodology the first search (aiming to identify studies
investigating the prevalence of amphetamine and/or cocaine use) yielded 2924
articles, of which 99 were evaluated in detail after analysing the abstracts. The
second, (aimed at identifying studies ascertaining the prevalence of ecstasy use),
yielded 251 articles, of which 23 were retrieved in full text form. The more general
search, designed to augment the previous two searches, yielded 2150 articles, of
which 68 were retrieved in full text form.
Data from studies identified that fulfilled these inclusion criteria are presented
in the tables below. In contrast to the review of LeDuc and Mittelman (in which rates
of amphetamine or cocaine use were generally combined), these data are presented
separately for each substance of interest. As determined by the inclusion criteria
employed, studies which ascertain combined levels of use of both amphetamine and
cocaine have not been included. Unless specified, prevalence of substance use has
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been ascertained by self-report. For each substance a distinction has been made
between studies in which a diagnosis of substance abuse or the dependence syndrome
is made and studies simply reporting a history of use. Studies ascertaining either of
the former are displayed separate from those simply reporting a history of use.
Four studies were identified which were published during the period of interest
and reported rates of amphetamine abuse or dependence in schizophrenia (Tables 2.3).
Five studies reported rates of cocaine abuse or dependence (Table 2.5), while none
reported rates of ecstasy abuse or dependence. Generally studies more commonly
reported any level of use rather than abuse or the dependence syndrome, this being
ascertained either for any point previously or in a defined period preceding the study.
Eight studies reported any use of amphetamines (Table 2.4), 10 any use of cocaine
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Table 2.3
Studies reporting current prevalence of amphetamine abuse or dependence syndromes
in people with schizophrenia
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Studies reporting any history of use of amphetamines in patients with schizophrenia
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Table 2.5
Studies reporting prevalence of current cocaine abuse or dependence syndromes in
people with schizophrenia
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Studies reporting prevalence of any history of cocaine use in people with
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Table 2.7
Studies reporting the prevalence of any history of ecstasy use in people with
schizophrenia
ND: no data; SD: significant difference
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In addition to the studies reported above, Barnes et al. and Duke et al. reported
on combined lifetime use of either amphetamine and/or cocaine in two London-based
studies.95'97 Duke et al. reported in 2001 a lifetime history of use of either (or both) of
8.7%, which rose to 23.9% in those aged under 36. In a 2006 first episode study
Barnes et al. reported a history of use in 37.7%. These rates, focusing as they do on
general stimulant use, are similar to the rates reported in comparable age groups in the
review of LeDuc et al. It must be noted however that the criteria for abuse in the latter
study was more stringent than the 'any exposure' criteria applied in these reports.
Interpreting the data ascertaining rates ofuse ofother substances by people with
schizophrenia
To summarise the findings relating to use of either amphetamines or cocaine,
this updated review reports a prevalence of current abuse of or dependence on
amphetamine of between 0.5% and 3.0% on the basis of four studies, and current
abuse of or dependence on cocaine of between 0% and 4.6% on the basis of five
studies. As would be expected, studies reporting any history of use of the above drugs
report consistently higher rates. Levels of exposure are however greatly influenced by
geographical location; this is illustrated by the fact that reported rates of lifetime
exposure to amphetamines ranged from 0% in Tunisia to 20.6% in an Australian
study,64,98 while cocaine exposure ranged from 0% in both a Swedish and Tunisian
study to 19.7% in a Canadian one.34,64'99 It is notable that even on combining the rates
of both amphetamine and cocaine abuse/dependence in these more recent studies, the
rates observed in these studies fall far short of the rates of stimulant abuse reported by
Le Due et al. It is only when rates of lifetime exposure are considered, a level of use
of substantially lesser magnitude than even the broadest interpretation of abuse
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permitted in the studies included in the report of Le Due et al., that the quoted rates
approach those reported in the earlier study. While this could be interpreted as
implying that the prevalence of stimulant use had fallen in people with schizophrenia,
I believe there is insufficient evidence for such a conclusion. Rather, this finding may
well once again illustrate the importance of geographical location in influencing the
findings of a study. Thus, the fact that only two of the studies identified in the period
following the Le Due et al. review are from the USA (and that one originates from a
rural area) may provide the explanation for the lesser rates observed in these studies.
Indeed, such a theory is given some weight by the findings of recent studies
undertaken in Canada and Australia.98'99 Similarly to the USA, stimulant use is
relatively common in these geographical locations; in-keeping with this it is in these
studies that the prevalence of stimulant use most closely approaches that reported by
Le Due et al..
Only three of the studies identified in this systematic review compared the
rates of stimulant use in people with schizophrenia to that in control populations.91'
100Each of these studies were concerned with stimulant use (rather than abuse or
dependence), and in each study separate comparisons were made for both
amphetamines and cocaine. In a Canadian study the rate of lifetime exposure to
cocaine was higher in people with schizophrenia than the age adjusted general
population prevalence.99 This however was the only significant difference observed.
When an Irish study compared cocaine use in the last 30 days by people with
schizophrenia to that in a control group obtained from the same general practices, for
example, no significant difference was observed (rates of use actually being non-
significantly elevated in the latter group).100 In the rural American study rates of
cocaine abuse were similar in those with schizophrenia and those with both bipolar
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affective disorder and major depression.91 No significant difference in rates of
amphetamine exposure was observed between schizophrenic and control groups in the
Irish or Canadian study,99'100 and levels of amphetamine use were actually (non-
significantly) higher in those with a bipolar illness than in schizophrenia in the rural
American study.91 It may thus be the case that the elevated rates of stimulant use in
people with schizophrenia (when compared to the general population) seen in the
urban American environment is less apparent in other contexts. As was seen with
other substances, the inflated level of stimulant use in schizophrenia is even less
marked when the comparator group also has a major mental illness.
This is the first systematic review of levels of MDMA (ecstasy) use by people
with schizophrenia. Given the chemical similarities between this drug and
amphetamine however,101 it is possible that some earlier studies (which may have
been included in the review of LeDuc et al.) classified exposure to this drug together
with amphetamine use.
No studies were identified in which prevalence of abuse of or dependence on
MDMA was ascertained. Four studies were identified however in which the
prevalence of some level of lifetime exposure to MDMA was ascertained. Of
particular note are two of these studies which were undertaken in London with data
gathering separated by many years. The data of Duke et al. were obtained in 1990;
while the year of data gathering is not specified in the study of Barnes et al., it was
likely some time later as this paper was published in 2006. The rate of MDMA
exposure reported in these two studies is very different. The earlier study reports that
only 0.8% of schizophrenic patients had ever been exposed to MDMA, while that of
Barnes et al. reports a rate of exposure of 32.9%. The rise in levels of exposure
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between these two studies is of course dramatic, and has occurred in the context of a
rise in use in the general population. Neither of these studies included a control group.
It is the case however that the British Crime Survey reported in 2004/2005 that 10.8%
of 16-24 year olds reported ever having used ecstasy in their lifetime;11 this does
indicate that (in Britain at least), rates of historic ecstasy use in those with
schizophrenia are elevated.
Summary
In summary, it is notable from this review that in the 15 years following the
paper by LeDuc et al., studies ascertaining the levels of use of stimulants by people
with schizophrenia have actually been relatively few. Of particular interest, only one
was identified which had been undertaken in the USA, the country from which 19 of
the 20 studies included in the review of LeDuc et al. originated. This indicates that
interest in stimulant use in schizophrenia may have waned since the 1980s/early
1990s, a fact which may be attributable to the increased interest in the relationship
between cannabis use and psychosis which has occurred during this period. It is clear
however that use of stimulant drugs by people with schizophrenia remains common,
though the degree to which this is elevated above that by people from comparable
socioeconomic groups is far from clear. Additionally, it seems to be the case that in
recent years there has been a considerable rise in the number of people with
schizophrenia who have used ecstasy. In the case of both stimulants and ecstasy
substantial evidence has accumulated of adverse psychiatric sequelae secondary to
use.76'102 It is thus important, as has been established in this chapter, to have a clear
idea of the prevalence of such exposures in the psychiatric population. It is also
important of course to consider if specific psychiatric consequences would be
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expected to occur in the population who have/are vulnerable to schizophrenia on
exposure to drugs of abuse, and this will be considered in the next chapter. Prior to
this however, the association between psychosis and stimulants must be considered in
more detail. This is necessary as, as was alluded to in the opening paragraph of this
section, the observation that stimulant use could result in psychosis was a seminal
event underpinning the first conceptualisations of the dopamine hypothesis of
schizophrenia. The reasons for an association between more general drug use and
schizophrenia will be discussed later.
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2.2 The association between stimulants and psychosis
As mentioned above, it has been recognised since the 1940s that use of
amphetamines could precipitate psychosis in previously unaffected people. By the
1970s the work of various groups had elucidated that amphetamines act by releasing
catecholamines, and a role for amphetamine in inducing the release of dopamine in
the central nervous system had been suggested, (reviewed in Sulzer et al.10).
In parallel with these observations advances were also occurring in the
understanding of how neuroleptic drugs produced their antipsychotic effect.
Dopamine was first implicated as important in the actions of these drugs by the
seminal work of Carlsson and Lindqvit, who reported in 1963 that antipsychotics
increased the metabolism of dopamine when administered to animals.103 The
centrality of dopamine to psychosis became fully apparent in the 1970s, with the
finding that the clinical effectiveness of antipsychotic drugs was directly related to
their affinity for dopamine receptors.104
It was around these two strands of data that the dopamine hypothesis of
schizophrenia crystallised. In its initial formulation this essentially stated that it was
an excess of transmission at dopamine receptors that was responsible for the genesis
of psychotic symptoms.105 Clearly this is in-keeping with the facts both that
stimulation of dopamine release by amphetamines resulted in psychotic symptoms,
and dopamine blockade by antipsychotics attenuates them.
Though the original formulation of the dopamine hypothesis remains
recognisable, modifications have been made as our understanding of the brain
abnormalities in schizophrenia has increased. One such reformulation was made by
Davis et al. in 1991,106 following the publication of PET data demonstrating reduced
52
cerebral blood flow in the frontal cortex in schizophrenia. This enabled him to
incorporate regional specificity in to the dopamine hypothesis, emphasising the
importance of 'hypofrontality'. This hypofrontality was directly correlated with low
CSF dopamine metabolite levels, leading to the suggestion that it indicated low frontal
dopamine levels. Thus, this modified version of the dopamine hypothesis involved a
shift from a global hyperdopaminergia explaining all facets of schizophrenia to
regionally specific abnormalities involving prefrontal hypodopaminergia and a
subcortical hyperdopaminergia. Clearly this subcortical hyperdopaminergia could still
be driven by amphetamines, meaning the production ofpsychotic symptoms by these
drugs was still compatible with this hypothesis.
Progressive advances in neuroimaging have further informed the dopamine
hypothesis. Molecular imaging studies have confirmed that presynaptic striatal
dopaminergic function is elevated in patients with schizophrenia and reported that this
correlates with the symptom dimension of paranoia.107'108 It has also been
demonstrated that people with schizophrenia exhibit enhanced striatal dopamine
release following amphetamine challenge, and that the magnitude of this dopamine
release correlates with the worsening of psychotic symptoms experienced on exposure
to the drug.109 Additionally, neurochemical imaging studies have confirmed that at
clinical doses all currently licensed antipsychotic drugs block striatal D2 receptors,
and that it is this blockade of heightened transmission which leads to a resolution of
symptoms for most patients (reviewed in Howes et a/.110).
In recent years it has also become apparent that as well as worsening
symptoms in established schizophrenia, certain substances can also increase the risk
of developing the condition in the first place. As will be discussed later, cannabis is
now widely accepted as an independent risk factor for schizophrenia. In addition, PET
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imaging work has shown that even a few doses of a stimulant may sensitize the
striatal dopamine system and can lead to enduring increases in dopamine release to
amphetamine even after many months of abstinence.111 In keeping with this, it has
been reported that individuals with a history of methamphetamine psychosis can
experience subsequent spontaneous recurrence of their paranoid-hallucinatory states
112* •in response to stress. This can occur even in the absence of further use of the drug,
suggesting that the development of stimulant-induced psychosis might itself be related
to persisting brain damage or changes in brain metabolism which leave the individual
113 • ...
at increased risk of subsequent further psychoses. Thus, and in contrast to the initial
reports by Connell,74 the effects of amphetamine use may not all be transient, and may
actually have long term implications for an individual's risk of ultimately developing
schizophrenia. Indeed, such a possibility is given further credence by Japanese studies
reporting that in approximately 15% of cases methamphetamine-induced psychosis
runs a chronic course, persisting even if there is complete abstinence from further
i 114
drug use.
In addition to substance use, accruing data have demonstrated that numerous
other environmental factors can potentially contribute to dopamine dysregulation. It
has been reported, for example, that striatal dopamine release in response to stress was
increased in people who reported low maternal care during their early childhood,115
and animal experiments have repeatedly shown that postnatal rearing conditions can
lead to profound and lasting changes in the responsiveness of mesocorticolimbic
dopamine neurons to stress and psychostimulants.116'117 Obstetric complications have
• *118also been associated with an increased risk of subsequent schizophrenia, a possible
mechanism being suggested by animal studies which demonstrated that hippocampal
dysfunction (a brain structure particularly vulnerable to hypoxia-associated obstetric
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complications119) can lead to increased striatal dopamine release.120 Genetic variables
have also been associated with dopaminergic abnormalities. Most notably, and as
already discussed, variants of the catechol-O-methyltransferase gene (involved in
dopamine catabolism) have been shown to interact with early cannabis exposure to
• 1 91
increase the subsequent risk of psychosis and, in other studies, to increase stress
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reactivity and paranoid reactions to stress (reviewed in van Winkel et al. ).
The thrust of the data outlined above has been that a variety of different
factors, including drug exposure, can contribute to the common end point of abnormal
striatal dopamine release. In arriving at the most recent formulation of the dopamine
hypothesis of schizophrenia however, two further areas of research in have been
important. The first of these is the widely replicated finding of elevated presynaptic
striatal dopamine availability in schizophrenia, this being the most consistently
detected dopaminergic abnormality in the illness.123 This observation provides an
explanation for the greater amphetamine-induced dopamine release observed in
people with schizophrenia,124 and in turn explains why people with schizophrenia are
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more prone to the psychotomimetic effects of these drugs. These data are largely
compatible with the dopamine hypothesis as originally formulated. The second strand
of data are more genuinely novel however, deriving from work implicating a distinct
role for subcortical dopamine systems in incentive or motivational salience and
reward prediction.110
The work demonstrating the role of dopamine in motivational salience
provides a conceptual framework linking the neurochemical dysfunction of abnormal
striatal dopamine release to the clinical expression of the symptoms of schizophrenia.
It is fundamental to the 'third version of the dopamine hypothesis of schizophrenia',
recently reviewed by Howes and Kapur.110 As outlined in this review: "The abnormal
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firing of dopamine neurons and the abnormal release of dopamine leads to an aberrant
assignment of salience to innocuous stimuli. It is argued that psychotic symptoms,
especially delusions and hallucinations, emerge over time as the individual's own
explanation of the experience of aberrant salience. Psychosis is, therefore, aberrant
salience driven by dopamine and filtered through the individual's existing cognitive
and sociocultural schemas-thus allowing the same chemical (dopamine) to have
different clinical manifestations in different cultures and different individuals". The
strength of this model is twofold. Firstly, it is compatible with multiple routes
(genetic, neurodevelopmental, environmental or social) leading to the striatal
hyperdopaminergia, explaining how a wide range of factors can be associated with
subsequent risk of psychosis. Additionally however it provides a convincing
explanation of how the symptoms themselves can come in to being, a feature that was
sorely lacking from earlier formulations of the dopamine hypothesis.
It is thus the case since its initial formulation (largely as a consequence of
recognition of the association between amphetamine use and psychosis), the
dopamine hypothesis has been modified considerably. These reformulations have
enabled it to incorporate novel data as they have come to light. As these additional
data have accrued it has become apparent that a number of drugs other than
amphetamines may also be associated with psychosis, this association being believed
to be particularly robust in the case of cannabis. This has again been attributed, to
variable degrees, to the dopaminergic effects of these drugs.110 Thus, despite the
modifications, the idea that dopaminergic transmission remains the final common
pathway for psychosis has remained remarkably robust.
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2.3 Integrating prevalence of use data and the dopamine hypothesis of
schizophrenia
A number of robust facts can thus be taken from the preceding review. Firstly,
it is the case that people with schizophrenia have a great propensity to use a variety of
substances, though this may also be a feature of bipolar affective disorder. Secondly,
certain substances can undoubtedly induce (at least transient) psychotic symptoms,
and this effect is more pronounced in those with a diagnosis of schizophrenia. Thirdly,
the dopamine hypothesis provides a model through which the consumption of drugs
that precipitate the release of dopamine and the experience ofpsychotic symptoms
can be linked. While these three facts are generally accepted, what has been more
contentious is whether the induction of psychotic symptoms can be regarded as
causally related to the (generally chronic) disorder known as schizophrenia, and
whether the drugs in question (cannabis, amphetamines and indeed a number of other
substances), can truly increase an individuals risk of developing this condition. I will
thus now consider the variety of explanations postulated to explain why there is such




Why is there an excess of substance use in schizophrenia
3.1 Reasons given by people with schizophrenia for their substance use and the
subjective effects of this use
As will be a theme in subsequent sections, early studies tended to lump
together use of a variety of substances, and employed relatively unstructured
interviews to ascertain motivations for any substance use. Frequently no comparator
group (e.g. non-schizophrenic substance misusers) was included. One such example is
the 1989 study by Test et al., in which schizophrenic substance misusers stressed the
reasons for their substance misuse as being anxiety reduction, relief of boredom, and
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as a means for social contact. In 1995 Muesser et al. employed more sophisticated
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methodology. Firstly they used structured interviews. Additionally however, they
also compared the strength of endorsement of various potential drives for use of
alcohol, cannabis or cocaine between people with a history of schizophrenia with and
without a history of past or present abuse of each of these substances. By this
approach they were able to demonstrate that the relationship between substance use
disorders and expectancies displayed strong substance-specific expectations; namely,
alcohol expectancies were related to alcohol disorders but not to drug disorders,
whereas marijuana and cocaine expectancies were more strongly related to drug than
to alcohol use disorders. It was also notable that motivations for use of the substances
varied between alcohol and use of marijuana or cocaine (the latter two substances
being considered together in this section of the paper). Whereas socialization, coping,
and pleasure-enhancement motives were all strongly related to a history of alcohol use
disorders, only coping motives were strongly related to a history of drug abuse (an
explanation of what these groupings of motivations represent is detailed in Table 3.1).
This study thus emphasises the point that it is important to consider that differences
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may exist in the motivations to use different substances. While this is a phenomena
130 •
that has been recognised in the substance misuse literature in general, it can be
forgotten when considering the reasons why associations exist between use of
particular substances and schizophrenia.
Given the above considerations, in the following section I will restrict my
summary of self report data to those obtained in relation to a specific substance. The
additional criteria which studies must meet are comparable to those employed in the
reviews ascertaining the prevalence of use of various substances in the schizophrenic
population; specifically, they must use standardised criteria for diagnosing
schizophrenia, at least 80% of the population sampled must have a diagnosis of
schizophrenia and subjects included in the study must be aged 16-65. It is also
important to note that only non-experimental studies are summarised here. By this I
mean that the methodology employed in the studies included in this section centred on
asking people with schizophrenia what effects they attributed to use of a particular
substance, in the absence of that substance being accutley consumed. Experiment
studies, undertaken by administering a given substance to people with schizophrenia
and then rating the effects will be discussed in a subsequent section (Section 3.2.1)
Enhancement motives Coping motives Social motives
1. Because you like the feeling
2. Because it's exciting
3. To get high
4. Because it's fun
5. Because it makes you feel
good
1. To relax
2. To forget your worries
3. Because you feel more self-
confident or sure of yourself
4. Because it helps when you
are feeling nervous or depressed
5. To cheer up when you're in a
bad mood
1. As a way to celebrate
2. Because it's what most of
your friends do when you get
together
3. To be sociable
4. Because it is customary on
special occasions




Items on the Cooper et al. Drinking Motives Questionnaire (DMQ); these
motivational categories were employed by Muesser et al. in their 1995 paper, also
being utilised to ascertain motivations for cannabis and cocaine use
Note: Each item is self-rated on a scale from 1 (never/almost never) to 4 (almost always).
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3.1.1 Cannabis
Data ascertaining both the reasons for cannabis use and subjective effects of
this use (ascertained by self-report outwith the context of acute consumption) in
people with schizophrenia were recently reviewed by Dekker et al.132 They identified
five studies, each of which fulfilled my inclusion criteria. A supplementary literature
search undertaken by myself revealed only one additional relevant study; this was
undertaken by Schaub et al. in Switzerland and was published in 2008.133 On
reviewing these studies the most common reasons given for use of this drug were to
increase pleasure (a major motivator in all studies and reported by >95% in two),134'
135 • • *133135
to relax/decrease anxiety (>80% in four studies) " and out of a need to be more
sociable (33-81%).134-137 Use out of a desire to decrease psychotic symptoms was a
relatively rarer motivation than those just described; nevertheless, it was reported as a
drive to cannabis use by 40% of people questioned in two studies.134'135 The
methodology employed in a German study by Lambert et al. was slightly different
138from the studies outlined above, but it still fulfilled inclusion criteria. In this study,
rather than the proportion of people volunteering/indicating support for particular
statements being ascertained, people with schizophrenia were asked to state their
single most important reason for using cannabis. When this methodology was
employed the motivations outline above constituted three of the top four reasons
138 • • •
given. A further study of note included patients younger than my inclusion criteria
(at least one patient was 15). In this study again the top three reasons given for
cannabis use were to increase pleasure/get high, to relax and to be more sociable;
these reasons were in fact very similar to those given by a non-psychotic cannabis
using comparison group.139
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A small number of studies were also identified ascertaining the subjective
effects people with schizophrenia reported on using cannabis (patients being
questioned outwith the context of acute consumption). In these studies the majority of
patients did indeed report that they believed use of cannabis did improve mood and/or
reduce anxiety/have a calming effect.134'136'140 In each of these studies it was also
reported however that this was believed to be at the cost of worsening psychotic
symptoms.
3.1.2 Alcohol
A limited number of studies have investigated the subjective effects that
people with schizophrenia report on using alcohol and the reasons they give for use of
this substance. Again in these studies these attributions/reported effects were explored
outwith the context of acute use of the substance. Noordsky et al. reviewed the early
work in this area and found it somewhat contradictory.141 Whereas Alpert and Silvers
(1970) found that patients reported alcohol reduced the discomfort caused by
hallucinations,142 Kesselman et al.'s patients reported that it worsened their
symptoms.143 This was in contrast to the report of Dixon et al., who found that while
patients with schizophrenia and comorbid alcohol or drug disorder reported that
alcohol decreased depression and anxiety, and increased calm and trust, they reported
that it had no effect on hallucinations and suspiciousness.140 Noordsky et al. 's own
study consisted of interviewing 66 outpatients with schizophrenia or schizoaffective
disorder who used alcohol with a structured interview specifically designed to
ascertain subjective responses to alcohol.141 Nineteen of these 66 subjects had a
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current, and 38 a lifetime, alcohol use disorder (DSM-III-R abuse or dependence).
Improvement in anxiety, tension, dysphoria, apathy, anhedonia and sleep difficulties
was reported by over 50% of the sample. Similar numbers reported that alcohol
worsened (31%) or relieved (26%) psychotic symptoms. Lifetime alcohol use disorder
was strongly associated with reporting positive effects of alcohol, this being the case
for the reported effects of alcohol on both psychotic and non-psychotic symptoms.
Clarifying the beneficial effects that alcohol was reported to have on psychotic
experiences, Noordsky et al. state that patients often reported that alcohol relieved the
dysphoria associated with these symptoms rather than the symptoms themselves; to
illustrate they quote one patient as saying: 'Drinking doesn't make the voices go
away, but they do not bother me as much'.
The only subsequent study investigating this issue in a structured but non-
experimental manner was undertaken by Pristach et al}44 In this study 42 people with
an established diagnosis of schizophrenia, 23 ofwho had a past or current alcohol use
disorder (DSM-III-R abuse or dependence) were interviewed. Participants were asked
about their reasons for drinking and the effects they experienced both in the month
before their first episode of illness and in the month before their current admission.
The most commonly given reasons for alcohol use were to be more sociable, to
celebrate, to relieve depression, and to forget problems and worries. Subjects with a
history of an alcohol use disorder were more likely to report using alcohol to alleviate
depressive symptoms or alleviate worries, whereas they were less likely to cite
increased sociability as a reason. Interestingly, in this study more subjects once again
reported that alcohol consumption worsened hallucinations and delusions (12 and 13
subjects respectively) than reported that it helped them (4 and 7 respectively). In this
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study those with a history of alcohol abuse or dependence were much more likely to
report an increase in suspiciousness and paranoia with drinking.
It is thus the case the effects of alcohol use which people with schizophrenia
report when questioned outwith the context of acute use of the substance remain
inconsistent. Some themes do emerge however. Most obviously, and in-keeping with
studies undertaken in the general population,145 the most common reasons given for
drinking are to socialise, improve mood, and reduce anxiety. People with
schizophrenia rarely report that alcohol reduces psychotic symptoms; indeed, greater
numbers tend to report that it worsens these symptoms..
3.1.3 Tobacco
Reasons given for smoking by the general population include tension
reduction/relaxation, relief from boredom, socialization, stimulation/to aid
concentration and addiction.146'147 Given the particularly strong association between
schizophrenia and smoking however, it is clearly important to establish if the same
reasons for smoking are reported in this population. Thankfully, a number of studies
have specifically addressed the reasons that people with schizophrenia give for
smoking. Two such studies, which did not include a control group of non-
schizophrenic smokers, reported that the most prevalent reported reasons for smoking
in schizophrenia bore marked similarities to those in the general population.
Specifically, they included relaxation, habit, settling nerves, sedative effects, control
of negative symptoms (which could be regarded as comparable to the need for
'stimulation'), and addiction.148'149
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Clearly, if there are different subjectively reported motivations for smoking in
those with and without schizophrenia, these are most likely to be identified by studies
which include a non-schizophrenic control group. Two such studies were identified.
While these did find that the reasons given for smoking by people with and without
schizophrenia were similar, the emphasis placed on different perceived benefits did
differ between the two groups. Specifically, the study of Gerpegui et al. reported that
patients more frequently reported the effects of cheerfulness, agility, concentration,
and calmness.150 Similarly, the study of Barr et al. reported that patients with
schizophrenia placed greater emphasis than controls on the perceived benefits of
pleasure derived from the act of smoking as well as psychomotor stimulation.151 The
latter construct indicates a desire to improve concentration and psychomotor energy,
which clearly overlaps with the perceived benefits of concentration and agility
reported by Gurpgui et al. It is thus the case that while the motivations for smoking
reported by those with and without a diagnosis of schizophrenia are similar, there is a
difference in the emphasis placed on specific factors between the two groups.
3.1.4 Stimulants and ecstasy
A small number of studies have ascertained the reasons that people with
schizophrenia give for using amphetamines, but none were identified addressing
reasons for use of cocaine or ecstasy. In the study of Fowler et al. the main
98
motivations given for amphetamine use were drug intoxication and dysphoria relief;
similar motivations were cited by Baker et al., though it is important to note that only
38% of the subjects included in this study actually had a diagnosis of
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schizophrenia.152 In an Australian study however the subjective benefit of a reduction
153
in negative symptoms was also volunteered.
3.2 Theoretical explanations for the association between schizophrenia and
substance misuse
In section above I have outline the reasons that people with schizophrenia
themselves give for their substance use. This is informative, but given that these data
are entirely subjective it clearly has major limitations. Indeed, the limitations innate to
self-report data are likely particularly prescient when considering reasons for
substance misuse, given that denial and rationalisation are believed to play such a
considerable role in the maintenance of these behaviours.154 A comprehensive review
of the most prominent theories postulated to explain this association, together with a
critical evaluation of the evidence underlying them, is thus necessary. In the following
section I will review these data. The three dominant theories postulated to explain the
association are detailed below:
1. Schizophrenia causes substance use (self medication)
2. Substance misusers are at greater risk of developing schizophrenia
3. Common causality- the same people are at increased risk of substance misuse and
schizophrenia
As was discussed in Section 3.1, it is easily conceivable that the association between
substance use and schizophrenia differs for different substances. This being the case,
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when possible data relating to each of the substances detailed earlier as of particular
interest to the current study will be considered separately.
3.2.1 Schizophrenia causes substance misuse (the selfmedication hypothesis)
When asked why they use substances people with schizophrenia frequently
report that it is for relief of sympotms. In theory, this drive could arise from a desire to
alleviate either symptoms arising from the condition itself, or side-effects consequent
to the use of medications prescribed with the intention of providing relief from the
symptoms of schizophrenia. Thus, both of these possibilities will be explored. This
discussion will begin with consideration of the possibility that having schizophrenia
results in people having a greater tendency to self-medicate with any drugs of abuse.
Given that the effects of different drugs are pharmacologically diverse however, I will
then consider this possibility for each of the drugs of abuse considered in this study;
these are specifically tobacco, alcohol, cannabis, stimulants (amphetamine and
cocaine) and ecstasy.
How can the selfmedication hypothesis be explored?
The central argument of the self medication hypothesis is that people use
drugs to alleviate symptoms. This hypothesis has been particularly associated with
Khantzian, who proposed it in 1985 in a formulation largely based on psychodynamic
theory.155 Khantzian believed that a drug users' choice of drug is a result of an
interaction between the psychopharmacological properties of the drug and the
affective states from which the addict was seeking relief, meaning that the drugs
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chosen by an individual could be predicted on the basis of their psychiatric disorder.
As initially formulated this theory suggested that all people with schizophrenia would
be driven to use the same drugs. It was subsequently refined however, with greater
emphasis placed on the possibility that it was specific symptoms rather than the entire
disorder which provided the drive to use specific drugs.156
Given the above, if we are to be able to ascertain if the drive to use substances
does indeed derive from an attempt to address specific symptoms, then clearly we
need to know what these symptoms are. Thus, before considering this potential
explanation further, it is important to characterise what are the symptoms of this
condition. These are outlined in detail in Table 3.2, though in practice are most
commonly categorized as either positive symptoms, (essentially delusions and
hallucinations), and negative symptoms, (symptoms such as lack ofmotivation, an
inability to experience pleasure, and blunted affect).
Either at least one of the syndromes, symptoms, and signs listed under (1) below, or at least two of the
symptoms and signs listed under (2) should be present for most of the time during an episode of
psychotic illness lasting for at least one month (or at some time during most of the days).
(1) At least one of the following must be present:
(a) thought echo, thought insertion or withdrawal, or thought broadcasting;
(b) delusions of control, influence, or passivity, clearly referred to body or limb movements or
specific thoughts, actions, or sensations; delusional perception;
(c) hallucinatory voices giving a running commentary on the patient's behaviour, or discussing the
patient among themselves, or other types of hallucinatory voices coming from some part of the body;
(d) persistent delusions of other kinds that are culturally inappropriate and completely impossible
(e.g., being able to control the weather, or being in communication with aliens from another world).
(2) Or at least two of the following:
(a) persistent hallucinations in any modality, when occurring every day for at least 1 month, when
accompanied by delusions (which may be fleeting or half-formed) without clear affective content, or
when accompanied by persistent overvalued ideas.
(b) neologisms, breaks, or interpolations in the train of thought, resulting in incoherence or
irrelevant speech;
(c) catatonic behaviour, such as excitement, posturing or waxy flexibility, negativism, mutism, and
stupor;
(d) "negative" symptoms, such as marked apathy, paucity of speech, and blunting or incongmity of
emotional responses (it must be clear that these are not due to depression or to neuroleptic medication)
Table 3.2
ICD-10 general diagnostic criteris for schizophrenia
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As will become apparent, the self medication hypothesis is notoriously
difficult to prove or disprove. It may be expected that if it can be demonstrated that
use of a particular drug does result in reduced experience of a particular symptom
then this provides support for self-medication. This seems fairly logical, but is
complicated by the fact that the acute and chronic effects of use of a particular drug
may be quite different. Examples of this abound, but it is possibly best illustrated by
the well recognised fact that though the acute effects of alcohol are anxiolytic, when
used chronically alcohol is associated with anxiety disorders.137 Nevertheless, it may
be the case that short term benefit is worth longer term worsening of symptomatology.
Indeed, persistence of substance-taking behaviours in the face of overt evidence of
harm is a central feature of addictions, constituting the essence of one of the DSM-IV
and ICD-10 criteria for the diagnosis of dependence.23'158 It would be expected that
perceived or experienced short term benefits of substance use must play a significant
role in these ongoing behaviours. Thus, despite the proviso outlined above,
investigation of the possibility that the pharmacological effect of drugs of abuse may
provide even temporary relief from the experience ofpositive, negative and other
symptoms of schizophrenia is clearly necessary.
An alternative way to investigate the self medication hypothesis is to establish
if the symptoms experienced by those who have both schizophrenia and a substance
misuse problem are significantly different from those with schizophrenia alone. It
may be expected, for example, that if a specific drug of abuse genuinely alleviates the
experience of a particular symptom, then people with both schizophrenia and habitual
use of this drug would experience a lesser magnitude of this particular symptom than
those with schizophrenia alone. Again however, the fact that this is genuinely the
reason for an association between use of a particular substance and schizophrenia is
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very difficult to support or disprove. It could equally be argued that the association of
more severe illness with a greater level of drug use is because people with a more
severe illness have a greater need for some relief or, and completely contrary to the
self medication hypothesis (and as will be discussed later), that this level of substance
use has actually contributed to the severity of the illness experienced. The self
medication hypothesis will now be considered for each of the substances of particular
interest to this report.
3.2.1.1 Cannabis
As reviewed in Section 3.1, people with schizophrenia who used cannabis
reported a number ofpositive effects (e.g. relaxation, increased pleasure and increased
sociability), though there was some acknowledgement that use of this drug could
result in worsening of psychotic symptoms. Delta-9-tetrahydrocannabinol (THC) has
long been recognised as the principle active ingredient in cannabis,159 and a number of
studies have experimentally investigated the effects of this drug in normal subjects. In
addition to THC however it is now also known that a further cannabinoid present in
cannabis, cannibidiol, may also have an impact on the mental state (see below). This
illustrates the heterogeneity of what is known as cannabis, and the fact that different
strains with different THC/cannabidiol ratios can potentially have different effects.
Given this, in the passage below I will review the psychiatric effects of each of THC,




It is widely accepted that cannabis produces euphoria and relaxation,
perceptual alterations, time distortion, and the intensification of ordinary sensory
experiences, such as eating, watching films, and listening to music.160 It is also
accepted that cannabis use can cause unpleasant side effects, most commonly anxiety
and panic attacks.160 Though these effects are accepted as almost common knowledge
however, modem studies that have actually investigated the acute effects of cannabis
use in the general population are few. This is understandable; given that cannabis is a
controlled substance which can potentially cause harm such studies are difficult to
conduct experimentally. Thus, much of these data rely on self-report. It would be
expected that such reports would have the greatest chance ofbeing accurate if the
nature of the subjective experience was ascertained shortly after exposure. Reflecting
this expectation, Verdoux et al. undertook a naturalistic study with 79 cannabis-using
university students.161 Employing an experience-sampling method, they aimed to
achieve recording of both cannabis use and symptom experience at the times they
were actually occurring. They reported that within this non-clinical population there
was a positive association between cannabis use and the experience of unusual
perceptions. Interestingly, even though subjects with high psychosis vulnerability
were more likely to report unusual perceptions and feelings of thought influence in
periods of cannabis use, the above association was observed even when psychosis
proneness was included into the statistical model. The investigators also reported that
the effects of cannabis were time-limited and restricted to the 3 hours surrounding its
consumption, with no evidence that use of cannabis is increased following the
occurrence of psychotic-like experiences.
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A recent study investigated the acute effects of cannabis use in an indisputably
experimental manner.162 This was achieved by assessing individuals 10-15 minutes
after smoking a cannabis 'spliff (from participants own cannabis supply). In this
study it was again reported that cannabis use reliably increased the experience of
psychotic-type symptoms across all users; as in the previous study this effect was
particularly pronounced in people with increased psychosis-proneness (determined on
the basis of high scores on the Schizotypal Personality Questionnaire). The idea that
underlying psychosis proneness may influence the experience of cannabis use has
actually gained increasing credence in this research area, and will be discussed further
below.
It is more practicable to experimentally investigate the effects of THC
administration than those of the native compound. A number of studies have
evaluated the consequences of THC exposure in the general population, assessing this
by self-report as well as formal cognitive/psychomotor testing. The most influential
was that of D'Souza et al., in which THC was administered by intravenous
infusion.163 This study suggested that though THC administration did result in the
transient experience of euphoria, it also increased anxiety and resulted in positive-type
symptoms which included suspiciousness, paranoid and grandiose delusions,
conceptual disorganization, and illusions. Subjects also manifested negative-type
symptoms, which including blunted affect, reduced rapport, lack of spontaneity,
psychomotor retardation, and emotional withdrawal. Other studies have shown similar
effects of THC administration,164' 165and additionally demonstrated that use of the
drug impairs executive function and inhibits motor control.165'166 It has also become
increasingly apparent that the adverse effects associated with THC use may only
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become evident at higher doses of the drug,166and that habitual cannabis users may
develop a degree of tolerance to these effects.167
As noted above, though the effects of drug exposure in the normal population
are informative, it is conceivable that these could be altered in people with
schizophrenia. One study has however managed to experimentally determine the
effects of THC administration in people with schizophrenia. This was again
undertaken by D'Souza et al., and consisted of the administration of either Omg,
2.5mg or 5mg of THC intravenously, followed by clinical, neurochemical and
neuropsychological assessment for a period of 200 minutes afterwards.168 This study
found that THC transiently exacerbated a range of positive and negative symptoms,
perceptual alterations, cognitive deficits, and medication side effects associated with
schizophrenia. The effects on learning and memory were even more pronounced than
had been observed when the same methodology was employed on a group of well
control subjects. In addition, subjects with schizophrenia seemed to be more
susceptible than controls to the effects of THC on the experience ofpositive
symptoms, though this did not reach statistical significance. Cannabis administration
did not produce any obvious "beneficial" effects; specifically, there was no suggestion
that it was associated with a reduction in anxiety. The results of the study were thus
consistent with other studies suggesting that cannabis has a negative influence on the
symptomatology of schizophrenia, and did not provide evidence that would support
the self-medication hypothesis as an explanation for the co-occurrence of
schizophrenia and substance misuse.
As was acknowledged by D'Souza et al. in the above paper, it is conceivable
that though THC does not have beneficial effects on schizophrenia symptomatology,
other substances present in cannabis may. Though THC is generally accepted as the
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principle active ingredient in cannabis, it is only one of many compounds present in
the substance. Indeed, in recent years there has been renewed interest in another
compound long recognised as being present in cannabis called cannabidiol (CBD). As
early as the 1970s, it was suggested that cannabidiol may reduce the anxiety
associated with THC administration,169 an effect that was reproduced by Zuardi et al.
in 1982.170 The distinct effects of cannabidiol compared to THC have also been
demonstrated using functional imaging techniques.164'171 It has also been
demonstrated that when administered with THC to a normal population, as well as
having anxiolytic effects cannabidiol can also attenuate the psychotogenic effects of
170 171
the latter drug. ' Additionally, even if it is administered in the absence of THC
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cannabidiol can have anxiolytic effects.
In keeping with the above findings, it has recently been suggested that
cannabidiol may have beneficial effects on schizophrenia symptomatology, and that it
may even have antipsychotic properties.173 Indirect evidence of such an effect has
been provided by a study which demonstrated that the experience of psychotic-type
symptoms was in fact rarer in people who consumed cannabis with higher ratios of
cannabidiol to THC.174 It is important however to establish if there is direct evidence
for the cannibidiol having beneficial effects in people with schizophrenia; clearly if
this were the case it would support the possibility that people with schizophrenia may
indeed consume cannabis for the potential benefits that one of the components of this
substance can confer.
Though there are a number of annedotal reports of cannabidiol having
beneficial effects for psychotic symptoms in schizophrenia,173'175 to date only one
randomised controlled trial employing cannabidiol in the treatment of psychotic
patients has been undertaken. Only preliminary reports have been published from this
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trial at the time of writing. Over a four week period the effects of CBD and
amisulpride were compared in the treatment of acute schizophrenic and
• _ i -if.
schizophreniform psychosis. This showed that CBD significantly reduced acute
psychotic symptoms after 2 and 4 weeks of treatment when compared to baseline. In
this trial CBD did not differ from amisulpride except for a lower incidence of side
effects. Though this is the only trial of the clinical use of cannibidiol in schizophrenia,
when combined with evidence that cannabiol has beneficial effects in animal models
predictive of antipsychotic activity,177 it does suggest that cannabidiol may have the
potential to improve the symptoms of schizophrenia.
In summary, there is little evidence from the few experimental studies that
have investigated the effects of cannabis use on symptomatology that it provides relief
from the symptoms of schizophrenia. It seems even less likely that THC, the
substance primarily responsible for the psychoactive effects of cannabis, has any
beneficial effects on symptomatology associated with the condition. It is conceivable
however that cannabidiol, a substance which was long thought to be an inactive
component of cannabis may indeed confer some potentially beneficial effects; so
much so that it has been trialled as an antipsychotic. This underlines the importance of
viewing cannabis as an entity with a variety of components, and considering that the
relative proportions of these various components can influence the effect a user
experiences from cannabis use. It also raises the issue that different strains of cannabis
may have different effects, and that skunk (a variety of cannabis with a very high
THC:CBD ratio) may have particularly propsychotic effects. As mentioned above,
this is an area of active research.174
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Non-acute effects
A further potentially useful source of information on the effects of cannabis
use on symptomatology experienced in schizophrenia is to compare the symptoms
experienced by subjects with schizophrenia who use the drug compared to those who
don't. Such observational study is inevitably vulnerable to innumerable confounders
and the difficulty of disentangling cause and effect. It may be expected however that
if cannabis use confers benefits people who use the drug would experience a milder
profile of symptoms. Conversely, a detrimental effect could mean that users are more
impaired. The association of cannabis use with positive, negative and depressive
symptoms will be considered separately.
A number of cross-sectional studies have compared positive symptom
expression in people with schizophrenia who use cannabis to those who do not.
Interestingly however this is not an area which has been subject to systematic review;
this likely reflects the difficulties in both aggregating data from studies with disparate
methodologies and of differentiating what are and are not intoxication effects.
Unsurprisingly given the propsychotic effects of cannabis consumption, these studies
generally report increased positive symptoms in people with schizophrenia who
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consume cannabis; ' this is not a universal finding however, ' and a report to
the contrary (i.e. that people with schizophrenia who consume cannabis exhibit
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reduced psychotic symptoms) does exist.
In 2006 Potvin et al. published a meta-analysis of case-control studies
comparing ratings of negative symptoms (as measured by the SANS) in people with
schizophrenia who did and did not use cannabis. On pooling results from the three
studies eligible for conclusion, they determined that those people with schizophrenia
who used cannabis did experience significantly fewer negative symptoms than
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1 • • l82abstinent subjects. Additionally, Potvin et al. undertook a meta-analysis comparing
the weight of depressive symptoms in people with schizophrenia who used cannabis
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compared to those who did not. Though only two studies were identified explicitly
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addressing this question, ' they did not suggest that there was a difference in
depressive symptoms between the two groups. This is further evidence that cannabis
is not effective in relieving dysphoria/low mood when used by this population.
Synthesis of the above data suggests that use of cannabis by people with
schizophrenia is likely associated with a greater weight of positive symptoms, is
associated with a lesser load of negative symptoms, and is not associated with any
difference in depressive symptoms. It could be argued from these data therefore that
cannabis may serve to attenuate negative symptoms. Given the nature of these cross-
sectional data however, such a conclusion would seem a step too far; it is of course
equally eminently possible that the association occurs in the opposite direction i.e.
people with schizophrenia with fewer negative symptoms are more likely to use
cannabis.
Impact ofcannabis use in individuals with the extendedphenotype ofschizophrenia
The consequences of cannabis use by people with the extended phenotype of
schizophrenia may also be informative. The concept of the extended schizophrenia
phenotype derives from the observation that the relatives of people with schizophrenia
frequently exhibit subclinical, psychotic-type symptoms bearing marked similarities
to the symptoms of schizophrenia. These include positive symptoms, such as unusual
belief systems and perceptual experiences, and negative symptoms in the form of
social withdrawal, anxiety, and depression.18" These are known as 'schizotypal
symptoms', and the extended phenotype of schizophrenia as 'schizotypy' (discussed
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further in Section 4.2.2.3). Schizotypy exhibits developmental as well as genetic links
to schizophrenia, with elevated rates of schizotypal traits being present in both those
destined to develop schizophrenia as well as in relatives of individuals with the
condition. It is generally regarded as being a milder phenotypic expression of
schizophrenia.186 The utility of studying individuals such as these derives from the
fact that the impact of cannabis use can be ascertained in individuals who exhibit
schizophrenia-like characteristics, but are not subject to the potential confounders of
chronic illness and medication.
It could be speculated that though cannabis use may make established
psychotic symptoms worse, it is actually beneficial when these are expressed in a
milder form. Given that there are high rates of schizotypal symptoms in people
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destined to develop schizophrenia, this could initiate the association observed m
those with established schizophrenia. That an association between schizotypy and
cannabis use exists has been demonstrated in cross-sectional studies in the general
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population. Interestingly however, and as has already been discussed (above),
Verdoux et al. reported that in the general population increased psychosis-proneness
was associated with people being more likely to report unusual perceptions and less
likely to report pleasurable experiences on using the drug.161 Supporting these
findings, Barkus et al. also reported that those with higher ratings of schizotypy were
more likely to experience psychotic symptoms on exposure to cannabis and were also
more likely to report unpleasant, dysphoric/amotivational-type after effects following
use of the drug.189'190 Similarly, in a prospective study of a cohort at clinically high
risk of schizophrenia, (help-seeking adolescents and young adults considered to be at
heightened clinical risk for or prodromal to a nonaffective psychosis), longitudinal
assessments showed participants to have significantly more perceptual disturbances
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and worse functioning during epochs of increased cannabis use.191 These findings are
similar to those in studies of established schizophrenia, and suggest that in the context
of schizotypy/schizophrenia prodrome cannabis use is once again associated with both
the induction of psychotic symptoms and general unpleasant effects; once more this is
difficult to reconcile with the self-medication hypothesis. A single experimental study
provides further support that psychosis-prone individuals are particularly vulnerable
to the psychotogenic effects of cannabis.162 It demonstrated that following
administration of THC these individuals do indeed experience enhanced
psychotomimetic states compared to those who are less psychosis prone. The
induction of additional pleasant or unpleasant effects was however not ascertained in
this study.
Summary
On considering the studies reviewed above, data supporting the self-
medication hypothesis as an explanation for the association between schizophrenia
and cannabis use are weak. Though one constituent of the drug (cannabidiol) may
have beneficial effects, use of the substance as a whole worsens both anxiety and
psychotic symptoms. These effects likely also occur in the extended phenotype of
schizophrenia. Interestingly, it seems likely that the negative effects of cannabis use
have become more pronounced as the concentrations of THC in cannabis have
increased. There is no experimental evidence that any of the constituents benefit
negative symptoms, suggesting that the suggestion of such an association by case-
control studies is more likely attributable to people with schizophrenia with fewer
negative symptoms being more likely to use the drug.
82
3.2.1.2 Alcohol
As discussed in Section 3.2, common reasons people with schizophrenia give
for alcohol use are to reduce anxiety and elevate mood, with relatively fewer reporting
that it alleviates psychotic symptoms; indeed, it is in fact more commonly reported
that it makes the latter symptoms worse. It is of course the case that self-reported
reasons for behaviour are potentially unreliable, being prone to problems such as
recall bias. As discussed above, when considering substance use this unreliability is
likely magnified even further, being influenced by the denial and rationalisations so
much a part of these conditions. Clearly it is thus desirable to obtain experimental
data, utilising robust methodology to characterise the objective effects of alcohol use
in schizophrenia. If these effects can be compared to those in a normal population,
then any differences may offer some insight in to why people with schizophrenia are
particularly prone to use alcohol.
The acute effects of alcohol use in the normal population have been well
1 0?
characterised. At low doses (1-2 drinks, but it varies among individuals), alcohol
tends to produce relaxation, reduced inhibitions, impaired concentration, slowed
reflexes, reduced reaction time, and reduced concentration. As consumption increases
these effects are magnified, with the onset of slurred speech and difficulty in walking
at blood alcohol concentration levels of 0.15-0.2%. At 0.3% most people will be on
the verge of unconsciousness or be comatose, and death is possible at levels of 0.35-
0.4%.
Only a single study could be identified which used experimental methodology
to investigate the effect of alcohol on the experience of symptoms of schizophrenia.
This was a randomized, double-blinded, placebo-controlled controlled study, which
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compared the effects of alcohol exposure in 23 patients with schizophrenia (treated
with antipsychotics and without a diagnosis of an alcohol use disorder) to that in 14
193 • •
healthy controls. Neither patients nor controls had any history of an alcohol use
disorder. Relative to healthy subjects, people with schizophrenia reported greater
euphoria and stimulatory effects in response to alcohol. In the people with
schizophrenia alcohol also produced small transient increases in positive psychotic
symptoms and perceptual alterations but did not affect negative symptoms. On
cognitive testing alcohol also impaired several aspects of immediate and delayed
recall, vigilance and distractibility; although people with schizophrenia tended to
perform worse on these measures, there was no significant group by alcohol dose
interaction.
D'Souza et al. conclude that their results do not support the 'self-medication'
hypothesis of alcohol and substance use in schizophrenia, as alcohol did not reduce
any of the core symptoms of the illness. They do acknowledge that exclusion of
alcohol-abusing subjects opens up the possibility that a subset of individuals who may
derive these benefits from alcohol were not part of the study; it is notable however
that their finding do seem to parallel those from self-report studies which did include
such groups. While alcohol did not relieve psychotic symptoms, D'Souza et al. do
suggest that the increased euphoric and stimulatory responses to alcohol observed in
schizophrenia patients compared to controls may increase their vulnerability to
alcohol problems. These findings suggest the possibility of a 'shared vulnerability' to
alcohol problems and schizophrenia (as proposed by Chambers et al., and which will
be discussed later); while they speculate that brain reward circuitry dysfunction may
explain these increased effects, D'Souza et al. do acknowledge that treatment with
antipsychotic drugs could also play a role.
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Studies investigating the association between chronic alcohol use and scores
on schizophrenia rating scales will be discussed below. The manner in which studies
were undertaken means that these data are most appropriately considered with studies
exploring the associations between substance use and outcomes of schizophrenia.
Also relevant to discussion in this section however is the limited evidence base
exploring the acute effects of alcohol on symptom expression through the utilisation
of observational methodology. This consists of a single study undertaken by Alterman
et al., which utilised nursing notes and interviews with nursing staff to characterise
the acute effects of alcohol consumption in inpatients with schizophrenia who became
intoxicated with alcohol during the course of their inpatient care.194 Unspecified
changes in sleep pattern, mood and behaviour were reported in 22 out of 25 patients.
It is also reported that 'hallucinations' occurred in over a quarter ofpatients.
Unfortunately the symptomatology experienced by patients who use alcohol in this
study is too poorly characterised to add substantially to data provided by D'Souza et
al. No studies were identified exploring the effects of alcohol in people with the
extended phenotype of schizophrenia.
3.2.1.3 Smoking
Acute effects
As detailed in section 3.1, tension reduction/relaxation effects are repeatedly
reported by smokers as beneficial effects of tobacco use. Nicotine is the component of
tobacco generally regarded as responsible for its psychoactive effects,195 and
consequently would be expected to produce these effects in experimental conditions.
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It is somewhat surprising therefore that meta-analysis of placebo-controlled laboratory
studies of the subjective effects of nicotine reported that it actually decreased
relaxation and increased tension/jitteriness.196 Though this could potentially be
explained by participants not being tolerant to tobacco, such an explanation is in fact
not feasible as this effect was observed in smokers as well never-smokers.
It is also widely believed that smoking tobacco has beneficial effects on
attention and memory.197 The evidence supporting these purported cognitive benefits
is rather stronger; for example, a number of studies have reported that in nicotine-
dependent smokers, nicotine administration is associated with improved performance
on tasks that require vigilant attention.197 Additionally, and regardless of smoking
status, nicotine administration also has been reported to improve reaction time.198
The above data provide some interesting insights. Firstly, it establishes that
though smoking does not result in relaxation, it may indeed convey some cognitive
benefits in the general population. Secondly, it also demonstrates that the benefits that
users perceive from smoking can bear little relation to the experimentally derived
effects of use of the drug; i.e. non-experimental self-reported accounts of the effects
of substances need to be treated with considerable scepticism. Importantly however,
while experimental data elucidating the effects of smoking in the general population
are interesting, it is of course the case that the effects experienced by people with
schizophrenia could potentially differ substantially. It is thus once again the case that
if we are to ascertain whether the self-medication hypothesis does have any validity in
explaining the association between smoking and schizophrenia it will be essential to
establish (via experimental means), what the effects of smoking actually are in this
specific population. Furthermore, studies which specifically investigate if the effects
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of tobacco use/nicotine administration do differ between those with and without
schizophrenia will be particularly informative; if such a difference does exist then it
may also go some way to explaining why people with schizophrenia have an
increased level of tobacco use. A number of studies have addressed exactly these
issues; those which assess the effects of nicotine administration in people with
schizophrenia, either with or without a comparator group of non-schizophrenic
controls, will be discussed below.
Studies have utilised a variety of experimental designs to ascertain the effects
of nicotine administration in people with schizophrenia. Smoking status has ranged
from schizophrenic non-smokers to schizophrenic smokers who have been abstinent
overnight. Consistent with findings in the non-schizophrenic population, smoking by
people with schizophrenia has been shown to improve sustained attention, spatial
accuracy and verbal memory. It also increases prepulse inhibition, a form of startle
plasticity which has been reliably demonstrated to be reduced in people with
schizophrenia.199 Smoking thus has a normalising effect on this abnormality. Even
more interestingly, in studies including a non-schizophrenic control group it was
demonstrated that the attentional effects are greater in schizophrenic than other
smokers,200 and this may be particularly true for response inhibition.201
In addition to cognitive benefits, there is also evidence that smoking cigarettes
may provide some relief from the negative symptoms experienced by people with
schizophrenia. This was suggested by a study of Smith et al., which demonstrated that
the smoking of high-nicotine cigarettes resulted in a reduction in negative symptoms
without affecting positive symptoms.202 This effect was not observed in participants
who smoked de-nicotinized cigarettes. It has been suggested that this effect may be a
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consequence of nicotine raising dopamine levels in the nucleus accumbens and
prefrontal cortex.199
There is also evidence that smoking may help reduce unpleasant side effects of
neuroleptic medication, an effect which may arise through a number of mechanisms.
Firstly, there are reports that smoking increases the metabolism of antipsychotics, an
effect which would obviously result in reduced side affects (as well, of course, as
reduced efficacy).203 There have also been reports however that the benefits of
smoking on antipsychotic side effects may also be more specific. It has been reported,
for example, that application of nicotine patches results in a reduction of antipsychotic
induced rigidity and akathisia,204'205 it being suggested that nicotine-induced
dopamine release may be responsible for this effect.199 In keeping with these potential
benefits a relationship between antipsychotic treatment and smoking has long been
recognised, McEvoy et al. demonstrating in 1995 that patients with schizophrenia
smoke more after starting haloperidol.206
Non-acute effects
An observational, non-experimental, methodology which could yield insights
in to the effects of tobacco use on schizophrenia symptomatology is to compare this
symptomatology in people with schizophrenia who smoke and do not smoke. An
example of a study employing such an approach is that of Zabala et al., who reported
that first-episode psychosis patients who are nicotine users had better cognitive
functioning in the areas of attention and working memory than patients who were not
nicotine users.207 No significant differences were detected in sociodemographic and
clinical data between the two groups, and they attributed these differences to
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beneficial effects of smoking. Obviously, this form of study design is highly
vulnerable to unidentified confounders, but it is interesting that similar associations
are reported with smoking to those in experimentally designed studies outlined above.
Impact ofsmoking in individuals with the extended phenotype ofschizophrenia
The impact of smoking on symptomatology in people with the extended
phenotype of schizophrenia may also be informative. As previously emphasised, these
data have the particular advantage ofbeing able to demonstrate associations without
the confounds of chronic illness and medication. A number of different approaches
have been employed in exploring the relationship between the extended phenotype of
schizophrenia and smoking, these focusing on individuals sharing genetic and/or
symptomatic characteristics with people with schizophrenia. The increased rates of
smoking in those sharing familial characteristics with people with schizophrenia has
been most convincingly demonstrated in a twin study investigating smoking rates in
twins of people with schizophrenia. This study found that unaffected co-twins had a
frequency of ever daily smoking (88%) similar to that in male schizophrenia probands
(83%) and higher than male twin controls (66%). The OR of ever daily smoking for
the co-twin of a schizophrenic proband were 3.7 times greater than the odds of being a
regular smoker among twins from pairs in which neither has schizophrenia.208
Other studies have focused more explicitly on the relationship between
schizotypy and smoking. These have reported both that smokers are more likely to
report schizotypal symptoms,209and that a significant relationship exists between
smoking status and self-reported levels of schizotypy. Indeed, the latter has been
reported in both the general population and in relatives ofpeople with
210
schizophrenia." There are thus data to support the suggestion that schizophrenia
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spectrum disorders (as well as the condition itself) are associated with an increased
risk of smoking. What has not been ascertained however is what the experimental
effects of nicotine administration are in the extended phenotype of schizophrenia, and
if use of the drug by this population does confer benefit. Thus, though the data
outlined above do demonstrate that schizotypy itself is associated with schizophrenia,
they do not inform us if this relationship s driven by the beneficial effects of tobacco
use on the extended phenotype. Thus, though the positive relationship between
schiztypy and smoking may be driven by the fact that those who are more schizotypal
have a greater need for the beneficial effects of tobacco use, the association could
equally be driven by the fact that the two are independently attributable to one or
more common risk factors.
Nevertheless, as the current study is concerned with people at high genetic risk
of schizophrenia (which is, of course itself associated with schizotypy), the finding
that schizotypy itself is associated with smoking is certainly interesting. It is
conceivable that, just as schizophrenia patients might smoke in order to self-medicate
cognitive deficits present after the onset of psychosis, so those at elevated genetic risk
of the condition might smoke more in an attempt to use nicotine to self-medicate their
premorbid cognitive dysfunction. There is certainly substantial evidence that such
deficits exist in this group,211 indicating that the high risk group under investigation in
the current study may already be at elevated risk of using tobacco to alleviate
cognitive deficits that they already posses, even in the absence of frank psychosis.
Thus, it is conceivable that even in the currently well high risk group that is the focus




It is thus the case that the data detailed above demonstrate a number of reasons
for an association between smoking and schizophrenia, each of which likely
contributes to the high prevalence of smoking in the condition. On considering these
data the possibility that self-medication may play a role in bringing about the
association between smoking and schizophrenia cannot be discounted. A drive to
ameliorate pre-existing cognitive deficits present in those destined to develop
schizophrenia may place them at an elevated risk of smoking even before illness
onset; following onset of psychosis the beneficial effects of cigarette smoking on
worsening cognitive deficits, negative symptoms and the effects of antipsychotic
treatment may magnify this drive.
3.2.1.4 Stimulants and ecstasy
Given the centrality of the observation that stimulants could provoke psychotic
symptoms in people without schizophrenia (see Section 2.2), the suggestion that the
association between amphetamine use and schizophrenia may be driven by self-
medication may seem counter-intuitive. Indeed, as previously discussed, it is
indisputably the case that drugs such as amphetamines have a particularly
psychotomimetic effect in people with schizophrenia and clearly worsen psychotic
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symptoms. A number of researchers have however suggested that stimulant drugs
may have beneficial effects on the negative symptoms of schizophrenia, and a number
of trials have been undertaken investigating these effects. These trials have generally
employed modafanil, a drug regarded as having similar but milder effects to
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amphetamines and possessing little abuse potential.212 A small number of studies have
utilised amphetamine however.
Angrist et al. administered 0.5mg/kg of J-amphetamine to 26 clinically stable
patients with predominantly 'deficit state' schizophrenia who were not receiving
antipsychotic treatment at the time of the experiment.213 Over the next three hours,
though a minority of patients did exhibit clinical deterioration, overall a statistically
significant decrease in negative symptoms as measured by the BPRS was observed.
These findings were not confirmed in a subsequent similar study, though it was the
case in this later study that some diminution of negative symptoms was observed in
the subset ofpatients with more severe negative symptoms.214 This led the authors of
the latter study to speculate that for amphetamine to effect a change in negative
symptoms, then these symptoms must be relatively severe; this explanation was
indeed compatible with their own data and the previously published studies they
reviewed. That amphetamine may confer some benefit in patients with schizophrenia
is also suggested by a study reporting improved performance on the Wisconsin card
sort test (WCST, one of the most commonly used tests of executive function) in
schizophrenia subjects administered the drug.215 Additionally, studies demonstrating
the beneficial effects of modafanil on cognition in schizophrenia are also in-keeping
with these findings.216 Adding to these studies, Kirrane et al. reported that
amphetamine administration improved visuospatial working memory in a sample of
people with schizophrenia-spectrum personality disorders (predominantly schizotypal
personality disorder); this effect was greater than that seen in a comparator group of
normal controls.217
As was discussed in relation to cannabis, some insight may be provided on the
effect of stimulant use on symptoms of schizophrenia by comparing symptom profiles
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in people with schizophrenia who do and do not use these drugs. Unfortunately
however no studies could be identified specifically comparing positive, negative or
depressive symptom severity in schizophrenic patients who used amphetamines to
those who did not; in all studies which could potentially have provided this
information amphetamine users were grouped together with users of other drugs.
No experimental studies have been undertaken examining the effects of cocaine on
symptoms of schizophrenia. It has been reported however that schizophrenic patients
who had recently used cocaine exhibited fewer negative symptoms than those who
218had not. Additionally, three studies assessed positive symptom severity in
schizophrenic subjects shortly after admission with an acute psychotic exacerbation.
These reported that estimates of positive symptom severity are similar in
schizophrenic patients who used cocaine to those who did not.219"221 Meta-analysis
reports that people with schizophrenia who use cocaine experience fewer negative
symptoms but similar levels of depressive symptoms when compared to abstinent
182 183
patients. ' Smelson et al. have reported that there is no difference on cognitive
testing between people with schizophrenia who use cocaine compared to those who
222do not. Two studies undertaken by Serper et al. have however reported that
comorbid patients do exhibit memory impairments compared to non-using patients
with schizophrenia.223 No studies could be identified examining the effects of MDMA
on the symptoms of schizophrenia.
Data on the effects of stimulant use in people with schizophrenia spectrum
(personality) disorders arc limited. In addition to the study of Kirrane et al. detailed
above and undertaken in people with predominantly schizotypal personality disorder,
Satel and Edell did report that cocaine users who experience transient paranoia while
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intoxicated exhibited more traits of psychosis-proneness than individuals who did not
have transient cocaine-induced paranoid symptoms.224
In summary therefore, experimental data are compatible with the possibility
that though stimulant use (either amphetamines or cocaine) can temporarily relieve
negative symptoms, it results in a worsening ofpositive symptoms of schizophrenia.
Cross-sectional data in this area are sparse, but what does exist is also compatible with
the former possibility. As was discussed in relation with cannabis however, cause and
effect is impossible to disentangle from these cross-sectional data, which limits their
usefulness. Nevertheless, taken as a whole the existing data are compatible with the
possibility that people with schizophrenia do indeed use stimulant drugs in an attempt
to relieve negative symptoms.
3.2.1.4 Synthesis of data examining the viability of the self-medication hypothesis as
an explanation for the association between substance misuse and schizophrenia
As reviewed above, there are considerable data relevant to consideration of the
validity of the self-medication hypothesis as an explanation for the association
between schizophrenia and substance use. On reviewing these data, two principles
stand out as fundamentally important in establishing if evidence supports this
hypothesis: firstly, it is important to look beyond a conceptualisation of schizophrenia
as simply psychotic symptoms and also to consider the cognitive, affective and
motivational features of the condition; and secondly, the diverse pharmacological
effects of drugs of abuse does justify considering these substances separately. When
this is done a number of conclusions can be drawn:
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1. None of the substances investigated appear to have any significant effect in
attenuating positive psychotic symptoms. Conversely stimulants, cannabis and
possibly even alcohol worsen the experience of psychotic symptoms. Indeed,
people with schizophrenia/on the schizophrenia spectrum appear to be
particularly sensitive to the psychotomimetic effects of these substances.
2. Stimulants and possibly also tobacco smoking may result in a mild attenuation
of negative symptoms.
3. Tobacco smoking and possibly also stimulant use may transiently benefit a
number of cognitive deficits, such as attentional and memory impairment.
4. Alcohol may transiently elevate mood and relive anxiety, and it is possible that
people with schizophrenia are particularly susceptible to the euphoric and
stimulant effects of this drug.
It is thus the case that overall the existing data suggest that self-medication, if this is
interpreted as relief of psychotic symptoms, is not a feasible explanation for the
association between substance misuse and schizophrenia. Nevertheless, particular
substances may have some beneficial effect on symptoms associated with the broad
phenotype; evidence for this seems to be particularly strong for tobacco improving the
attentional deficits associated with the condition.
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3.2.2 Substance use causes schizophrenia or influences the course ofthe condition
Schizophrenia is the archetypal form of insanity, and throughout times and
cultures has inspired intense fear in the general population.223 Given that this fear of
insanity is such a core feature of the human condition, it is understandable that the
introduction of psychoactive drugs in to societies, particularly if they are believed to
provoke psychotic symptoms, is frequently associated with widespread concern that
use will lead to massively increased rates of schizophrenia. Such a response followed
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widespread use of both cannabis and LSD in the 1960s, ' and remains a
preoccupation with the popular press.228 Clearly schizophrenia cannot be entirely
attributable to drug use, given that it is recognised to occur in both people and
societies with very low or even non-existent levels of use of these substances.
Nonetheless, it is conceivable that use of a particular drug does contribute to the risk
of developing the condition without this use being an invariable prerequisite for the
condition to occur. Such a model of contribution to risk would both be compatible
with the occurrence of the condition in the absence of any drug use and also be a
potential explanation for the increased prevalence of substance use in schizophrenia;
as people who use drugs are at increased risk of developing the condition, so drug use
and schizophrenia co-occur more commonly than would be expected by chance. As
discussed in Section 3.2.1, it is an undeniable fact that drugs such as amphetamines
and cannabis can provoke psychotic symptoms in the normal population, and that
people with schizophrenia are particularly susceptible to these effects. Thus, the
possibility that drug use can increase the risk of develop schizophrenia (as well as the
experience of transient psychotic symptoms) does demand serious consideration.
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In examining the evidence for the possibility of drug use contributing to risk of
schizophrenia, each of the drugs of abuse that are the focus of this study will be
considered individually. Data will primarily be derived from epidemiological and
cohort studies, but reports characterising chronic drug-induced psychosis will also be
considered. As will be discussed, the boundaries between the concepts of drug
induced psychoses and schizophrenia have become increasingly blurred. In addition to
a role in causation of schizophrenia, this section will also consider evidence that
substance misuse modifies the course of schizophrenia. Given the fact that substance
misuse is so common in established schizophrenia, consideration of the latter issue is
clearly of considerable importance. This section will thus comprise the following
subsections:
1. Evidence that various substances increase risk of developing schizophrenia: clinical
observational studies
2. Evidence that various substances are associated with increased rates of
schizophrenia: population-based studies
3. Impact of use of various substances on the course of schizophrenia
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3.2.2.1 Evidence that various substances increase risk ofdeveloping schizophrenia:
clinical obsen>ational studies
3.2.2.1.1 Cannabis
The possibility that cannabis may contribute to the aetiology of schizophrenia
has been considered more than any other drug, this being the subject of substantial
media interest and numerous journal editorials. That such an association should be
postulated is unsurprising; as has already been discussed, this drug is more commonly
used than any other illicit drug, rates of use are further elevated in schizophrenia, it is
known to provoke psychotic symptoms, and people who have schizophrenia are
particularly susceptible to this psychotogenic effect. That proving (or indeed
disproving) a role in causality has been so difficult once again reflects the obstacles
encountered in a research area that relies almost entirely on observational data. A
consensus has emerged however that cannabis does contribute to the risk of
schizophrenia (as well as precipitating transient psychotic episodes), and the data
from which this evolved will be summarized below. This evidence takes four main
forms: cross-sectional data that schizophrenia is associated with cannabis use (see
Section 2.1.1); observation of a protracted cannabis-induced psychosis with
similarities to schizophrenia; evidence from cohort studies; and evidence from
population data. The second and third of these bodies of evidence will be discussed
below, with population data being discussed in a subsequent subsection. Particular
emphasis will be placed on characterising who is most vulnerable to the risk-
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modifying effects of cannabis. Additionally, I will also discuss the related issue that
cannabis impacts on the course of schizophrenia in an additional subsection.
Supportfor a distinct cannabis-inducedpsychosis
That persistent cannabis use has the potential to produce protracted psychotic
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episodes in addition transient psychotic symptoms has long been suggested. '
Clearly, if this could be established to be the case then this psychosis could be
characterised and its features compared to those of schizophrenia; if clearly
distinguishable it would constitute a discrete diagnostic entity, if not it may provide
evidence that cannabis contributes to the aetiology of schizophrenia. A small number
of studies have compared persistent psychoses believed to be attributable to cannabis
intake to schizophreniform psychoses in those who have not used the drug.
Differences that have been reported are that cannabis-induced psychoses exhibit more
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hypomania and agitation and less affective flattening and auditory hallucinations, or
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more violence and panic but less thought disorder and loss of insight. In the face of
these inconsistent reports, other researchers have reported that symptom profiles in
the two conditions are actually very similar.233 Nevertheless, one fundamental
difference between the two conditions is consistently described; that is that whereas
(even in these more protracted episodes) the former condition is transient, with
symptoms generally resolving in days,234 the latter condition is characterised by its
chronicity.
The observation described above is reflected in clinical practice by the fact
that a diagnosis of drug induced psychosis is generally only made when a psychosis
develops shortly after drug use and resolves when drug use ceases i.e. the condition is
largely defined by its transience. Indeed, this is formalised in the diagnostic criteria of
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both DSM IV and ICD-10; DSM-IV suggests that a diagnosis of substance-induced
psychotic disorder should be reconsidered if symptoms last for longer than a month,
while in ICD-10 the diagnosis is deemed inappropriate if symptoms persist beyond six
months. Thus, in clinical practice, if a drug-induced psychosis does not resolve it
ceases to be a drug induced psychosis. Despite the obvious circularity of this
argument, it does reflect the generally accepted belief that there is in fact insufficient
evidence to propose that 'cannabis psychosis' exists as a distinct entity; instead,
persistent psychotic symptoms occurring in an individual who has used cannabis are
generally regarded as schizophrenia. Indeed, though the reasoning behind this
interpretation does sound a little like sophistry, there is in fact evidence to support it;
persistent psychoses in people who have used cannabis are indistinguishable from
schizophrenia, and a large follow up study of people diagnosed with cannabis
psychosis demonstrated that over a mean follow-up period of 5.9 years, 44.5% of the
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sample went on to receive a diagnosis of schizophrenia-spectrum disorders. It is
thus the case that the observations outlined above cannot tell us that cannabis causes
psychosis, as it may simply be that those ultimately destined to develop schizophrenia
are simply more vulnerable to more protracted psychotimetic effects on using the drug
the drug. Clearly therefore investigation of an aetiological role for cannabis
necessitates other research methodologies; evidence deriving from them will be
discussed below.
Longitudinal studies
Just as the association between cannabis consumption and transient psychotic
symptoms does not mean cannabis causes a chronic psychosis, so cross sectional
studies reporting an association between cannabis use and schizophrenia tell us
100
nothing of causality. Instead, to address this question studies must ascertain if
cannabis consumption when well is associated with the subsequent onset of the
condition.
A number of researchers have applied longitudinal methodology to samples
from the general population to address this question. This was first undertaken using a
large historical, longitudinal cohort study of all Swedes conscripted between 1969 and
1970.23<> As Sweden mandates military service, this included 97% of all males aged
18-20 years. The relationship between self-reported cannabis use at the time of
conscription and psychiatric hospitalization for schizophrenia in the ensuing 15 years
was examined. A dose-response relationship was observed, with individuals who
reported having used cannabis more than 50 times being six times more likely than
non-users to be diagnosed with schizophrenia in the follow-up period. Adjusting for
other risk factors did reduce the strength of this association, but nonetheless the
relationship remained significant; after these adjustments people who had used
cannabis 1 to 10 times were 1.5 times more likely to develop schizophrenia, while
those who had used it 10 times or more were 2.3 times more likely. These data have
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subsequently been reanalysed, with the follow-up period extended to 27 years. This
re-analysis also improved on the earlier report in a number of other ways. Most
importantly it increased number of potential confounding variables included in the
analysis, additional factors such as other drug use, urbanicity, IQ and social
integration also being incorporated in to the statistical model. Though reduced, the
adjusted odds ratio for cannabis use and schizophrenia remained significant, those
with a history of any use of cannabis having a 1.5, (CI 1.1-2.0), times risk of
developing schizophrenia compared to never users. Indeed, this elevated risk was also
robust to the exclusion of subjects who developed schizophrenia within 5 years of
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cannabis conscription, making it highly unlikely that the observed association was
attributable to cannabis use arising as a consequence of prodromal manifestations of
psychosis. Once again, in these analyses a dose dependent relationship between
cannabis exposure and the subsequent development of schizophrenia was evident.
The relationship between adolescent cannabis use and schizophrenia has also
been investigated using prospective methodology. Two of the most notable of these
studies were birth cohorts undertaken in New Zealand, in Dunedin and Christchurch.
The former study achieved complete follow-up in 759 of 1037 of the originally
recruited participants, these people being assessed intensively on risk factors for
psychotic disorders from birth.238 Of particular note the research protocol of this study
included assessment ofpsychotic symptoms at age 11 years, (i.e. before the onset of
cannabis use), and also distinguished between early- and late-onset cannabis use. A
significant relationship was found between cannabis use by age 15 years and an
increased risk ofboth psychotic symptoms and actual schizophrenifrom disorders by
age 26 years. Though controlling for other drug use did not affect this relationship,
adjusting for psychotic symptoms reported at age 11 years did. Though the
relationship between cannabis use and psychotic symptoms remained significant, that
between cannabis use and schizophreniform disorder did not. While it could be
argued that this casts some doubt on cannabis having an aetiological role, raising the
possibility that the association between cannabis use and schizophrenia could be
driven by self medication ofprodromal symptoms, such an explanation seems
unlikely. Instead, it is generally regarded as more likely that this loss of significance
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reflects the small number of psychotic disorder outcomes observed in the sample.
Such an interpretation is strengthened by findings in the Christchurch study, a second
birth cohort study which also collected data on cannabis use and psychotic symptoms
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at various timepoints.240 Similarly to the Dunedin study, this found that a history of
cannabis dependence was associated with increased psychotic symptoms at age 18
and 21. Additionally however, it also determined that the presence of psychotic
symptoms at the age of 18 appeared to inhibit, rather than encourage, subsequent
cannabis use. This strengthens the case for a causal link between cannabis use and the
development of psychotic symptoms, being incompatible with the possibility that this
association is driven by 'self-medication'. Though these data are compelling, a clear
weakness of the latter study is its reliance on psychotic symptoms rather than
diagnosed disorder as the outcome measure.
Several other cohort studies have longitudinally investigated the association
between cannabis use and subsequent psychosis, and a number of reviews have been
undertaken synthesising these data. Among the most robust and comprehensive of
these reviews is that of Moore et al.24X They searched for all relevant studies
published up until September 2006. Studies were included in the review if they were
population-based longitudinal studies, or case-control studies nested within
longitudinal designs. As well as schizophreniform disorders, a variety of other
diagnostic outcomes were permissible for a study to be included. Amongst these were
'non-affective or affective psychoses' and the even broader outcome of 'psychotic
symptoms'. The potential vagueness of the latter outcome was limited by the
clarification that caseness on the basis of 'psychotic symptoms' required the presence
of either delusions, hallucinations or thought disorder.
Moore et a!, identified 7 studies sufficiently homogeneous to be included in
the meta-analysis. These are detailed in Table 3.3, this being reproduced from their
published meta-analysis. Moore et al. report that there was no evidence to support the
presence of publication bias, and that the unadjusted results of all studies reported
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evidence of an increased risk of psychosis in people who used cannabis compared
with non-users. These associations were reduced, but nevertheless persisted, in six of
the studies after adjustment for confounding factors. On pooling these data, there was
an increased risk of a psychotic outcome in individuals who ever used cannabis
(OR=l-41, 95% CI 1-20-1-65). Six of the studies also provided dose response data.
On pooling these data findings were consistent with a dose-response relationship
between self-reported frequency of cannabis use and the risk of subsequently
developing psychotic symptoms or a psychotic disorder, with the greatest risk in
people who used cannabis most frequently (OR=2.09, 95% CI: 1.54, 2.84). Three
studies utilised the narrower definition of casesness representing psychotic disorder
rather than simply exhibiting psychotic symptoms;237'238'242 on pooling data from
these three studies an increased risk of psychotic outcomes in individuals who had
ever used cannabis was again seen (OR=2-58, 95%CI 1-08-6-13).
The conclusion of the meta-analysis of Moore et al. would seem to provide
robust evidence for the role of cannabis in the aetiology of schizophrenia. This
position is further strengthened by the fact that these conclusions are very similar to
those from a number of earlier systematic reviews and meta-analyses.243"245 Only one
significant cohort study of this issue has been published since the review of Moore et
al. (see McGrath et al., below) and it seems unlikely that further cohort studies will
add substantially to the evidence base. It is the case however that an association seen
in an observational study does not necessarily reflect a causal relation. Thus, despite
the seemingly robust evidence for cannabis contributing to risk for schizophrenia, a
number of alternative explanations for the observed associations could potentially be
proposed.
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Firstly, it could be argued that in a number of studies the association between
cannabis consumption and schizophrenia could potentially be driven by intoxication
effects. The thrust of this argument would essentially be that a history of cannabis use
is associated with psychotic symptoms because it predicts subsequent cannabis use,
and the transient psychotic symptoms induced by this are mistakenly diagnosed as a
psychosis outcome. It is the case however that the majority of the studies included
took steps to exclude this possibility. Though it could conceivably be difficult to
exclude this effect completely in people who are smoking daily, it is nonetheless
highly unlikely that cannabis intoxication would result in a diagnosis of
schizophrenia. Thus, though this possibility may justify caution in the interpretation of
some of the studies included in the review, it is not tenable that this effect resulted in
the outcomes seen in, for example, the Swedish conscript study.
Other alternative explanations for the results observed in the cohort studies
reviewed centre on reverse causality and residual confounding. The exclusion of
people with psychosis at baseline makes reverse causation (i.e. psychosis gives rise to
substance misuse) unlikely. As discussed above, the methodology of the Christchurch
study means that this possibility is particularly untenable in it.
It is certainly the case that in six of the seven studies included in the review, (the
exception is the study of Wiles et a/.),246 the increased risk of psychosis in cannabis
users compared to non-users was robust to the inclusion of a comprehensive list of
confounding factors. These included likely candidate confounders, such as use of
other drugs and markers ofpremorbid disturbances that are commonly observed in
patients with schizophrenia. Nevertheless, it is also the case that the resulting
reductions in effect sizes were frequently substantial, and the pooled effect size
reported by Moore et al. could be regarded as relatively modest. This does raise the
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possibility that the association is attributable to residual confounding; i.e. it is due to
one or more known or unknown variables being inadequately controlled for in the
analysis. While this is an unavoidable possibility in cohort studies, two approaches
have been implemented to minimise its potential influence.
The first of these approaches is the utilisation of more searching statistical
methods to control for confounding factors. This was undertaken by Fergusson and
colleagues, who applied a sophisticated structural equations modelling design that
accounted for both observed and nonobserved confounding factors to examine the
association between cannabis use and psychotic symptoms in a re-analysis of data
from the Christchurch study.247 In addition they extended the follow up period of the
cohort in this analysis, data on psychotic symptoms being acquired at the additional
age point of 25. Consistent with the earlier study, this analysis determined that daily
users of cannabis had rates ofpsychotic symptoms that were between 1.6 and 1.8
times higher (PO.OOl) than non-users. An alternative approach to reduce residual
confounding is the use of sibling pairs analysis. This was recently employed by
McGrath et al., and focused primarily on the importance of age of onset of cannabis
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use on the rate of subsequent development of psychosis. It will be discussed m
more detail in the appropriate section below, but also demonstrated an association
between cannabis and psychosis and that the association appeared to move from
cannabis use to symptoms of psychosis, rather than vice versa.
A further alternative explanation that has been proposed to explain the
relationship between cannabis use and schizophrenia is that rather than cannabis use
being a risk factor for schizophrenia per se, it simply precipitates the condition among
vulnerable individuals destined to develop the condition. That is, among persons who
would have developed the disorder regardless of whether they used cannabis or not.249
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Indeed, the association between cannabis use and younger age of onset of psychosis
does have considerable support, being reported in several independent studies.44'250-252
Though such an explanation could explain the findings of increased rates of psychosis
among cannabis users in studies with relatively short periods of follow up, it is
however not a feasible explanation for those studies in which subjects were followed
up for many years. In the Swedish conscript study for example, men were recruited at
age 18-20 and followed up for 27 years i.e. until aged approximately 38. By this time
it would be expected that the vast majority of people destined to develop
schizophrenia would have done so. As a difference in rates of schizophrenia between
cannabis exposed and unexposed groups was clearly apparent, an explanation that
cannabis simply brings forward expression of illness is clearly not tenable.
In summary therefore, the data from longitudinal epidemiological studies of
general population samples indicate that cannabis use is associated with elevated risk
of subsequent psychotic symptoms and illnesses including schizophrenia. Despite
considerable torturing of these data this association stubbornly persists, and this body
of research provides some of the strongest evidence to date that cannabis use is
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Who is most at risk?
I. The influence of age of first cannabis use on risk of schizophrenia
A number of studies have suggested that the association between cannabis and
subsequent psychotic illness appears to be highly dependent on the age when drug use
begins. For example, in the Dunedin Birth Cohort study it was reported that whereas
initiation of cannabis use by the age of 18 years doubled the odds of developing a
schizophreniform disorder by the age of 26 years, initiation by 15 years quadrupled
this risk.238 Though it has been suggested that this association may simply have arisen
because initiation of cannabis use at a younger age is associated with greater
cumulative exposure, such an explanation was not supported by a cross-sectional
study undertaken by Stephanis et al.25~ Their study investigated the association
between self-reported cannabis use and positive and negative dimensions of psychosis
(rather than schizophrenia itself). They demonstrated that self-reported first use of
cannabis below age 16 years was associated with a much stronger effect than first use
after age 15 years, this association existing independent of life-time frequency of use.
Though studies in which data are acquired retrospectively must be interpreted with
some caution (given their vulnerability to recall bias), when combined with findings
from the Dunedin study this report does suggest that the relationship between early
cannabis use and psychosis does indeed exist independent of total quantities used.
Prospective cohort studies (such as the Dunedin study) reduce vulnerability to
recall bias. As discussed above however, even in these studies there can be substantial
threats to the validity of the findings. Primary among these is the potential for residual
confounding, this being repeatedly raised as a concern when the relationship between
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cannabis use and subsequent schizophrenia has been investigated utilising this
methodology.
Primarily in response to these concerns about the possibility of residual
confounding, elucidation of the association between cannabis use and age of onset of
psychotic symptomatology has most recently been attempted by McGrath et al. using
sibling pair analysis.248 They argue that this model of study design enables the
association between cannabis use and psychosis-related outcomes to be examined
while reducing the influence of these factors, since differences are less likely to be
attributable to shared genetic and environmental exposures. Thus, the application of
this approach nested within a prospective birth cohort will reduce the influence of
unmeasured residual confounding. If a significant association between cannabis use
and psychosis related outcomes was not detected in sibling pairs, they argue, it would
seriously weaken the argument that cannabis use was a risk-modifying factor for
psychosis-related outcomes.
In the study of McGrath et al., the researchers were particularly interested in
the association between early cannabis use and subsequent psychosis-related
outcomes. The researchers found that for the total cohort (including many more
subjects than just the sibling pairs), those with duration since first cannabis use of six
or more years (implying first use of cannabis by about age 15) had a significantly
increased risk of nonaffective psychosis. This finding corresponds with the previously
discussed studies investigating the impact of adolescent cannabis use on the
subsequent development of psychosis. The sibling pairs analysis was limited to scores
on the Peters et al. Delusions Inventory (PDI), an instrument used to measure
delusional-like experiences in clinical and community populations. For each pair, the
authors calculated difference scores for duration since first cannabis use and PDI total
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score. The association between time since first cannabis use and PDI score remained
statistically significant in the sibling subset analysis. Though a weakness of this study
is that age of first cannabis use was again determined retrospectively, this study does
provide further support for the hypothesis that early cannabis use is a risk-modifying
factor for psychosis-related outcomes in young adults.
Despite the establishment of this association, it is not know why the effect of
cannabis consumption is greater in those who begin cannabis use early in
adolescence. While it has been argued that it could be because they are more likely to
become heavily dependent on cannabis, this is not supported by the study undertaken
by McGrath et al. Instead, it seems more likely that the significance of this early use
of cannabis may instead arise from the fact that it is occurring at a time when many
neurobiological and hormonal changes are taking place. Cannabis use in this time of
rapid biological change may be more likely to lead to alterations in neurobiology that
increase psychosis risk.256'257
II. High risk groups
As detailed in Section 3.2.1.1, individuals from the general population with a
greater propensity to experience psychotic symptoms experience a more
psychotogenic effect on consuming cannabis. A number of studies have taken these
investigations further, and investigated if people at increased risk of schizophrenia are
at greater risk of actually developing psychosis if they consume the drug. These
studies take a number of forms. In one manifestation the high risk group is determined
on the basis ofbeing symptomatic, clinically compromised, help-seeking and at
imminent risk of psychosis, but not yet floridly psychotic. This group is labelled as
ultra-high risk, and an example of such studies are those conducted in the Personal
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Assessment and Crisis Evaluation (PACE) clinic in Melbourne, Australia.258 In an
alternative approach the high risk group is determined at an earlier stage, and on the
basis not of symptoms but of a genetic propensity for schizophrenia. These are
generally called high risk studies, and the current study is one such example. A third
approach has also been employed. In this predisposition to psychosis is determined by
the degree of expression of psychotic-type symptoms at the point of entry in to the
study; in contrast to ultra-high risk studies these individuals are from the general
population (e.g the study of Henquet et al.,254 previously mentioned in the review of
longitudinal studies above).
The only previous study of cannabis use and risk of subsequent schizophrenia
in a population at high genetic risk that could be identified was a previous analysis of
data from the Edinburgh High Risk Study by Miller et al 259 Though this study did
report an association between illness onset and frequent cannabis use just prior to
onset, an association was not reported between early cannabis use and subsequent
schizophrenia. It is notable however that the focus of this earlier analysis was
predominantly on cannabis use in the period immediately preceding the development
of psychosis, and relatively broad categories of cannabis exposure were employed.
Given that these could have obscured an association between early cannabis use and
schizophrenia, a re-analysis of these data will be included in this report.
Philips et al. used data from the aforementioned PACE clinic to investigate the
association between cannabis use and the development of a first psychotic episode in
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a group of 100 young people at ultra-high risk of psychosis. They had either
subthreshold psychotic symptoms or a combination of a first-degree relative with a
psychotic disorder and recent functional decline. Though thirty-two per cent of the
cohort developed an acute psychotic episode over the 12-month period following
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recruitment, cannabis use or dependence in the year prior to entry to this study was
not associated with a heightened risk of developing psychosis. While the authors
concluded that cannabis use did not appear to contribute to the onset of psychosis,
they acknowledge several limitations to the study design, including a low level of
cannabis use in the sample, and the lack of monitoring of cannabis use. It is also the
case of course that analysis of cannabis use was limited to that in the year prior to
recruitment. Given that considerable data have stressed the importance of age of first
cannabis exposure in determining risk, it may be that what is essentially an extended
prodromal period is already too late in the development of psychosis to observe the
risk modifying effects of the drug. In-keeping with this possibility, an American study
focussing on a similar population found that a lifetime history of cannabis abuse or
dependence was associated with transition to psychosis.261
A number of studies have identified individuals at elevated risk of psychosis
within a general population sample on the basis of exhibiting psychotic or psychotic-
type symptoms. An example of this third form of study is van Os et al. 's Dutch
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general-population based longitudinal study. In this study vulnerability to psychosis
was determined by meeting DSM-III-R diagnostic criteria for a psychotic disorder
(though not necessarily requiring treatment), and incident psychosis by having a
psychotic disorder requiring treatment. They reported that the difference in risk of
psychosis at follow-up between those who did and did not use cannabis was much
stronger for those with an established vulnerability to psychosis at baseline than for
those without one. Comparable findings were reported by Henquet et al., in their
study of 2437 adolescents and young adults in Munich.2"14 Similarly to the Dutch
cohort, individuals who reported psychotic symptoms at baseline were much more
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likely to experience psychotic symptoms at follow-up if they used cannabis than were
their peers who did not have such a history.
III. Genotype
Taken in its entirety, the data outlined above do indicate that those with a
genetic vulnerability to psychosis are more sensitive to the deleterious effects of
cannabis. This makes intuitive sense; given that the vast majority of young people
who use the drug do not become unwell, it is only tenable for cannabis to have a
causal role in psychosis if some individuals are more genetically vulnerable to its
effects. The first example of a genetic by environment interaction predisposing to
schizophrenia was described by Caspi et al., in a further investigation of the Dunedin
birth cohort.121 It was demonstrated by these researchers that a functional
polymorphism in the catechol-O-methyltransferase (COMT) gene moderates risk of
the development of schizophrenia on exposure to cannabis.
The enzyme produced by the COMT gene plays an essential role in the
breakdown of dopamine in the prefrontal cortex. In 1996 Lachman et al. reported that
a common genetic polymorphism in humans resulting from a G to A missense
mutation in this gene generated a valine (Val) to methionine (Met) substitution at
codon 158 (Vall58Met).262 This altered gene product has less enzymatic activity and
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consequently is associated with slower break down of dopamine. The functional
polymorphism of the COMT gene an individual posseses is believed to have
particular significance for the efficiency of prefrontal cortex functioning, possession
of the high activity COMT Val allele having been associated with impaired memory
and attention.264
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Caspi et al. have shown that COMT moderates the influence of adolescent
cannabis use, with at least a fivefold increased risk of developing schizophreniform
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disorder in cannabis users homozygous for the high activity Val allele. In contrast,
homozygosity for the Met allele offered relative protection (odds ratio 1.1), whereas
the risk for heterozygotes was intermediate (odds ratio 2.5). These researchers also
demonstrated that was no correlation between the COMT genotype and cannabis use,
indicating that the COMT genotype does not influence cannabis consumption.
The COMT-variation-cannabis-use interaction has since been investigated
experimentally. Henquet et al. gave study volunteers either THC or a placebo, and
noted that carriers of the COMT Val allele were more likely to develop impairments
of memory and attention than carriers of the Met allele.265 Those with the
homozygous Val genotype were also more sensitive to the effects of THC on
psychotic symptoms, but this was dependent on their pre-existing proneness to
psychosis. Still further support for the association of this polymorphism with
psychotic symptoms has come from the application of an experience sampling
technique. This was utilised to collect data on cannabis use and occurrence of
symptoms in daily life in patients with a psychotic disorder and healthy controls.266
Carriers of the COMT Val allele, but not Met homozygotes showed an increase in
hallucinations after cannabis exposure, conditional on prior evidence ofpsychometric
psychosis liability. These data thus support Caspi et al.'s initial report that genetic
variables moderate the effect of cannabis exposure, a finding which constitutes the
first example of a genetic by environmental interaction predisposing to schizophrenia.
117
3.2.2.1.2 Alcohol
Though overshadowed by cannabis research in recent years, consideration of
the possibility that alcohol use may play a role in the aetiology of schizophrenia is not
entirely novel. Indeed, such speculation has long been supported by the observation
that chronic alcohol consumption may occasionally result in the generally self-
limiting psychotic disorder known as alcoholic hallucinosis. In this condition auditory
hallucinations and delusions of reference and persecution are prominent, though other
schizophrenic symptoms such as thought disorder and passivity are generally
267absent. Symptoms can appear relatively suddenly, are experienced outwith the
withdrawal period (though may first arise during it), and are experienced regardless of
whether the patient is drinking or abstinent. In one case series it was reported that men
who developed alcoholic hallucinosis were significantly younger at the onset of
alcohol problems, consumed more alcohol per occasion, developed more alcohol-
related life problems and had higher rates of drug experimentation.268 Case series of
prognosis have reported that only a few (5-10%) continued to have symptoms for six
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months or more if abstinence was maintained. Renewed drinking did however tend
to bring about a return of hallucinations.
The data outlined above clearly demonstrate that alcohol consumption can
result in psychotic symptoms, and that in the minority of people who develop them
they can be chronic. This raises the possibility that heavy alcohol consumption may
precipitate an attenuated form of schizophrenia in vulnerable individuals. This
possibility was however undermined by the findings of family and genetic studies,
which failed to demonstrate a greater prevalence of schizophrenia in relatives of
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patients with alcoholic hallucnosis.270 This was taken to imply that genetic
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predisposition for the two conditions were independent from each other, and there
was thus little potential for alcoholic hallucinosis to shed light on the pathophysiology
of schizophrenia. Instead, the basis of alcoholic hallucinosis was presumed to be
subtle alcohol-induced damage or dysfunction, this possibly located in the temporal
lobes.272 Once this distinction between alcoholic hallucinosis and schizophrenia was
apparently established, interest in alcohol as a risk factor for schizophrenia, (as well
as alcoholic hallucinosis itself), became almost non-existent. As illustration of this,
only a handful of either treatment or imaging studies have been undertaken in relation
to alcoholic hallucinosis in the last decade. The limited imaging data relating to the
condition will be discussed in Section 4.4.
Despite waning interest in alcoholic hallucinosis, a small number of studies
have investigated if a history of alcohol abuse/dependence is associated with the
subsequent development of schizophrenia. The largest study to explore this was
undertaken by Lewis et al., and used data from the Swedish conscript survey linked to
the Swedish National Register of Psychiatric Admissions.273 This is the same database
previously discussed in relation to its application to exploring if a similar relationship
existed with cannabis.237 Lewis et al. report that there was an increase risk of
schizophrenia in those with an ICD-8 diagnosis of alcohol abuse at age 18, this
persisting after controlling for numerous confounders present at the point of initial
assessment (including, for example, non-specific psychiatric symptoms and drug
abuse). Similar findings were also reported in a subsequent study using Israeli data,
though in this analysis drug and alcohol use disorders were analysed together.274
It is thus the case, on the basis of the limited data available, that alcohol use
disorders do seem to be present in people destined to develop schizophrenia at a rate
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greater than one would expect by chance. One potential explanation is that this is a
consequence of self medication for prodromal features of schizophrenia. In contrast to
the detailed analyses undertaken to exclude this possibility as an explanation for the
comparable association seen with cannabis, such detailed analyses have not been
undertaken for alcohol. It is interesting however that in the study of Lewis et al. the
association between alcohol and abuse and schizophrenia remained significant even
after controlling for non-specific psychiatric symptoms. The other possible
explanation is that excessive or very early use of alcohol does indeed constitute a risk
factor for schizophrenia. There is little additional published data to support this, but
investigation of this possibility will be a focus of the current study.
A role for alcohol (as well as the other substances under investigation in this
study) in the aetiology of schizophrenia is easily conceptualised within the framework
of the stress-vulnerability theory of schizophrenia. Indeed, this theory could also
provide a model by which alcoholic hallucinosis and schizophrenia can be regarded as
related disorders, despite findings from the aforementioned genetic and family studies
suggesting that they are quite distinct. By the stress-vulnerability model, alcohol
interacts with other risk factors for schizophrenia to increase an individual's
vulnerability to developing the condition. In this context the finding that those with
alcoholic hallucinosis have no family history of schizophrenia is actually not
anomalous. As was previously discussed by Picchioni and Murray, this model would
predict that as a consequence of heavy alcohol consumption some individuals (likely
those with fewer susceptibility genes for schizophrenia) develop alcoholic
hallucinosis, generally a temporary and self-limiting phenomena. Those with a greater
predisposition for schizophrenia however, on exposure to similar or even lower levels
of alcohol, may go on to develop a condition indistinguishable from classical
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schizophrenia.276 Thus, alcohol consumption could potentially both give rise to
alcoholic hallucinosis in some individuals, and in others be a risk factor for
schizophrenia.
3.2.2.1.3 Tobacco
Though illicit drugs have long been suspected as potentially contributing to
the risk of schizophrenia, the possibility that such an association could exist with
tobacco smoking has received little attention. This is likely attributable to the fact that
tobacco is not associated with overt psychotomimetic effects. It is the case however
that tobacco is the most commonly abused drug in people with schizophrenia and it
does seem theoretically possible that repeated activation by nicotine of the
mesolimbic system over a long time could precipitate the onset ofpsychosis in
vulnerable individuals. It is also the case that increased rates of smoking predate the
onset of schizophrenia (see Section 3.2.1.3), and that a positive association exists
274between the number of cigarettes smoked and the risk of developing the condition.
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Though the latter association was not observed in the Swedish conscript study, a
study in the general population has demonstrated a prospective association between
smoking and the subsequent self report of incident psychotic symptoms.246
Additionally, a small study in an ultra-high risk cohort also suggested that cigarette
smoking was associated with transition to schizophrenia, though this may have been
confounded by cannabis use.261 No data were identified suggesting that smoking had
an adverse effect on the course of schizophrenia and, as reviewed in Section 3.2.1.3,
there is some suggestion smoking has cognitive benefits in the condition. It is thus the
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case that the possibility of causative association between smoking and schizophrenia
must be considered cautiously and has sparse support in the published literature; it
will however not be dismissed in my analysis of the high risk dataset.
Diagnosis of a psychotic disorder caused by tobacco use is theoretically
possible within ICD-10, but no reports of such an effect were identified by a thorough
literature search.
3.2.2.1.4 Other drugs
As was previously discussed in section 2.2, the association between
amphetamines and psychosis was central to the formulation of the dopamine
hypothesis of schizophrenia. That a relationship exists between these drugs and
schizophrenia was reinforced by Section 2.1.4, which demonstrated that cross-
sectional studies have generally reported that people with schizophrenia use
amphetamines at a greater rate than the general population. As was done with
cannabis however, consideration of the possibility that amphetamines contribute to
risk for schizophrenia requires two further pieces of information: Firstly, how does
the psychosis induced by amphetamines compare to schizophrenia; and secondly,
does use of amphetamines increase the subsequent risk of schizophrenia. These issues
will be considered for amphetamines below. Additionally, the same issues will also be
considered for cocaine and MDMA (ecstasy).
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Amphetamines
The psychosis associated with amphetamine use has been of great interest to
schizophrenia researchers since its recognition. These early researchers soon
recognised that it had a closer resemblance to schizophrenia than comparable
conditions produced by other drugs. This led to it being regarded it as a 'model
psychosis', with the potential to provide insights into the processes giving rise to
schizophrenia.75 Even in these early case series however it was reported that
amphetamine psychosis and schizophrenia did display some differences; specifically,
the researchers state that visual hallucinations are more prominent in the former
condition, while thought disorder is absent. Interestingly, and as was the practice in
the studies outlining cannabis psychosis, in three cases in which psychotic symptoms
persisted, individuals were diagnosed as having schizophrenia. In the 'amphetamine
psychosis' cases by contrast symptoms did not persist beyond 10 days.
Numerous other studies were undertaken in the 1960s and 1970s
characterising amphetamine psychosis. They argued both in support of and against the
presumption that many similarities exist between amphetamine psychosis and
schizophrenia.76 Over time however a consensus has emerged that though symptoms
of acute amphetamine psychosis and schizophrenia are similar, visual and tactile
hallucinations are indeed more common in the former condition.278
In recent years a derivative of amphetamine, methamphetamine, has been
increasingly popular in America.279 This drug is created by the addition of a methyl
group to amphetamine, resulting in a product with greater lipophilicity than the parent
drug. It can consequently achieve increased central nervous system concentrations
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and thus has an augmented relative potency. Widespread use of this drug has been
accompanied by concerns that it may be particularly neurotoxic, and may be
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particularly liable to precipitate psychosis. Though large scale recreational use of
methamphetamine is a relatively recent phenomenon in the West, it has a much more
established history in Japan. In that country the potential for methamphetamine to
produce persistent psychotic symptoms has long been recognised. Specifically, it has
been reported that while the majority of cases of methamphetamine psychosis do
resolve within a month, 11% persist beyond this,280 and 5% had residual
symptomatology many years later.281 These chronic psychoses display considerable
clinical overlap with schizophrenia, though affective flattening and alogia may be less
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pronounced. Additionally, it does seem that in some cases in which resolution of
psychotic symptoms does occur, the experience ofpsychological stress results in
relapse in the absence of further drug exposure.282 This phenomenon is believed to
represents a sensitisation effect. Both of these findings indicate that use of
methamphetamine can indeed result in sustained abnormalities, these persisting long
after use of the substance has ceased.
In practice, and as was discussed in relation to cannabis, schizophreniform
conditions which persist for a sustained period of time are eventually diagnosed as
schizophrenia. Underpinning this practice is the central belief that drug induced
psychoses are essentially most characterised by their transience. As discussed above
however it does seem that, in vulnerable individuals at least, amphetamine (and
particularly methamphetamine) use does have the potential to cause a more chronic
psychotic condition which may be difficult to distinguish/indistinguishable from
schizophrenia. The brain structural changes consequent to (meth)amphetamine use
which potentially underpin this will be discussed in a later chapter, but these findings
do provide support for the supposition that amphetamine/methamphetamine use does
indeed have the potential to increase the risk of developing chronic psychoses. Indeed,
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such a perspective is given further support by a recent study of Australian
methamphetamine users. This reported that among individuals with no known history




Cocaine and amphetamines are both psychomotor stimulants, with broadly
similar actions at the synaptic level (such as, for example, blocking reuptake of
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dopamine released from the meso-limbo-cortical dopamine terminals). It is
unsurprising therefore that cocaine, similar to amphetamine, can also induce psychotic
symptoms. The development of frank psychosis appears to be more sporadic than is
the case with methamphetamine, but symptomatology is similar. As was the case with
methamphetamine, a variety of schizophrenic-type symptoms are reported but tactile
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and visual hallucinations are more pronounced than is the case in schizophrenia.
Protracted psychotic symptoms were more likely in those people with a prior history
of psychiatric illness.
MDMA
MDMA (ecstasy) is a further amphetamine derivative, which became
increasingly popular as an illicit substance in the UK in the 1990s.286 Its effects on the
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central nervous system predominantly involve serotonin. The potential for MDMA
to induce psychotic symptoms has been recognised since shortly after its use became
commonplace, at which time it was also suggested that in some individuals the
experience of psychotic symptoms could be protracted.286 Landbaso et al. recently
published data on a cohort of 32 individuals who presenting with hallucinatory-
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delusional symptoms after repeated consumption of ecstasy (and who did not
consume other drugs).102 At baseline schizophreniform symptoms such as
hallucinations, conceptual disorganisation and blunted affect were common. Over the
six month follow-up period these symptoms all improved substantially, though
remained present to a mild extent in some individuals. When combined with case
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reports of persistent psychoses following MDMA use, ' it does seem that, (in
vulnerable individuals at least), this drug does have the potential to cause protracted
psychotic episodes. As always in this sort of research it is impossible to exclude the
possibility that these individuals may have developed persistent psychotic symptoms
irrespective of use of MDMA. The frequency of co-occurrence does however serve to
make this explanation unlikely.
3.2.2.2 Evidence that various substances are associated with increased rates of
schizophrenia: Findings from population-based studies
As reviewed above, data associating cannabis with the subsequent
development of psychosis have come predominantly from cohort and experimental
studies. There is an alternative approach to investigation of the link between
substance use and schizophrenia however; namely to examine changes in population
rates of psychosis and schizophrenia and to compare these to known trends in use of a
specific substance. If it is indeed the case that exposure to a particular drug is a
significant risk factor for schizophrenia, then an increase in levels of consumption of
that drug by a given population would be expected to be associated with a
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comensurate increase in psychosis incidence. If such an association was not seen, then
this could call in to question the veracity of this putative association. Data
investigating the association between population levels of particular drugs and
psychosis incidence will now be discussed.
Association between population levels ofcannabis use and incidence of
psychosis/sch izoph ren ia
It has been reported that cannabis use increased dramatically in many Western
societies in recent decades, though this increase may have dropped off in recent years.
Even in the face of such general trends however, and as discussed in Section 2.1,
levels of substance use can vary greatly between different nations, or even regions
within these nations. For investigation of associations between cannabis use and
incidence of schizophrenia to be meaningful therefore, these trends must be
investigated at relatively local levels.
In 1998 Boutros et al. reported that in Connecticut a rapid increase in new
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schizophrenia admissions coincided with a peak period for drug-related admissions.
This is the first study that I could identify which explored the association between
these variables. It was based on first admissions data for drug abuse and
schizophrenia/paranoid disorders from all Connecticut state hospitals from 1965 to
1983. A clear increase in schizophrenia/psychosis admissions is evident, beginning in
the early 1970s and peaking in 1979. The authors suggest that increased drug use
from the late 1960s may have contributed to the increase in first admissions of
patients diagnosed with psychotic disorders some years later. Unfortunately, the
authors do not explore associations between admission rate for use ofspecific drug
classes and admissions for psychosis. Thus it is unclear which specific drugs were
127
responsible for the rise in drug abuse admissions that occurred concurrent with the
rise in admissions for schizophrenia/paranoid disorders. It would be expected
however, (on the basis of current clinical practice at least), that the proportion of these
drug admissions specifically attributable to cannabis use per se would be relatively
small. Conversely, cannabis was responsible for the bulk of the general increase in
illicit drug use observed in the American population during this period.290 Thus, it is
conceivable that the increase in admissions for psychotic disorders and the increase in
admissions for drug abuse occurred somewhat independent from each other, though
both were attributable to the general increase in drug use in the American population;
i.e. the increase in opiate use resulted in the increase in admissions for drug abuse,
whereas the increase in cannabis use contributed to the increase in admissions with
psychosis. Unfortunately, this possibility is not explored in the paper.
Subsequent studies have examined the association between levels of use and
incident cases of psychosis specifically for cannabis. In one such study, Degenhardt
and colleagues utilised Australian data acquired from birth cohorts dating from 1940
to 1979. During this period there was both a steep rise in both the prevalence of
cannabis use and a marked decrease in the age of initiation of use. This was not
accompanied by a corresponding increase in the incidence of schizophrenia, leading
the authors to conclude that cannabis did not appear to be causally related to the
291incidence of schizophrenia.
A more recent study by Ajdacic-Gross challenged the conclusion outlined
above.292 This study was based on an analysis of admissions for psychosis in Zurich
between 1977 and 2005. In their overall analysis of the data, they report that first
admission rates of patients with psychotic disorders were constant in men over this
time period, and actually showed a downward trend in women. On looking at the data
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stratified by age however, they demonstrate that distinct patterns are apparent in
particular age groups. Specifically, they report that though in males there is actually a
slightly decreasing trend in first admission rates in most age groups until the early
1990s, at this point this trend reverses for the youngest male age group, (those aged
15-19 years). Subsequently, after a 2-3 year time delay, this reverse is also seen in the
20-24 year olds. By contrast, a comparable trend reversal is not seen in the youngest
female age groups, nor is it apparent in older age groups of either sex. In
endeavouring to explain this pattern, the researchers discuss the fact that during the
1990s cannabis availability in Zurich increased substantially; specifically, lifetime
prevalence of cannabis use in 15-16 year old teenagers rose from 15% (boys) / 5%
(girls) in 1990 to 41% / 30% in 1998, the rise in consumption of the drug being most
pronounced in this group. They discuss the fact that as young men are heavier
consumers of cannabis than young women, the increase in psychosis admissions that
is observed is occurring in exactly that group experiencing the most dramatic rise in
cannabis consumption during this period. They conclude that these data provide
further support for an association between cannabis consumption and first admissions
with psychosis.
Hickman and colleagues looked at the same question using UK data, and
reported results that are more equivocal.293 No reliable data on changing rates of
cannabis use over the period of interest are available in the UK. The authors instead
relied on a single national survey in which people of different ages reported when they
had first and most recently used cannabis and their approximate frequency of use
between these points; from these data time trends in use by age could be constructed.
The authors report that large increases in cannabis use occurred between the early
1970s and the late 1990s, but that the biggest increases among young people were
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more recent. High-quality data on psychosis incidence were also relatively recent, and
therefore a possible prior influence of cannabis on this incidence could only be
modelled. Despite these limitations, the authors do report that to date an increase in
incident rates of schizophrenia corresponding to the increased rates of cannabis
consumption has not been observed. On modelling the relationship between the two
factors they do suggest that this apparently contradictory finding may be explicable by
the increases in psychosis attributable to cannabis use being less substantial, and
consequently less noticeable, than some had assumed. Nevertheless however, they go
on to say that if a truly causal relationship did exist then this would lead to larger
increases in schizophrenia incidence, unlikely to be missed by reliable surveillance,
by around 2010. They emphasised the importance of such an increase being detected
by robust surveillance systems. They did also emphasise however that even if such an
increase in incident cases of schizophrenia were not observed, this did not rule out the
possibility that cannabis played an aetiological role. It is conceivable that a change in
other factors (e.g. better obstetric care) could have masked or diminished the recent
and future projected increases in schizophrenia occurrence due to cannabis. This
could of course further explain why no change in overall schizophrenia trends has
been observed despite increases in general population rates of cannabis consumption.
The most recent study addressing this issue was undertaken by Frisher et al.,
utilising retrospective analysis of data from the General Practice Research Database
for 183 practices in England, Wales, Scotland and Northern Ireland.294 They
investigated if a substantial rise in UK cannabis use from the mid-1970s was
associated with changes in the annual incidence and prevalence of schizophrenia and
psychoses from 1996 to 2005. They reported that between 1996 and 2005 the
incidence and prevalence of schizophrenia and psychoses were either stable or
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declining, and concluded that the specific causal link between cannabis use and the
incidence of psychotic disorders was not supported.
In conclusion therefore, the findings from studies that have compared changes
in population rates of psychosis and schizophrenia to known trends in cannabis use
have been inconclusive. It must of course be remembered however that the ability to
test this hypothesis is entirely dependent on the availability and quality of data on
rates of cannabis use and psychosis in the population. Often these data are
rudimentary, and of dubious quality. Additionally, and as discussed by Hickmen et al.,
potential confounding factors abound. Thus, that any conclusion drawn from the data
outlined above must be interpreted in a guarded manner.
Association between population levels ofother drug use and incidence of
psychosis/schizophrenia
As is apparent from the above, data exploring the relationship between
population levels of cannabis use and incident rates of schizophrenia are sparse. Data
exploring this relationship for alcohol and other illicit drugs are however even scarcer.
I will now discuss these limited data; obviously the provisos discussed in
interpretation of the studies outlined above apply equally to these studies.
A single study has investigated the association between the levels of alcohol
consumption in a society and rates of hospitalisation for schizophrenia.295 This was
ascertained using American data spanning the years 1934 to 2005, and reported in
letter form in 2009. The correlation between admission rates for schizophrenia and
per capita absolute alcohol consumption was explored separately for beer, wine and
distilled spirits. For first admission rates this association was explored separately for
men and women; for total admission rates only combined male and female data were
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available. To clarify the direction of the association, (i.e. the temporal order of
changes in alcohol consumption levels and incident cases of schizophrenia), lag
correlation analysis was employed.
Cawood and Bartko report that for distilled spirits the correlations were
positive, significant, and always highest at zero lag years; this was the case both in
males and females and for both first and total admissions. Correlation values for beer
were positive and significant, but lower than those for distilled spirits. Those for wine
were inconsistent. The findings suggest that alcohol use is a tenable risk factor for
schizophrenia, acting close to the onset of schizophrenia, and that this association is
stronger for distilled spirits than beer. The authors suggest that the greater effect from
spirits than beer may be because consumption of concentrated alcohol overwhelms
first pass metabolism, resulting in rapidly peaking high blood alcohol levels with
damage to brain cells and neural connectivity in areas implicated in schizophrenia.
Beer drinking involves the continuous administration of more dilute alcohol; thus,
even if more total alcohol is consumed the process outlined may not occur, resulting
in a weaker association with schizophrenia.
No data could be identified exploring the relationship between population
levels of either smoking or amphetamine use and schizophrenia. In their study
examining this association in relation to cannabis use, Ajdacic-Gross et al. did
consider the possibility that an increase in ecstasy use was contributing to the increase
in schizophrenia in young males observed in Zurich.292 Overall however, and as
outlined in the passage above, they placed greater emphasis on the possibility that
these changes were attributable to increased levels of cannabis use.
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Summary
In conclusion therefore, data demonstrating an association between changes in
levels of alcohol/illicit drug use and a consequent effect on schizophrenia incidence
are sparse. Those studies which have been undertaken are vulnerable to innumerable
potential confounders, both positive and negative. It is therefore difficult to use these
data to either confirm or refute suggestions that use of specific substances does affect
the risk of the subsequent development of schizophrenia.
3.2.2.3 Impact ofuse ofvarious substances on the course ofschizophrenia
An additional way in which the association between drug use and
schizophrenia can be ascertained is by investigating the impact of these substances on
the course of the illness. Given the increased prevalence of use of a variety of licit and
illicit substances in schizophrenia, information on the impact that such behaviours
have on the course of the illness is of course important in itself. Such data can also
however provide indirect evidence supporting or refuting the possibility that these
substances contribute to the aetiology of condition. Specifically, if an environmental
exposure was genuinely a risk factor for the condition, then it may be expected that
continued exposure to that factor could have a detrimental impact on outcomes such
as scores on symptom rating scales or relapse ofpsychosis. Conversely, if use of the
substance had no influence on outcomes, then this could be interpreted as implying
that a role in aetiology is less likely. Clearly interpretations such as these do have
limitations. Specifically, it does remain conceivable that a factor which impacts on the
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course of schizophrenia only exerts its detrimental influence once schizophrenia is
established; conversely, a factor could genuinely increase risk of developing the
condition, but have a benign effect on its course once schizophrenia is established.
Additionally, it is also conceivable that substance misuse could have a detrimental
impact on outcomes simply through being a predictor of non-compliance with
medication. While accepting these provisos is important however, it does nonetheless
remain the case that data examining the impact of substance use on the course of
schizophrenia do remain important in achieving a comprehensive understanding of the
relationship between these behaviours and the illness.
In Section 3.2.1 studies investigating the cross-sectional association between
use of a variety of substances and symptom profile in schizophrenia was investigated.
This demonstrated that substance misuse was generally associated with a greater
severity of symptoms, which cast some doubt on the possibility that self-medication
was driving the association between substance misuse and the condition. The current
review will be limited to those studies investigating the longitudinal association
between drug use and schizophrenia outcomes. Clearly such studies can much more
reliably inform us that the use of drugs by people with schizophrenia is indeed
impacting on the outcomes oserved. Initially I will briefly review data examining the
impact of non-specific substance use on schizophrenia outcomes. Greater emphasis
will however be placed on the impact that use of specific substances has on the course
of the illness. In all of these reviews only studies which employed outcome measures
directly relevant to illness severity (i.e. scores on symptom rating scales or relapse of
psychosis/necessity for readmission) will be included. This is because other measures
of adverse outcomes (for example, rates of violent offending), could be attributable to
substance use per se, rather than directly reflecting symptom severity.
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A small number of studies have compared readmission rates in substance
misusing schizophrenic patients to those without such comorbidity. In one such study,
readmission rates in 11 of the former patients were compared to those in 11 of the
9Qf\ • ...
later over a period of at least two years. All patients were receiving antipsychotic
treatment through depot preparations, thus ensuring medication compliance. The
mean number of readmissions in the substance misusing group, (in which cocaine,
alcohol and cannabis were the substances predominantly used), was 2.5; this
compared to 0.5 in the group which did not abuse substances. Active substance abuse
was associated with significantly (p<0.001) higher readmission rates to the hospital
because of symptom recurrence.
Subsequent studies have reported results comparable to those of Gupta et al.
In an Australian prospective study, for example, Hunt et al. reported that substance
use was associated with a shortening of mean time to next admission from a median
9Q7
of 37 months to 10 months. The patients in this analysis were once again all
reported as being compliant with medication (defined as regularly taking prescribed
medication >75% of the time). Drake et al. have expanded further on these findings,
reviewing studies exploring the impact of abstinence from alcohol/drug use on the
course of schizophrenic illness. They report that if abstinence is achieved, then this is
accompanied by a decrease both in scores on symptom rating scales and rates of
hospitalisation.298
A small number of studies have addressed the impact of substance misuse on
schizophrenic illness specifically in first episode subjects. The single study in which
80% or more of the subjects included had a diagnosis of a schizophrenia spectrum
disorder found that substance misusers had higher scores on symptom rating scales at
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a median follow up period of 14 months.62 Studies in which fewer than 80% had a
diagnosis of a schizophreniform disorder (though the vast majority did have this
diagnosis), reported greater rates ofpsychotic relapse in the substance misusing
3.2.2.3.1 Impact of cannabis use on the course of schizophrenia
A number of studies have specifically looked at the impact of cannabis use on
the course of schizophrenia. In one of the earliest reports, Negrete et al. reported that
during a 6-month observation period subjects who used cannabis presented with a
significantly higher degree of delusional and hallucinatory experiences than those
who did not.178 They also made a higher average number of visits to the hospital
during the same period. A higher frequency of relapse in continuing cannabis users
OA1
was also reported in a Spanish study published in 1994. In the same year this issue
was addressed using prospective methodology and attempting to control for
confounders in a highly influential paper by Linszen et al., who assessed 93 patients
T09
with a recent onset schizophrenic illness on a monthly basis for a year. The 24
patients who were cannabis users both experienced earlier psychotic relapse, and had
more frequent relapses in the year of follow-up than the patients who did not use the
drug. Additionally, the authors reported a dose-response relationship between
cannabis use and relapse; daily users relapsed earlier and more often than less than
daily users who, in turn, relapsed sooner and more often than the patients who did not
use cannabis. These relationships persisted even after statistical correction for
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premorbid adjustment and use of alcohol and other drug use during the follow-up
period.
Zammit et al. published a systematic review of the effect of cannabis use on
outcomes of psychotic disorders in 2008. Studies were included if they were
longitudinal studies ofpeople with psychosis, or case-control studies nested within
longitudinal designs, where cannabis use was measured at a time prior to the outcome
being measured. Studies were not excluded if they included individuals with affective
psychoses, but in all studies the vast majority of individuals had schizophreniform
disorders. As well as the outcome measures of relapse/readmission and scores on
symptom rating scales, outcomes less directly related to symptom severity (e.g. harm
to self or others, non-compliance with treatment) were also included.
Zammit et al. identified 13 studies meeting their inclusion criteria, of which
only 7 looked only at people with schizophrenia (or schizophrenia-spectrum
disorders). The seminal study of Linzen et al., (mentioned above), was excluded as it
was believed that the methodology employed could have resulted in the inclusion of
individuals increasing or initiating cannabis use secondary to the outcome studied (i.e.
relapse resulting in cannabis use rather than vice-versa). Given this concern, cannabis
users were determined by cannabis use at baseline rather than during the follow-up
period. Though it is probably the case that most cannabis users will continue to use
the drug over the follow up period, given that some may stop using the substance this
could result in a reduction in the strength of any associations seen. The variety in
outcome and exposure measure definitions used, as well as the content of statistical
results presented, meant that it was not possible to pool data in a meta-analysis.
In the reviewed studies, cannabis use was consistently associated with a greater risk of
relapse or rehospitalisation. Associations with scores on symptom rating scales were
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less consistent, but cannabis use was generally associated with higher positive
symptom ratings. In the three studies in which the issue was addressed, cannabis use
was reported as being associated with poorer treatment compliance. The reviewers
discuss the issue of confounding at some length. They believe the two most likely
sources of this to be use of alcohol and other drugs, and baseline illness severity and
level of functioning (the latter, they report, could potentially lead to reverse causation
effects). Of the 13 studies included in the review only 3 make any adjustment for use
of other substances, and only five adjust for baseline illness severity. These studies
did report a significant association between cannabis use and relapse/rehospitalisation.
Though less emphasised in this review, an important additional factor which could
confound the association between cannabis use and relapse/worsening
symptomatology is of course treatment non-compliance. This was controlled for in the
1994 study of Martinez-Arevalo et ai, in which the association between cannabis use
T01
and relapse remained robust. Generally however treatment non-compliance was
regarded as a poor outcome in and of itself, rather than a factor directly responsible
for the association between cannabis use and relapse/worsening of symptoms. The
studies undertaken in patients on depots (described above) are clearly particularly
informative in this regard; they clearly demonstrate that even in the context of full
treatment compliance substance misuse can precipitate relapse.
3.2.2.3.2 Impact of alcohol use on the course of schizophrenia
In one of the earliest studies of the impact of alcohol use on outcomes of
schizophrenia, Drake et al. reported in 1989 that alcohol use was strongly associated
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with rehospitalisation.304 In this prospective study of 115 patients with established
schizophrenia, 68% of heavy users of alcohol returning to hospital at least once in the
year following recruitment to the study, compared to 27% of abstainers. Similar
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findings have also been reported by Osher et al. in another American study.
As in studies investigating the impact of cannabis use, in the reports outlined
above no correction was made for the possibility that the association between alcohol
use and poor outcomes was mediated by medication non-compliance. For this reason
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a 1999 report by Gerding et al. is particularly significant. This study employed
methodology similar to that utilised by Gupta et al. in their investigation of the impact
of cannabis on schizophrenia relapse, including only patients being treated with depot
preparations. This obviously ensured medication compliance, enabling the effects of
alcohol use to be ascertained free of an important potential confounder. In keeping
with the studies reviewed above, Gerding et al. reported that patients with alcohol
dependence were more likely to be admitted during the two years of the study, had a
greater total number of admissions and when they were admitted these admissions
were longer. It does seem that the association between alcohol use and relapse of
schizophrenia is indeed a robust finding, and exists independent of the effects of
medication non-compliance.
3.2.2.3.3 Impact of tobacco use on the course of schizophrenia
Both the acute effects of tobacco on schizophrenic symptoms and studies
comparing symptom load in schizophrenic smokers and non-smokers were reviewed
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above. No longitudinal studies were identified investigating the impact of tobacco use
on psychotic relapse. A single two-year prospective study has however reported that
cigarette smoking at baseline was a significant predictor of suicidal behaviour.307
3.2.2.3.4 Impact of use of other drugs on the course of schizophrenia
Cross-sectional studies investigating the association between stimulant drugs
and schizophrenia symptom severity were outlined in Section 3.2.1.4. Few studies
have investigated the longitudinal association between use of these substances and
schizophrenia outcomes however.
As previously discussed, given the association between substance use and
medication non-compliance, studies in patients treated with depot antipsychotic
preparations are of particular importance. Approximately half of the subjects in the
aforementioned study of Gupta et al. of patients receiving depot antipsychotics used
cocaine, indicating that this drug is indeed associated with psychotic relapse.296 An
additional study undertaken in people with schizophrenia treated with depot
antipschotics provides even more compelling data however. It compared rates of
hospitalization in depot treated subjects who specifically abused cocaine to people
TAO
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without this comorbidity. It demonstrated that patients maintained on depot
neuroleptics who abuse cocaine are hospitalized at significantly higher rates than
nonabusing patients similarly medicated. Though comparable data for amphetamines
are not available, given their comparable acute effects, similar findings would be
expected for this class of drug. It thus seems to be the case, despite the claims that
amphetamines can have beneficial effects on the symptoms of schizophrenia (Section
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3.2.1.4), that in reality recreational use of these drugs (as well as cocaine) has an
adverse effects on outcomes in the condition. The effects of MDMA (ecstasy) use on
the course of schizophrenic illness has not been specifically investigated.
3.2.3 Common causation
The final possibility that has been proposed to explain the association between
substance misuse and schizophrenia is common causation; i.e. the same risk factors
give rise to both conditions. This hypothesis argues that if disorders are
predominantly the result of a set of risk factors and these are the same or similar for
two disorders, then 'comorbidity' reflects the fact that the pathways by which people
develop one disorder are the same as those by which they develop another.
There is much to suggest that this hypothesis may have some relevance from the data
already discussed. For example, one compelling reason is that, as is evident from
Section 2.1, people with schizophrenia misuse a diverse range of substances rather
than the condition being consistently associated with a particular pharmacological
group of licit or illicit drugs. Indeed, the drugs used by an individual tend to reflect
(though levels of use exceed) general patterns of drug use in the population in which
the patient resides. This is at odds with both the self medication and drug use as
aetiological factor hypotheses. If all excessive drug use was to be explained by the
former hypothesis, then it would be expected that drugs with particular
pharmacological or symptomatic effects would predominantly be used, which does
not seem to be the case. Similarly, if the latter were the complete explanation the
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association, the drug use/schizophrenia relationship would again be expected to be
particularly strong with particular substances as only specific drugs would be
expected to have an effect on aetiology.
Thus, on considering the above, it does seem that people with or destined to
develop schizophrenia may have an innate vulnerability to drug use in general. The
common factors which might potentially contribute to the development of both
disorders are biological, personality and social/environmental variables. These will
each be discussed in turn.
3.2.3.1 Biological
Genetic
There is a good deal of evidence to suggest that genetic factors contribute to
an individual's risk of schizophrenia 309 and to substance use disorder.310'311 It has
also been reported that a genetic propensity for substance misuse can be shared across
substances.312'313 A handful of studies have specifically addressed the question of
whether schizophrenia and substance misuse share a common genetic vulnerability,
the primary method employed in elucidating this being examination of family history.
For such a link to be supported, studies would be expected to find that patients with
schizophrenia have more relatives with substance use disorders than people in the
general population or that people with substance use disorder are more likely to have
family members with schizophrenia. The studies that have been conducted to date
have however been conflicting. Though one study did report that dually diagnosed
patients are more likely to have family members with substance use disorders than
142
patients with schizophrenia alone,141 other studies have not found this to be the
case.314'315 In summary, while it is possible that genetic vulnerability may contribute
to the development of comorbid substance use in some patients, the available
evidence does not appear to support the idea that the high rates of comorbidity
observed occur as a result of a common genetic basis for both disorders.
Neuropathology
As reviewed in Section 2.3, the dopamine hypothesis retains an important role
in our understanding of the genesis of schizophrenia. Central to this theory, even in its
most recent incarnation, is the idea that functional hyperactivity of a network of
dopamine neurones projecting to the nucleus accumbens plays an important role in the
genesis ofpsychotic symptoms.110 It is the case however that this system, the
mesolimbic dopamine system, has also been central in our understanding of the
development of drug dependency. Indeed, it is now firmly established as the major
neural substrate for the reinforcing effects of drugs of abuse (see Section 1.2 and
Koob & Le Moa ) The fact that the core features ofboth substance dependence and
psychotic symptomatology rely on the same neural substrate offers a parsimonious
explanation for the observation that the two conditions co-occur more often than
would be expected by chance. It has led to speculation that the excess of substance
misuse observed in schizophrenia may actually arise as a consequence of the
neuropathology associated with the condition impacting on the neural circuitry
mediating drug reward and reinforcement. As a consequence, this theory would
suggest, people with schizophrenia are biologically more vulnerable to the rewarding
effects of drug abuse and thus at increased risk of addictive behaviour.
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This hypothesis was first coherently formulated by Chambers et al.3]1 They
emphasised the failings of the self-medication hypothesis of comorbidity, and
proposed that schizophrenia and substance use are actually independent
manifestations of the same disease. Utilising findings from human and animal studies,
they hypothesized that abnormalities in hippocampal-cortical function in
schizophrenia impair the inhibitory hippocampal projections to the nucleus
accumbens, resulting in reduced inhibitory control over dopamine-mediated functional
hyperresponsivity to dopamine release. In this model, dysregulated neural integration
of dopamine and glutamate in the nucleus accumbens resulting from frontal and
hippocampal dysfunction could lead, in subjects without prior drug exposure, to neural
and motivational changes similar to those in long-term substance use. Thus, the
dopamine dysregulation innate to having/being at risk of developing schizophrenia
also renders these people are particularly susceptible to substance misuse problems.
Rather than substance misuse arising as a result of self-medication, Chambers et al.
argue, a predilection to drug use is in fact a primary disease symptom.
Impairment in cognitive functioning.
The possibility that people with schizophrenia use substances for their
cognitive benefits was discussed in Section 3.2.1. Impairment in cognitive functioning
has also been proposed as a common factor that may increase risk for both substance
use disorder and schizophrenia.318 Such impairment could reflect genetic factors, early
environmental factors, or a combination of both. The evidence is mixed that cognitive
deficits are predictive of later development of substance use disorders; low IQ has
• 319 320 • 321 322been associated with increased risk in some studies, ' but not in others. '
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Conversely, there is strong evidence that cognitive impairment increases risk of
developing schizophrenia.323 Thus the possibility that cognitive impairment is a
common risk factor for both conditions cannot be excluded, and should ideally be
controlled for in prospective studies investigating putative associations between
substance misuse and the subsequent development of schizophrenia.
3.2.3.2 Personality
Blanchard et al. proposed in 2000 that the prevailing understanding of
comorbid substance use in schizophrenia was constrained by a failure to examine
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individual differences in personality, stress and coping. They proposed that it was
these enduring individual differences, rather than transitory psychotic
symptomatology, that were likely to place an individual at a sustained increased risk
of substance misuse. The essence of this theory is that certain personality traits are
associated with both schizophrenia and substance misuse, and that it is consequent to
this association that the two conditions co-occur more commonly than would be
expected by chance. In constructing this theory Blanchard et al. focussed primarily on
the two personality dimensions they reviewed as having considerable empirical
support for being associated with substance misuse in the general population; namely,
negative affectivity/neuroticism (NA/N) and disinhibition/impulsivity (DIS/IMP).
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NA/N is characterized by the experience of general negative mood states.
326 It is associated with decreased tolerance for stress; lowered threshold for
experiencing negative affects; the tendency to dwell upon and magnify mistakes,
frustrations, and disappointments; and to have negative appraisals of self and
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326others. Conversely, individuals high in DIS/IMP are oriented towards feelings and
sensations of the immediate moment and are less concerned by future implications of
behaviour. Impulsivity, irresponsibility, risk taking, norm rejection, and danger
seeking have been identified as core features of DIS/IMP.327 NA/N and DIS/IMP have
been found to be largely independent personality dimensions, each with its own
• 99^ 997
unique correlates. ' Both of these personality traits have been found to be
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associated with the development of substance use disorders in longitudinal studies.
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For Blanchard et al. 's theory to hold, both of these personality dimensions
would also have to be over-represented in people with schizophrenia. On considering
NA/N first, it has indeed been demonstrated that people with schizophrenia exhibit
high negative affectivity, and that this is a stable characteristic.331 This alone of course
does not exclude the possibility that this elevated negative affectivity simply arises as
a consequence ofhaving a schizophrenic illness (rather than been associated with
increased risk of it). Emphasising the primacy of this characteristic however, elevated
neuroticism has also been found to be a feature of preschizophrenic adolescents,332
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and the healthy relatives of people with schizophrenia. Interestingly, and of
particular relevance to the current study, anxiety-type symptoms were also noted to be
prominent in high risk subjects even at the point of recruitment in to the EHRS (when
subjects were all clinically well).334 That the association between negative affectivity
and substance misuse remains relevant in the context of schizophrenia has also been
specifically investigated. Evidence to support this was reviewed in Sections 3.1 and
3.2.1 and is further outlined by Blanchard et a/.324
Data identifying disinhibition/impulsivity as a risk factor for substance misuse
problems are particularly robust, being supported by numerous independent
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longitudinal studies. ' The available data once again suggest that a comparable
association exists with schizophrenia, longitudinal methodology demonstrating that
impulsive, undercontrolled behaviour in childhood does characterize individuals
O n too m .
destined to develop schizophrenia. ' Once again, such an association also receives
some support from the EHRS. In this study the related characteristics of delinquent-
aggressive behaviour in adolescents at risk of schizophrenia was found to be a
11Q
significant predictor of later schizophrenic illness. As was the case with negative
affectivity and schizophrenia, it is important to establish that that
disinhibition/impulsivity remains associated with substance misuse in the specific
context of schizophrenia. The available evidence does suggest that this is indeed the
case,340 and rates of substance misuse are certainly increased in people comorbid for
schizophrenia and antisocial personality disorder.341
3.2.3.3 Social and environmental factors
A number of social and environmental factors that could potentially underpin
both disorders have also been hypothesized. Economic and social disadvantage, for
example, are widely accepted as being associated with both substance abuse and
schizophrenia. Thus, (as some studies reviewed in Section 2.1 did), it is important to
match cases and controls for these criteria when comparisons are made ofprevalence
of substance misuse in people with schizophrenia to that in other groups. Another
possible mechanism linking the two, rarely considered, is traumatic early childhood
experience. We know that members of the general population who report physical or
sexual abuse in childhood are more likely to abuse substances in adulthood 342 and
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that, for some, childhood abuse can also contribute to psychosis.343 Scheller-Gilkey et
al. compared 70 patients with schizophrenia and a history of substance abuse with 52
patients without a history of substance abuse and found that the former had
significantly higher scores on a measure of childhood traumatic events and on a PTSD
scale.344
3.3 Synopsis ofdata investigating relationship between drug use and schizophrenia
The wealth of data outlined above confirms that, as may be expected from
what is known about substance misuse in the general population, the reasons why a
particular individual with schizophrenia has a substance misuse problem are
complicated. Self medication and shared vulnerability factors may both play a role,
and the extent of this role would be expected to vary both between individuals and
between different substances. Nevertheless, evidence that some substances may
actually contribute to risk of developing the condition does remain compelling. The
evidence for such an association is strongest for cannabis, the drug which likely also
has the least evidence of there being any desirable consequences for use in
schizophrenia. Conversely, there is evidence that tobacco smoking may ameliorate
some of the cognitive deficits seen associated with schizophrenia, and there is little
evidence that it increases risk of the condition. Other substances fall somewhere in the
middle; alcohol for example may transiently reduce the anxiety associated with
schizophrenia, and so use may be driven by a degree of self medication. Evidence that
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alcohol may contribute to the risk of schizophrenia is relatively weak, but the
possibility is notably under-explored.
In considering whether use of a particular substance could contribute to the
risk of developing schizophrenia it is important to consider the consequences that that
drug can have for brain structure. If use of a drug can give rise to structural brain
changes then it both makes it more biologically feasible that it can give rise to a
psychiatric illness such as schizophrenia. This may be particularly the case if the
structural abnormalities seen are similar to those associated with the condition.
Additionally, if the brain structural abnormalities consequent to use of a particular
substance associated with increased risk of schizophrenia (e.g. cannabis) can be
characterised, then this may give clues to the nature of the pathophysiological process
by which use of the substance confers this risk. Data addressing these issues will be




Review of structural imaging findings
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4.1 Structural imaging findings in substance misuse
The data investigating reasons for the relationship between substance abuse
and schizophrenia were discussed in Chapter 3. As was apparent from this review,
there is considerable evidence that cannabis use contributes to the risk of developing
schizophrenia. Evidence supporting such an association for other substances is
weaker, but is nonetheless conceivable for amphetamines and possibly also cocaine,
ecstasy and alcohol. As discussed in Section 3.2.2 demonstration of these associations
is however fraught with difficulties; furthermore, it is also unlikely that further cohort
studies of a similar design, (cohort studies being the most robust study design that can
feasibly be employed in humans to demonstrate these associations), will significantly
advance our understanding of these relationships.
If substance use does result in an increase in psychosis risk, then this must be
mediated by biological changes arising as a consequence of substance use. Logic
dictates that underpinning these biological changes must be abnormalities in brain
structure or function. Though it is of course conceivable that these could be
undetectable with currently available technology, brain imaging does at least have the
potential to detect these abnormalities. Thus, while Type II errors remain a distinct
possibility, demonstrating that habitual use of drugs of abuse was indeed associated
with structural brain changes could substantially enhance our understanding of this
process. It would strengthen the case that use of these substances increased an
individual's risk of psychiatric pathology, and potentially suggest the mechanism or
mechanisms by which this occurred. Furthermore, if these abnormalities transpired to
be similar to those seen in schizophrenia, then this may inform our understanding of
how use of this substance may result in an increased risk of this condition.
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As ever, a number of provisos must first be acknowledged however. As will
become apparent from the discussion that follows, much of the imaging data in this
area are from cross-sectional studies. Consequently, they can tell us little about
causation. It is frequently assumed that any differences observed when imaging
findings in substance-misusing populations are compared to those in controls arise
entirely as a consequence of the effects of substance use on the brain. This is
obviously not the only feasible explanation for this association however, and the
possibility that structural abnormalities predate substance misuse and are themselves
contributing to the risk of substance misuse must of course be considered. In teasing
apart these possibilities, longitudinal studies are of particular value.
An important further consideration is multiple substance use, an issue which is
increasingly the rule rather than the exception. Given its prevalence, it has the
potential to be an important confounder of any apparent specific substance/structural
imaging abnormalities which are observed. It is thus important that any studies which
are included in the following discussion have ascertained the extent to which this is an
issue in their study populations, and state whether or not it has been controlled for.
With these considerations in mind, I will now review data examining the
structural brain imaging abnormalities associated with habitual use of the drugs of
abuse commonly encountered in the UK. I will begin with a brief review of imaging
findings associated with drug use in general, and then go on to discuss findings in
relation to specific substances.
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4.1.1 Imagingfindings associated with increased risk ofalcohol/drug use
It is widely acknowledged that substance use disorders tend to aggregate in
families, and that genetic factors play a major role in this. For example, family, twin,
and adoption studies have convincingly demonstrated that genes make a substantial
contribution to the development of alcohol dependence, with heritability estimates
ranging from 50 to 60 percent for both men and women.345 Though less well
researched, it has also been reported that there is a strong genetic basis to cannabis
abuse and dependence,346 and the concept of there being a general genetic propensity
to drug use has increasingly gained credence.347 Though specific factors may well
differ for different substances of abuse, these genetic studies do therefore suggest that
some of an individual's risk of developing an addiction problem is innate, and present
from birth. This being the case, it may be that some of this increased risk is reflected
in abnormalities of brain structure which are associated with an innate propensity to
substance use (and are present in the absence of the effects that use of these
substances subsequently have on the brain). As relatives of people with substance
misuse problems share many of the same genetic characteristics, then these
abnormalities would also be expected to be apparent in the relatives of people with
substance misuse problems. Thus, the most obvious way to identify if brain structural
abnormalities are associated with a propensity to drug use (while avoiding the
possibility that substance misuse by these individuals is itself contributing to any
imaging abnormalities seen), would be to image individuals who are relatives of
people with substance misuse problems but have never used/only used at low levels
the substance in question. This approach does have a major flaw however. Namely,
selecting individuals on the basis of not exhibiting problematic use of a substance
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raises the obvious concern that they do not share the propensity of their affected
relatives to problematic use of the substance in question (so explaining why they have
not developed a problem). Consequently they may not actually display any of the
imaging abnormalities postulated to be associated with problematic use of the
substance. If this was the case they would obviously tell us little about the imaging
characteristics which are associated with substance use.
One way potential way around the above problem is to utilise identical twins,
but this is itself fraught with its own difficulties, and no such studies could be
identified. An alternative approach, analogous to that employed in the EHRS in
relation to schizophrenia, is to scan people who are at risk of substance use, but have
not yet reached the age at which this behaviour would be expected to begin. If they
are compared to individuals without this propensity, then this may indeed inform us of
the imaging findings associated with this innate predisposition. This model of study
does also has its own potential pitfalls; for example, could any abnormalities seen
actually be consequent to antenatal substance exposure, to which these individuals are
likely to be at greater risk? Nevertheless, this study design does have the potential to
provide useful information.
A small number of studies have indeed employed the latter approach, all of
which have focussed on individual at high risk of alcohol dependence. These studies
have exclusively been undertaken by two research groups, Hill et al. in Pittsburgh and
Senegal et al. in Bangalore. Hill et aids initial study compared amygdala and
hippocampal volume in 17 male individuals at high risk of alcohol problems on the
basis of family history to 17 matched control subjects with no such history.348 Mean
age of the former group was 17.6, and the latter group 17.3. After controlling for
current alcohol consumption (as well as a number of other variables), they reported
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that the at-risk subjects exhibited significantly reduced volume of the right amygdala.
No difference was observed in total grey or white matter volumes, the left amygdala
or either hippocampi. In subsequent studies of the same data set, cerebellar and
orbitofrontal cortex volumes were compared between the two groups. They reported a
tendency for cerebellar volume to be increased in adolescents and young adults at
high risk for alcohol use disorders,349 and that right orbitofrontal cortex volume was
significantly reduced in this group (in the context of their being no difference in total
orbitofrontal volume). Hill et al. also discuss that age regression of total grey
matter volumes suggested a slower reduction in grey matter volumes among the
offspring of alcoholics during adolescence. The authors suggest that this may indicate
a delay in grey matter pruning or slower maturational increases in white matter.
The studies of Benegal et al. focussed on a slightly younger high risk group, mean age
of high risk subjects being approximately 15. In contrast to the report of Hill et al.,
Benegal et al. reported that cerebellar volume was decreased in their study of high
risk alcohol-naive subjects which employed both region of interest and voxel-based
morphometric analyses.351 This study also noted that when compared to controls, high
risk subjects also had decreased grey matter volume in the thalamus, superior frontal
gyrus, and cingulate gyrus. A subsequent study by the same group compared corpus
callosum morphology in the high and low risk subjects. 52 Total corpus collosal area,
and that off the genu and isthmus regions were significantly smaller in high-risk than
low-risk subjects after controlling for age and intracranial area.
The findings outlined above require replication, and the suggestion of some
contradictory results in the findings of the two groups, (most notably in relation to
cerebellar volume) suggests they may not be robust. Nevertheless, these studies do
underline the importance of always considering the possibility that not all of the
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abnormalities detected in the brains of alcoholics are necessarily a consequence of
alcohol exposure. Given the lack of data, the relevance of these findings to users of
other drugs is a matter of speculation.
4.1.2 Imagingfindings associated with general drug use
In the review below I will discuss data relating to the use of specific drugs of
abuse. Prior to this there are however a number of studies of drug use in
general/multiple substance use which are important to mention. Firstly, is a 2006
study of adolescent recreational of users of both alcohol and cannabis undertaken by
Yucel et al,353 This employed linear regression analyses to establish if use of alcohol
and cannabis use were predictive of hippocampal, amygdala and whole-brain
volumes. They reported that use of cannabis and alcohol at an earlier age were
independently predictive of larger amygdala volumes. By contrast, longer duration of
cannabis use was predictive of smaller hippocampal volumes. Secondly, a case
controlled study was undertaken comparing total volumes of grey and white matter,
frontal grey and white matter, both lateral ventricles, and cerebral spinal fluid in 16
male substance abusers (mean age 38.8) to 16 controls.354 Substance abusers used a
variable combination of cannabis, cocaine, methamphetamine and heroin; however,
neither substance abusers nor control subjects were currently abusing alcohol or had
any previous history of alcohol abuse or dependence. Substance abusers had
significantly less frontal white-matter volume percentage than controls, but there were
no significant differences in any of the other brain volumes measured. The authors
acknowledge that the cross-sectional nature of the study means that it can not
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distinguish whether the difference in frontal lobe white matter is explained by a direct
neurotoxic effect of drug use on white matter, a pre-existing abnormality in the
development of the frontal lobe or a combination of both effects.
4.1.3 Associations between use ofspecific drugs and brain imaging abnormalities
Data examining structural imaging abnormalities associated with use of
specific substances will be detailed below. A number of themes will recur in review
of these studies. Firstly, concurrent use of other substances is a common feature, and
the extent to which studies acknowledge/model for this does differ. Thus, the
possibility that results are confounded by use of other substances must always be kept
in mind. Second is the fact that the majority of studies that have been undertaken are
cross-sectional in design. This means that though authors frequently assume that any
abnormalities observed in association with substance use are caused by that substance
use, the cross-sectional design (in association particularly with the findings of
Benegal et al., see above), means that this can be questioned. Where available




Two reviews of imaging studies investigating structural and functional brain
imaging findings in cannabis users have been published in recent years. The first of
these was published by Quickfall and Crockford in 2006,355while the second was
published by Martin-Santos et al. in 2009.356Both studies employed a comprehensive
search strategy. While inclusion/exclusion criteria were relatively lenient in the
Quickfall and Crockford study, they were more restrictive in the study of Martin-
Santos et al. The specific inclusion/exclusion criteria employed in the latter study
were that structural imaging studies had to: comprise subjects at least 18 years of age;
match cases and controls for age, sex and handedness; not include participants with
any other psychiatric or neurological disorder; and that participants did not have other
substance use disorders. Martin-Santos et al. identified eight structural imaging
studies evaluating the effects of chronic cannabis use. Five of these utilised
volumetric methodology, while the remaining three were diffusion tensor imaging
(DTI) studies.
To identify relevant studies published after the search undertaken by Martin-
Santos et al. I employed search criteria comparable to that which they employed.
Obviously the publication period was extended, studies published up to May 2010
being included. This methodology identified only two additional studies of relevance;
a study by Mata et al. comparing cerebral gyrification in cannabis users to people
with no history of illicit drug use,357and a study by Medina et al. comparing prefrontal
cortex volume in cannabis users to controls.358 These studies, together with those
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Table 4.1
Studies investigating structural brain imaging abnormalities in cannabis users
My discussion of the available data on structural imaging abnormalities
associated with cannabis use will centre on the studies outlined above. In addition
however, I will also include a number of studies not meeting these criteria, but of note
for historical or other reasons.
The earliest study to employ a case-control design to compare structural
imagine findings in subjects who did and did not use cannabis employed
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pneumencephalography and was published by Campbell et al. in 1971.368 Though it
suggested the presence of enlarged ventricles in the cannabis using subjects, these
findings were confounded by a number of variables; not least amongst these, for
example, was the fact that many of the patients were initially referred with
heterogeneous neurological complaints. As pneumencephalograpy was superseded by
computer tomography in the 1970s, so this technology was applied to scanning the
brains of cannabis users. Interestingly however, only one study could be identified
employing this technology to anything even approximating a standard case-control
design. This, a study undertaken by Hannerz and Hindmarsh, compared certain brain
imaging characteristics in cannabis smokers to those from normal people who did not
use the drug.369 Specifically, the means of measures such as transverse diameter of the
lateral horns and the largest diameter of the third ventricle were compared between
the two groups. In contrast to the pneumencephalography findings Hannerz and
Hindmarsh report that no differences were identified between cases and controls. The
sole exception to these findings was one cannabis-using subject who reported daily
alcohol abuse; in his case the researchers felt there was unquestionably pathology.
The next significant advance in neuroimaging was MRI, studies employing
this technology being summarised in Table 4.1. With the exception of the three DTI
and a single GI study, the reports included in the table compare either direct (e.g.
semi-automated ROI) or proxy (e.g. voxel-based morphometry) measures of structure
volume in cases and controls. This thus constitutes six relevant studies undertaken in
adults investigating the impact of cannabis on brain structure volume. None of the
studies reported significant differences in global measures of brain volume. In two of
the studies however, significant regional differences are found. Firstly, Matochik et
al. found that cannabis users had reduced grey matter volume in the right
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parahippocampal gyrus, while this was conversely increased in the right thalamus."61
More recently, Yucel et al. reported bilateral volumetric reductions in the
hippocampal and amygdalar areas in a group of 15 chronic cannabis users compared
to controls.365 These findings do suggest that if brain structural abnormalities are
associated with cannabis use they are most likely to be identified in the region of the
hippocampus. Such speculations aside however, what is most apparent from these
data is that, (in keeping with what was suggested by early CT studies), there is
currently no consistent evidence for either global or regional volumetric differences
between cannabis users and normal controls.
In addition to the volumetric studies, three of the studies in Table 4.1
compared DTI findings in cases and controls. DTI is a technique used to examine the
integrity of white matter tracts, quantifying white matter structural integrity in terms
of mean diffusivity (MD) and fractional anisotropy (FA). MD quantifies the
magnitude of water diffusion in each image voxel, while FA quantifies the
directionality and coherence ofwhite matter fibre tracts. When boundaries to water
diffusion are reduced, (i.e. white matter structural integrity is impaired), MD increases
while FA decreases. Two of these studies found no differences between cannabis
users and controls.362'364 The third study reported a significant increase in mean
diffusivity, but no decrease in fractional anisotropy associated with cannabis use, in
the prefrontal section of the corpus callosum.366 Finally, the most recent study by
Ashtari et al. reported reduced fractional anisotropy, increased radial diffusivity, and
increased trace in the arcuate fasciculus (tracts underpinning fronto-temporal
connectivity).367 This study does need to be interpreted with considerable caution
however, as there are important potential confounders; of note, cannabis users were
dawn from an offender population (unlike the controls), and alcohol intake was not
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controlled for. Importantly, these considerations meant it was in fact excluded from
the review of Martin-Santos et al. Thus, and similarly to the findings from the
volumetric/VBM studies demonstrating minimal differences in regional grey matter
volumes, the DTI studies do not provide strong evidence of major cannabis effects on
the integrity of white matter fibres.
Finally, there is the single study comparing gyrification in cannabis users and
... . .
controls. The main findings of this study were that cannabis users had bilaterally
decreased concavity (more flattening) of the sulci, and thinner sulci in the right frontal
lobe. The authors suggest that the most likely explanation is that cannabis use during
adolescence may affect normal neurodevelopment, especially in the prefrontal cortex,
leading to a pattern of decreased gyrification with less concave and thinner sulci.
They do acknowledge however that multiple hypothesis testing means that the
possibility that the results are attributable to a type I error cannot be excluded.
On considering the above data, it is apparent that at present there is no
consistent evidence of brain structural abnormalities being associated with cannabis
use. Where single studies have identified regional brain volume loss (e.g. Yucel
detecting hippocampal volume loss), these have not been identified in other studies
specifically investigating that brain region (e.g. Block and Tzolis), and must therefore
be treated with scepticism. Unsurprisingly, this is also the conclusion reached by other
groups who have reviewed these data. While meta-analysis may have the potential to
reveal some subtle effects, the heterogeneous nature of the studies undertaken to date
means this is not feasible at the present time.
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4.1.3.2 Alcohol
4.1.3.2.1 Review of findings across age groups
Alcohol is Western society's favourite drug, and chronic, heavy use has long
been recognised as resulting in catastrophic cognitive impairment. Given this, it is
perhaps unsurprising that studies investigating the structural imaging consequences of
alcohol abuse and dependence are considerably more numerous than those
investigating these associations in people who abuse cannabis. Many of these studies
have been undertaken in older alcoholics with very many years of alcohol
dependence. The subjects included in these studies have also often been rather
heterogeneous. This issue is particularly important in this area, as brain changes in
those who have experienced the most catastrophic sequelae of alcohol dependence
(e.g. Korsakoff s psychosis) are likely to be substantially different from those in
people who have drunk heavily, but not experienced such a dramatic event. Thus,
while findings in these older populations are clearly important, they may have limited
relevance when considering the impact of alcohol use on structural imaging measures
in younger people with much shorter alcohol use histories. Given these
considerations, though important data arising from studies undertaken in older
individuals will be considered in this review, its primary focus will be the impact of
alcohol use on brain structure in people under the age of forty. These data are
obviously of particular relevance to the current study, concerned as it is with a
population in late adolescence/early adulthood.
The early history of brain imaging of alcohol dependent subjects was reviewed
by Krill et al. in 1999.370 In this review they discuss the heterogeneity of the studies
164
reviewed and the fact that differences in the manner in which the heavy alcohol using
groups are defined, (e.g. mean consumption over a certain threshold per day versus
fulfilment of DSM-IV criteria for alcohol dependence), may also produce
fundamental differences in the populations being studied. Additionally, they note that
sequelae resulting from uneven drinking patterns (e.g. binge drinking) have rarely
been addressed, but that this may result in different pathology due to the higher blood
alcohol levels attained during these periods. Current drinking status is also an
important consideration, as some of the brain abnormalities associated with alcohol
use are know to correct with cessation of drinking.
As reviewed by Krill et al., the first studies to demonstrate brain shrinkage in
alcoholics achieved this by employing pneumoencephalography to identify ventricular
"X11 . ...
enlargement. Following computerized tomography becoming available in the
-379 -37-3
1970s, these initial findings were confirmed and extended. ' Indeed, these CT
studies demonstrated not only that alcoholics without overt clinical signs of brain
damage had larger ventricles, wider cerebral sulci and wider Sylvian and
interhemispheric fissures; additionally, application of a longitudinal study design
demonstrated that with abstinence some resolution of these abnormalities could
374
occur.
With the introduction of MRI in the 1980s, more accurate determination of the
structural abnormalities associated with alcohol use could be achieved. This modality
has the potential to delineate discrete neuroanatomical structures, meaning that the
regional changes giving rise to brain shrinkage can be elucidated. Initially MRI
studies in alcoholics further confirmed the findings of CT studies, noting ventricular
enlargement and that this was party reversible following abstinence.375'376With
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improved MRI resolution, so the capacity of this technique to measure and compare
the volume of specific brain structures did begin to be utilised however.
Much of the MRI imaging work in alcohol dependence was undertaken by Sullivan
and Pfefferbaum, who recently reviewed MRI findings in chronic alcoholism in a
• • 177 .... . .
2005 publication. This review primarily addresses 'uncomplicated' alcoholism, by
which is meant alcoholics free of the severe syndromes arising from alcohol-
associated nutritional deficiencies or electrolytic imbalance. As well as Korsakoff s
psychosis these clinically dramatic conditions include Marchiafava-Bignami disease,
which primarily affects the corpus callosum and results in a disconnection syndrome;
central pontine myelinolysis, which affects myelin in the central pons and can cause
paraplegia; and alcoholic cerebellar degeneration, which results in severe ataxia of
gait and posture. Sullivan and Pfefferbaum note that the application of quantitative
MRI analysis techniques to scans from these 'uncomplicated' alcoholics reveals that
T7Q TRO
both cortical grey matter ' and white matter sustain widespread volume loss,
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which is greatest in the prefrontal cortex and white matter. ' They also report that
in most brain regions and structures examined, an age-alcoholism interaction is
observed, older alcoholics having greater volume shrinkage for their age than younger
alcoholics. In one study, this interaction was shown to be independent of the
possibility that older alcoholics had the opportunity to drink more alcohol for a longer
TRO
time than younger alcoholics.
As well as these cortical changes, Sullivan and Pfefferbaum also note that
subcortical and brainstem structures are also affected in uncomplicated alcoholism.
Interestingly, the brain structures affected are the same as those affected in the clinical
syndromes outlined above (albeit to a lesser degree), and include the corpus
callosum,382' 383 pons,384 cerebellar hemispheres, and vermis.385 On considering the
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brain abnormalities in Korsakoff s syndrome, the amnesia has traditionally been
lor
attributed to lesions of the thalamus and mammillary bodies, but more recently was
also related to hippocampal volume loss.387 Similarly to the other specific syndromes,
more subtle volume loss has also been detected in these regions in non-amnesic
TOO T OQ
chronic alcoholics. Notably, this has been reported in the mammillary bodies, '
TQrv inn m ...
anterior hippocampi, and thalamus, as well as in other regions including the
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caudate, putamen and nucleus accumbens.
Subsequent to the review of Sullivan and Pfefferbaum, Marinus Verbatun
undertook a review of MRI findings in studies of those termed 'low to moderate' or
'social drinkers' published from 1997 to December 2006.392 By his usage, the term
'social drinking' referred to people who were not dependent on alcohol, but could be
consuming up to 40 drinks a week (the upper limit of consumption for inclusion in the
review). The particular focus of the review however was on the effects of 'moderate
drinking', which they defined as consuming up to 21 standard glasses of alcohol a
week. Only seven studies were found fulfilling their inclusion criteria (necessitating,
for example, data on age, number of drinks consumed etc.). These are summarised in
Table 4.2. Findings were generally rather inconsistent. Nevertheless, in two studies a
significant linear relationship was found between brain shrinkage and alcohol
consumption, even when the latter was at non-dependent levels. Specifically,
increasingly wider sulci and/or increasingly larger ventricles were reported as amount
of consumed alcohol increased in two populations with mean ages of 57393 and 75.394
Other studies however (e.g. Kubota et al. 2X) reported that age was the main factor
responsible for brain shrinkage, and that only heavy alcohol consumption (35 or more
UK units per week) increased such normally occurring shrinkage significantly. On the
basis of these (and a small number of other studies , included in Table 4.2), the
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authors concluded that even the consumption of light and moderate doses of alcohol
led to shrinkage of the brain, with increases in white matter volume but decreases in
grey matter volume. On reviewing the included studies however, the central data
supporting this conclusion comes from the observation of dose response
TQ-3 "3QC
relationships. " Extension of these findings to moderate drinkers is actually rather
questionable, as many of the subjects driving these associations were actually
drinking at 'heavy' rather than 'moderate' levels. Even more concerning, the
conclusion drawn in relation to white matter is clearly at odds with that reported in
studies of dependent subjects, summarised by Sullivan and Pfefferbaum. Furthermore,
these conclusions are actually not supported by a number of studies included in the
review, e.g. Kubota et a/.321 Despite these concerns, it is notable that a large American
study (mean age 60.6) published after this review once again found a negative linear
association between alcohol consumption and reduced brain volume (unfortunately,
grey and white matter were not investigated separately); this study did indeed suggest
that moderate alcohol consumption (8-14 drinks a week) may well be associated with
reduced brain volume.396 No other relevant recent studies were identified on
undertaking a literature search, and given the current state of the literature it is my
impression that the evidence that moderate alcohol consumption is associated with
structural brain imaging abnormalities is equivocal at best.
In interpreting all the above findings, it is also important that the influence of
age is not forgotten. All the discussed studies were undertaken in people who were
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Studies identified by Marinus Verbatun investigating structural imaging abnormalities
in non-dependent drinkers.
Table has been modified from original publication, and additional relevant data extracted from the
included publications.
Key: SFG: superior frontal gyms; MOG: middle occipital gyrus; PrCG: precental gyms; PoCG:
postcentral guys; MIG: middle inferior gyms; rFG: right frontal gyrus (Brodmann area 6)
Longitudinal studies
A substantial proportion of the longitudinal MRI studies investigating the
impact of alcohol use on brain structure have again been undertaken by Sullivan and
Pfefferbaum. Their controlled longitudinal MRI studies of alcoholics in recovery or
relapse have revealed that with short-term (about 1 month) abstinence from alcohol
cortical grey matter increases in volume. With longer-term abstinence (about 1 year),
the third ventricle shrinks, but with relapse it expands and white matter shrinks.400
Over a 5-year interval, the degree of excessive drinking in alcoholics is related to the
degree of cortical grey matter loss, especially in the frontal lobes.401 Additional
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studies have suggested that cortical white matter volume may be particularly
amenable to recovery with abstinence,402'403 but it remains vulnerable to further
decline with continued drinking.400 Although the mechanism for either volume loss or
restoration with abstinence remains unclear, Sullivan and Pfefferbaum discuss that it
probably involves changes in both myelination and axonal integrity in white matter
• • • • 377and glial and dendritic changes in cortical neuropil.
Diffusion Tensor Imaging
Sullivan and Pfefferbaum also discuss the DTI data for brain microstructural
compromise in chronic alcoholism. As discussed in relation to cannabis, DTI is a
technique used to examine the integrity of white matter tracts. Given the apparent
propensity for alcohol consumption to be particularly associated with white matter
volume loss, then it would be expected that this imaging technique would be sensitive
to the detection of abnormalities consequent to alcohol consumption.
Sullivan and Pfefferbaum report that their studies using DTI in uncomplicated
alcoholism found abnormally low anisotropy in regionally defined white matter of
alcoholic men404 and women.405 As discussed in relation to cannabis, this indicates
that white matter structural integrity is impaired in these regions. They note specific
deficits in both men and women in the callosal genu and centrum semiovale, and
additional deficits in the callosal splenium in men. Pericallosal white matter was also
affected.404 In women, the white matter abnormality identified with DTI went
undetected with structural MRI, 5 emphasising the greater sensitivity of DTI to
detection of abnormalities in these structures. In interpreting these results, Sullivan
and Pfefferbaum once again emphasise the importance of an age-alcoholism
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interaction, citing findings that older alcoholics have greater abnormalities for their
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age than younger ones in support of this.
Amone et al., in their 2006 report, review DTI studies specifically
investigating the corpus callosum.366 By the time of this review data from two further
studies were available, both of which were undertaken by or involved Pfefferbaum's
group.406'407 This review confirms white matter pathology in the corpus callosum in
association with alcoholism, studies consistently reporting reduced FA which is most
pronounced in the genu followed by the splenium. Effects in the genu were more
pronounced in women, whereas those in the splenium were restricted to men. As
previously discussed, the finding of reduced FA suggests that the integrity of white
mater tracts in these regions has been compromised. Given that the genu and the
splenium of the corpus callosum connect left and right frontal sites and parietal and
occipital sites respectively,408 this localisation implies that it is connections between
these brain regions which are compromised. It is notable that these findings are
occurring in similar regions to those in which MRI reported deficits in alcoholics;
though DTI is more sensitive to white matter deficits, it does thus seem that there is
indeed overlap between the regions detected as abnormal with the two techniques.
Post mortem findings
Sullivan and Pfefferbaum also discuss MRI findings in alcoholism in relation
to post mortem studies of people who have had the condition. Findings are consistent,
these studies reporting white matter abnormalities in brainstem and subcortical
structures, including the cerebellar vermis,409 mammillary bodies,410 hippocampus,411
and corpus callosum, which thins 412 and atrophies 413 Although white matter
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pathology is reported more often than grey matter pathology, neuronal loss does occur
but is restricted to the superior frontal cortex.414"416
4.1.3.2.1 Systematic reviews of structural brain abnormalities in young alcohol
abusers
The mean age of all subjects included in the studies addressing structural brain
imaging abnormalities in cannabis users was under 40. By contrast, in the studies
undertaken in alcohol dependent/heavy alcohol users the mean age was generally at
least late 40s, and often participants were in their 70s. The greater age of these
subjects implies that they had many years of exposure to alcohol, and so findings
from these studies may not be relevant to younger populations (such as are the focus
of the current study). This issue is particularly relevant given the robust age-alcohol
interaction which has been repeatedly stated.
Given the above, I felt it important to conduct a systematic review of studies
specifically addressing structural imaging findings in younger age groups. Such
studies should give a better indication of the 'pure' effects of alcohol on the brain,
minimising the effect of confounders such as cerebrovascular disease and the
influence of an age-alcohol interaction. Such a review is acutely needed; despite the
studies investigating if structural brain abnormalities predate use of alcohol in high
risk subjects (see above), data investigating the presence (or otherwise) of imaging
abnormalities in younger populations of alcohol abusers/dependent subjects have not
been synthesised. In undertaking such a review, the immediate question is what age
constitutes young. Given that it has long been accepted alcohol-related brain changes
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are evident by the fifth decade of life,380 the cut off age I have taken for 'young' is 40.
Furthermore, studies undertaken in people under 40 could either be in young adults or
adolescents (i.e. people under the age of 18). As the effects of alcohol on the brains of
these two age groups could potentially differ, my review will comprise of two
components. The first will identify studies of alcohol abusing subjects (and controls)
with a mean age of less than 40, but greater than 18. The second will focus on
adolescents, participants in included studies having a mean age of less than 18.
Systematic review in young adults
Methods for systematic review
Methodology for both systematic reviews was identical other than the
selection of age range of interest. Searches were performed on Medline (1970-May
2010), EMBASE (1970-May 2010) and Psychlnfo (1970- May 2010). The following
search terms were used: alcohol abuse OR alcohol dependence OR alcoholism OR
alcohol drinking AND neuroimaging OR brain imaging OR computerized
tomography, CT OR magnetic resonance imaging, MRI OR diffusion tensor imaging,
DTI. Both free-text and expanded medical subject headings were used. Subject
headings were adapted to the specific subject headings of the biomedical databases
used. The search strategy was supplemented by inspecting the reference lists of
included articles.
I was primarily interested in case-controlled studies (expecting these to be
present in the greatest numbers); however, cohort studies are clearly of great value,
and any identified will also be discussed. For inclusion studies had to utilise CT,
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structural MRI, or DTI scanning methodologies. Additionally, subjects with specific
neurological syndromes, even if directly related to alcohol use (e.g. Korakoff s
syndrome), must have been excluded from the study and subjects must not have been
chosen on the basis of cognitive deficits or other adverse sequelae of alcohol use.
Similarly, studies were not regarded as eligible for inclusion if subjects had been
identified by any specific clinical characteristics (e.g. antisocial traits); this was felt
important as selection on the basis of such characteristics could potentially confound
findings. Studies employing any generally accepted, quantitative form of image
analysis technique directly comparing tissue volume/density or integrity in the two
groups were acceptable; it was expected the majority of studies would utilise either
ROI-based approaches or VBM. Inclusion criteria for case-controlled studies were
inclusion of a control group of healthy volunteers. For inclusion in the review of
young adults mean age of alcohol using subjects had to be greater than 18 but less
than 40. For inclusion in the review of adolescent studies mean age had to be greater
than 14, but less than 18. Studies undertaken only in people in these age ranges were
identified by limiting searches to the appropriate age ranges. This had to be modified
for different search engines, and in some search engines (e.g. in EMBASE), the only
adult age limits available included all people aged 18-65.
Methods for young adult systematic review
Primary research studies were considered for inclusion if they were published
as a peer-reviewed article in English and compared a sample of adults (aged 18-40)
with an alcohol problem (abuse or dependence) with a group of healthy controls.
Studies could either compare the groups cross-sectionally, or compare changes over
time. If both models of analysis were included in a single study, both analyses will be
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reported. Additionally, if different studies have used the same patient sample but
investigated different brain structures, then both reports will be included.
Results for young adult systematic review
The search outlined above identified 1458 potentially relevant studies,
abstracts of which were assessed for inclusion. On review of the abstracts, one-
hundred and thirty articles warranted retrieval in full text form for evaluation. Study
flow and reasons for exclusion are summarised in Figure 4.1. Unfortunately, there
were substantial difficulties in obtaining some of the older studies, this being a
problem predominantly for CT studies undertaken in the 1970s. Given that the
structural brain changes that would be expected in young alcohol abusing subjects
would be expected to be relatively subtle, it was thought to be doubtful that these
studies would add much to the data provided by more recent MRI studies. It was also
apparent from an earlier review of CT studies, that few of these would actually meet
the inclusion criteria;417 notably, only a single case-control study included in this
review focused on the age group of interest, and this did not employ a quantitative
methodology.418 Thus, ifdifficult to obtain it was believed reasonable to exclude these
older CT studies, a fact which do not believe to be significantly detrimental to the
review as a whole.
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Figure 4.1
Study flow and reasons for exclusion in systematic review of structural imaging
findings in adult problem drinkers aged under 40.
Five studies were thus identified which fulfilled the inclusion criteria. All were
cross-sectional, and are summarised in Table 4.3. Common reasons for studies being
excluded were: too old, difficult to obtain CT study; possibly relevant study but
unobtainable; not employing quantitative structural methodology; mean ages of either
alcohol using subjects and/or controls exceeding 40; duplicate publication of the same
data; review article; and no control group/not normal controls. Structural data were
extracted from all included studies and recorded along with a description of the image
analysis technique employed, the type and unit of measurement (area or volume) and
characteristics of the subject and control groups which possibly confounded any
observed differences (including age, gender ratio and use of other substances).
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Study Imaging Image Gend Mean age Inclusion Drinking Use of Structures Findings
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Agartz et MRI Semi- 26:26/ M: Hospitalised Abstained Excluded Hippocampal R hippocampus smaller in
al. 19994" automated 17:19 36.9(6.2)/ for DSM-III- for at least if used in volume AD men and women.
ROI 35.7(8.2) RAD 3 weeks preceding Non- L hippocampus smaller In
F: No history 6 months hippocampal AD women.
37.4(5.6)/ psychosis, (except brain volume Non-hippocampal brain
35.6(7.9) DTs or tobacco) volume only reduced in
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Studies investigating structural imaging abnormalities in adult problem drinkers aged
under 40
AD= alcohol dependence; DTs= delirium tremens
*If genders have been analysed separately, mean age is displayed separately for each gender.
Otherwise mean age is combined.
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The brain imaging abnormalities observed in uncomplicated alcohol
dependence are generally regarded as predominantly a consequence of the toxic
effects of the substance of the brain. It would be expected therefore that the extent of
abnormalities seen would be a function of both duration of exposure and total amount
of alcohol consumed. This being the case, it is unsurprising that the magnitude of
abnormalities seen in the younger subjects included in this review are less pronounced
than in reports from older populations. Nevertheless, even in these younger
populations some themes do emerge. Specifically, it does seem that even in these
younger individuals grey matter deficits may be seen in the prefrontal cortex (this
-37O TOI
possibly being particularly the case in the dorsolateral region). ' Volume
reduction of the hippocampi is much more contentious; though Agartz et al. did detect
this in one study, they did not detect it in another.419'420 While one possibility is that
this inconsistency may reflect the different gender balance of these two studies, with
women being particularly vulnerable to this effect, these conflicting findings do
suggest that any abnormalities that do exist are subtle. Corpus callosum area was
reduced in two studies, though this was a consistent finding only in women, again
suggesting that they may be more susceptible to the effects of alcohol on the brain.
Systematic review in adolescents
Primary research studies were considered for inclusion if they were published
as a peer-reviewed article in English and compared a sample of adolescents (aged 14-
18) with an alcohol problem (abuse or dependence) with a group of healthy controls.
A small number of studies specifically focused on binge drinking; these were also
178
included. As with the young adult systematic review, studies could either compare the
groups cross-sectionally, or compare changes over time. If both models of analysis
were included in a single study, then both can be included. Additionally, if different
studies have used the same patient sample but investigated different brain structures,
then both reports will be included.
Results for the adolescent systematic review
The search outlined above identified 209 potentially relevant studies, abstracts
of which were assessed for inclusion. Thirty five articles were retrieved in full text
form for evaluation. Study flow and reasons for exclusion are summarised in Figure
4.2. Five studies were identified which fulfilled the inclusion criteria; all were cross-
sectional, and are summarised in Table 4.4. Examples of reasons for studies being
excluded were: mean ages of either alcohol using subjects and/or controls exceeding
18, duplicate publication of the same data and study focusing on a high risk rather
than alcohol abusing/dependent population. Structural data were extracted from all
included studies and recorded along with a description of the image analysis
technique employed, the type and unit of measurement (area or volume) and
characteristics of the subject and control groups which possibly confounded any
observed differences (including age, gender ratio and use of other substances). Before
considering the findings of the systematic review, a small number of studies not
meeting criteria for inclusion in the review but nonetheless of relevance to subsequent
discussion must be considered.
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Figure 4.2.
Study flow and reasons for exclusion in systematic review of structural imaging
findings in adolescent problem drinkers.
Firstly, in 2003 Tapert et al. reported findings from a small pilot study which
used diffusion tensor imaging to investigate corpus callosum microstructure integrity
among 8 teenagers with AUD and 8 non-abusing controls.421 This was presented at a
conference rather than being published in a peer reviewed journal, and so is not
included in the table below. Nevertheless, this low powered study reported a trend
towards lower FA in the splenium in the alcohol abusing group (0.79 ± 0.03 versus
0.83 ± 0.04, p = .055). This trend was weaker in the body of the structure, (p = .084)
and not present in the genu (p = .650). A second study of note is that of McQueeny et
al., not eligible for inclusion in the review as the mean age of alcohol using subjects
was 18.09.422 Nonetheless, given the young age of the subjects (the majority of whom
were actually under 18), it seems more appropriate to include it here than in the
discussion of adult studies (above). This was a DTI study focusing on 14 adolescents
with a history of binge drinking, which they defined as consumption of at least 5 or 4
alcoholic beverages (for males or females, respectively) in one sitting during the 3
months prior to imaging. Controls were 14 teens without a history of a binge drinking.
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Neither group had a history of abuse or dependence on alcohol or any other drug.
Binge drinkers had lower FA than controls in 18 white matter areas throughout the
brain, including the corpus callosum, superior longitudinal fasciculus, corona radiata,
internal and external capsules, and commissural, limbic, brainstem, and cortical
projection fibers. They exhibited no areas of higher FA. In-keeping with the pilot
study of Tapert et al., this study suggests that exposure to large doses of alcohol
during youth may compromise white matter tract coherence.
Two further studies compared white matter integrity in alcohol users who also
used cannabis. Tapert et al. 's group found that when binge drinking individuals were
compared to those who binge drink and use cannabis, abnormalities were actually less
49 T
pronounced in the dual substance abusing group. A subsequent report from the
same group reported a rather mixed picture of FA abnormalities in dual substance
using subjects compared to controls; in a number ofpredominantly left sided regions
FA was reduced (e.g. left superior longitudinal fasciculus, left postcentral gyrus),
while in several exclusively right-sided regions it was increased (e.g. anterior limb of
internal capsule).424 Data extracted from the five studies eligible for inclusion in this
systematic review are summarised in Table 4.4. On considering the totality of data
available on structural brain imaging in adolescents with alcohol use disorders it is
apparent that studies are few, and that this limits the conclusions which can be drawn.
The few DTI studies in this population are characterised primarily by their
inconsistencies, though it may be that adolescent drinkers do exhibit reduced FA in
certain regions of the corpus callosum. The four volumetric studies also present rather
contradictory data, though prefrontal white matter may be reduced in females, and
reduced left hippocampal volume is reported in two studies each undertaken by
independent researchers. Hippocamapal volume reduction was not reported in
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individuals at high risk of alcohol use disorder,348 suggesting that this abnormality
may well be consequent to alcohol exposure rather than being a trait characteristic of
people vulnerable to such conditions. As was previously discussed in relation to data
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4.1.3.2.3 Summary of findings in younger populations of alcohol abusers
The main findings from these studies are that any brain abnormalities detected
in young populations of alcohol misusers are subtle, this being in some contrast to the
gross and repeatedly reproduced abnormalities seen in older populations. If any
abnormalities are apparent in these younger populations they seem to be most
detectable in the hippocampi and frontal cortex, and may be more obvious in women.
On balance however, it is questionable if abnormalities would be expected even in
these brain regions in younger populations of even quite substantial alcohol misusers.
Given the subtle nature of any abnormalities which are/are not present, meta-analysis
of these data would be very useful. Unfortunately however, once again the
heterogenous nature of the studies which have been undertaken means that this is not
possible.
4.1.3.3 Tobacco
As reviewed in Section 2.1, tobacco is the most commonly used drug of abuse
by people with schizophrenia. It is also used by approximately one third of the general
population, generally being consumed by smoking. The association between smoking
and cardiovascular disease has long been established, and people who do smoke are at
increased risk of cerebrovascular accidents. It is conceivable however that tobacco
smoking may also be associated with structural brain abnormalities in the absence of
an individual having a medical history of experiencing a stroke. To investigate this
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possibility I undertook a systematic review of studies comparing magnetic resonance
imaging scans in smokers to non-smoking controls. This review will be outlined
below.
4.1.3.3.1 Systematic review of structural imaging findings in smokers
Methods
The methodology employed for this systematic review was comparable to that
employed in the systematic reviews of the structural imaging effects of alcohol
(outlined above). Searches were again performed on Medline (1970-May 2010),
EMBASE (1970-May 2010) and Psychlnfo (1970- May 2010). The following search
terms were used: tobacco OR smoking AND magnetic resonance imaging, MRI OR
diffusion tensor imaging, DTI. Both free-text and expanded medical subject headings
were used. Subject headings were adapted to the specific subject headings of the
biomedical databases used. The search strategy was supplemented by inspecting the
reference lists of included articles.
I was again primarily interested in case-controlled studies (expecting these to
be present in the greatest numbers); however, cohort studies are clearly of great value,
and any identified will also be discussed. For inclusion studies had to utilise structural
MRI or DTI scanning methodologies. Additionally, as before, subjects with specific
psychiatric or medical syndromes must have been excluded from the study. Studies
employing any generally accepted, quantitative form of image analysis technique
directly comparing tissue volume/density or integrity in the two groups were
acceptable; it was expected the majority of studies would utilise either ROI or VBM.
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Inclusion criteria for case-controlled studies were inclusion of a control group of
healthy volunteers.
Primary research studies were considered for inclusion if they were published
as a peer-reviewed article in English and compared a sample of adults (aged 18-65)
with nicotine dependence (being delivered through smoking) with a group of healthy
controls. Studies could either compare the groups cross-sectionally, or compare
changes over time. If both models of analysis were included in a single study, both
analyses will be reported. Additionally, if different studies have used the same patient
sample but investigated different brain structures, then both reports will be included.
Studies were excluded if subjects had experienced a cerebrovascular accident (stroke
or TIA), as investigating the association between smoking and cerebrovascular
disease was not the objective of this study. This review was concerned with studies
ascertaining if non-ischaemic structural abnormalities were detectable in the brains of
adults who smoked. As white matter intensities are generally considered to reflect
covert vascular brain injury,430 studies quantifying the relative concentrations of these
abnormalities in smokers and non-smokers were considered to be beyond the scope of
this review. This was decided while acknowledging accumulating (though conflicting)
data that white matter hyperintensities are prominent in the brains of young people
with no history of cerebrovascular disease but major mental illness.431
Results
The search outlined above identified 969 potentially relevant studies, abstracts
of which were assessed for inclusion. Two further articles were identified through
supplementary search strategies. Twenty two articles were retrieved in full text form
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for evaluation. Study flow and reasons for exclusion are summarised in Figure 4.3.
Four studies were identified which fulfilled the inclusion criteria; all were cross-
sectional, and are summarised in Table 4.5. Examples of reasons for studies being
excluded were: not structural imaging data, individuals had experienced
cerebrovascular events, and abuse/dependence on substances other than tobacco.
Structural data were extracted from all included studies and recorded along with a
description of the image analysis technique employed, the type and unit of
measurement (area or volume) and characteristics of the subject and control groups
which possibly confounded any observed differences (including age, gender ratio and
use of other substances). Before considering the findings of the systematic review, a
small number of studies not meeting criteria for inclusion in the review but
nonetheless of relevance to subsequent discussion must be considered.
Figure 4.3
Study flow and reasons for exclusion in systematic review of structural imaging
finding in adult smokers.
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Structural data were extracted from all included studies and recorded along
with a description of the image analysis technique employed, the type and unit of
measurement (area or volume) and characteristics of the subject and control groups
which possibly confounded any observed differences (including age, gender ratio and
use of other substances). Eligible studies are summarised in Table 4.5.
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Table 4.5
Studies investigating structural imaging abnormalities in adult smokers.
ACC: anterior cingulated cortex
Three studies did not meet inclusion criteria as they focused on individuals
whoab used substances other than tobacco; in all cases these compared alcohol
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abusing populations who did and did not smoke. Though not meeting inclusion
criteria for the review, they do however warrant discussion. Gazdzinski et al., in their
2006 report, compared regional grey and white matter volumes in 24 alcohol
dependent subjects who smoked to 13 who did not.434 They reported that cigarette
smoking was associated with less parietal and temporal grey matter and with more
temporal white matter. A subsequent report from the group utilised a non-treatment-
seeking heavy drinking sample, again comparing regional brain volumes in those who
smoked (17) to those who did not (16).435 Smoking heavy drinkers demonstrated
smaller temporal and total grey matter volumes than non-smoking heavy drinkers.
These findings led the authors to suggest that the combination of chronic heavy
alcohol consumption and cigarette smoking has particularly deleterious effects on
cortical grey matter.
Gazdzinski et al. recently published longitudinal data and further baseline
analyses from their study investigating the co-morbid effects of alcohol dependence
and chronic cigarette smoking.436 The focus of this study was the comprehensive
investigation ofwhite matter injury and recovery by simultaneously employing
diffusion tensor imaging, magnetic resonance imaging and spectroscopy in the same
cohort. Baseline findings (one week post abstinence) were generally in keeping with
earlier data; for example, non-smoking alcohol dependent individuals demonstrated
higher MD than non-smoking light drinkers in the temporal and parietal lobes, this
indicating greater impairment of white matter structural integrity in the former group.
Differences in patterns of white matter recovery on comparing longitudinal data from
non-smoking and smoking alcohol-dependent individuals were rather unexpected
however. In non-smoking alcohol-dependent individuals, the increase in fractional
anisotropy of temporal white matter was accompanied by a pattern of decreased mean
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diffusivity in all regions over 1 month of abstinence; no corresponding changes were
observed in smoking alcohol-dependent individuals. As discussed above, this
indicates that repair of white matter structural integrity is occurring in the non¬
smoking subjects. In contrast, a pattern of white matter volume increase in frontal and
temporal lobes was apparent in smoking alcohol-dependent individuals but not in
non-smoking alcohol-dependent individuals. The authors conclude that these data
demonstrate that the pattern of white matter recovery following abstinence from
alcohol is greatly dependent on an individual's smoking status; microstructural
recovery predominates in non-smokers, whereas volumetric increases occur in
smokers.
4.1.3.3.2 Summary of structural brain imaging abnormalities in smokers
As was the case in young drinkers, data investigating the non-cerebrovascular
brain imaging associations of tobacco use are few. On reviewing the few studies
identified however, two do report reduced grey matter density in the prefrontal
cortex;432'433 indeed, in one of these studies this was detected on employing both
VBM and ROI-based methodologies. There is even less evidence for white matter
abnormalities in non-atherosclerotic smokers. Indeed, increased white matter volume
has been reported in alcohol dependent subjects who smoke (compared to alcohol-
dependent non-smokers),434 and increased white matter integrity has been reported
both when smokers are and are not alcohol dependent.396'436
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4.1.3.4 Structural imaging abnormalities associated with the use ofother drugs
The other drugs which have been the subject of previous reviews are
amphetamines, cocaine and ecstasy. I will also consider, in turn, data ascertaining
structural imaging abnormalities associated with the use of these substances. As ever,
but even more so when investigating these substances, the problem of multiple
substance use is a major issue. The extent to which included studies accounted for
substance misuse comorbidity will be a major consideration of this review.
4.1.3.4.1 Amphetamine
A number of reviews have been undertaken characterising the structural
imaging abnormalities associated with amphetamine use. The majority of these have
focused on methamphetamine, reflecting the explosion in use of this drug that has
occurred in the East Coast of America in recent years. Case-control studies, in which
structural imaging findings in methamphetamine users are compared to those in
normal controls, are detailed in Table 4.6. In addition, the few studies focusing on
amphetamine use (the stimulant more commonly used in the UK) are also included in
this table. Studies included in the aforementioned reviews have been supplemented by
a literature search using the search terms amphetamine OR methamphetamine AND
magnetic resonance imaging. Combined review of amphetamine and
methamphetamine studies is justified by the fact that though methamphetamine may
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be more potent, the actions of these two drugs are generally regarded as remarkably
similar.
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Study Imag¬ Image Gen¬ Mean Inclusion criteria Amphetami Use of other subs Structures Findings
ing analy¬ der age ne/methamp compared
mod¬ sis S/C (SD) hetamine
ality (M:F) S/C using status
(M/F)
Bartzokis MRI Semi- 9:0/ 27.8 Recruited from Currently Excluded ifmet Grey and white Reduced total
et al. automa 16:0 (4.3)/ treatment using DSM-IV criteria matter of whole volume of
2000437 ted 28.6 programmes and amphetamine for dependence on brain, temporal temporal lobe.
ROI (ND) research clinics. Met Mean(SD) opiates, lobes and frontal Trend towards
DSM-IV diagnosis of duration of benzodiazepines, lobes reduced grey
amphetamine amphetamine or other sedative- matter volume of
dependence use 6.7(3.9) hypnotics. One temporal lobe
Excluded if comorbid currently alcohol
psychiatric condition dependent, five past
of sufficient severity history of same. Five
to require treatment past history of
or clinically cocaine dependence
significant medical
condition
Thomson MR] Autom 10:11/ 31.9 Methamphetamine Mean(SD) No substance Whole brain Grey-matter
et al. ated 15:7 (1.47)/ users. No DSM-IV duration of dependence other deficits in the
2004438 segmen 35.3 diagnosis other than methampheta than MAor nicotine cingulate, limbic,
tation (1.66) MA or nicotine mine use and paralimbic
with dependence. 10.5(1.09) cortices.
cortical Excluded if on Reduced
and psychtropic hippocampal





Oh et al. MR] Semi- 23:4/ 36.7 Recruited through All users Excluded if lifetime Corpus NSD in either tota
2005439 automa 14:4 (5.6)/ advertisements in abstinent for history of exposure to Callosum. or subregional
ted 33.6 papers. Lifetime at least 4 any dependence Measured as a areas
ROI (6.7) diagnosis of weeks. Total forming drugs except single structure
DSM-IV MA IV MA use nicotine, caffeine, and divided in to
dependence. at least 50.0g alcohol and seven regions:
Excluded if DSM-IV prescribed rostrum, genu,
axis I disorder, medication. rostral body,
antisocial or anterior midbody,
borderline PD, posterior midbody,
significant medical isthmus and
illness splenium
Kim et al. MRI VBM 16:2 LTA: Recruited through All users Excluded if alcohol Whole brain After correction
2005440 (LTA) 35.6 advertisements in abstinent for dependence or for multiple
11:0 (5.2) papers. Lifetime at least 4 lifetime history of comparison, there
(STA)/ STA: diagnosis of weeks. exposure to any was a grey-matter
15:5 37.9 DSM-IV MA Divided in to dependence forming density decrease
(6.0) dependence. two groups, drugs except in the right middle
CTR: Excluded if DSM-IV (LTA and nicotine, caffeine, frontal gyrus.
33.2 axis I disorder, STA), based alcohol and This was most
(6.5) antisocial or on whether prescribed pronounced in the
borderline PD, had/had not medication. NSD STA group, with
significant medical used between prevalence the magnitude of
illness methampheta of drinking and reduction in the
mine in the smoking between LTA group being
last 6 groups intermediate
months. between the STA
Total IV MA group and
use at least controls.
50.0g
Jemigan MRI Semi- 17:4/ 38.2 DSM-IV diagnosis of Excluded if met Whole brain, Larger caudate,
et al. automa 17:13 (7.7)/ MA dependence. criteria for lenticular nucleus, lenticulate,
2005441 ted 38.1 Excluded if dependence on any nucleus accumbens and
ROI (10.5) schizophrenia, substance of abuse accumnbens, parietal cortices
neurological other than MA in the thalamus,




Chang et MRI Semi- 24:26/ M: History of DSM-IV Abstinent for No current or past Whole brain, Enlarged putamen
al automa 24:26 33.1 diagnosis of MA at least one history of other drug cerebellum (and and globus
2005442 ted (7.8)/ dependence. No week. dependence subregions), pallidus.
ROI 30.9 history of medical or Average MA corpus callosum Female MA users
(7.8) psychiatric illness use .25 g (and subregions), only also had
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F: which may confound /day, at least thalamus, enlarged mid-
30.9 findings 4 days per midbrain, globus posterior corpus
(6.4)/ week, for at pallidus, putamen, callosum
30.0 least 2 years. caudate
(9.2)
Chang et DTI Voxel- 23:9/ M: Recruited through Abstinent for Excluded if alcohol Frontal lobe white Significantly
al. based 20:10 36.0 newspaper greater than dependence or matter reduced FA in
2007443 ROI (6.7)/ advertisements. 4 weeks. lifetime history of regions in right
33.3 Lifetime DSM-IV Total MA exposure to any and left frontal
(6.6) diagnosis of MA abuse over dependence forming lobes in combined
F: dependence. 50.Og drugs except gender analysis.
29.0 Excluded if DSM-IV nicotine, caffeine, On examination of
(7.2)/ axis I disorder, alcohol and genders
28.7 antisocial or prescribed separately, this
(6.0) borderline PD, medication. No was only
significant medical significant difference significant in




Salo et al. DTI Voxel- 13:24/ 36.29 Lifetime diagnosis of Mean Excluded if other Corpus callosum No significant
2009444 based 9:8 (8.7)/ DSM-IV MA duration of substance genu and splenium difference between
ROI 32.18 dependence. use (SD) dependence (aside groups
(7.5) No other DSM-IV 11.61 (7.1), from nicotine) in last
Axis I disorder. and year, alcohol abuse in




Studies investigating structural imaging abnormalities in amphetamine users
Abbreviations: ND: no data; NSD: no significant difference; MA: methamphetamine
LTA: long term abstinent; STA: short term abstinent
Results
Despite only eight studies being identifiable which have compared structural
imaging findings in amphetamine/methamphetamine dependent subjects to controls,
this topic has been subject to two reviews.443'445 In both reports reviewers discuss the
findings of lower cortical grey matter volume and higher striatal volume in
amphetamine/methamphetamine abusers. These findings are also apparent in this
review, the latter finding seeming particularly robust. Hippocampal volume reduction
may also occur, though rather surprisingly this has only been specifically investigated
438
in a single study. On considering which particular regions of the cerebral cortex are
affected, the data are rather inconsistent. Whereas Kim et al. did report reduced
frontal lobe grey matter,440 this was not observed in two other studies.437'441 Similarly,
while a single study has reported reduced temporal lobe grey matter volume,437 this
has not been replicated in other studies (e.g. 441). Corpus callosum deficits seem
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particularly unlikely, these being detected by neither volumetric nor DTI
methodologies ,439'444
Both the reviews of Chang et al. and Bergman et al. discuss the possibility that
the robust finding of enlargement of the striatum could reflect either a compensatory
response to methamphetamine toxicity, or be a trait characteristic associated with risk
of amphetamine use. Given that the data reviewed are cross-sectional unfortunately
neither possibility can be refuted or confirmed. The study of Kim et al. investigated
regions of density reduction rather than increase, and no abnormalities were localised
to the stratum.440 In this study individuals who have been abstinent for longer and
shorter than six months were compared to each other and to normal controls.
Abnormalities in the prolonged abstinent group were intermediate between those in
the other two, suggesting that some recovery of structural abnormalities can occur.440
This does suggest that at least some of the brain structural abnormalities observed in
amphetamine users are the result of a dynamic process, and do not simply reflect trait
characteristics associated with a propensity to use the drug. Nevertheless, longitudinal
data investigating the dynamic effects of amphetamine use on brain structure would
clearly add substantially to the existing knowledge base.
4.1.3.4.2 Cocaine
A small number of studies have specifically compared MRI brain scans in
individuals with a history of cocaine dependence to those in normal controls. These
are detailed in Table 4.7. In addition to these case control comparisons a small
number of other studies are also of relevance to this discussion.
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Study Imag¬ Image Gen Mean age Inclusion criteria Cocaine Use of other subs Structures Findings
ing analy¬ der (SD) S/C using status compared
modal¬ sis S/C (M/F)
ity (M:
F)
Bartzokis et MR] Semi- 10:0/ 31.4(3.8)/ Recruited from Currently Excluded if met Grey and white Reduced total and
al. automa 16:0 28.6(ND) treatment using COC. DSM-IV criteria matter of whole grey matter
2000437 ted programmes and Mean(SD) for dependence on brain, temporal volume of
























Jacobsen et MRI Semi- 15: 35.6(5.7)/ Chronic COC Smoked Had consumed Whole brain, Enlarged caudate
al. automa 10/ 35.0(6.8) dependence without mean(SD) mean(SD)3.7 (5.2) caudate, putamen and putamen.
2001446 ted
ROI
11:9 comorbid Axis I
disorder.
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7ein et al. MRI Voxel- 29:0/ 39(7)/ Inpaients/ residents Currently Did not meet criteria Total and regional Reduction in


















2im et al. DTI Voxel- 12:0/ 44.17 Participants in COC Abstinent. No lifetime history of Various frontal Significant
2002448 based 10:3 (5.09)/ treatment studies and Average alcohol dependence regions reduction in WM
ROI 40.36 programmes. Met duration of or dependent on any Genu and FA in the inferior
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Vlatochik et MRI VBM 11:3/ 36.3(4.7)/ DSM-IV COC Abstinent Consumed fewer Cingulate gyrus, Reduced grey
al. 7:4 33.8(4.5) dependence. minimum 20 than 10 alcoholic perigenual and matter density in
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Studies investigating structural imaging abnormalities in cocaine users
Abbreviations: COC: cocaine
On reviewing the above studies, it is clear that the most consistent brain
imaging abnormality observed in cocaine dependent individuals is grey matter
reduction in the prefrontal lobe. Indeed, this was detected in the prefrontal cortex
(either in the structure as a whole or in subregions of it) in five of the six studies
which specifically investigated it. 447, 449, 450, 452, 453 Additionally, (though they are not
the subject of this review), this is also consistent with functional neuroimaging
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findings, which have demonstrated decreased prefrontal cerebral blood flow in
cocaine-dependent subjects.455'456
Several of the studies enable more accurate identification of which specific
subregions of the prefrontal cortex exhibit structural abnormalities in the context of
cocaine dependence. The three VBM studies are particularly interesting in this regard,
these consistently identifying reduced grey matter volume/density in the orbitofrontal
cortex. Localisation of abnormalities to the orbitofrontal cortex is notable, as deficits
of this brain region have been particularly associated with compulsive drug intake
behaviours,457 and functional dysregulation of the orbitofrontal cortex has long been
recognised in cocaine dependence.458'459
Reduced grey matter volume in the temporal cortex of cocaine dependent
subjects has also been reported by several independent groups. Specifically, it was
identified in two out of the three VBM studies and one of the two ROI studies which
specifically investigated it.437'449'452 These findings are also consistent with prior
functional brain imaging studies which have reported decreased temporal cortex blood
flow in cocaine abusers.460'46'Additionally, a single study reported reduced amygdala
volumes in cocaine-dependent subjects.451
Studies of white matter are much more inconsistent. One study did report that
white matter volume was reduced in the frontal cortex,448 but others have not. 447 DTI
studies have been similarly inconsistent; again, one study reported deficits in the
corpus callosum, while another did not.
All the data outlined above are cross-sectional, meaning it can not inform us of
direction of causality. It is the case however that a number of studies have examined if
correlations exists between structural findings and age. This was done, for example, in
the amygdala study.451 Notably, in this report no correlation was found between years
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of drug use and volume. Similarly, Lim et al. reported that the inferior frontal FA
decrease they detected in cocaine users was also unrelated to age and duration of use.
These findings have led authors suggest that these abnormalities may represents early
neural marker of cocaine use or possibly even constitute developmental traits that
increase the risk of drug dependence.4"1 In contrast however, other researchers have
reported that abnormalities do relate to duration of cocaine use.4"0 Cleary, and as has
previously been discussed, longitudinal studies in this area are greatly needed.
4.1.3.4.3 MDMA
Though the chemical structure of ecstasy is very similar to that of
amphetamine, the psychological effects produced differ substantially. Thus, it is
important to establish, (distinct from the review of amphetamine), if use of this drug is
associated with brain structural abnormalities. Case-control studies which have
addressed this question are detailed in Table 4.8.
A further cross-sectional study of the effects of ecstasy use also warrants
mention. This was undertaken by deWin et al., with recruitment being designed to
identify both heavy ecstasy users and 'polydrug-but-no-ecstasy' users.462 Rather than
directly comparing ecstasy using subjects to never exposed controls, this group then
used a regression model in which ecstasy history (as well as use of other drugs) was
dichotomised as either never exposed or consumed on greater than 10 occasions in
lifetime. By employing this model they hoped to better control for the polydrug use
which so frequently confounds these studies. Using this model the researchers then
investigated the association between ecstasy use and DTI measures (as well as a
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number of functional imaging variables). DeWin et al. reported that ecstasy use was
associated with decreased FA in the thalamus, suggesting axonal damage in this
structure. Interestingly, the other imaging tools employed (such as SPECT) also
localised abnormalities to this region.
Study Imag¬ Image Gende Mean Inclusion criteria MDMA Use of other Structures Findings
ing analy¬ r age using status subs compared
modal¬ sis S/C (SD)
ity (M:F) S/C
(M/F)*
Cowan el MRI VBM 17:14/ 24.3 Recruited via Used on at Vast majority Whole brain Reduced grey matter
al. 18:11 (3.5)/ newspaper Least 5 (unlike controls) concentration in left
2003463 21.7 advertisements. At occasions had used other temporal lobe, left
(3.3) least 5 lifetime drugs including frontal lobe, bilateral
episodes of MDMA cannabis, cocaine occipital lobes,
use. and bilateral cerebellum,
Excluded if history of hallucinogens and midline
substance brainstem. These
dependence or Axis I findings were
substance generally robust to
dependence controlling for the
effects of other drugs
of abuse
Moeller et DTI Voxel- 10:2/ 27.3 Did not meet DSM- Used on at Had consumed Corpus callosum Decreased
al based 13:7 (5.4)/ IV criteria for any least 15 significantly divided in to seven longitudinal
2007464 ROl 25.5 Axis I disorder aside occasions. more alcohol regions: genu, eigenvalues in corpus
(4.5) from substance abuse Mean than controls. rostral body, callosum rostral
duration since Majority had anterior midbody, body, indicating
last use 39.8 used cannabis, posterior midbody, axonal damage




Studies investigating structural imaging abnormalities in ecstasy (MDMA) users
In contrast to the paucity of prospective studies investigating amphetamine
and cocaine use, the research group of DeWin et al. has also successfully undertaken
a prospective imaging study investigating the effects of ecstasy on brain structure.465
This was achieved by identifying and assessing (including scanning) a group of
ecstasy-nai've individuals, at high risk of using the drug, before their first episode of
use. They were then followed up after they had used the drug with further assessments
at this point. Various imaging technologies were employed, including DTI. The initial
report from this group was an uncontrolled cohort study, comparing individuals
before and after ecstasy exposure. The mean inter-scan interval was 8.1+/-6.5 months,
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and the mean number of ecstasy tablets consumed was 1.8+/-1.3 tablets. The
researchers report that as well as changes in cerebral blood volume (a measure
indicating brain perfusion), ecstasy use was followed by an increase in FA in
frontoparietal white matter, and a decrease in apparent diffusion (ADC) in the
thalamus. As discussed above, axonal cell membranes are known to be responsible for
most of the restriction of water diffusion, with axonal damage leading to decreased
FA and increased ADC. These findings would thus not suggest that ecstasy exposure
was associated with reduced axonal integrity. After correction for multiple
comparisons however none of these structural differences remained significant
anyway, only the cerebral blood flow decrease in the dorsolateral frontal cortex
differentiating subjects before and after ecstasy use.
The above study was followed by a larger report, which did include a control
group.466 This was achieved utilising the whole cohort of 188 young people who were
ecstasy nai've but at high risk of using the drug. They were assessed as described
above, but follow up was after a longer time period, approximately 17 months after
their initial assessment. Successful follow up was achieved for 158 subjects of whom
64 had used ecstasy in the interim period and 94 had not. Of the 64 users, 59 agreed to
a follow-up assessment and these individuals were matched to 59 individuals from the
persistent ecstasy-nai've group. This report again demonstrated changes in cerebral
blood flow in the ecstasy-exposed group (in this case in the globus pallidus and
putamen), but also demonstrated DTI changes. Specifically, they demonstrated
decreased FA in thalamus and frontoparietal white matter, but increased FA in globus
pallidus. They also demonstrated an increased apparent diffusion coefficient in the
thalamus, in direct contrast to the earlier analysis of a subset of the cohort. It is thus
the case that these findings do suggest detrimental brain structural consequences of
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ecstasy use, possibly reflecting ecstasy-induced axonal damage in the thalamus and
frontoparietal white matter. It is of course the case that these findings also parallel the
cross-sectional study of heavy ecstasy users reported above.462
On considering the studies of De Win et al. together with the two cross-
sectional studies in Table 4.8, it does seem likely that, in the case of heavy ecstasy use
at least, use of the drug is associated with subtle brain imaging abnormalities. These
seem to be most likely to occur in the thalamus, given that it is here that abnormalities
are observed in those studies with the most robust methodology.
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4.2 Structural imaging findings in schizophrenia and those at high risk of
schizophrenia
The central aim of this study is to investigate if substance misuse by those at
high risk of schizophrenia promotes the development of the imaging abnormalities
associated with schizophrenia. Given this, it is clearly essential that the nature of these
imaging abnormalities is fully characterised. Additionally however, given that the
population being investigated is one at elevated genetic risk of schizophrenia, it is also
important to clarify if any brain structural abnormalities are already evident at people
at high risk of the condition. Given these requirements this chapter will have two
aims. Firstly to characterise the structural imaging findings in those with established
schizophrenia, and secondly to do the same for those people currently well but at
elevated risk of developing the condition.
4.2.1 Structural imagingfindings in people with established schizophrenia
On attempting to synthesise the imaging data relating to people with
established schizophrenia, one is immediately confronted with this issue of what
constitutes established illness. While this could potentially be defined as anything
from the point at which people have developed clear psychotic symptoms, this does
raise the concern that not all first episodes of psychoses are actually schizophrenic.
Thus, studies which include all people who present with a first episode of psychosis
may ultimately transpire to have contained substantial numbers of people with, for
example, an affective illness. Imaging findings in these individuals may differ
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substantially from those in schizophrenia.467 Equally, though evidence of actual
longitudinal decline in cognitive function in chronic schizophrenia is curiously
weak,468'469 it is also recognised that even in those people with an established
diagnosis of schizophrenia, symptom development is not static and the impairment
associated with the condition does tend to accrue over time.470 If this impairment were
to be reflected in imaging abnormalities, then it would be expected that those
individuals with the more chronic condition would display more pronounced brain
imaging abnormalities than those in whom schizophrenia has only recently been
diagnosed.471 It thus follows that the data on structural brain imaging abnormalities in
people with schizophrenia are best considered as relating to two overlapping
populations: those with the chronic condition, and those who have only recently
developed the condition (i.e. first episode patients). If neuroanatomical abnormalities
are indeed associated with schizophrenia, they would be expected to be most marked
in those with chronic condition. Thus, I will first consider the data relating to them.
4.2.1.1 Imagingfindings in chronic schizophrenia
As was the case in alcohol dependence, the first studies to apply in vivo
imaging technologies to the study of schizophrenia utilised pneumencephalography.
Though a primitive technique, and associated with considerable morbidity, these early
investigations did suggest that the lateral and third ventricles were enlarged in at least
472
some cases.
In the 1970s the less invasive technique of computerised tomography was
developed. This was utilised by Johnstone et al. to compare lateral ventricular
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volumes in a group of chronically institutionalised schizophrenic patients to that in
normal controls.473 They were significantly enlarged, a finding which was replicated
in the majority of subsequent studies. Indeed, not only was this finding demonstrated
in patients with less extreme illness severity,474 but it was also demonstrated that
treatment effects could not account for the increased ventricular size shown.47~In the
1980s MRI became available. With its superior resolution it enabled better delineation
of tissue types, and permitted the measurement of cortical and subcortical structures.
It was first applied to the study of schizophrenic patients in 1984,476 and has since
been applied in numerous studies. These studies have compared schizophrenics to
normal controls, but also looked at diagnostic, aetiological and prognostic
associations of various brain structural parameters. The two primary image analysis
techniques that have been utilised to enable comparison of structural imaging
characteristics in schizophrenics and controls are, as was the case in imaging studies
of substance misuse, region of interest approaches and voxel based morphometry.
Data obtained from both of these image analysis techniques have now been
extensively reviewed, and the subject of often multiple meta-analyses. These meta¬
analyses will be referred to in the following passage, with single studies being
emphasised if they are of particular importance.
Several meta-analyses of region of interest MRI studies in schizophrenia have
now robustly demonstrated a reduction in the volume of the whole brain, this being
particularly marked in grey matter and being associated with an increase in ventricular
volume.477'478 Meta-analytic methodology has also been applied to the synthesis of
studies comparing the volumes of specific cortical and subcortical structures. These
report that volume reductions are particularly prominent in temporal lobe structures,
with volumes of the hippocampus, amygdala, and the superior temporal gyri being
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reduced by a greater amount than the whole brain.479'480 This is also the case in the
prefrontal cortex,478 and the thalamus,481 while the corpus callosum is reduced to a
roughly similar extent as the whole brain.482
VBM data was itself synthesised by Honea et al., who undertook a meta¬
analysis of the 15 VBM studies comparing people with schizophrenia to controls
which had been published up until May 2004.483 They reported that the left superior
temporal gyrus and the left medial temporal lobe were reported as decreased in more
than 50% of studies, with fifty percent of the studies also reporting volumetric
decreases in the left parahippocampal gyrus, right superior temporal gyrus, left
inferior frontal gyrus, and left medial frontal gyrus. Moreover, superior temporal
gyrul volumes and reductions in medial temporal volumes correlated significantly
with positive symptoms and memory impairment respectively.472'484 It is notable that
only a minority of VBM studies reported volume reduction in the thalamus, a
structure demonstrated as reduced in volume by ROI methodology. Honea et al.
suggest that this may reflect the smoothing approaches employed, the studies with
positive findings in this (and a number of other regions) tending to have employed
smaller smoothing kernels. While such factors must be taken in to account when
reviewing the VBM data, it does nonetheless seem reasonable to conclude, as did
Lawrie et al., that VBM studies have generally supported the findings of ROI
485
approaches.
While the reports outlined above do robustly demonstrate that structural
imaging abnormalities are present in the brains of people with schizophrenia, they do
not inform us if these abnormalities are static or dynamic. To answer this question a
number of longitudinal studies have be undertaken in this population, ascertaining if
brain changes do occur over time. These were recently reviewed in a report published
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by Hulshoff Pol and Kahn, whose systematic review identified 11 MRI or CT studies
comparing longitudinal brain changes in chronically ill patients to those in healthy
controls.471 In this population, which had been ill for on average 10 years before the
initial scan, excessive brain tissue decreases and lateral ventricle volume increases
were observed over an interscan interval of one to five years. The tissue loss was most
pronounced in the frontal and temporal grey matter areas, with more pronounced
changes being associated with more negative symptoms, and a decline in
neuropsychological performance in some of the studies, but not consistently so. Of
particular interest, higher daily cumulative dose of antipsychotic medication intake
was either not associated with brain volume changes or with less prominent brain
volume changes. The authors conclude that the available data suggest that progressive
brain changes are indeed continuing to occur in chronically ill patients.
4.2.1.2 Imagingfindings in first episode schizophrenia
The meta-analytic studies outlined above consisted of studies undertaken in
patients who had had schizophrenia for variable periods of time, but in whom the
condition was generally well established. In the meta-analysis of thalamic size
undertaken by Konick et al. for example, the mean age of the 485 included subjects
481
was 34.8 meaning they had generally been ill for at least a decade. The meta¬
analysis of Wright et al. was similarly weighted towards people with the chronic
condition, with only 7 of the 58 studies included focussing exclusively on first
episode subjects.478 This emphasis on studies investigating well-established illness,
while it does facilitate diagnostic certainty, does have less desirable consequences.
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Importantly, it means that any structural imaging abnormalities observed in meta¬
analyses could potentially be attributable to the effects of chronic illness, medication
and other variables as well as to schizophrenia itself. For this reason it is important to
establish what the imaging findings are in people experiencing their first episode of
schizophrenia. While such studies do of course have their own potential pitfalls (e.g.
the inherent risk of including subjects who do not ultimately transpire to have
schizophrenia), clearly the potential for any abnormalities observed to be a
consequence of variables such as the non-specific effects of chronic illness or
antipsychotic exposure will be substantially reduced.
Two recent meta-analyses of studies which employed region of interest
techniques to compare brain regional volume in subjects with their first episode of
schizophrenia to normal controls were published in 2006 by Steen et al. and Vita et
486,487 ^ revjews the studies included focussed predominantly on first episode
of schizophrenia, but subjects with other related conditions (e.g. schizoaffective
disorder) were also included. The study of Vita et al. was a little more restrictive, and
consequently included fewer studies (21 versus the 52 included in the review of Steen
et al.). Despite these differences however, the conclusion of these two reports are
strikingly similar. Both report that whole brain volume is reduced and lateral and third
ventricular volumes increased in the first episode subjects. The only regional brain
structure which both studies report as significantly reduced in the first episode
subjects is the hippocampus, volume of this structure being evaluated in six of the
studies identified by Vita et al., and eleven of the studies identified by Steen et al..
Both groups discuss the fact that a paucity of data on other structures hinders meta-
analytic comparison of their volumes. Utilising four studies in each case, Vita et al.
do attempt this comparison for the temporal lobes and amygdala. Though volumetric
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differences are not significant on comparison to controls, this could clearly simply
reflect the limited data available.
More recently, Ellison-Wright et al. have applied meta-analytic techniques to
synthesise data from studies using VBM to compare MRI scans from people with first
• • • 488
episode schizophrenia to those from controls. Though the primary goal of this
interesting study was in fact to compare the pattern ofbrain deficits associated with
first-episode psychosis to that in chronic schizophrenia, comparisons between first
episode schizophrenics and normal controls were also undertaken. This component of
the report was based on seven VBM studies, these comparing 224 patients with first
episode of schizophrenia to 248 controls. Grey matter decreases were reported in the
anterior cingulate gyrus and the bilateral insulae, inferior frontal gyri,
unci/amygdalae, caudate heads and thalami. On comparing first episode individuals to
those with chronic schizophrenia, grey matter decreases were more pronounced in the
latter group in the cortex, this deficit being particularly marked in the medial frontal
gyrus and the dorsolateral prefrontal cortex. The authors note that localisation of
deficits in first episode subjects to the medial temporal lobe does demonstrate overlap
with the meta-analyses of ROI studies, but that the VBM meta-analysis does detect
more extensive abnormalities; this is of course not entirely surprising given that
detection of abnormality in a given region with this technique is not, as is the case
with ROI-based techniques, constrained by prior hypotheses. The authors also
discuss that their findings suggest that as an individual moves from the early to the
chronic condition, so brain abnormalities accrue in cortical regions. In keeping with
this, and as was discussed above, longitudinal studies have reported that frontal and
temporal cortical loss does continue to occur even after a schizophrenic illness is well
established.471'471
210
4.2.2 Structural imagingfindings in high riskpopulations
The current study utilises data obtained from a population identified as being
at high risk of schizophrenia. This risk is conferred by virtue of having two relatives
affected by the condition and having not yet passed through the age range when
schizophrenia most commonly develops. Given that the aim of the study is to
ascertain what the impact of substance use by this population is on brain structure, it
is clearly of great importance to clarify what brain imaging abnormalities are already
present in populations at elevated risk of the condition. Of most direct relevance in
this regard are of course previous reports from the EHRS, and a summary of previous
imaging findings from this study will be presented first. Data from other studies of
high risk populations are of course also of potential relevance however. These
potentially relevant study populations are as follows, and data arising from each will
also be discussed in turn:
1. Other studies which have characterised structural brain imaging findings in the
relatives of people with schizophrenia.
2. Studies in people with schizotypy, a condition believed to be closely related to
schizophrenia
3. Studies in people who are at elevated risk of schizophrenia for clinical reasons.
One of the great benefits of clarifying structural imaging characteristics in populations
such as those listed above is that people in these groups have not actually developed a
schizophrenic illness. Thus, these groups offer an opportunity to investigate any
structural brain abnormalities which are associated with schizophrenia free of
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potential illness-associated confounders such as antipsychotic medication treatment
and lifestyle factors associated with severe mental illness.
4.2.2.1 Previous findingsfrom the Edinburgh High Risk Study
As is apparent from the discussion above, it is now beyond doubt that patients
with schizophrenia have demonstrable abnormalities on structural brain imaging. It is
also clear that at least some of these abnormalities are present at the time of the first
episode of schizophrenia. If the development of the condition is to be more fully
understood however, then it is clearly crucial to ascertain from what point in an
individual's trajectory towards schizophrenia these abnormalities are apparent. Are
they present from birth, for example, or do they develop during the prodromal period
that frequently precedes psychosis?
Clearly, the ideal study design to address this question would be a prospective
study, with people being regularly scanned and clinically assessed from shortly after
birth to the onset of schizophrenia and beyond. Unfortunately however, such a study
is impractical for a variety of technological, clinical, and epidemiological reasons (for
further discussion of these issues see Chapter 5). An alternative method is to study at-
risk populations leading up to and during the time period of maximum risk of onset of
the disorder. Indeed, this was exactly the model which was adopted in the Edinburgh
High Risk Study, from which considerable data are already available.
The methodology of the EHRS will be discussed in more detail in Chapter 5,
but to appreciate the significance of findings from it, it is important to outline the
basic structure of the study now. The study essentially centred on the identification of
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a cohort of individuals aged 16-24 who were currently well, but at high risk of
developing schizophrenia. This risk was a consequence of having two close relatives
with the condition, one of these relatives generally being either a parent or sibling. A
total of 229 suitable HR subjects were identified. One hundred and sixty two provided
some clinical, neuropsychological, and/or imaging data, and 150 had one or more
sMRI scans between 1994 and 1999. A group of similarly aged healthy controls and
first episode subjects was also examined. Most of the HR subjects and controls
returned for at least one further sMRI and an fMRI scan between 2000 and 2005,
when the study ended.
Both baseline and longitudinal imaging findings from the EHRS have now
a oc
been widely published, and were recently summarised by Lawrie et al. Analyses of
baseline scans reported that the amygdalo-hippocampal complex was significantly
smaller (about 4% than controls), but about 4% larger than first episode subjects.489
The volume of the thalamus was also reduced in the high risk subjects compared to
the controls, but interestingly this was not the case in the first episode subjects. These
findings were largely replicated on VBM analysis, though deficits in the region of the
hippocampus were localised to the left parahippocampal gyrus with this
methodology.490 Additionally, the VBM analysis also showed anterior cingulate and
medial prefrontal reductions in grey matter density with a first episode schizophrenia
< high risk < controls pattern.
Psychotic symptoms were elicited with the Present State Examination, and
isolated or transient symptoms were found in more than half of the sample (many
more than who actually developed schizophrenia). In those with psychotic symptoms
at any point in the first 5 years of the study, the whole-brain volume at study entry
was reduced compared with those who did not have psychotic symptoms over this
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time.491 No other brain volumes at intake were related to a liability to psychotic
symptoms. As many of the participants had multiple scans, longitudinal analyses of
brain structural changes over time were possible. Those with psychotic symptoms,
and two or more sMRI scans over approximately 18 months, had significant
reductions in the (right) temporal lobes and nonsignificant reductions in whole-brain
and (left) AHC volume.492 Job et al. extended these findings of changes over time by
using VBM.493 While all high risk subjects had distributed changes in grey matter
concentration in the prefrontal and temporal lobes as compared with healthy controls,
these were more marked in those who had psychotic symptoms at one or both
assessments. Moreover, there were additional grey matter density reductions in left
(para) hippocampal uncus, fusiform gyrus, and right cerebellar cortex in the 8
individuals at high risk who subsequently developed schizophrenia when compared
with 10 individuals who also had psychotic symptoms but did not make the transition
to illness.
By the close of the study 21 subjects (13%) had developed schizophrenia, on
18720 of whom there was clinical data. As one of the aims of the study was to establish
if structural imaging measures could be used to predict who would ultimately develop
schizophrenia, this was specifically investigated. While analyses did fmd.that reduced
AHC or thalamic volume did have some predictive effect, unfortunately the predictive
effect of any baseline regional brain volumes (or indeed grey matter densities) for the
subsequent development of schizophrenia was weak.187'493 While longitudinal grey
matter loss, (particularly that in the inferior temporal gyrus), may constitute a more
accurate predictor, even this does not at present have clinical utility.494 What this
study does make absolutely clear however, is that brain structural abnormalities are
present in those at high risk of developing schizophrenia, and that (in those destined
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to develop the condition), brain changes do occur years prior to diagnosis. As the
individuals in this study were all well at the time of recruitment, these abnormalities
and changes are clearly due neither to the effects of medication, nor are they the
consequence of chronic illness. Clearly this raises the question of whether substance
misuse may be one of the factors which results in these changes arising. This
possibility is the focus of the current study.
4.2.2.2 Brain imaging abnormalities in the relatives ofpeople with schizophrenia
The EHRS investigated the brain imaging characteristics of a clearly defined
group of individuals at greatly elevated genetic risk of schizophrenia. While the
design of this study was unique, other studies have also characterised the brain
imaging characteristics of relatives of people with schizophrenia. The rationale behind
this stems from the fact that the first-degree relatives of people with schizophrenia
share 50% of a patient's genome. Given that schizophrenia has a 70-80%
heritability,495 any differences that exist between these relatives and normal controls
would therefore be expected to reflect the genetic risk factors they posses for the
condition. As was the case with the EHRS cohort, studying these unaffected relatives
has important advantages to investigating people who actually have schizophrenia. Of
particular importance, given that these individuals are well, any abnormalities which
are detected cannot be attributed to secondary effects of the illness or its treatment.
Boos et al. undertook a meta-analysis exploring exactly this question, synthesising
data from studies comparing both global and regional brain volumes in the non-
psychotic first degree relatives of patients with schizophrenia to those in healthy
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control subjects.496 They identified 25 studies eligible for inclusion, with volumes of
the following structures being ascertained in at least 3 studies: whole brain volume,
grey matter volume, amygdala-hippocampal complex, hippocampus, lateral ventricles
and third ventricle. This study found that the largest effect was observed for
hippocampal volume, with unaffected relatives exhibiting significantly smaller
volumes than controls, but larger volumes than their relatives with schizophrenia.
Smaller effects were also observed for cerebral grey matter (reduced in relatives), and
third ventricular volume (increased in relatives). Interestingly, analysis of lateral
ventricular volume, a robust finding in people with schizophrenia, did not show
significant effects. The authors conclude that brain volumes in relatives of patients
with schizophrenia do differ from those of healthy control subjects, and that this
reflects the increased vulnerability of these individuals to the development of
schizophrenia.
Out-with the EHRS, automated techniques of image analysis have not been
widely applied to the comparison ofbrain imaging characteristics in the relatives of
people with schizophrenia to normal controls. An independent group has however
also reported reduced grey matter density in the prefrontal cortex of relatives at high
risk for schizophrenia.497
4.2.2.3 Brain imaging studies in people with schizotypal personality disorder
A further group of interest when investigating biological markers associated
with schizophrenia are those individuals with 'schizophrenia spectrum disorders',
foremost among which is schizotypal personality disorder, (SPD), DSM-IV diagnostic
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criteria for which are detailed in Table 4.9. This condition, similarly to schizophrenia,
is characterized by positive or psychotic-like symptoms and negative or deficit-like
symptoms.498 The positive-like symptoms include ideas of reference, cognitive or
perceptual distortions, and magical thinking. Negative symptoms encompass social
deficit and interpersonal difficulties. Cognitive disorganisation is also seen. As well as
symptom similarity there is also evidence of a genetic association between the two
disorders, with a greater prevalence of schizotypal disorder being found in the
relatives of those with schizophrenia,499 and also psychophysiological correlates
between the two conditions.500 Similarly to what was discussed in relation to studies
in the relatives of people with schizophrenia, there are clear advantages to studying
people with schizotypal personality disorder rather than frank schizophrenia;
importantly, this group is freer from the multiple artefacts that potentially confound
schizophrenia research, including the effects of long-term medication treatment,
multiple hospitalizations or institutionalization, and prolonged functional impairment
secondary to chronic psychosis and social deterioration. Additionally, there must be
an underlying reason (or reasons) why these individuals do not express the more
severe phenotype of schizophrenia. Thus, the investigation of brain structural
abnormalities in schizotypy may lead to a greater understanding of why some
individuals progress to schizophrenia while others do not.
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A) A pervasive pattern of social and interpersonal deficits marked by acute discomfort with, and
reduced capacity for, close relationships as well as by cognitive or perceptual distortions and
eccentricities of behaviour, beginning by early adulthood and present in a variety of contexts,
as indicated by five (or more) of the following:
1) ideas of reference (excluding delusions of reference)
2) odd beliefs or magical thinking that influences behaviour and is inconsistent with
subcultural
norms
3) unusual perceptual experiences, including bodily illusions
4) odd thinking and speech (eg. vague, circumstantial, metaphorical, overelaborate or
stereotyped)
5) suspiciousness or paranoid ideation
6) inappropriate or constricted affect
7) behaviour or appearance that is odd, eccentric, or peculiar
8) lack of close friends or confidants other than first-degree relatives
9) excessive social anxiety that does not diminish with familiarity and tends to be associated
with
paranoid fears rather than negative judgements about self
B) Does not occur exclusively during the course of schizophrenia, a mood disorder with
psychotic features, another psychotic disorder, or a pervasive developmental disorder and is
not due to the direct physiological effects of a general medical condition
Table 4.9
DSM-IV diagnostic criteria for schizotypal personality disorder
Structural imaging findings in schizotypal personality disorder (SPD) were
reviewed by Dickey et al. in 2002,501 and Andrew Stanfield in 2007.502 The latter
review benefits from the inclusion of several important studies undertaken by Suzuki,
Takahashi and others in Tokyo; these involved a cohort of up to 39 people with SPD,
the largest such cohort ever studied.503'504 Given this, greater emphasis will be placed
on the Stanfield review. No relevant studies comparing structural brain imaging
findings in people with SPD and normal controls and published after the review of
Stanfield were identified.
The available data find little evidence of prefrontal lobe reduction in SPD,
with the Japanese group finding that it may even show subregional enlargements
relative to normal controls.503 By contrast, there is evidence for regional volume
reduction in the temporal lobes. The most consistent deficit observed in this structure
is in the superior temporal gyrus; three out of four studies which compared volume of
this region to that in controls identified reductions in the SPD subjects,504"506 whereas
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only one did not.507 By contrast, findings in the amygdala, hippocampus, Heschl's
gyrus and planum polare are more equivocal; in each case one positive and one
negative finding is reported for each structure. Temporal lobe abnormalities, localised
particularly to the superior and medial temporal gyri, were also reported in a VBM
C AO
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study from the Tokyo group. Other brain regions specifically investigated include
the cingulate gyrus, basal ganglia, thalamus, corpus callosum and lateral ventricles.
Three studies report that there is no evidence of volume differences between SPD
individuals and controls in the cingulate gyrus.509"511 Conflicting findings are reported
for the basal ganglia. Hazlett et al. found that there were no differences in the total
512*thalamic volume between individuals with SPD and normal controls; in a subset of
this group however, Byne et al. found the size of the pulvinar was reduced in both
schizophrenia and SPD relative to controls, whereas the mediodorsal nucleus did not
differ between the groups.513 The single study investigating corpus callosum volume
reported that the genu of the corpus was larger in patients with SPD than in control
subjects, whereas the posterior corpus was larger in controls.514 Two studies report
that lateral ventricular volume is not increased in SPD.515'51
On the basis of these finings Stanfield concludes that SPD is associated with
some temporal lobe structural abnormalities, in a similar but less severe pattern than
those seen in schizophrenia. By contrast the prefrontal region seems to be relatively
spared. Furthermore, he also argues that the findings of sparing of the mediodorsal
thalamic nucleus and the enlargement of the callosal genu add further weigh to this
explanation. Given that both of these regions are closely associated with the prefrontal
lobe, it would be expected that abnormalities of that structure would be reflected as
abnormalities of these regions.500'502 That such abnormalities are not detectable
suggests that communication from or through these structures with prefrontal regions
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powerful scanner (3T rather than 1.5T) once again reports that (left) hippocampal
• • ... S99
volume is reduced m UHR individuals. As they had previously reported however,
this measure did not differentiate those who made the transition to psychosis from
those who did not. In interpreting these results however it is important to
acknowledge that only 7 of the 66 ultra high risk subjects did actually develop
psychosis, which clearly raises the possibility of a Type II error. On considering these
most recent findings Wood et al. conclude that though hippocampal volume may be
reduced in UHR individuals, it seems unlikely that this measure will prove to be a
useful predictive marker for later psychosis
The Melbourne group have also recently specifically investigated if volume of
the superior temporal gyri predicts who will go on to develop psychosis.223 Using
semi-automated tracing methodology they reported that that though the structure was
significantly reduced bilaterally in UHR individuals, volume did not differ in those
who did and did not subsequently develop psychosis.
Other groups employing the same criteria for the identification ofUHR
subjects have now also published baseline data from their studies. Of note, Borgwardt
et al. utilised VBM to compare 22 controls and 35 UHR patients (12 of whom
developed psychosis over the following 2 years).524 Significantly reduced grey matter
volume was found in a number of regions, including the left hippocampus, but there
were no hippocampal differences between those who did and those who did not later
develop psychosis. By contrast, individuals who became unwell did have less grey
matter in the right insula, inferior frontal and superior temporal gyrus than those who
remained well. Similar findings were also reported by a German group (Witthaus et
al.), who reported that when compared to controls their UHR sample demonstrated
lower grey matter volume bilaterally in the cingulate gyrus and hippocampi and also
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525in the right inferior frontal and right superior temporal gyri. Additionally, a Korean
group which investigated cortical thickness reported thinning of the prefrontal cortex,
anterior cingulate cortex, inferior parietal cortex, parahippocampal cortex, and
superior temporal gyrus in the UHR group compared with healthy controls.526 By
contrast however, Ziermans et al. in their admittedly very young Dutch sample (mean
age 15.8) do not detect any differences between UHR individuals and controls.527
In a follow-up paper to their 2008 report Witthaus et al. acknowledge the
existence of conflicting data in this area, and that this is particularly problematic in
relation to whether or not hippocampal volume is reduced in UHR individuals
destined to become psychotic. They suggest one potential explanation for this
inconsistency is that it may be abnormalities of regional rather than total hippocampal
volume which are associated with risk of transition to psychosis.528 Specifically, they
suggest that it may be particularly reduction of hippocampus corpus and tail volumes
which are indicative of the prodromal phase of schizophrenia and represent risk
factors for transition into psychosis. As they acknowledge, whether such refinement
resolves the current confusion can only be answered by further studies.
Studies undertaken by the Melbourne and Swiss groups have incorporated
sequential scans, enabling exploration of the relationship between structural brain
changes over time and clinical outcomes. In their first longitudinal report, utilising
VBM methodology and based on 21 participants, Pantelis et al. demonstrated
reductions in grey matter in the left parahippocampal and fusiform gyri, left
orbitofrontal cortex and cerebellar cortex and bilateral cingulate gyri. These changes
occurred over approximately a year in 11 people as they developed a diagnosis of
psychosis, usually schizophrenia.520 In their review Wood et al. discuss the limitations
of applying VBM to these analyses, and specifically the fact that poor registration
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limited the sensitivity of the technique. Consequently they also applied a tensor based
technique, based on that described by Thomson et a/.438 but augmented by their own
processing, to a slightly extended sample of 35 UHR individuals. On applying these
more sensitive analyses they reported significantly greater brain contraction in the
right prefrontal region in those 12 UHR individuals who went on to develop psychosis
(five being diagnosed with schizophrenia spectrum disorders), indicative of an
accelerated rate of grey matter loss in these people.529 The authors do acknowledge
the limitations of this study, not least among these the fact that follow-up scans were
not acquired during or immediately after the psychosis onset, raising the possibility
that factors secondary to psychosis or its treatment contributed to the greater brain
change in the converters. Nonetheless, these findings do fit with a number of other
studies in unmedicated individuals (discussed above) implicating changes in the
prefrontal lobe as associated with transition to psychosis. Interestingly, and as Wood
et al. note in their review, the pattern of longitudinal change seen in the UHR group
who made the transition to psychosis was similar to that observed in healthy controls,
albeit exaggerated in magnitude; on this basis Wood et al. suggest that the transition
to psychosis is associated with an exacerbation of normal neurodevelopmental
processes.530 Once again, only further studies can ascertain what the factors
influencing these exaggerated changes are, but Sun et al. do cite previous findings
demonstrating larger pituitary volumes in UHR individuals who make the transition to
psychosis to suggest that activation of the hormonal stress response may play a
role.531
The Melbourne group have also investigated the possibility that white matter
changes differentiate those individuals who make the transition from UHR to
psychosis from those who do not.532 On comparing baseline MRI data from 75 UHR
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individuals, 23 of whom subsequently developed psychosis, individuals who later
developed psychosis had larger volumes of white matter in the frontal lobe,
particularly in the left hemisphere. Twenty one participants had a second scan, ten of
whom developed psychosis. Longitudinal comparison of these groups revealed a
reduction in white matter volume in the region of the left fronto-occipital fasciculus in
those who develop psychosis. Participants who had not developed psychosis showed
no reductions in white matter volume but increases in a region subjacent to the right
inferior parietal lobule. Two important limitations of this study are that the interscan
interval for the 'remained well' group was almost double that in the 'developed
psychosis' group and that many more of the psychosis group were treated with
antipsychotic medication; thought the former potential confounder was controlled for
in the analysis, the latter was not.
The Swiss group successfully followed up (and rescanned) 20 UHR
individuals, 10 of whom had developed psychosis.533 Their VBM analysis reported
that in subjects who developed psychosis there were longitudinal volume reductions
in the orbitofrontal cortex and the right superior frontal, inferior temporal and superior
parietal cortices, as well as the right hemisphere of the cerebellum and the left
precuneus. Conversely, there were no longitudinal changes in subjects who did not
develop psychosis. Though they clearly remain relevant factors in interpreting these
results, the difference in interscan interval between groups was less in this study than
in that of Waterfang et al., and fewer of the converters (approximately half) had been
treated with antipsychotics at the time of the second scan.
Given the superficial similarities between the methodology employed in the
EHRS and in 'ultra-high risk' studies some discussion of how comparable these
approaches are is essential. This is particularly important as many findings from the
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EHRS and ultra-high risk appear to be divergent. For example, hippocampal volumes
are reduced in those in the EHRS who go on to develop psychosis whereas those who
go on to develop psychosis in the Melbourne study have normal hippocampal volume.
The truth is that despite the superficial similarities between these two
methodologies they actually have the potential to recruit very different individuals.
Methodologies between different UHR groups does differ, so in this section I will
focus on those differences between the EHRS and the UHR studies undertaken by the
Melbourne group (whose UHR studies have been most influential).
Firstly, in contrast to the EHRS study (in which participants were identified by
virtue of a/more than one close relation/s with schizophrenia, the Melbourne group
used a 'close-in' strategy, recruiting symptomatic help-seeking individuals. It is
clearly possible that individuals who actively seek help for partial psychotic
symptoms/functional decline are quite different from those who are well but have a
family history of schizophrenia. This leads to a further potentially important
implication of this difference between the groups, namely the stage in development of
illness at which individuals are identified. As UHR subjects are, by definition, help
seeking, those who go on to develop schizophrenia may have already experienced
some structural brain changes in associateion with this (which could potentially
preceeed the development of psychosis by some time); consequently even
longitudinal studies in these subjects will not observe these already apparent changes
arise. The final important issue I will highlight relates to the illness that recruited
individuals actually develop. In the case of the EHRS all individuals who became
psychotic were diagnosed with schizophrenia. In the publications from the Melbourne
group the reported outcome is generally psychosis, which in only approximately 50%
of cases is a schizophreniform disorder. It is now established that imaging findings do
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differ in schizophrenia and bipolar affective disorder,467 meaning that utilization of
the concept of a unitary psychosis may cloud imaging findings somewhat.
4.2.3 Summary ofstructural imagingfindings in people with schizophrenia or at high
risk ofthe condition
On considering the imaging data deriving from both people with schizophrenia
and those at risk of the condition, a number of firm conclusions can be drawn. Firstly,
the evidence that structural imaging abnormalities exist in established schizophrenia is
now overwhelming. These are present at the whole brain level, manifesting both as a
reduction in total grey matter and increased ventricular volume, but reductions in a
number of brain regional volumes have also been repeatedly demonstrated. The brain
regions particularly affected are the medial temporal lobes (particularly the amygdala
and hippocampus), the superior temporal gyrus, the frontal lobes and the thaiami.
Comparable abnormalities are also present in first episode subjects, but they are less
pronounced; indeed, deficits in the frontal lobe in particular may be very subtle in
these individuals.
It has now also been established that structural abnormalities are also
detectable in people who are at high risk of schizophrenia for either genetic or clinical
reasons. These deficits are detectable in the medial temporal lobe/hippocampus,
regions of the prefrontal cortex and possibly also the thalamus. The magnitude of
these deficits is considerably less marked than in first episode subjects, a fact which
likely contributes to it not being detected in several studies of these high risk groups.
It is the case however that even the most consistently reported deficits in high risk
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groups (medial temporal lobe/hippocampal deficits) can not reliably predict who from
a high risk cohort will go on to develop psychosis. Several groups have now also
reported on longitudinal changes that occur in high risk subjects who do make the
transition to psychosis. These reports suggest that in these individuals further
temporal lobe volume loss occurs, seemingly some time before transition to
psychosis, while additional prefrontal lobe volume loss likely occurs in closer
proximity to the point of actual transition.
4.2.4 Influence ofgenotype on susceptibility to brain structural changes
As discussed above, many of the studies investigating brain structural
abnormalities in schizophrenia have identified their study group on the basis of a
genetic propensity for schizophrenia. In the EHRS the association between genetic
propensity and these abnormalities was also explored within the high risk group, the
relationship between volumes of various structures being related to the strength of
genetic liability to schizophrenia. Volumes of the PFC, thalamus, and whole-brain,
but not those of the AHC, were reported to be negatively associated with this
variable.491 Additionally, the influence of specific genes on structural imaging
findings has also been explored in the EHRS. Specifically, it was found that high risk
individuals with the COMT Val allele had reduced grey matter density in anterior
cingulate cortex, and that possession of this allele increased the risk of developing
schizophrenia in a dose dependent manner.334
Importantly, there is also evidence of a significant interaction between
genotype and cannabis use in determining an individual's risk of developing
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schizophrenia. Intriguingly, and as was discussed in Section 3.2.2.1.1, it is again the
• • 121*
COMT gene which has been reported as mediating such an interaction. Given such
data, it would obviously be desirable to explore specific gene/substance misuse
interactions further in this study. Specifically, it would be of great interest to explore
if there was an interaction between particular genotypes and vulnerability to the brain
structural and illness potentiation effects of cannabis within the high risk cohort. For
reasons ofpower however, (only 75 number of the high risk subjects were both
genotyped and had usable scans), this will not be possible. Thus, though brain
structural abnormalities potentially arising as a consequence of gene/substance misuse
interactions are clearly an important issue to explore, unfortunately I will not be
address them in this report. Consequently, given that it is beyond the scope of the
current report, I will not discuss the important issue of the contribution of specific
genes to an individual's risk of developing schizophrenia on exposure to cannabis any
further.
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4.3 Studies in dual diagnosis
As has been repeatedly stated, the central aim of this study is to investigate if
substance misuse by those at high risk of schizophrenia promotes the development of
the imaging abnormalities associated with schizophrenia. Essential in interpreting any
data investigating this possibility is, as has already been discussed, data establishing:
1) the structural abnormalities associated with use of drugs of abuse; 2) structural
abnormalities associated with the condition ofbeing at high risk of schizophrenia; and
3) the structural abnormalities associated with schizophrenia itself. Of arguably most
direct relevance to addressing this question however are studies which directly
investigate the brain imaging consequences of substance misuse by people who have
schizophrenia. What follows is a review of studies characterising brain structural
imaging findings in people with both these conditions. In this section I will also
include a summary of studies investigating structural imaging findings in alcoholic
hallucinosis. As this condition represents a phenomenon by which psychotic
symptoms are directly attributable to use of a substance (alcohol), it is clearly of
particular interest to this report.
4.3.1 Studies addressing the brain imagingfindings associated with substance misuse
by people with schizophrenia
4.3.1.1 Cannabis
Only a handful of cross-sectional studies comparing structural imaging
findings in cannabis using schizophrenic individuals to those in subjects with
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schizophrenia but with minimal exposure to cannabis have been undertaken. The first
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such study was undertaken by Cahn et al. and published in 2004. " It compared
volumes of the whole brain, total grey and white matter, cerebellum, caudate nucleus
and third and lateral ventricles in 27 patients with recent-onset schizophrenia and a
lifetime diagnosis of cannabis abuse or dependence to that in 20 patients with recent-
onset schizophrenia who were cannabis-naive. Patients with a lifetime diagnosis of
abuse of or dependence on a substance other than cannabis were excluded. The
cannabis exposed group was significantly younger than the comparator subjects, but
age was included as a covariate in the analysis. A significant difference in volume
was found in none of the brain regions investigated.
Two more recent MRI studies have again compared structural brain imaging
findings in people who do and do not smoke cannabis. The first, undertaken by
Szeszko et al., compared structural characteristics of the prefrontal lobes in 20 first
episode subjects who had an additional diagnosis of cannabis abuse, 31 first episode
subjects with no such history and 56 healthy controls without a history of any
substance misuse diagnosis.536 Six of the cannabis using first episode subjects had a
history of an alcohol use disorder, whereas this was the case for only two of the non-
cannabis using patients; use of other drugs was minimal. Antipsychotic exposure was
also minimal, the median duration of use of these drugs being quoted as 0 weeks.
Volumes of the superior frontal gyrus, anterior cingulate gyrus and orbital frontal lobe
were outlined manually using a semi-automated ROI approach and then automatically
segmented in to grey and white matter. These volumes were then compared between
the groups with age and intracranial volume included as covariates. Szezko et al.
report that first episode of schizophrenia patients who use cannabis had less anterior
cingulate grey matter than both patients who did not use the drug and healthy
231
volunteers. Significant differences were not observed in any other of the regions
studied. This result remained significant even when any patients with substance
misuse diagnoses other than cannabis were excluded from the analysis. In their
discussion Szezsko et al. speculate that the reason these findings contrast with those
of Cahn et al. likely derives from the fact that the latter study did not examine discrete
frontal cortical regions.
More recently Bangalore et al. (2008) analysed data from subjects similar to
those included in the Sezezsko et al. report.537 In this study MRI scans from 15 people
experiencing a first episode of schizophrenia who had a lifetime history of cannabis
use on more than 10 occasions were compared with 24 similar patients who were
cannabis naive and 42 healthy volunteers who did not use cannabis. Eight of the
cannabis using patients were polysubstance abusers, though specific substances are
not detailed. Bangalore et al. conducted a voxel based morphometric analysis of a
priori determined regions of interest, focusing on CB1 receptor rich brain regions.
These regions included the DLPFC, hippocampus, posterior cingulate and cerebellum.
Though they report that there were no statistically significant differences in age and
gender between the groups, these factors were included as covariates in the analyses.
Bangalore et al. report that in the main analysis comparing the cannabis exposed and
unexposed first-episode subjects, a trend towards reduced grey matter density in the
right posterior cingulate was observed in the former group, this being significant in
post-hoc analyses conducted separately for the individual a priori hypothesized
regions. Comparisons were also made between the groups using modulated
normalized images, these being believed to better identify volume (rather than
density) differences between subjects. This noted a decrease in grey matter volumes
of the right posterior cingulate and left hippocampus in the cannabis exposed
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(compared to unexposed groups); no differences were noted between cannabis
unexposed subjects and controls.
A further cross-sectional volumetric MRI study, this undertaken by Wobrock
et al. is also relevant to this discussion.538 In this study 20 patients with recent onset
schizophrenia or schizoaffective disorder (onset within the last three years) and a
history of alcohol or drug abuse were compared to 21 schizophrenia/schizoaffective
disorder patients without such comorbidity. Substances used by the comorbid group
were heterogeneous, but all had used cannabis; additionally abused substances were
cocaine (8), amphetamines/ecstasy (7), opiates (2), alcohol (2), and hallucinogens (1).
Volumes of the amygdala-hippocampal complex, superior temporal gyrus/Heschl's
gyrus and cingulate gyrus were ascertained using semi-automated ROI methodology,
and compared between the two groups while covarying for age and height. No
significant difference was observed between the groups in volumes of any of the
structures investigated.
In addition to the cross-sectional data, a single longitudinal study investigating
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the impact of cannabis on brain volume loss over time has now been published.
This study was based on the same cohort ofpatients previously reported on by Cahn
et al. In this follow up study brain volume loss over a five year period was compared
between 19 with patients with a diagnosis of a schizophrenia spectrum psychosis who
used cannabis and no other illicit drugs in the inter-scan period, 32 patients with a
schizophrenia spectrum disorder who used no illicit drugs in the inter-scan period, and
31 healthy controls who did not use any illicit drugs. An automated brain
segmentation tool was applied to both baseline and follow up scans to obtain volumes
of the total brain, total grey and white matter of the cerebrum, and lateral and third
ventricles. At baseline there was no difference on any of these measures between the
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groups aside from for third ventricular volume, which was significantly larger in the
non-cannabis-using schizophrenic group in relation to healthy comparison subjects.
Over the five years of the study however cannabis using patients did show
significantly greater loss of grey matter and lateral and third ventricular enlargement.
The authors stress that this excessive brain volume loss could not be attributed to
differences in baseline characteristics, such as brain volume or clinical measures;
indeed, they stress that the cannabis-using group did not display more pronounced
brain volume abnormalities at onset compared to the nonusing group, and there was
no significant difference in scores on symptom rating scales. Similarly, the effects of
medication cannot explain the difference as medication use over the follow-up period
was qualitatively and quantitatively similar in both groups. No significant correlations
were present between brain volume change and measures of symptomatic and
functional outcome in either of the patient groups. Patients who continued to use
cannabis did show a less pronounced improvement in positive and negative symptoms
compared to nonusing patients however.
It is thus the case that two of the four available cross-sectional studies report
brain structural abnormalities on comparing people experiencing their first episode of
schizophrenia who use cannabis to those who do not use the drug.536'537 In each of
these studies abnormalities were detected in the cingulate, though in each case
different subregions (either the anterior or posterior cingulate) were investigated.
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Additionally, one of these studies detected abnormalities in the hippocampus,
whereas the only other study investigating this region (it actually looked at the
coo
amygdalahippocampal complex as a single entity) did not. A single longitudinal
study has further strengthened the case that cannabis use by people with schizophrenia
is associated with magnified brain structural changes. Given that structural imaging
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studies have not found any consistent alterations in brain structures in cannabis using
adolescents, the finding of structural brain changes in schizophrenia patients with
comorbid cannabis use are of particular interest. They may suggest that it is an
interaction between schizophrenia pathophysiology and cannabis use which is
resulting in the structural brain alterations observed in these studies.
4.3.1.2 Alcohol
As is apparent from Sections 4.1.3.2 and 4.2.1, the nature of the brain
structural deficits in schizophrenia and chronic alcohol dependence overlap. This
observation prompted the first study directly comparing brain structural brain imaging
findings in the two conditions, this being undertaken by Sullivan et al. and published
in 1998.540 In this American study brain structural volumes were compared between
62 detoxified alcohol dependent subjects (abstinent for approximately one month and
without significant psychiatric or medical comorbidity), 71 schizophrenics (without a
history of alcohol abuse or dependence) and 73 healthy controls. The ages of
participants included in each group spanned many decades, the youngest being 21 and
the oldest 70; though the alcoholic group was significantly older than the
participitants with schizophrenia (mean age 44.6 vs. 44.0), age was included as a
covariate in the analyses. Semi-automated methodology was used to segment grey and
white matter and divide the cortex into six regions on the basis of anatomical
landmarks; lateral ventricular volume and third ventricular area (the latter being
determined on the slice on which it appeared largest) were also ascertained. On
comparing these measures across the groups, Sullivan et al. report that whereas both
groups had grey matter volume deficits and CSF volume enlargement, only the
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alcoholics had white matter volume deficits. Furthermore, whereas the schizophrenics
had significantly greater volume deficits in the prefrontal and anterior superior
temporal grey matter than in the more posterior cortical regions, the deficits in the
alcoholics were relatively homogeneous across the cortex. On statistical comparison
only the superior temporal lobe deficits were significantly greater in the schizophrenic
patients than the patients with alcohol dependence.
The same group built on this early work, scanning a fourth group of men,
these people being comorbid for schizophrenia (or schizoaffective disorder) and a
lifetime history of alcohol abuse or dependence.541 This enabled a four way
comparison of structural imaging findings between 35 comorbid men, 64 people with
schizophrenia/schizoaffective disorder alone, 62 men with alcohol dependence alone,
and 62 healthy men. The comorbid group matched the schizophrenia group on age
and illness severity, but was younger and had consumed five times less alcohol in
their lifetimes than the alcohol dependence alone group. The same image analysis
methodology was utilized as in the previous study of Sullivan et al., though obviously
in this case comparisons were made across four groups rather than three. On
undertaking these comparisons, Mathalon et al. report that grey matter volume
deficits relative to controls were present in all three patient groups. These were
particularly pronounced in the comorbid group, these people having greater prefrontal
cortex and anterior parietal grey matter volume loss than either the alcoholic or
schizophrenic controls. By contrast however deficits in the temporal lobe, a region
known to exhibit abnormalities in schizophrenia, were equivalent. Mathalon et al.
conclude that, as they had hypothesised, it does appear that people comorbid for
schizophrenia exhibit compounded grey matter volume deficits. As would be
expected given evidence that it is affected in both disorders, these compounded
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deficits are particularly pronounced in the prefrontal cortex. Additionally however, it
seems that the anterior parietal region is also susceptible to these compounding
effects; by contrast, the temporal lobe is not.
Mathalon et al. go on to compare the magnitude of the prefrontal deficit in the
comorbid patients to that in the two patient comparator groups. They note that the
prefrontal grey matter volume deficit of the comorbid patients (mean z=-\ .70) was
equivalent to the additive effects of alcoholism (mean z=-0.71) and schizophrenia
(mean z=—1.00). As they discuss however, given that the lifetime alcohol
consumption of the comorbid patients was nearly five times less than that in the
alcoholic patients, the compounded effect of schizophrenia and alcoholism may best
be characterized as interactive rather than additive. In other words, comorbid patients
exhibited the full detrimental effect of alcoholism on prefrontal (and anterior parietal)
grey matter volume, despite significantly less lifetime alcohol intake than the
alcoholic patients. The authors conclude that their data provide biological evidence
consistent with clinical observations of heightened vulnerability to adverse outcomes
among patients with schizophrenia who also have alcohol problems.
The same group has also published three other studies investigated the effects
of comorbidity on the volumes of various subcortical structures. These studies utilise
the same subjects and focussed on the cerebellum, the pons, the thalamus and the
stiatum (caudate, putamen and nucleus accumbens). In each case volumetry was
undertaken using semi-automated ROI methodology, with adequate inter-rater
reliability.542"544 The only other group to investigate the effect of alcohol consumption
on brain structure in schizophrenia was a Scandinavian group, who investigated a
group of drinkers with schizophrenia who were not receiving treatment for an alcohol
problem.545 Their findings will be considered after those published by the group
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comprising Sullivan, Pfefferbaum, Mathalon and others.
Sullivan et al. found regional volume deficits in the cerebellum and pons in
the comorbid compared to schizophrenia alone group, but this was not the case for the
thalamus or striatum.542"344 The two studies with positive findings will be discussed
further. Firstly, in the study focussing on the cerebellum, the vermis was divided in to
four regions and each cerebellar hemisphere was outlined separately.342 Volume of the
fourth ventricle was also ascertained. On comparing these volumes between the
groups, the comorbid group had significantly greater cerebellar hemisphere and
vermian grey matter volume deficits and fourth ventricular enlargement than in either
single diagnosis group, despite significantly lower levels of alcohol consumption
compared with the alcoholic group. The authors propose a model of cerebellar
supersensitivity to alcohol-related tissue volume deficits in schizophrenia to explain
these findings. As further support for this they report that among the combined group
of patients with schizophrenia, (both with and without a diagnosis of alcoholism),
lifetime alcohol consumption was significantly related to grey matter volume in the
anterior superior vermis, with amount of alcohol consumption accounting for the
observed group differences in vermian volumes. As they stress, this relationship also
argues against the contention that these vermian volume deficits predated the onset of
alcoholism, increasing confidence that the have arisen secondary to alcohol use. They
conclude by cautioning that by virtue of a supersensitivity of the cerebellum in
schizophrenia to the detrimental effects of alcohol, patients with schizophrenia and
alcohol problem comorbidity are exposed to risks for motor and cognitive dysfunction
common to both diseases.
The study focusing on the thalamus and pons also employed semi-automated
ROI methodology to enable comparison of structure volumes across the four
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participant groups.543 Interestingly, in this study volume deficits in either structure
were not identified on comparing the (non-alcoholic) schizophrenia group to the
controls. Additionally, thalamic volume did not differ between alcoholic patients with
schizophrenia and controls or between patients with schizophrenia with and without
comorbid alcohol dependence. It was however reduced in those people with alcohol
dependence alone. By contrast however deficits in the pons were apparent in both the
subjects with alcohol dependence alone and those subjects comorbid for alcohol
dependence and schizophrenia when compared to the healthy controls. The authors
conclude that patients with schizophrenia and comorbid alcohol dependence are at
risk for alcohol-related reduction of pontine structures that are not necessarily affected
by schizophreniaper se. They suggest the absence of volume loss in the thalamus in
comorbid subjects may be explained by the effects of alcohol dependence on the
thalamus in schizophrenic patients being mitigated by the antipsychotic medication
they receive. Again they conclude by emphasizing that the comorbid group had
consumed a fifth of the alcohol of the schizophrenia alone group, indicating a
particular vulnerability in schizophrenia. This puts patients with schizophrenia and
comorbid alcoholism at particular risk for impairment in cognitive and motor
functions involving fronto-ponto-cerebellar circuitry.
As mentioned above, the study ofNesveg et al. investigated the effects of
alcohol on brain structure in a population of 69 patients with schizophrenia who were
non-clinical alcohol consumers; i.e. they were not recruited on the basis of having an
alcohol use disorder.545 They were compared to 97 healthy control subjects. Both
subjects with schizophrenia and control subjects demonstrated a negative association
between historic levels of alcohol consumption and white matter volumes. A
significant association between alcohol consumption and grey matter volume is not
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reported. Unfortunately, in this study a direct comparison was not made between
people with schizophrenia who did and did not use alcohol; given that the
methodology of this study is so different from that of the American group, the results
of the two studies are not directly comparable.
The report of Nesveg et al. aside, it is thus the case that the body of work
outlined above suggests that people with schizophrenia are particularly at risk of brain
structural abnormalities in association with heavy alcohol use. It seems to be
particular brain regions which are susceptible to this, the prefrontal cortex, anterior
parietal grey matter, cerebellum and pons being identified as such regions to date. It is
of course the case that these data arise from a single cohort of patients. The study of
Nesveg et al. employed a design which was not comparable, meaning that repetition
of the study of Sullivan et al. remains urgently needed. Nevertheless, it is the case that
the studies of Sullivan et al. are well conducted and are consistent with the
observation of particularly poor outcomes arising in cases of schizophrenia and
alcohol dependence comorbidty. They make a strong case for people with
schizophrenia being particularly vulnerable to brain structural sequelae secondary to
heavy alcohol use, providing a biological underpinning to the devastating
consequences of comorbidity which are observed clinically.
4.3.1.3 Tobacco
A single cross-sectional study has been undertaken comparing brain structure
in 14 schizophrenic patients who do and 18 who do not smoke tobacco. The study
also included 32 healthy comparison controls ofwhom only 2 smoked. Remarkably,
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no information is given about use of any other substances in any of the included
groups. Whole brain, voxel-wise analysis of regional grey matter was conducted using
VBM. As has been demonstrated in other studies, the schizophrenic group as a whole
had reduced grey matter in regions such as the orbitofrontal cortex, dorsolateral
prefrontal cortex and superior temporal gyri. Somewhat surprisingly however,
compared to those who did not smoke, schizophrenic smokers had relative
preservation of lateral prefrontal and superior temporal grey matter.546 The authors
suggest that it is possible that these unexpected findings are explained by nicotine, in
the context of schizophrenia at least, having a neuroprotective effect.
The report of Tregallas et al. has been followed by a longitudinal study which
compared brain structural changes over five years in smokers to those in non-
smokers.547 This study included both 96 patients with schizophrenia (54 smokers/42
non-smokers) and 113 healthy control subjects (35 smokers/78 non-smokers). This
was undertaken by the same group which published on the effects of cannabis over
the same time period,539 and may have utilsed some of the same patients. The authors
do state however that none of the patients had a diagnosis of drug abuse or
dependence at baseline, though three did have such a diagnosis at follow up. Van
Haren et al. report that cigarette smoking does not explain the excessive brain tissue
loss over time that they observed in patients relative to the healthy controls. They do
report however that extremely heavy smoking (>25 cigarettes per day, a level of
consumption present only in the patient group) was associated with excessive brain
loss over time, although this did not explain the excessive tissue loss in the
schizophrenia patients as a whole.
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4.3.1.4 Other drugs
Despite the extensive literature searches undertaken, no structural imaging
studies could be identified which specifically elucidated the structural brain imaging




The psychiatric enigma that is alcoholic hallucinosis (AH) was introduced in
Section 3.2.2.1.2. In ICD-10 it is classified as Alcohol Induced Psychotic Disorder
and is described as being characterised by hallucinations, delusions, psychomotor
disturbance and abnormal affect; these symptoms occur in the context of a clear or
only marginally clouded sensorium. AH occupies an interesting position in
psychiatry, being a psychotic condition for which causation is essentially entirely
attributed to an environmental exposure, heavy alcohol consumption. Though
generally transient, it does have the potential for chronicity; in possibly 10% of
patients the condition will run such a course.548 The psychosis experienced closely
resembles schizophrenia, though a recent report does outline a number of features in
which the two conditions differ. Specifically, patients with AH are reported to exhibit
greater levels of depressive and anxiety symptoms, fewer negative and disorganized
symptoms, better insight and judgment, and less functional impairment compared to
patients with schizophrenia.549 Previous researchers have also reported that
schizophrenic symptoms such as thought disorder and passivity are generally absent
in this condition.
Given the clinical overlap between the two conditions, early researchers were
optimistic that study of AH may have the potential to shed light on the
pathophysiology of schizophrenia.350 Family and genetic studies failed to demonstrate
a greater prevalence of schizophrenia in relatives of patients with AH however, which
led to genetic predisposition for the two conditions being regarded as independent.271
This limited interest in AH, which combined with its rarity has meant that little
research has been undertaken into the condition in recent years. Reflecting this lack of
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research, I could find no structural imaging studies investigating the structural
imaging characteristics of people with this condition. There have however been a
small number of functional imaging studies. Given the relevance of AH to the current
study I will outline the findings from these, despite the fact that findings from
functional imaging studies are in general outwith the scope of the current report.
Up until this year even the totality of functional imaging studies consisted solely of
PET and single photon emission computed tomography (SPECT) reports undertaken
as single case studies in individuals with unusually chronic AH. These have
consistently reported a significant absolute or relative decrease in metabolism in
either one or both thalami.551~5:>3 Interestingly in those subjects in whom the
hallucinations resolved these abnormalities normalised.551'553
Earlier this year the first case controlled imaging study investigating AH was
published.554 This utilised SPECT to compare regional cerebral blood flow (rCBF) in
19 patients with AH, 16 with schizophrenia, 20 with uncomplicated alcohol
dependence and 19 healthy volunteers. Increased rCBF was demonstrated in the right
calcarine area (medial occipital lobe) in patients with AH compared to healthy
volunteers, with a trend towards increased rCBF to the frontal and temporal lobes and
the right pallidum. Decreased left sided rCBF to the putamen, parietal, mid-frontal
and mid-temporal lobes and heterogenous flow to the cerebellum were demonstrated
in patients with AH when compared to patients with uncomplicated alcohol
dependence. The left posterior cingulate and right cerebellum showed higher and
lower rCBF respectively in patients with AH compared to patients with schizophrenia.
The authors conclude that their findings implicate the right occipital lobe and possibly
the cerebellum in the pathogenesis of AH. They state that they could not confirm the
reduced rCBF to the thalamus suggested in previous case reports. Overall, on
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integrating these data with previous reports, it is clear that the presence or absence of





Questions raised by the systematic review and hypotheses to be tested in this
study
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In the preceding chapters a body of work is reviewed which has greatly
increased our understanding of substance misuse, schizophrenia and the condition of
'dual diagnosis'. It is the case however that many questions about the inter¬
relationship of these conditions continue to be unanswered. It is my hope that
answers to some of these remaining questions may be provided by this study, and
later in this chapter I will outline the specific questions which this study aims to
address. Firstly however I will summarise those themes from the preceding chapters
which are of particular importance in guiding the focus of the data analysis sections.
This will be followed by a consideration of findings from (nonhuman) experimental
studies which may also have relevance in informing our understanding of the
relationship between substance misuse and psychosis. This will lead on to a
discussion of the specific hypotheses that this study is designed to address.
5.1. The importance of dopamine in addiction and psychosis
The importance of dopaminergic mechanisms in the development of substance
dependence was discussed in Section 1.2. As part of this discussion the centrality of
the mesolimbic dopaminergic pathway both in the experience of pleasure (reward)
and imbuing the prevailing circumstances with salience (and so promoting memory)
was reviewed. This pathway, centred on the nucleus accumbens, is believed to be
crucial when drug use is initiated. As use continues however, it is argued that
TO
projections to the dorsal striatum become more important. In this way behaviour
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evolves from being a declarative process involving prefrontal executive functions into
a habitual behaviour utilizing working memory circuitry.31
As discussed in Section 2.2 however, dopamine is also regarded as central in
the development of psychosis. This was suggested by the key observations that
stimulation of dopamine release by amphetamines resulted in psychotic symptoms,
whereas dopamine blockade by antipsychotics attenuated them. In recent years one of
the most influential hypotheses proposed to explain the mechanism by which
dopamine overactivity in mesolimbic circuits could give rise to psychotic symptoms
has (similarly to the addiction literature) focused on the importance of dopamine in
imbuing salience to phenomena. Kapur proposed that psychosis is predominantly a
condition of increased salience, which arises as a consequence of dopamine release
and through which neutral experiences are mistakenly endowed with personal
meaning.110
The overlap between the models proposed to explain the development of
addiction and psychosis do not end there however. Further overlap is also apparent
when the importance given to frontal lobe abnormalities is considered. In our
understanding of schizophrenia, the idea that there is simultaneously overactivity of
dopamine in the striatum and underactivity in the prefrontal cortex remains
influential.106 Complementing this in the addictions field, there is burgeoning
neuroimaging and neuropsychological evidence suggesting that chronic drug abusers
show deficits in tests of inhibitory control and decision making.555"557
It should thus be clear from the above that there is much overlap in the roles
dopamine is purported to have in the models formulated to explain both the
development of addiction and psychosis. As reviewed in Section 3.2.3, this is in-
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keeping with the suggestion (first coherently formulated by Chambers et a/.317), that
the excess of substance misuse observed in schizophrenia may actually arise as a
consequence of neuropathology associated with schizophrenia itself. By this argument
this neuropathology impacts on the neural circuitry mediating drug reward and
reinforcement, meaning that people with schizophrenia are biologically more
vulnerable to the rewarding effects of drug abuse and thus at increased risk of
addictive behaviour. Utilising findings from human and animal studies, Chambers et
al. hypothesized that abnormalities in hippocampal-cortical function in schizophrenia
impair the inhibitory hippocampal projections to the nucleus accumbens, resulting in
reduced inhibitory control over dopamine-mediated functional hyperresponsivity to
dopamine release. In this model, dysregulated neural integration of dopamine and
glutamate in the nucleus accumbens resulting from frontal and hippocampal
dysfunction could lead, in subjects without prior drug exposure, to neural and
motivational changes similar to those in long-term substance use.
It is conceivable however that the overlap between the neural circuitry
important for the development of schizophrenia and addiction has implications
beyond simply explaining why people with schizophrenia are at increased risk of
developing substance misuse problems. Though not proposed by Chambers et al, it
also seems conceivable that in an adolescent at risk of schizophrenia (by, for example,
abnormalities of hippocampal-cortical function), dysregulated neural and motivational
changes arising as a consequence of substance use could further increase their risk of
actually developing the condition. In short, by stimulating dopaminergic circuits
directly (amphetamine) or indirectly (cannabis), (and possibly by resulting in other
changes as well), certain illicit drugs could interact with other risk factors for
psychosis, influencing an individual's risk of making the transition to illness. Thus, as
250
well as explaining why people with schizophrenia are more likely to develop
substance misuse problems, the overlap between the neural circuitry implicated in
addiction and psychosis could provide a possible explanation as to why certain drugs
(see Section 3.2.2.1) appear to increase an individual's risk of developing
schizophrenia. Data supporting the possibility that certain drugs of abuse can indeed
have this effect will be discussed below.
5.2 Data from the review section supporting the possibility that substance use
can increase the risk of an individual developing schizophrenia
5.2.1 Use ofsome drugs in adolescence is associated with an increased risk of
developing schizophrenia
The evidence that use of various substances may increase an individual's risk
of developing schizophrenia is reviewed in Section 3.2.2.1. The strongest evidence
comes from cohort studies, which suggests that, even when confounders are
controlled for, cannabis use is associated with an increased risk of subsequently
developing schizophrenia. Two further important findings have arisen from this
research however. Firstly, it was reported that early use of cannabis is associated with
a greater risk of developing psychosis than later use, with several studies reporting
998 9 55 948
that use before age 16 was associated with particular risk. ' ' Secondly, it was
shown that an allelic variant moderated the influence of adolescent cannabis use, with
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cannabis users homozygous for the high activity Val allele having an at least fivefold
increased risk of developing a schizophreniform disorder, whereas homozygosity for
the Met allele offered relative protection.121 These findings are important as they
suggest that particular individuals, by virtue of factors such as youth or genetic
variants, are particularly vulnerable to the risk modifying effects of cannabis use.
Consequently, it is conceivable that structural brain abnormalities arising as a
consequence of cannabis use may be detectable in specific, vulnerable populations
which would not be observed in the general population.
In contrast to the considerable research examining if cannabis is a tenable risk
factor for schizophrenia, comparable studies for other drugs of abuse are few. It is
notable however that chronic heavy alcohol use has long been associated with
induction of a hallucinatory state (alcoholic hallucinosis). Additionally, and as
discussed in Section 3.2.2.1.2, in their analysis of data from the Swedish conscript
study Lewis et al. report that there was an increased risk of schizophrenia in those
with an ICD-8 diagnosis of alcohol abuse at age 18.237 In a Japanese study 5% of
methamphetamine psychosis cases were shown to have residual symptomatology
many years later.281
The reports outlined above suggest that cannabis use, and possibly also use of
alcohol or methamphetamine, may indeed contribute to an individual's risk of
developing schizophrenia or other protracted psychoses. Furthermore there is a
suggestion (arising from the cannabis and alcohol data at least), that certain
individuals, by virtue of youth or genetic variability, may have a particular
vulnerability to these effects. This is particularly interesting when considered with the
possibility (discussed above) that it could be the dysregulated neural and motivational
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changes arising as a consequence of substance use which increase an individual's risk
of developing the condition. It seems understandable that use of such substances at a
time of rapid biological change and particularly by a person already at elevated
genetic risk of psychosis would be more likely to lead to alterations in neurobiology
that increase psychosis risk.256'257
5.2.2 Brain imaging abnormalities in dual diagnosis individuals are more
pronounced than those observed in people with either schizophrenia or substance
misuse alone.
Data reviewed in Sections 4.3.1.1 and 4.3.1.2 reported that individuals with
established schizophrenia with a history of heavy use of either cannabis or alcohol
exhibit more pronounced brain volume loss than those who do not use these
substances. Though cannabis using control groups were not included in the former
studies, in the case of the alcohol study an alcohol dependent control group was. In
this study it was reported that the deficits observed in the alcohol-using schizophrenic
group were considerably greater than the additive effects of alcohol and schizophrenia
alone. Indeed, the combined effect of schizophrenia and alcoholism were reported as
being best characterized as interactive rather than additive. Mathalon et al refer to this
group as exhibiting compounded effects, and suggest that individuals with
schizophrenia have a particular sensitivity to brain volume loss on exposure to
alcohol.541 The available data suggest that this may also be the case for cannabis given
that (in contrast to studies in the normal population) substantial grey matter loss is
reported in people with schizophrenia who use the drug.539
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If it is true that people with schizophrenia have a particular susceptibility to
the brain structural consequences of alcohol and cannabis use, then it is conceivable
that this susceptibility is present prior to illness onset. If this is the case, it may
characterise a group in whom alcohol or cannabis use is a particularly important risk
factor for the development of psychosis. In the section above it is discussed that the
risk modifying effects of cannabis appear to be particularly pronounced in
adolescents, particularly those possessing genetic variants associated with risk of
schizophrenia. Thus, it may be expected that adolescents at elevated risk of
schizophrenia for genetic reasons may be a group in whom the structural brain
consequences of cannabis use (as well as alcohol and possibly other drugs) may be
particularly pronounced.
5.3 Findings from animal studies of relevance to understanding the relationship
between substance misuse and psychosis
The data reviewed above suggest that cannabis use is a risk factor for
schizophrenia, and that if the drug is used in adolescence the individual may be
particularly vulnerable to this risk modifying effect. Additionally, as reviewed in
Section 3.2.1.1, experimental studies have also demonstrated that acute administration
of THC produces transient psychotic symptoms. Obviously however, true
experimental studies examining whether repeated administration of cannabis/THC to
an adolescent population results in an increased risk of subsequent schizophrenia
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(rather than simply acute and transient psychotic symptoms) are not feasible. This
however can be explored through animal models, which also offer the opportunity to
directly examine the neurobiological consequences of adolescent cannabis/THC
exposure. Important studies in this research area will be outlined below. In addition to
studies examining the consequences of cannabis/THC exposure, relevant animal
studies examining the consequences of alcohol use will also be included.
Animal data examining this possibility that cannabis can affect the central
nervous system during a critical period and result in irreversible changes were
recently reviewed by Bassong and Niesink.558 They note early research
demonstrating that not only can administration of cannabis extracts to rodents cause
long-lasting effects at the behavioural level,559"561 but that exposure of immature rats
to THC induces more irreversible residual effects on behaviour than in mature rats.562
Clearly this suggests that age during exposure may be a critical determinant of
neurotoxicity outcome.563 They go on to note that this possibility is further supported
by later animal studies demonstrating that chronic peri-pubertal, but not adult,
cannabinoid exposure causes long-lasting alterations in memory and behaviour, with
functions mediated by the PFC such as working memory and prepulse inhibition
(abnormalities also observed in schizophrenia) being particularly effected.564"566
Other studies provide insights into what may be occurring at a cellular level.
As discussed by Demerika et al in their 2011 paper,567 molecular and cell biology
research has demonstrated that endocannabinoids promote oligodendrocyte progenitor
survival,568 and control axonal growth by inducing chemorepulsion or collapse of
axonal growth cones.569 Cannabionoid-1 (CB- 1) receptor activation increases
astroglial progenitor proliferation and differentiation in vitro, and neural progenitor
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proliferation and astrogliogenesis are decreased in adult CB1-deficient mice.5'0 In
keeping with these findings studies in rats have demonstrated that when exogenous
THC is added, CB1 receptors in the hippocampus are down-regulated,571 and
endocannabinoid-mediated synaptic plasticity as well as the formation of new
577 57^
synapses is blocked. ' Other studies reported that the number of hippocampal
neurons and synapses were decreased after THC administration and hippocampal
neurons were smaller.574'573 Together these preclinical studies support the view of
THC inhibiting neurogenesis. In adult rat studies these effects are observed
predominantly in the hippocampus. Given data that human adolescence is a time of
dramatic change in brain structure and connectivity, with widespread synaptic
refinement and myelination occurring in cortical and subcortical in addition to
hippocampal changes,576 the effects of human adolescent cannabis exposure could
potentially be even more pronounced. These effects could be detectable as change in
volume of specific structures in human imaging studies.
In summary therefore the above suggests that cannabis (or THC) exposure at a
vulnerable period in neurodevelopment could conceivably adversely influence brain
maturation, increasing an individual's risk of developing schizophrenia. This most
likely occurs through THC interfering with the interaction of endogenous
cannabinoids with CB1 receptors which are critically involved in brain maturation.
Through this means it is likely that THC disturb this normal physiological process,
potentially resulting in disturbed neurotransmitter release, subtle neurotoxic effects,
structural defects and potentially psychosis.
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In keeping with the paucity of data from other fields of research, the potential
contribution of alcohol exposure to the neurodevelopmental abnormalities believed to
be important in the development of schizophrenia has received little attention in
animal work. Indeed, no studies could be identified which had investigated the effect
of adolescent alcohol exposure utilising animal models ofpsychosis. That the
adolescent brain is particularly vulnerable to the effects of alcohol does seem to be the
case however, being suggested by animal experiments undertaken by several groups.
Firstly, studies of the effects of binge drinking on rat brain structure have
found that the effects are age-dependent, forebrain damage being more pronounced in
the adolescent than adult rats.577 Furthermore it has also been reported that ethanol
more potently inhibits NMDA-mediated excitation and stimulus-induced long-term
potentiation in hippocampal slices from early adolescent rats versus slices from adult
hippocampus.578'579 In addition, adolescent rat brain has been found to be particularly
sensitive to ethanol induced inhibition of neurogenesis.580 Finally, a recent study
found that a binge-drinking model of consumption increases cell death in the
neocortex, hippocampus and cerebellum, and produced adverse neurobehavioural
consequences detectable adults. Behavioural deficits on motor coordination and
conditional discrimination learning tasks in alcohol-exposed animals persisted into
adulthood.581
Consideration of the above data does suggest that alcohol-related toxicity
could potentially result in deranged dynamic synaptic remodeling of the maturing
adolescent brain. As is discussed by Crews et al., this may have the effect of
enhancing the strong learning components of heavy drinking behaviours while
simultaneously resulting in the loss of important self-control and goal setting
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components of the maturing brains executive centres.582 One manifestation of this is a
persisting propensity to alcohol problems, likely reflected in the fact that individuals
who start drinking before the age of 15 are four times more likely to become alcohol
dependent at some time in their life."83 It is also conceivable however that these same
effects (a primed 'reward system', impaired executive function and other, potentially
even more dramatic consequences of aberrant synaptic remodelling) may also
increase an individual's risk of developing psychosis. This is an area which (at the
very least) would seem to warrant further research.
5.4 Hypotheses which will be tested in this study
The findings outlined above are central to the design of the current study. This
will utilise data from the Edinburgh High Risk Study to examine whether people who
are at familial risk of schizophrenia (and who are consequently assumed to be at
elevated genetic risk of the condition) have a particular vulnerability to the brain
structural consequences of substance use. This will be examined in a number of
stages:
1. The brain structural associations of historic substance use (up to point of entry
in to the study) will be contrasted between those at elevated risk of
schizophrenia for familial reasons and matched controls. The null hypothesis
is: 'the brain structural abnormalities associated with historic substance use
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are no different in those at high risk of schizophrenia for familial reasons
compared to controls'.
2. Within the high risk group the relationship between different levels of use of
specific substances and volume of specific brain structures will be examined.
The null hypothesis for this part of the study is: 'within the high risk group
there is no relationship between historic levels of use of specific substances
and volume of specific brain structures'.
3. The brain structural consequences of substance use between scan points will
then be compared between high risk individuals who do and do not use
specific substances between the scan points. The null hypothesis in this part of
the study is: 'longitudinal structural brain changes in individuals at high risk of
schizophrenia are not influenced by use of substances of abuse.'
Other secondary considerations will include examination of the influence of substance








The objective of the Edinburgh High Risk study was to identify people at high
genetic risk of schizophrenia when well, and follow them up during the period during
which they would be expected to develop schizophrenia. High risk individuals were
defined as young people aged between 16-25, who did not have a history of serious
psychiatric problems and had never been considered as psychotic, but who had at least
two first or second degree relatives affected with schizophrenia.
Identification of high risk subjects was a labour intensive process. It was done
by examining casenotes of all patients with schizophrenia known to individual
hospitals where there appeared to be two related cases. Consent was sought from one
of the affected subjects to speak to a healthy relative, from whom a full family history
was obtained. In taking this history particular emphasis was given to the possibility of
there being family members, aged 16-25, who were first or second degree relatives of
the affected subjects. This methodology has been fully described in a number of
published works.584
When planning the investigation it was calculated that the likelihood of
genetically high risk individuals such as those recruited developing schizophrenia by
the age of 30 was between 10 and 15%. It was therefore determined that 200 high risk
subjects should be sought, with a view to 20-30 of them developing schizophrenia.
Two control groups, each planned to be of about 30 subjects to enable comparison
with those who went on to develop schizophrenia, were also recruited. One group was
of age-matched individuals with no family history of psychotic disorder, while the
other was age-matched cases of first episode schizophrenia who were not known to
have a family history of the condition. In this study I will make no reference to the
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first episode schizophrenia control group; this is because the issue of primary interest
is the impact of substance misuse on brain structure in people who are at high risk of
schizophrenia, but currently well. As discussed, studies have already been undertaken
investigating the structural associations of substance misuse in people with
established schizophrenia (Section 4.3.1).
Two hundred and twenty nine suitable high risk individuals who were
prepared to consider inclusion in the study were identified and, in the first five years
of the study, 162 of these provided useful data. In order to achieve these numbers
participants were recruited from mental health services over much of Scotland. Thus,
in addition to having substantial numbers of subjects from the city of Edinburgh,
people were also included from families living in the rural areas of Argyll, Clyde,
Borders, Forth Valley, Lothian, Highlands & Islands and the towns and cities of
Inverness, Dumfries, Perth and Greenock. These are areas of stable population where
traditional patterns of family life largely persist, providing the extended family
networks necessary for the study. As subjects were from such diverse environments,
the well controls were recruited from the social networks of the subjects themselves.
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6.2 Plan of study, assessments used, and characteristics of participants
The study was conducted in two phases. The first took place from 1994 to
1999 and the second from 1999 until 2004. In the first phase all of the high risk
subjects and both groups of controls were assessed at the point of entry in to the study
in terms of psychopathology, neuropsychology and brain structure as determined by
structural magnetic resonance imaging (MRI). As part of this battery of assessments,
lifetime highest level of use of drugs of abuse was ascertained by self report in face to
face interviews. Of the high risk subjects successfully recruited to the study 147 had
usable scans, and so could be included in the following analyses.
Following entry in to the study, assessment of the high risk subjects and well
controls were then repeated approximately every two years. These repeat assessments
included a repeat MRI scan, assessment ofpsychiatric symptomatology, and
ascertainment of both current levels of substance use and levels of exposure to
tobacco, alcohol and illicit drugs in the intervening period. Both at initial assessment,
and at follow up the main psychopathological instrument used was the Present State
Examination, ninth edition (PSE-9).585 Present State Examination (PSE) ratings were
also obtained after diagnosis in subjects who became ill. After confirmation of a
diagnosis of schizophrenia people left the study, and thus no further assessments were
obtained. Unfortunately, the MRI scanner used in the study changed in 1998, meaning
that only the second round of scans were all conducted with the same scanner as those
at baseline. Quantitative comparison across a change in scanner is of uncertain
feasibility while utilising standard image analysis methods.586 For this reason the
longitudinal analyses only utilise scans taken at timepoints 1 and 2.
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A control group of 36 healthy individuals without any family history of
schizophrenia was recruited from the same areas of Scotland as the high-risk
participants. These people were of similar age to the high-risk group and their
numbers were comparable to the number of people expected to develop psychosis.
They underwent the same assessments, including scanning, as the high risk subjects.
6.2.1 Collection and analysis ofbaseline demographic and drug use data
6.2.1.1 Quantification oflevels ofdrug use up to point ofentry into study
As discussed above, on entry into the study lifetime use of alcohol, cigarettes
and illicit drugs was ascertained by self report in face to face interviews. Current
levels of substance use were also recorded, in a similar manner. At follow up
assessments, the researchers recorded level of use since last seen, and again recorded
current substance use.
Information on use of all substances was comprehensively recorded for the
vast majority of participants at the vast majority of assessments. The manner in which
it was recorded did exhibit some variability however, and to some extent was
substance dependent. In the case of cannabis for example, consumption was generally
recorded as frequency of consumption (e.g. has smoked cannabis twice a week for
approximately six months) rather than absolute quantities consumed (e.g. % ounce a
week). In relation to cannabis use it is important at this point to comment on the type
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of cannabis that the subjects included in this study would have consumed. At the time
this study was conducted use of 'skunk' cannabis was not common, and the form of
cannabis which would have been consumed would most commonly have been
cannabis resin, which has a considerably lower THC:cannabidiol ratio. As discussed
in Section 3.2.1.1 preparations with a relatively high THC:cannabidiol ratio may be
particularly psychotomimetc.
Alcohol consumption was often recorded as number of units consumed per
week, both currently and historically. This was however far from universal, and in a
substantial number of cases consumption was not documented in a manner that could
feasibly be quantified on a simple ratio scale; this would include, for example, '>21
units/week but no symptoms of dependence' or 'regular but less than 14 units a
week'. Alcohol consumption was actually recorded in such a manner for a
considerable number of subjects; it was the case for 51 of the 140 subjects with both
baseline scans and data on past alcohol consumption.
Given the manner in which data were collected, for substances such as
cannabis, cigarettes and ecstasy a categorical scale to quantify substance use was
unavoidable. Ideally in the case of alcohol I would have employed a ratio scale, using
number of units per week to quantify historic highest level of use of alcohol. This
would however have meant excluding the 51 subjects on whom useable data on
alcohol use had been collected, but not as a specific number of units per week. Given
my wish to include as many subjects with usable data in my analyses as possible, this
did not seem the optimal approach. Instead, it seemed most appropriate to employ a
categorical system for quantification of levels of use of alcohol as well as the other
substances under investigation. With this approach, all 140 subjects with usable data
on highest levels of alcohol use could be included in the analysis.
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The volume, pattern and frequency in which different drugs of abuse are
consumed varies with the substance under consideration. This necessitates derivation
of a categorical scale appropriate for each substance. Optimally, the cut-off points in
such a scale would fulfil two criteria: (1) They would reflect potentially biologically
significant points of transition in level of drug use; (2) They would reflect the manner
in which drug use data were collected, enabling inclusion of the maximum number of
subjects. The categorical scale chosen for each of the substances under discussion is
discussed further below:
Alcohol
The categorical scale to quantify highest level of use of alcohol at baseline is
detailed in Table 5.1. As can be seen, we included an 'occasional use' category, for
people who had a history of alcohol consumption, but this has never exceeded 3
units/week. The inclusion of this minimal use category was felt to be necessary for
two principle reasons. Firstly, and particularly given the prevalence and levels of
alcohol consumption in Scotland (91.5% of Scottish adults drink alcohol, and 34% of
men usually exceed government recommendations),5 it was conceivable that teetotal
subjects may have quite different characteristics to those who did consume alcohol,
but at a low level. There is certainly considerable evidence to support this possibility.
Abstention from alcohol use has been reported to be associated with social isolation,
social anxiety, hostility and depression.587 Additionally, though these data do
admittedly arise from older populations, there are also reports of lower scores on
■ ■ * 588 589 * • 398
cognitive testing ' and structural imaging abnormalities in lifetime abstainers
compared to low/moderate drinkers.
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Category Level of use
Teetotal Lifetime abstinence
Occasional Maximum level of use never exceeded approximately 3 units/week
Regular Consumption has been >3 units/week, but never exceeded government
recommended safe limits (14 units/week for women and 21 units/week for
men)
Excessive use Consumption has exceeded government recommended safe limits, but no
history of dependence
Dependence History of alcohol dependence syndrome
Table 6.1.
Categories employed in ordinal scale quantifying historic levels of alcohol
consumption
In addition to there being a rationale for separation of low users of alcohol from
lifetime abstainers, it also seemed important to distinguish between low and moderate
users of the drug. I thus devised two categories for people who did consume alcohol,
but not exceeding government recommendations; the occasional use category of
people who did not consume more than 3 units/week, and the category of regular use
but never having exceeded government recommendations (21 units/week for men and
14 units/week for women). This was important because grouping all non-teetotal
subjects who reported using alcohol within government recommendations together
(particularly given the accepted belief that people may under-report their
consumption), would group a wide range of alcohol consumption levels together. At
the lower end would be those reporting 'a glass of wine once a week' or 'occasionally
a pint of lager once a week' (genuine very low users), while at the other would be
some, (e.g. '10 pints of lager a week'), who may even just exceed government
recommendations. Specifically choosing 3 units a week as the cut off enabled our
inclusion of subjects reporting 'a pint a week' (pints being the most common quantity
in which alcohol is consumed in Scotland), within this group. A similar approach has
321 393been used in other studies to identify comparable groups of occasional drinkers. '
Given the considerations discussed above, I believed the separation of lifetime
abstainers, occasional users and regular users to be clearly justified. As well as being
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theoretically robust however, it also provided other advantages. Specifically, it
enabled the identification of a group of very low users of alcohol unlikely to posses
the atypical characteristics that could potentially be associated with being teetotal. As
will become apparent in the subsequent section discussing the statistical methods
used, the use of logistic regression is largely dependent on the presence of such a
group.
The fourth and fifth alcohol consumption categories were, respectively,
alcohol consumption exceeding government recommendations (but no history of
dependence) and a history of alcohol dependence syndrome. In this instance I
believed that a history of the dependence syndrome was a more appropriate cut-off
point rather than an arbitrarily chosen consumption level.
Other substances
Categories comparable to those employed in the quantification ofhistoric
levels of alcohol consumption were used for the other substances. These are detailed
in Tables 6.2-6.5. The categories used in cannabis consumption are similar to those
189used by previous researchers (see Table 6.2). Similarly, the method for
quantification of historic levels of tobacco consumption was fairly standard (see Table
6.3).590'591 A relatively small number of studies have been conducted quantifying
levels of ecstasy and amphetamine use, but these have generally employed approaches
to quantification similar to that in Table 6.4.592'59j This scale was also used to
quantify exposure to LSD.
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Category Level of use
Never Report that they have never consumed cannabis
Isolated Have consumed cannabis on a maximum of three occasions
Occasional Have consumed cannabis on more than three occasions, but frequency of use
has never reached monthly
Frequent Have used cannabis regularly. This has been on at least two occasions in a
single month, but never exceeded three days in a single week
Most days/daily Level of use has exceeded three days in a single week
Table 6.2
Categories employed in ordinal scale quantifying historic levels of cannabis
consumption
Category Level of use
Never Non-smoker
0-10 Smoker, but not more than 10 cigarettes (or equivalent) a day
11-20 Smoker, consuming 11-20 cigarettes (or equivalent) a day
>20 Smoker, consuming >20 cigarettes (or equivalent) a day
Table 6.3
Categories employed in ordinal scale quantifying historic levels of tobacco
consumption
Category Level of use
Never Report that they have never consumed the drug
Isolated Have consumed the drug on a maximum of three occasions
Repeated Have consumed the drug on more than three occasions, but frequency of use
has never reached monthly
Frequent Have used the drug regularly, this being on at least two occasions in a single
month.
Table 6.4
Categories employed in ordinal scale quantifying historic levels of ecstasy,
amphetamine, cocaine and LSD consumption
Participants were also questioned about use of other illicit drugs of interest,
such as solvents, opiates, benzodiazepines and cocaine. Exposure to any of these
substances was however relatively rare. For use of opiates and benzodiazepines, a
scale incorporating a history of dependence was employed (see Table 6.5). For
solvents the scale used was identical to that for ecstasy and amphetamines.
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Category Level of use
Never Report that they have never consumed the drug
Isolated Have consumed the dmg on a maximum of three occasions
Repeated Have consumed the dmg on more than three occasions, but frequency of use
has never reached monthly
Frequent Have used the dmg regularly, this being on at least two occasions in a single
month.
Dependence History opiate/benzodiazepine dependence syndrome
Table 6.5
Categories employed in ordinal scale quantifying historic levels of opiate and
benzodiazepine consumption
6.2.1.2 Other relevant data collectedfrom subjects
In addition to ascertainment of level of drug use and brain imaging,
participants in the study were given detailed clinical and neropsychiatric assessments.
These included ascertainment of IQ using the Wechsler Adult Intelligence Scale
Revised,594'594and quantification of the experience of schizotypal symptoms using the
Rust Inventory of Schizotypal Cognitions (RISC).595
The experience of schizotypal cognitions, as measured by the RISC, has been
shown to be one of the strongest predictors of the subsequent development of
schizophrenia.187 Given the significance of this measure in this population, it will be
informative to establish if scores on it vary with level of drug exposure. As a measure
ofpsychotic-type symptomatology, it will also useful in suggesting whether or not
self-medication of subclinical psychotic symptoms may be playing some role in
substance use.
Low IQ is itself associated with risk of development of schizophrenia, and is
also associated with use of some substances (see Section 3.2.3.1). It will thus be
important to compare it across levels of substance use, and it will also be included as




Statistical testing was conducted with the Statistical Program for the Social
Sciences 14. Data were checked for normalcy and outliers by plotting graphically and
conducting the Kolmogorov-Smirnov test. Demographic and clinical variables were
compared between high risk (and control) subgroups with different levels of exposure
to the various substances with analysis of variance and the x2 test.
6.2.1.4 Comparison ofdemographic and clinical characteristics between subjects
with different level ofexposure to the substances of interest
High risk subjects
One hundred and 47 high risk and 36 healthy control subjects had usable
scans. For the vast majority of individuals full information on past and present use of
each of the three substances of primary interest was available. However, information
on alcohol use was not available for 7 high risk subjects, cannabis use for 5, and
tobacco use for 10.
Demographics and clinical details, organised by level of use of each of the
three substances, are shown for high risk subjects in Table 6.6. There is a (non¬
significant) trend for more males in the highest exposure groups to both cannabis and
alcohol. There is also a significant difference in age across the alcohol exposure
groups, occasional users tending to be younger. Additionally, there is a significant
difference in IQ across the tobacco exposure groups, the heaviest smokers having the
lowest IQ. There was no significant difference in RISC scores between individuals
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with different levels of exposure to alcohol or tobacco. A difference did however
exist between those with different levels of exposure to cannabis, those with greater
levels of exposure tending to have higher scores.
Some high risk subjects had a history of use of illicit drugs other than
cannabis. In only three subjects, with a history of opiate addiction, did level of past
use constitute dependence. Data on levels of use of cocaine, ecstasy, amphetamines









10(7.1) 28 (20) 56 (40) 37 (26) 9 (6.4)
Mean age in
years (SD)
20.9 (2.3) 19.8 (3.2) 21.4 (2.8) 21.9(2.8) 21.2 (2.9) .05
Gender (M:F) 4:6 14:14 29:27 18:19 7:2 .53
Handedness
(R:L:both)
10:0:0 23:4:1 51:2:3 32:2:1 7:0:2 .16
Mean IQ (SD) 100.9(16.9) 104.0(16.0) 98.4(12.2) 94.9 (9.4) 94.3 (8.9) .06




Nil Isolated Occasional Frequent Most days P
Number of
subjects (%)
50 (35.2) 23 (16.2) 26(18.3) 15(10.6) 28 (19.7)
Mean age in
years (SD)
21.1 (3.0) 21.5 (3.3) 21.7 (2.5) 20.6 (2.5) 21.0 (2.9) .77
Gender (M:F) 20:30 11:12 15:11 8:7 20:8 .11
Handedness
(R:L:both)
42:5:2 22:0:1 24:1:1 13:1:0 23:2:3 .65
Mean IQ (SD) 98.4 (14.3) 101.8 (13.9) 100.1 (12.8) 96.6 (7.0) 95.3 (11.1) .41




Nil 0-10 11-20 21 + P
Number of
subjects (%)
62 (45.3) 42 (30.7) 20 (14.6) 13 (9.5)
Mean age in
years (SD)
21.4(3.1) 20.6 (2.5) 21.0(3.0) 22.5 (2.7) .20
Gender (M:F) 32:30 24:18 10:10 7:6 .94
Handedness
(R:L:both)
55:5:2 37:3:1 16:1:2 12:0:1 .72
Mean IQ (SD) 102.1 (13.6) 95.3 (9.3) 101.6(12.6) 89.8 (8.4) <.01
RISC (SD) 28.0 (10.5) 32.1 (10.5) 31.5 (12.8) 27.1 (12.6) .24
Table 6.6
Demographic details of high risk subjects in each of the substance exposure
categories.
a
Exposure categories, based on highest level of consumption of alcohol during period of maximal use,
are as follows: teetotal = no history of alcohol use; occasional = use never exceeded approx 3
units/week; regular = regular use but not exceeding 14U/week for women or 21U/week for men;
exceed safe limits = exceeding safe recommendations; dependence = history alcohol dependence.
b
Exposure categories, based on highest level of exposure to cannabis during period of maximal use, are
as follows: nil = never used cannabis; isolated = used on maximum of 3 occasions; occasional = regular
use, but less than monthly; frequently = use of cannabis monthly or greater; most days = use of
cannabis more than three days a week.
c
Highest level of tobacco use: number of cigarettes (or equivalent) per day.
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Drug Level of use: N (% of all high risk subjects with that level of use)
Never Isolated Repeated Frequent
Cocaine 140 (94.6) 0 2(1.4) 0
Ecstasy 111 (75.0) 9(6.1) 9(6.1) 13 (8.8)
Amphetamine 96 (64.9) 21 (14.2) 13 (8.8) 12(8.1)
LSD 103 (69.6) 14(9.5) 14 (9.5) 11(7.4)
Table 6.7
Highest levels of use of cocaine, ecstasy, amphetamines and LSD by the high risk
subjects.
Control subjects
Demographic details and data on use of alcohol, cannabis and tobacco for the
control subjects are detailed in Table 6.8. Information on tobacco use was available
for all of the control subjects, and that on both alcohol and cannabis use unavailable in
only one case. Data on use of cocaine, ecstasy, amphetamines and LSD are given in









2 (5.7) 4 (11.4) 18(51.4) 10 (28.6) 1 (2.9)
Mean age in
years (SD)
20.4 (2.7) 21.1 (2.8) 22.9(1.5) 21.1 (1.4) 22.6d .77
Gender (M:F) 1:1 2:2 8:10 4:6 1:0 .11
Handedness
(R:L:both)
1:0:1 4:0:0 17:1:1 8:1:1 0:1:0 .65




Nil Isolated Occasional Frequent Most days P
Number of
subjects (%)
12 (34.3) 8 (22.9) 7 (20.0) 7 (20.0) 1 (2.9)
Mean age in
years (SD)
20.3 (2.7) 21.1 (2.8) 22.9 (1.5) 21.1 (1.4) 22.6" .25
Gender (M:F) 7:5 1:7 4:3 4:3 0:1 .15
Handedness
(R:L:both)
9:2:1 7:1:0 7:0:0 6:0:1 7:0:0 .61




Nil 0-10 11-20 21 + P
Number of
subjects (%)
18 (50.0) 10(27.8) 6 (5.6) 2 (5.6)
Mean age in
years (SD)
21.4 (2.5) 20.6 (2.1) 21.6(1.7) 20.9 (5.0) .26
Gender (M:F) 10:8 3:7 2:4 2:0 .04
Handedness
(R:L:both)
15:2:1 9:1:0 5:0:1 2:0:0 .81
Mean IQ (SD) 108.8(13.6) 97.9 (13.1) 106.8(12.6) 101.5(27.6) .03
Table 6.8
Demographic details of control subjects in each of the substance exposure categories.
a
Exposure categories, based on highest level of consumption of alcohol during period of maximal use,
are as follows: teetotal = no history of alcohol use; occasional = use never exceeded approx 3
units/week; regular = regular use but not exceeding 14U/week for women or 21U/week for men;
exceed safe limits = exceeding safe recommendations; dependence = history alcohol dependence.
b
Exposure categories, based on highest level of exposure to cannabis during period of maximal use, are
as follows: nil = never used cannabis; isolated = used on maximum of 3 occasions; occasional = regular
use, but less than monthly; frequently = use of cannabis monthly or greater; most days = use of
cannabis more than three days a week.
c
Highest level of tobacco use: number of cigarettes (or equivalent) per day.
d Standard deviation not calculable as only single subject
Drug Level of use: N (% of all high risk subjects with that level of use)
Never Isolated Repeated Frequent
Cocaine 33 (94.3) 0 0 2 (5.7)
Ecstasy 28 (80.0) 2 (5.7) 3 (8.6) 2(5.7)
Amphetamine 25 (71.4) 1 (2.9) 5(14.3) 4(11.4)
LSD 28 (80.0) 1 (2.9) 6(17.1) 0
Table 6.9
Highest levels of use of cocaine, ecstasy, amphetamines and LSD by the control
subjects.
275
6.2.2 Collection and analysis oflongitudinal drug use data
As discussed above, participants were followed up for up to ten years
following entry in to the study. Outcome, in terms of whether or not they developed
schizophrenia, is thus known for all subjects who had a baseline scan. In addition
however, substantial numbers have had subsequent detailed assessments, including
ascertainment of drug use in the intervening period and further MRI scanning.
The EHRS study was initially funded for five years. Recruitment of subjects
took approximately three years, and rescanning was planned (in those who had not
become unwell), after approximately eighteen months. This meant that only half of
the subjects recruited were in the study long enough to be able to have a second scan
during the initial funding period. Thus, in the initial part of the study, only 66 of the
subjects recruited had a second scan. Subsequently additional funding was obtained,
and those subjects who were not rescanned in the initial period did receive a second
scan. Unfortunately however, and as discussed in the opening to Section 5.2, by this
time the scanner available for use by the study had changed. Thus, these scan were
undertaken with a different scanner. It is widely acknowledged that scanner change
during the course of a longitudinal study introduces substantial problems, impacting
on the consistency of data.472'586 When investigating what are likely to be subtle
effects, (such as we would expect to observe in association with generally non-
dependent levels of substance use), such factors can potentially have an important
impact on the chances of observing positive findings, increasing the likelihood of a
type II error. The fact that 66 subjects had two scans undertaken using the same
scanner thus makes these subjects a particularly important group. Given this
consistency of scanner use, (combined with our knowledge of drug use in the interim
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period), we have an opportunity to investigate, in a longitudinal manner, the impact of
substance use on brain structure in this unique group of people at genetically high risk
of schizophrenia. Such data are sorely lacking in schizophrenia research. These
analyses will thus have particular value, and constitute an important compliment to
the baseline data.
It is thus the case that the substantial drop in participant numbers between
scanning times 1 and 2 (147 vs. 66), is largely explicable by the manner in which the
study was conducted. Additionally, a small number of subjects were not rescanned
because they had developed schizophrenia between recruitment and the second scan
point. As it had been planned from the outset that individuals would leave the study
once they became unwell, it is thus the case that the vast majority of eligible subjects
were rescanned; consequently, though the numbers with a scan at timepoint 2 was
substantially lower than the total number recruited, this does not represent subjects
being Tost' from the study. There is thus no reason to believe that those subjects in
whom follow up was achieved are not representative of the group as a whole.
Only 20 control subjects had baseline and follow-up scans with the same
scanner. Clearly this is too small a number to enable meaningful exploration of the
effects of substance use with in this group. Consequently longitudinal data from these
subjects will not be discussed any further. I do not believe that the lack of a normal
control group detracts substantially from the longitudinal analyses; clearly the
comparison of primary interest is between high risk subjects who do and do not use
the various substances of interest.
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6.2.2.1 Quantification oflevels ofdrug use between scans
Complete drug use data were available for the majority of those subjects who
were scanned at both timepoints 1 and 2. As at baseline, this was ascertained by face
to face interview, participants being asked about levels of use of the various
substances of interest since the first assessment.
Ideally, similarly to analyses of baseline data, I would have wished to
investigate if a dose response relationship existed between substance use and structure
volume change. The desirability of establishing the presence or absence of such a
biological gradient arises from the fact that this has long been regarded as an aid in
inferring if causation is the link between an exposure and an outcome.596 By these
criteria, the establishment of such an association bolsters the argument that it is
genuinely the drug exposure which is resulting in structure volume change.
Unfortunately however, given the much reduced subject numbers available for the
longitudinal analysis, this was not feasible. Instead, in these analyses data on use of
each drug of interest were dichotomised, with the following cut-offs being employed:
cannabis use during this period or not; alcohol use exceeding government
recommendations during this period (greater than 14 units/ week for women and 21
units/week for men) or not; ecstasy use during this period or not; amphetamine use
during this period or not; tobacco smoker during this period or not. This approach of
dichotomisation of users and non-users does in fact have an established history of use
in longitudinal studies for the investigation of brain structural changes consequent to
drug use.539 The choice of some of the specific cut off points does however require
some further explanation.
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Firstly, the choice of cut off points for cannabis consumption (and other illicit
drugs) must be explained. It is the case that including subjects reporting any use of
cannabis in the inter-scan period will result in inclusion of people with only isolated
exposures to the drug in the interim period in the exposure group. It may be expected
that, even if cannabis does have effects on brain structure, the effects associated with
such low levels of cannabis exposure will be minimal. This raises concerns, as the
inclusion of these people in the exposure group will potentially dilute any effects that
are present and result in a Type II error. Unfortunately however, though this concern
is genuine, choosing an alternative cut off to this does not seem feasible. If only
subjects with greater than isolated exposures to cannabis in the interim period were
included in the analysis, then there would be only 20 subjects in the exposure group.
The analysis would consequently be relatively low powered. On balance it thus seems
that, though the effects occurring may be less in these subjects (and thus it may
jeopardise the chances of positive findings), including those people with low levels of
consumption of cannabis in the interim period in the exposure group is the best
decision overall. This has the clear benefits of yielding reasonably balanced groups to
contrast (see below), has literature precedent, and enables the inclusion of all
available subjects.
As in the cannabis analyses, the relatively low numbers of subjects available
for longitudinal analyses meant investigation of a dose response relationship between
alcohol consumption and brain structural abnormalities was also not possible. Given
the concerns discussed about the potential non-representativeness of the teetotal
subjects, an important decision was whether or not to exclude these subjects from the
longitudinal analyses. For two distinct reasons however I did not believe that this was
appropriate. Firstly, due to the smaller numbers of subjects with scans at timepoints 1
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and 2, the priority was to maximise inclusion of subjects; excluding the teetotal
subjects would have resulted in a substantial loss of data. Secondly, as this was a
longitudinal analysis, I believed that the arguments for exclusion of teetotal subjects
on grounds of unrepresentativeness were less robust. In undertaking the baseline
analysis, the concern was that these subjects may posses confounding factors,
resulting in their characteristics being out of keeping with the general trend of
associations with alcohol consumption. Any such factors would however be expected
to be trait characteristics, and as such would not be subject to change over time; they
thus would not confound the longitudinal analysis. As such, there was little rationale
for excluding them from this analysis.
Concerns could also potentially be raised about inclusion of subjects in the
'regular use' category in these analyses. As will be discussed in more detail on
considering subjects included in the baseline VBM analyses (see Section 7.2.6.2),
there are sound arguments for exclusion of these subjects from the analysis, on the
basis that the intermediate nature of their alcohol consumption levels will obscure
differences that may well be present. Though ideally this would be done, again
because of the relatively low number of subjects available for the longitudinal
analyses, in practice this was not feasible. Thus, the 63% of subjects who used alcohol
regularly but reported this as being within government recommendations were also
included in the analysis, being placed in the 'not exceeding government
recommendations category'.
Consumption of other drugs in the interscan period (namely tobacco, ecstasy,
amphetamine, cocaine, opioids and benzodiazepines) was binarised as either did or
did not use during the interscan period. Thus, use of the drugs to any extent conferred
membership of the 'used' category, and complete abstinence membership of the 'not
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used category'.
6.2.2.2 Other relevant variables from subjects with longitudinal data
Demographic and clinical details of subjects who did and did not use cannabis,
alcohol and tobacco in the interscan period are detailed in Tables 5.10, 5.11 and 5.12.
As for subjects included in the baseline analysis, RISC score at the time of the initial
scan has been included in this table; as before I believed these data to be potentially
informative in indicating if subclinical psychotic-type symptoms could be
contributing to drug use. Other data included are that which may potentially be
important to include as a covariate in the subsequent longitudinal analyses. Though
IQ was included as a covariate in the baseline analyses, given the within-subject
nature of any longitudinal analyses, I did not believe it appropriate to include this as a
covariate in these. This is in common with the models employed by previous
investigators.539 Thus it is included in the tables for descriptive purposes only.
6.2.2.3 Statistical analyses
Statistical testing was conducted with the Statistical Program for the Social
Sciences 14. Data were checked for normalcy and outliers by plotting graphically and
conducting the Kolmogorov-Smirnov test. Demographic and clinical variables were
compared between high risk subjects with and without each drug exposure with the
independent t test and the % test. Rate of change in whole brain volume between the
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scan periods was calculated by subtracting whole brain volume at the time of the
second scan from that at the first and dividing the difference by the time that elapsed
between the scans (i.e. [WBV2-WBVl]/time between assessments).
6.2.2.4 Comparison ofdemographic and clinical characteristics between subjects in
different between scan substance misuse categories
Scans were obtained at both time points in 66 high risk individuals of whom
data on use of all the substances of interest in the inter-scan period were available for
57. Longitudinal analyses will thus focus on these subjects.
Of the 57 subjects eligible for inclusion in longitudinal analyses, 25 consumed
cannabis between the two assessments while 32 did not. Demographic and clinical
characteristics of these two groups are compared in Table 6.10. In addition to the
substances detailed in Table 6.10, two subjects used opiates, two cocaine and three
LSD in the period between scans; in all cases these people were in the cannabis
exposure group. As can be seen from Table 6.10, though demographic variables and
score on the RISC were reasonably well balanced between the two cannabis exposure
groups, the prevalence of use of tobacco, ecstasy and amphetamines were all greater
amongst the cannabis consuming subjects.
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No cannabis use Cannabis use P
N = 32 N = 25
Mean age at first assessment 21.11 (2.87) 21.76 (2.52) .38
(SD)
Gender (male/female) 15:17 15:10 .33 (a)
Handedness (R:L:both) 28:4:0 21:2:2 .24 (a)
IQ (SD) 100.59 (14.73) 100.12(11.69) .90
Exceed recommended max 4 7 .18 (b)
alcohol consumption
Smoke tobacco 8 18 <.001 (a)
Use ecstasy 0 9 <.001 (b)
Use amphetamines 0 10 <001 (b)
Days between assessments (SD) 648.38 (128.06) 679.12 (206.85) .49
Rust Inventory of Schizotypal
Cognitions baseline score
25.44 (9.94) 27.92(11.70) .39
Table 6.10.
Demographic and clinical characteristics of high risk subjects who do and do not
consume cannabis between timepoints 1 and 2.
P = independent t test, except (a) = chi squared and (b) = Fisher's exact test
Table 6.11 compares demographic and clinical variables in subjects whose
alcohol consumption between the two scan periods did and did not exceed
government recommendations. In addition to the substances detailed in Table 6.11,
two subjects used opiates, two cocaine and six LSD in the period between scans. All
the LSD and cocaine using subjects were in the 'within recommended limits' group,
while the two subjects who used opiates were in the hazardous/harmful drinking
group.
In contrast to the cannabis exposure contrasts, in the case of alcohol the
exposure group did score significantly higher on the RISC. In terms of use of other





limits N = 46 limits N = 11
Mean age at first assessment 21.31 21.73 .650
(SD)
Gender (male/female) 5:6 25:21 .596 (a)
Handedness (R:L:both) 39:5:2 10:1:0 .762 (a)
IQ (SD) 101.93 (13.52) 93.91 (11.04) .073
Use cannabis Y:N 18:28 7:4 .184 (a)
Smoke tobacco Y:N 17:29 9:2 .007 (a)
Use ecstasy Y:N 6:40 3:8 .354 (b)
Use amphetamines Y:N 7:39 3:8 .387 (b)
Days between assessments (SD) 656.09 (144.05) 686.00 (246.35) .597
Rust Inventory of Schizotypal
Cognitions baseline score
24.80(10.12) 33.73 (10.60) .012
Table 6.11
Demographic and clinical characteristics of high risk subjects who do and do not
report hazardous or harmful levels alcohol consumption between timepoints 1 and 2.
P = independent t test, except (a) = chi squared and (b) = Fisher's exact test
Table 6.12 compares demographic and clinical variables in subjects who did
and did not smoke tobacco between the two scan periods. Of those subjects who used
other substances between scan points, both opiate users, one of the two cocaine users
and four of the six LSD users were smokers between the scan ponts.
Again in contrast to the comparisons made on the basis of cannabis
consumption, people who use tobacco in the interscan period had higher ratings on the










Mean age at first assessment
(SD)
21.50(2.90) 21.27 (2.53) .755
Gender (male:female) 16:15 14:12 .866 (a)
Handedness (R:L:both) 28:3:0 21:3:2 .275 (a)
IQ (SD) 101.39(15.11) 99.19(11.13) .54





Use ecstasy Y:N 1:30 8:18 .008 (b)
Use amphetamines Y:N 2:29 8:18
Days between assessments (SD) 662.84 (137.09) 660.69 (198.46) .962




Demographic and clinical characteristics of high risk subjects who did and did not
smoke tobacco between timepoints 1 and 2.
P = independent t test, except (a) = chi squared and (b) = Fisher's exact test
6.2.3 Does RISC rating predict alcohol or tobacco use independent of its association
with the use ofother substances?
As discussed above, in those subjects for whom longitudinal data were
available, there was a strong associations between RISC rating at point of entry in to
the study and subsequent levels of both alcohol and tobacco consumption. This is
despite RISC ratings not being significantly different between the alcohol and tobacco
exposure groups at point of entry in to the study (see Table 6.6). This difference is not
simply due to exposure groups to these substances being determined in a different
manner in the baseline and longitudinal analyses. Specifically, when baseline RISC
ratings are compared between those with a history ofbeing smokers (with any level of
consumption) and those with no such history there is no significant difference seen.
The same is also true when people with a history of exceeding government alcohol
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intake recommendations are compared to those who have no such history. This raises
the intriguing possibility that those with a higher RISC rating at entry in to the study
may have an increased risk of subsequent use of these substances.
Teasing apart these effects is made more difficult by the substantial cross-
correlation between use of these two substances; smokers are more likely to be heavy
drinkers, making it difficult to ascertain if these behaviours are independently
predicted by RISC rating. To ascertain if this was the case, I employed logistic
regression in an attempt to clarify if either alcohol or tobacco use were predicted by
RISC rating at point of entry in to the study. This analysis was undertaken while
controlling for use of other substances, age and gender. This analysis will be detailed
in Section 9.4.
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6.3 History of substance use at entry into study and subsequent development of
schizophrenia
Nineteen of the subjects with baseline data on drug use went on to develop
schizophrenia. The %2 test or likelihood ratios (where sample size was small) were
used to compare numbers developing schizophrenia in high and low exposure groups.
Rate of development of the illness was compared between: 1) Those with a history of
alcohol dependence and those without, 2) Those who had used cannabis at a rate
greater than isolated and those who had not and 3) Smokers and non-smokers. Where
significant differences were found, odds ratios (OR) were calculated. As relatively
few people had used the other substances under investigation, comparable analyses
were not undertaken for them.
In undertaking these analyses it was decided not to control for numerous
factors which could potentially confound such an association (e.g. other substance
use, IQ etc). This was decided as the primary aim of this study was to ascertain the
consequences of substance misuse by this at risk population on brain structure.
Subject numbers in the current study are obviously substantially smaller than studies
designed to investigate specifically if substance use is associated with an increased
237risk of subsequent schizophrenia (e.g. Zamit et al. ); consequently the current study
is inadequately powered to enable inclusion of all the covariates that would ideally
have been incorporated in to such an analysis. Nonetheless, this basic calculation will
clearly give an indication of whether or not use of a specific substance is associated
with an increased risk of subsequent schizophrenia in the population under study.
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6.4 Other considerations
6.4.1 History ofsubstance use between timepoints and subsequent development of
schizophrenia
For the reasons discussed in Section 6.2.2, the number of subjects with scans
at timepoint 2 was substantially lower then at timepoint 1. Again as discussed above,
one of these reasons was that subjects who developed schizophrenia between the
timepoints did not have a second scan. As a consequence, of those subjects who did
go on to develop schizophrenia, longitudinal data were available for many fewer than
baseline data. In fact, in contrast to the 19 subjects with baseline data who went on to
develop the illness, only 8 of those with longitudinal data went on to develop the
illness. Given this marked loss of power it did not seem feasible to investigate if use
of a specific substance between the timepoints was associated with subsequent risk of
schizophrenia.
6.4.2 Reliability ofself report as a measure ofsubstance misuse
A criticism which could potentially be levelled is the reliance on self report as
a means of determining substance misuse history. It could be postulated that people
may not give a truthful account of their substance use, thus meaning that this
approach is unreliable. While an objective method to determine history of drug use
would have been desirable, unfortunately no appropriate tool exists. Given that we
288
were interested in lifetime history of drug use, drug testing would have added little to





Scanning methods and overview of approach to image analysis
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7.1 Scanning methods
Each participant underwent MRI scanning on a 1 T Siemens (Erlangen,
Germany) Magnetom scanner. Midline sagittal localization was followed by two
sequences to image the whole brain. The first scan was a double-spin echo sequence
that gave simultaneous proton density and T2-weighted images (repetition time [TR]
= 3565 msec, echo time [TE] = 20 and 90 msec, 31 contiguous 5 mm slices acquired
in the Talairach plane, field of view 250 mm), which were used to exclude any gross
brain lesions. The second scan, for the volumetric analysis of whole brain and
regions, was a fast gradient echo sequence consisting of a 180° inversion pulse
followed by a Fast Low Angle Shot collection (flip angle 12°, TR =10 msec, TE = 4
msec, TI = 200 msec, relaxation delay time 500 msec, field of view 250 mm), giving
128 contiguous 1.88-mm-thick slices in the coronal plane orthogonal to the Talairach
plane. Any inhomogeneity in the head coil was corrected for after scanning a flood
phantom (see Whalley et al. for further details).598 Regular phantom scanning was
employed to ensure the reliability of the scan sequences over the course of the study.
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7.2 Plan for image analyses
This study will have two fundamental features guiding its structure. The first
will be that for analysis of baseline and longitudinal data, both semi-automated hand
tracing and an automated technique will be employed in image analysis. The second is
that findings from baseline analyses will be used, as much as appropriate, to plan
longitudinal comparisons. The importance of these two approaches will be discussed
below.
7.2.1 Importance ofincluding automated processes as well as ROI
The remarkable sophistication of MRI allows neuroanatomical structures to be
visualised in vivo with exquisite detail. Thus, cerebral structures preferentially
affected in a given disorder can be identified, together with the manner in which they
are altered. Quantitative tools such as volumetric measures based on manually traced
regions of interest have been extensively used to assess the overall size ofbrain
structures in individuals with schizophrenia, though data from people who are
destined to develop the condition but still well at the time of assessment are few (see
Section 4.2). This methodology has revealed important insights into brain
abnormalities associated with schizophrenia, many of which have already been
discussed.
Despite the insights gained from manually traced region of interest techniques
however, sole reliance on such approaches has considerable limitations. Firstly, by
their very nature these approaches rely on changes in the total volume of a structure to
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be able to detect any abnormalities. This can be a particular weakness when applied to
a population such as that in the EHRS, in which all are well at the time of assessment
and not all of whom will ever develop schizophrenia; in such a population it is likely
that any abnormalities present are fairly subtle, and changes in overall size of
structures fairly minimal. This is likely the case even in the context of additional
insults, such as exposure to drugs of abuse. Automated voxel based techniques, such
as VBM, have the potential to detect very localised, substructural changes.5" They
may thus be able to detect abnormalities missed by ROI techniques as the magnitude
of these substructural abnormalities falls within the range of measurement error of the
structure as a whole.
A further advantage of techniques such as VBM arises from the fact that in a
given condition brain structure may differ in multiple brain areas, and without
assessment of other areas of the brain, a particular regional loss may lack specificity.
As it relies on preselected regions of interest, which are then hand traced, analysis at
the whole brain level is not feasible with semi-automated ROI techniques. VBM, by
contrast, is not limited by these constraints.599 Furthermore, automated procedures are
not as labour intensive as manual measurements, and as they are almost completely
user-independent, inter- and intra-observer variations are avoided.5"'600
Despite the accepted potential advantages of automated techniques such as
VBM however, it is also generally acknowledged that they do have their own
limitations. These arise primarily as a consequence of the fact that inferences drawn in
VBM are dependent upon local coregistration, and due to the limitations of the
currently available algorithms the degree of registration varies across the brain. This,
when combined with the fact that significance corrections are made for multiple
comparisons over the whole brain, can mean that SPM-based automated techniques
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can potentially be overly conservative, and not identify findings which are genuinely
present. Indeed, it is recognised that this can be a particular issue when applied to
structural imaging data (the techniques originally having been developed for the
analysis of functional imaging data).601
The limitation of VBM outlined above means that ROI techniques remain the
gold standard method for image analysis. Nevertheless however, techniques can be
applied to focus the VBM analysis and limit the volume over which correction for
multiple comparisons is applied. Most commonly this is achieved by restricting the
analysis to regions which have been determined a priori to be ofparticular interest.601"
603 This is achieved by using the small volume correction (SVC) function in SPM,
significance being correcting for the voxels included in this restricted analysis rather
than the whole brain. An important consideration in undertaking these analyses is thus
which regions to target with these small volume corrections. This will be discussed
when planning of the specific VBM analyses are discussed later. An obvious problem
with this approach is that these SVCs can only be employed in regions for which there
are pre-existing reasons to believe that structural abnormalities will be found.
Similarly to ROI techniques, the identification of abnormalities is dependent on
expecting them to be present in a particular region, meaning once again that
unexpected but potentially important abnormalities will only be picked up if they are
detectable at whole brain level.
There is also a further limitation of VBM which must also be acknowledged,
and which is not easily correctable. It essentially arises as the flip side of the ability of
VBM to detect very localised abnormalities. Given this sensitivity for the detection of
localised changes, VBM is unfortunately less sensitive to the diffuse, distributed
effects which may well be identified by hand tracing techniques.604 This is a limitation
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which reflects the fundamental methodology underpinning the technique and is
largely insurmountable.
Given the considerations outlined above, it would be expected that VBM and
manual tracing techniques have differing sensitivities. Indeed, this is exactly what has
been observed in studies applying the two techniques to the same dataset.604,605 It
follows from this that for optimal image analysis both methods should ideally be
employed. This enables the advantages of each technique to be exploited and the
sensitivity of image analysis maximised. It also follows however, (as has again been
noted by previous researchers),606 that the abnormalities detected by VBM and hand-
tracing may not always exactly tally. Thus, though analysis of the current dataset is
undoubtedly best served by the combined use of complementary methodologies, it
would not be entirely unexpected if the regions identified as exhibiting abnormalities
in association with substance misuse by the two approaches did differ. In this study
VBM will be used to compliment ROI based analysis of baseline data, and Tensor-
Based Morphometry (TBM, a complementary technique better suited to the analysis
of longitudinal data) used to compliment longitudinal ROI-based analyses.
7.2.2 Determining regions in which small volume corrections will be employed
As discussed above, the use of SVCs is an established practice in VBM
analysis. This is also the case in TBM analyses. The use of an SVC in a particular
circumstance must however have clear justification, this arising from an a priori
expectation that abnormalities would be expected to be found in the particular region
to which an SVC is being applied. On the basis of the literature review, the
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amygdala/hippocampus would qualify as such a region, being consistently
demonstrated to exhibit abnormalities which may predate development of illness,
(Section 4.2) and also possibly exhibiting abnormalities in association with abuse of
several of the substances of interest (Section 4.3). Other candidate regions would be
the thalamus and frontal lobes, and if there is evidence from the ROI analyses to
suggest that abnormalities of these regions would be expected in association with use
of a substance in this population, then thalamic and frontal lobe SVCs should
certainly be considered. The initial plan for investigation will thus be that these
regions, similar to the regions chosen for investigation with manual tracing, will be
specifically investigated for abnormalities in association with a history of substance
use with specific SVCs.
7.2.3 Using baseline findings to guide longitudinal analyses
As is apparent from the literature review in Section 4.2.2, longitudinal studies
examining the impact of substance misuse on brain structure in people at genetic risk
of schizophrenia are particularly lacking in the imaging literature. Given the rarity of
these data, it is thus particularly important that optimal use is made of the dataset
available to me. This necessity is compounded by the fact that, for the reasons
discussed in Section 6.2, the number of subjects on whom longitudinal imaging data
are available is substantially fewer than those with baseline data. This reduces
statistical power to detect structural imaging consequences of drug use by this
population, and makes it unlikely that any effects that are present will be robust to
correction for multiple comparisons.
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Given the above considerations, it is particularly important that the analyses
that are undertaken on the longitudinal data are carefully planned. If this is the case,
then the number of comparisons undertaken can be kept to a minimum, and the need
for correction for multiple comparisons obviated.
Abnormalities of a number of brain regions (in particular the AHC and frontal
lobes) have been so repeatedly reported in schizophrenia, that it would be difficult to
exclude exploration of structural changes in them from any longitudinal analysis of
imaging findings in a high risk population. For other regions, though there may be
replicated findings of abnormalities in established schizophrenia, the case for their
inclusion in the current longitudinal analysis is less irrefutable. The most appropriate
regions to include in the analysis need to be chosen. As there is no study directly
comparable to the present, pre-published data can only be used to guide the selection
of these regions to a limited extent. What will be available however will be results
from the (greater powered) baseline analysis. It would be expected, (if they did indeed
arise as a consequence of substance exposure), that the brain structural abnormalities
observed in association with substance misuse in the baseline analyses will overlap
with those occurring between timepoints 1 and 2. It thus seems reasonable that
findings from the baseline analysis are used to guide the selection ofbrain regions for
longitudinal study. In this way the number of analyses can hopefully be minimised,
statistical power maximised, and any brain structural abnormalities arising in
association with substance use accurately identified. Baseline findings will thus be
given appropriate importance in planning longitudinal analyses, how these findings




Analysis of baseline data
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8.1 Volumetric analysis
8.1.1 Semi-automated volumetric methodology
Image processing used the software package Analyze (Mayo Foundation,
Rochester, MN, USA) to outline neuroanatomical structures and ascertain their
volumes, with a semi-automated combination of automated edge detection and
SQR ....
manual editing. Structures were identified with the assistance of a MRI brain
atlas,607 and volumes were calculated by summing voxels on all brain slices included.
The volumes of structures with the strongest pre-existing evidence of structural
abnormalities secondary to substance use were included in this analysis. Structures
selected were the: lateral ventricles, third ventricle, fourth ventricle, right and left
prefrontal lobes, amygdala-hippocampal complex (AHC) and thalamic nuclei. Strict
anatomical definition criteria incorporating anatomical landmarks were used to define
these structures. These, together with relevant references justifying the use of
particularly contentious boundaries, are outlined in Table 8.1. Further explanatory




Pre-frontal lobes Frontal pole, when
distinct from meninges




Thalamic nuclei When clearly distinct
from surrounding white
matter and walls of
third ventricle
Slice anterior to crus
fornicis
Walls of third ventricle








Last slice of temporal
lobe609
Naturalistic
Lateral ventricles As defined by the
autotrace, frontal
horns included
As defined by the
autotrace, occipital
horns included
As defined by the
autotrace
Third ventricle When chamber is
enclosed by the optic
chiasm, as defined by
the autotrace
Last slice of conical
shape as distinct from
transverse cerebral
fissure beyond
As defined by the
autotrace
Fourth ventricle First slice of rhomboid
shape as distinct from
the cerebral aqueduct,
as defined by the
autotrace
As defined by the
autotrace




Summary of definition criteria of regions of interest.
For the purposes of this study, all thalamic nuclei were grouped together, as
MRI resolution makes distinction between the individual thalamic nuclei difficult.
Lateral and posterior boundaries are often indistinct. Given this, the posterior
boundary of the thalamic nuclei was defined as the last slice in which the grey matter
of the pulvinar nucleus was distinct from the emerging gyrus fasciolaris of the
posterior hippocampus with the eras fornicis obscured behind it. Laterally, the
posterior limb of the internal capsule was used as a boundary.
The distinction between the amygdala and hippocampus is also difficult due to
resolution. For the purposes of study definition, both nuclei were defined together as a
complex. Anterior, as the temporal stem appears, the gyri that enclose the amygdaloid
nucleus become more evident. The lateral boundary was defined by the medial aspect
of the temporal horn of the lateral ventricle, and the white matter of the temporal
stem. The medial boundary was defined by the edges of the subiculum bordering the
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subarachnoid space. Moving posterior, as the pulvinar nucleus disappears, the full
extent of the eras fornicis is revealed and the fibre bundles gyrus fasciolaris and
fasciolaris cinerea of the posterior hippocampus emerge. The posterior hippocampus
was defined as distinct from the pulvinar nucleus when the full extent of the eras
fornicis was present. Manual outlining of the thalami and AHC are illustrated for
anterior and posterior regions of the brain in Figure 8.1. For clarity selected other




Sample of manual tracing.
a. Illustration of manual outlining of thalamus and AHC on an anterior slice of an
edited whole brain.
b. Illustration of regional outlining of a more posterior slice.
In both examples, for reasons of clarity, other brain regions have also been identified.
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Volumetric image processing was done by three investigators, who examined
all the brain regions above on five brains to ensure reliability between raters (mean
correlation coefficient 0-94 [range 0-78-0-99]). Intra-class correlation co-efficients
(ICCs) for each of the structures of interest were as follows: 0.99 for whole brain and
lateral ventricles, 0.98 for prefrontal lobes, 0.93 for third ventricle, 0.92 for fourth
ventricle, 0.84 for thalamus, 0.82 for the amygdalo-hippocampus. All the semi-
automated ROI data were available to me, thus meaning I did not need to undertake
any of the hand tracing myself.
The ICCs quoted above are generally regarded as acceptable in image
analysis.610 To maximise the rigour with which repeatability of volumetric
measurement was ascertained however, an additional method based on proposals
made by Bland and Altman was also included.611 By this methodology, the mean
difference observed between a pair of raters (equivalent to bias between raters) was
compared to the mean volume of the raters. This yielded an overall mean difference
between ratings by different raters as a percentage of mean volume. For each of the
regions of interest this was as follows: 0.7% for the whole brain, 0.8% for prefrontal
lobes, 2.2% for the lateral ventricles, 4.4% for the third ventricle, 5.3% for the
thalamic nuclei, 9.4% for the amygdalo-hippocampus.
In addition the main rater also measured her intra-rater reliability every six
months on the same five brains. Given the longitudinal nature of the EHRS, this was
of course fundamental to the validity of the study. Intra-class correlation co-efficients
for each of the structures of interest were as follows: 0.99 for whole brain and lateral
ventricles, 0.83 for prefrontal lobes, 0.97 for third ventricle, 0.98 for fourth ventricle,
0.88 for thalamus, 0.81 for the amygdalo-hippocampus. Similarly to the additional
methodology employed in examining mean differences between raters, mean error
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over time was calculated by dividing the mean difference between a pair of ratings by
the mean volume of the two. Expressed as a percentage, the mean error over time was
less than 1% for the whole brain, 4.1% for the prefrontal lobes, 5.5% for the lateral
ventricles, 4.5% for the thalamic nuclei and 3.2% for the amygdala-hippocampus. It
was however 23.3% for the third ventricle, indicating that despite the satisfactory ICC
for this structure, there is potential for substantial measurement error in manually
delineating this structure.
8.1.2 Statistical analysis ofvolumetric data
As before, statistical testing was conducted with the SPSS 14. Analyses were
conducted for both high risk and control subjects. Wherever possible, due to their
f\ 19
greater power, parametric methods of analysis were employed. Data were checked
for normalcy and outliers by plotting graphically and conducting the Kolmogorov-
Smirnov test. In common with other studies, the distribution of ventricular volumes
showed a right sided skew.516 These data were therefore log transformed prior to the
regression analysis. Subsequent standardised residuals were checked for normality.
The relationship between substance use and structure volumes was explored in
two steps: firstly, investigation of a dose-dependent relationship and subsequently by
multiple regression analysis. This two-step analysis was required because of the
potential collinearity between both the levels of different substances used by
individuals and the effects of the various substances on structure volumes. Multiple
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regression has the potential to clarify which relationships do exist, while accounting
for potential confounders.
For the reasons discussed in Section 6.2.1, level of substance use was
ascertained using an ordinal, rather than ratio measure. This precluded the use of a
parametric technique, such as Pearson's correlation, for exploration of the existence
of a dose response relationship between the level of each substance used and structure
volume. Instead I used Spearman's correlation co-efficient, a non-parametric test,
with separate analyses being performed for each substance and each region of interest.
I also wished to establish if the relationship between substance use and structure
volume was significantly different on comparing the high risk and control groups. To
enable this, the significance of differences between correlation coefficients in the high
risk and control groups was tested using Fischer's Z test.
Multiple regression analysis employed a backward elimination model.
Separate analyses were undertaken for each of the structures which showed a
significant dose-response relationship between levels of use and structure volume.
These structures were the third and lateral ventricles and the prefrontal lobes. For each
analysis the dependent variable was volume of the structure of interest (e.g. third
ventricle) with the predictor varibles entered simultaneously into the full model.
These blocks were: gender; age; whole brain volume; alcohol use; cannabis use; and
tobacco use. Gender was entered as a binary variable, age and whole brain volume as
continuous variables. In the blocks representing exposure to each of the substances,
levels of use were represented as dummy variables in relation to a reference group. In
the case of cannabis and cigarettes the reference group was no use ever. As there were
only 10 teetotal subjects (and there is reason to believe that the characteristics of
teetotal individuals are not in-keeping with the general trends seen with increasing
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levels of alcohol use, see section 6.2.1), for alcohol the reference group was
occasional use.
In undertaking this backwards elimination analysis SPSS begins with all of the
predictors included in the model. The programme then tests if any of the predictors
can be removed without having a substantial effect on how well the model fits the
observed data. The first predictor to be removed will be the one that has the least
impact on how the model fits the data. This then proceeds in successive steps until the
only predictors left are those which have a substantial influence on the dependent
variable. As discussed above, these analyses complement the initial dose-respone
analyses by clarifying which factors are indeed significant precitors of structure
volumes while accounting for potential confounders.
Analysis was also repeated with current IQ (measured using the Wechsler
Adult Intelligence Scale Revised),394 as an additional block. Due to low subject
numbers, the multiple regression analyses were not undertaken in the control group.
As was expected, a number of the high risk subjects had used illicit drugs
other than cannabis. Regression analysis was therefore repeated excluding any
individuals with a history of dependence on any substance other than alcohol,
cannabis or tobacco. As excluding subjects with any level of exposure to illicit drugs
other than cannabis would have resulted in too great a loss of statistical power, it was
not feasible to repeat regression analysis without these subjects. A supplementary
regression analysis was therefore run including level of past use of ecstasy,
amphetamines and LSD as additional regression blocks. This was felt to be important
in view of the possibility, (data investigating this possibility for ecstasy and
amphetamines were reviewed in Section 4.1.3.4), that these drugs could themselves
impact on brain structure.
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8.1.3 Results
8.1.3.1 Dose response relationships
Structures with significant or near significant relationships between level of
exposure to a substance and raw volume in high risk subjects are shown in Table 8.2.
Level of cannabis use correlated significantly and positively with volume of the left
and right lateral ventricles (P = .013 and .007 respectively) and third ventricle (P =
.001; association shown graphically in Figure 8.2). Level of alcohol consumption also
correlated significantly and positively with volume of the left and right lateral
ventricles (P = .023 and .005 respectively; right lateral ventricle association shown
graphically in Figure 7.2) and third ventricle (P = .031). Conversely, the level of
alcohol consumption showed a negative correlation with volume of the left and right
prefrontal lobes (P = .022 and .049 respectively). No significant associations were
found between tobacco use and volumes of any of the structures of interest. The
associations between substance use and structure volumes outlined above were not
apparent in the control group (see Table 8.3); though power to detect such an
association was admittedly lower, it was absent even at trend level. Additionally, on
application of Fisher's Z test, there were significant interactions between group
membership and the stmctural consequences of both cannabis and alcohol use. For
cannabis this was significant in the third ventricle (Z = 3.05, P = .002), while for
alcohol this was significant in the right prefrontal lobe (Z = -2.5, P = .02) and third
ventricle (Z = 3.45, P = <.001).
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A striking feature of alcohol structure volume/exposure relationships in the
high risk subjects is the existence of a 'J-shaped curve'; it seems that despite a clear
tendency for a history of greater alcohol consumption to be associated with larger
ventricular volume, third, fourth and lateral ventricular volumes in lifetime abstainers
are greater than in those with a history of occasional use (e.g. Figure 8.2). A
complementary relationship is seen in the frontal lobes. This pattern is not seen with
tobacco and cannabis (e.g. Figure 8.3).
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Brain region Level of exposure to cannabis
Nil Isolated Regular Frequent Most days Correlatio
n analysis
Whole brain 1327.04 1341.76 1349.0 1317.06 1387.49 r= .129
volume (135.51) (132.33) (139.26) (81.63) (109.09) P= .126
Left lateral 3.45 4.78 4.52 (3.20) 4.51 5.83 OOOII1*.
ventricle (2.21) (3.11) (4.00) (5.70) P= .013
Right lateral 3.08 4.44 4.19 4.30 5.23 r= .226
ventricle (1.81) (4.09) (2.53) (2.63) (5.70) P= .007
Third ventricle 0.31 0.34 0.45 0.53 0.47 r= .271
(0.19) (0.18) (0.32) (0.25) (0.31) P= .001
Left frontal 76.94 72.31 75.67 76.58 78.70 r = .044
lobe (12.37) (13.46) (11.59) (10.40) (10.77) P = .603
Right frontal 79.44 77.60 79.52 79.97 81.38 OOpII
lobe (12.52) (14.68) (12.92) (10.29) (12.57) P = .494
Level of exposure to alcohol
Teetotal Occasiona Regular Exceed Dependen Correlatio
1 safe limits t n analysis
Whole brain 1334.48 1384.96 1326.41 1324.84 1391.75 r = -.062
volume (90.99) (118.75) (136.61) (125.59) (66.98) P= .465
Left lateral 4.97 2.89 4.07 5.37 7.06 r = . 192
ventricle (2.77) (2.00) (2.20) (4.12) (8.78) NOIIa.
Right lateral 3.92 2.75 3.78 4.79 7.31 II -T-
ventricle (1.70) (0.77) (2.74) (3.44) (8.89) P= .005
Third ventricle 0.38 0.29 0.39 0.47 0.50 mOOII5s.
(0.21) (0.14) (0.24) (0.29) (0.42) P= .031
Left frontal 77.6 81.51 75.00 72.15 78.38 r = -.194
lobe (7.26) (14.18) (1.12) (10.47) (10.32) P= .022
Right frontal 78.65 84.65 79.31 75.76 79.84 r = -. 166
lobe (7.79) (1.25) (13.40) (12.13) (11.19) P= .049
Level of exposure to tobacco
Smoking Nil 0-10 10-20 20+ Correlatio
n analysis
Whole brain 1357.37 1332.05 1319.07 1352.07 r = -.062
volume (135.56) (121.08) (124.60) (109.29) P= .173
Left lateral 4.36 4.19 4.32 6.94 r = .040
ventricle (2.83) (3.11) (2.47) (7.83) P= .639
Right lateral 3.81 4.07 4.01 6.04 r=.079
ventricle (2.68) (2.87) (3.00) (7.80) P = .361
Third ventricle 0.37 0.42 0.40 0.49 <NII
(0.27) (0.26) (0.15) (0.35) P= .099
Left frontal 77.33 75.81 73.34 75.80 r= -.146
lobe (11.58) (12.55) (11.96) (12.47) P= .089
Right frontal 80.80 80.63 76.04 75.34 r- -.151
lobe (12.37) (11.84) (15.77) (11.29) P= .079
Table 8.2
Mean (SD) volumes (in cm3) of regions of interest in high risk subjects with histories
of increasing exposure to alcohol, cannabis and tobacco.
Data are displayed only for brain regions in which a significant correlation was observed in high risk
subjects between volume and level of exposure to at least one substance.
For information on intake level which costitues each the use historic use groups see Section 5.2.1
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Brain region Level of exposure to alcohol
Teetotal Occasional Regular Excessive use aDependence Correlation
analysis








1299.51 r = -.141
P= .290








3.52 r = .017
P= .924


















0.30 r = -.456
P= .006








83.93 r = -.071
P= .551








83.93 r = -.276
P= .109
Level of exposure to cannabis
Nil Isolated Regular Frequent aMost days Correlation
analysis








1157.63 r = -.051
P= .772








3.23 r = .225
P= .193


















0.26 r = -.309
P= .071








73.29 r = .104
P= .551








64.70 r = -.059
P = .647
Level of exposure to tobacco
Smoking Nil 0-10 11-20 21 + Correlation
analysis





























































Mean (SD) volumes (in cm3) of regions of interest in control subjects with histories of
increasing exposure to alcohol, cannabis and tobacco.
Data are displayed only for brain regions in which a significant correlation was observed in high risk
subjects between volume and level of exposure to at least one substance.
aNo standard deviation as only a single subject.
For information on intake level which costitues each the use historic use groups see Section 5.2.1
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T eetotal Regular Dependent
E>ceedsafe limitsOccasional
Level of alcohol use
Figure 8.2
Bar graph illustrating increased volume (SE) of the right lateral ventricle (in cm
association with increasing levels of alcohol exposure.
0.60 -I
! Error Bars show Mean +/- 1.0 SE
Bars show Means
Never Isolated Occasional Frequent Mostdays
Level of cannabis use
Figure 8.3
Bar graph illustrating increased volume (SE) of the third ventricle (in cm ) in
association with increasing levels of cannabis exposure.
8.1.3.2 Regression analyses
The correlation analysis outlined above did not control for potentially
confounding factors or cross-correlation between the substances of interest.
Blockwise multiple regression analysis was therefore undertaken, focusing on
structures already demonstrating a significant relationship between volume and level
of substance use. Only the 135 subjects for whom data were available on use of all
substances under investigation were included in the regression analysis. Given low
number of control subjects, (together with the absence of dose response relationship
between historic substance use and structure volumes in this group), the regression
analysis was not undertaken for them.
Output from the regression analysis is shown in Table 8.4. With a single
exception (discussed below), the inclusion of IQ as an additional factor in the model
did not significantly alter the results. Several findings are particularly noteworthy.
Firstly, as expected from the dose response analysis above, level of alcohol
consumption was a significant predictor ofboth right and left ventricular volumes. As
well as higher levels of alcohol consumption being positively correlated with
ventricular volume however, even relatively modest consumption of alcohol (at levels
within government recommendations), was correlated with ventricular enlargement.
Interestingly, lifetime abstinence also positively correlated with lateral ventricle
volume.
Alcohol use exceeding UK government recommendations (more than 14
units/week for women or 21 units/week for men) correlated with reduced left frontal
lobe volume. This correlation was significant on the right side only with inclusion of
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IQ in the model (R = 0.54, P = .049). No level of alcohol consumption was correlated
with third ventricle volume (despite the strong dose response relationship).
Third ventricular volume did however correlate positively with frequent use of
cannabis. Left ventricular volume also correlated positively with use of cannabis most
days. Though isolated use of cannabis correlated negatively with volume of the left
frontal lobe, this was not within the context of a dose response relationship. Tobacco
consumption of more than twenty cigarettes a day correlated negatively with volume
of the right frontal lobe; again the dose response relationship between tobacco use and
volume of the right frontal lobe had not reached significance.
Re-running the regression analysis excluding the three subjects with a history
of opiate dependence did not alter the above findings. However, re-running the
regression analysis with inclusion of highest use of amphetamines, ecstasy and LSD
as additional regression blocks did. Although alcohol use exceeding safe
recommendations remained a significant predictor of left lateral ventricle and left
frontal lobe volumes (R2 = 0.226, P = .002 and R2 = 0.590, P = .031 respectively), it
was no longer a significant predictor of right lateral ventricle volume. Frequent
cannabis use remained a significant predictor of third ventricular volume (R = 0.148,
P = .015), but not left lateral ventricle volume. Most notably however in this
expanded regression model a history of frequent (highest level of use greater than or
equal to monthly) and repeated (highest level of use several times a year)
amphetamine use were predictors of increased right and left lateral ventricular volume
(R2 = 0.125, P = 0.005 and R2 = 0.226, P = 0.011 respectively), and repeated use of
ecstasy was a predictor of increased left lateral ventricle volume (R = 0.226, P —
0.011).
314
Despite the dose response relationships between alcohol and cannabis and
structure volumes, it was not always the highest drug exposure level which came out
of the regression model as being significant predictors. For this reason the regression
analysis was repeated, combining the two highest exposure groups to each drug to
create a single dummy variable representing all subjects with a history of substantial
exposure to either substance. The combined cannabis exposure category correlated
significantly with third ventricular volume, this being the case both with and without
the inclusion of other illicit drugs in the regression model (R = 0.149, P = .014 in
both cases). Similarly on combining the two highest alcohol exposure groups, the
resulting variable correlated significantly with left and right lateral ventricular and left
frontal lobe volume, both with and without inclusion of other illicit drugs in the
regression model. Output for each of the structures listed was R2 = 0.229, P = .008; R2
= 0.161, P = .003; and R2= 0.614, P = .043 respectively for each of the structures
mentioned with other illicit drugs included, and R2 = 0.131, P = .001; R2 = 0.167, P =
<.001; and R = 0.591, P = .025 respectively for each of the structures without other




Independent variables Beta t (df) P value Adjusted R2
(complete
model)




Teetotal 0.23 2.59(134) .011 .11 Regular use of alcohol
becomes non-significant
(p = .066)
Regular use of alcohol 0.21 2.06(134) .042
Exceed safe limits of alcohol 0.33 3.32 (134) .001
Use of cannabis most days 0.20 2.31 (134) .022
Right lateral
ventricle
Whole brain volume 0.26 3.19(134) .002 .14 Nil
Teetotal 0.19 2.13 (134) .035
Regular use of alcohol 0.26 2.34 (134) .021
Exceed safe limits of alcohol 0.40 3.74(134) <.001
Alcohol dependence 0.29 3.20(134) .002
Left frontal
lobe
Whole brain volume 0.69 12.00(134) <001 .58 Nil
Exceed safe limits of alcohol -0.12 -2.18 (134) .031
Isolated use of cannabis -0.13 -2.31 (134) .023
Age -0.15 -2.64(134) .009
Right frontal
lobe
Whole brain volume 0.67 11.1 (134) <001 .54 Exceed safe limits of
alcohol becomes
significant (P = .049)
Exceed safe limits of alcohol -0.10 -1.6(134) .106
>20 cigarettes a day -0.13 -2.2(134) .032
Age -0.14 -2.3 (134) .020
Third ventricle Frequent use of cannabis 0.20 2.6(134) .012 .15 Nil
Gender -0.33 -4.1 (134) <001
Age 0.15 1.9 (134) .065
Table 8.4
Correlation of variables of interest with regional brain volumes as determined by the
primary regression analysis.
Logistic regression employed a backward elimination model, with the independent variables of interest
allotted to 6 blocks. These blocks were gender, age, whole-brain volume, alcohol use, cannabis use,
and tobacco use. This methodology is explained further in Section 8.1.2.
8.1.4 Discussion
Though the findings detailed above do seem robust, a number of points require
further clarification. Firstly, as reported above, it is notable that for some substances
the level of use that significantly correlated with structure volume in the regression
model was not the highest level of exposure. For example, "excessive use" of
alcohol rather than "dependence" positively correlated with right ventricular volume,
despite mean ventricular volume in the latter group being greater than the former
(4.79cm3 and 7.31cm3, respectively). In the case of alcohol exposure, this is
explained by the number of subjects in the highest exposure group being relatively
few compared with the excessive use category. This is not so for cannabis exposure
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however, there being more subjects in the "most days" than "frequent" category, yet
the latter emerging as having a significant correlation with third ventricular volume. It
is for this reason that the analyses were repeated combining the two highest exposure
groups. That these combined exposure category correlated significantly with
ventricular volumes in each case reinforces the veracity of the association between
cannabis exposure and third ventricular volume and alcohol use and lateral ventricular
volume.
It is also the case that though the majority of findings from the regression
analysis were robust to inclusion of past use of amphetamines, ecstasy, and LSD as
additional regression blocks, this was not universally the true. Specifically, on
inclusion of these additional variables heavy use of alcohol was no longer a
significant predictor of right lateral ventricular volume and frequent use of cannabis
was no longer a significant predictor of left ventricular volume. It seems most likely
that this loss of significance is explained by the loss of power resulting from the
inclusion of additional factors; clearly however these results do need to be viewed
with a little more caution than associations which were robust to the inclusion of these
additional covariates.
Data on control subjects have been included for completeness. Given their
small numbers we have not focused on them in detail, but it is the case that the
absence of structural associations comparable to those observed in high-risk subjects
is in keeping with findings from other studies (see Sections 4.1.3.1 and 4.1.3.2). The
finding of decreased third ventricular volume with increasing history of alcohol
exposure is notable however and requires further comment. This was unexpected and
may not be reproducible in a larger sample of control subjects. It is notable however
that nonconsumption of alcohol is very unusual in Scotland,5 and as such teetotal
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individuals may possess characteristics atypical of the general population. As such, it
is conceivable that some unidentified confounding factor and/or factors are driving
this unexpected relationship. Such factors may also be of relevance in understanding
the comparable trend toward third ventricular volume reduction observed in this
group in association with cannabis consumption.
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8.2 Voxel-based morphometric analysis
As discussed in Section 7.2.1,1 believed the optimal approach for analyses of
both baseline and follow up scans was to complement the hand-traced volumetric data
with automated analyses. The baseline data were thus also subject to analysis using
voxel-based morphometry. This required some modification of the contrasts made.
This, together with other considerations important in planning the VBM analyses will
be discussed below.
8.2.1 MR1 acquisition
The MR images used in VBM analysis were the same dataset used for region-
of interest measurements and full MR image acquisition details have been described
previously (see Section 7.1).
8.2.2 Choice ofsubject groupings for exposure comparisons
Ideally the VBM analysis would replicate the volumetric analyses, enabling
direct comparison of findings between the two methodologies. However, the scales at
which the two methodologies operate at are very different, meaning that exactly
equivalent comparisons are innately impossible. It is also the case that the logistic
regression employed in the ROI analysis cannot be implemented in VBM, due to the
constraints required to approximate the massively parallel general linear model
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required for voxel wise analysis. It is thus the case that a different statistical model
must be utilized for the VBM comparisons.
Ideally any contrast chosen should maximise the inclusion of subjects. This is
important both in ensuring that any findings are scientifically robust and in
maximising the power of any analyses undertaken. The latter point is particularly
relevant given that VBM is generally recognised as a conservative technique.613 The
most parsimonious contrast model, which would clearly include all eligible subjects,
is to compare those individuals with levels of exposure to a drug which could be
postulated to be harmful against those who have never experienced this level of
exposure. The point of cut off in level of substance use which determines inclusion in
either of these two groups will need to be considered for each drug individually,
taking into account any relevant pre-existing evidence of what may constitute
potentially harmful use in this population. As research in this area is so sparse
however, it is expected that in most instances this decision will be largely intuitive.
Consideration of cut off points is discussed for each substance of interest to the
current study below.
In the volumetric regression analyses variables that could reasonably be
expected to influence structure volumes were included as covariates. It is equally
important that this is also done when constructing the VBM analyses. It is the case
however that inclusion of multiple covariates results in a substantial loss of degrees of
freedom; this reduces the chance of finding differences between the two exposure
groups through increasing chances of a Type II error. For this reason, though analyses
will be undertaken with the inclusion of all relevant covariates, they will also be run
without the inclusion of these covariates. The latter analyses are regarded as
exploratory and the findings are viewed with caution.
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8.2.3 Control group
Only 8 of the control subjects had a history of consumption of cannabis
frequently or most days. Similarly 11 had histories of alcohol use exceeding
government recommendations. We believed these numbers too small for contrasts to
be sufficiently powered for meaningful analysis. This is particularly so given the
conservative nature of VBM. Given this, VBM analysis was not undertaken in the
control subjects. Any structural imaging abnormalities observed in association with
substance misuse in the high risk group will thus be considered primarily with
reference to findings in normal subjects reported in previously published work. In this
way it can be ascertained if they are particular to this genetically at risk group.
8.2.4 Use ofsmall volume corrections (SVCs)
The use of SVCs in VBM analyses was previously discussed in Section 7.2.2.
The choice of which would be appropriate SVCs to use in the following VBM
analyses needs now to be considered further. As discussed in Section 7.2.2, this
choice will be informed by the findings from both the volumetric analysis and the
wider neuroimaging literature. It is important that these comparisons are chosen
selectively, to avoid multiple comparisons.
An AHC SVC will be employed in analyses investigating the structural
imaging associations of use of all substances. I believe this is important, as though the
baseline volumetric analyses did not find evidence of volume reduction in the AHC in
association with use of any of the substances under investigation, the weight of
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evidence demonstrating abnormalities of this region in schizophrenia is particularly
robust. Other regions with particularly strong evidence for abnormalities in
schizophrenia are the frontal lobes and thalami (see Sections 7.2.2 and 4.2.1).
Exposure related reductions in pre-frontal lobe volume were observed in association
with both alcohol and cannabis in the volumetric analyses, with high levels of alcohol
consumption emerging from the regression analyses as predicting both right and left
pre-frontal lobe volumes. Despite the absence of a dose response relationship, heavy
tobacco consumption predicted left frontal lobe volume. Given these findings,
application of a prefrontal lobe SVC also seemed justified in the exploration of the
structural imaging consequences of all three substances.
The most robust structural abnormality observed in association with cannabis
consumption in the volumetric analyses of baseline data was third ventricular
enlargement. There was a strong dose response relationship, and cannabis
consumption was the only substance to predict third ventricular volume in the
regression analysis. These findings suggest that cannabis consumption may be
associated with relatively localised deficits, particularly affecting areas surrounding
the third ventricle. As the third ventricle is bounded by the thalamus and
hypothalamus, on both the right and left sides, it is these structures which are most
likely to have exhibited the tissue loss resulting in enlargement of the structure. Of the
two structures it is the thalamus which constitutes the majority of this boundary, the
walls of the third ventricle being formed predominantly by the anterior and
dorsomedial thalamic nuclei.607 It would thus be expected that any volume loss
occurring in association with cannabis use would be most likely to have occurred in
this region.
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Given the above discussion, I believed specific exploration of cannabis
associated volume loss in the regions surrounding the third ventricle to be justified.
As the ROI analysis could not pinpoint where volume loss had occurred to give rise to
third ventricular enlargement, I employed a 12mm spherical SVC centred at the centre
point of the third ventricle. This enclosed all of the third ventricle and the
immediately surrounding tissues; given the anatomy of this brain region the
immediately surrounding structure was predominantly the dorsomedial thalamic
nucleus. Given the absence of positive findings from ROI analyses investigating the
impact of use of other substances on third ventricular volume, this SVC was not
employed in investigating structural abnormalities associated with alcohol and
tobacco.
The other two SVCs (for the AHC and frontal lobes) were constructed from
anatomical designations taken from Duvernoy614 and supplemented by readings from
Talairach and Tournoux,607'614 these were previously employed by Moorehead et
a/.615 The amygdala-hippocampal complex SVC comprised the right and left
amygdala, hippocampus, entorhinal area and parahippocampal gyrus. These SVCs
have been used in a number of previous publications deriving from this cohort.493'602'
616
8.2.5 Scan preprocessing
This was undertaken using SPM (http://www.fil.ion.ucl.ac.uk/spm/spm
99.html) running in Matlab 6.1 (The MathWorks, Natick, MA, USA). A study-
specific template was first constructed from all high risk scans. Since this group
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contained scans from subjects with all levels of substance exposure, it was believed to
represent the entire study population and therefore minimised bias for spatial
normalisation. The scans were normalised to the generic SPM T1 template using 12-
point linear affine transformation. A study-specific T1 template was created from the
mean image calculated from all the normalised T1 images and smoothed at 8-mm
full-width at half maximum (FWHM).
To generate study-specific brain tissue a priori maps, the normalised images
were segmented into grey matter (GM), white matter (WM) and cerebrospinal fluid
(CSF) using SPM cluster analysis with a modified mixture model and the SPM GM,
WM and CSF a priori probability maps. A brain tissue mask was produced using the
"Xtract brain" function. This removes the extracerebral voxels from both the GM and
WM segmented images using a series of dilation functions and adds together the
segments forming a binary image of extracted brain tissue. Multiplication of this
image with the original segmented images removes the extracerebral voxels. Mean
images were calculated from the CSF and extracted GM and WM segments and
smoothed at 8-mm FWHM to produce study-specific a priori maps.
To process the images using the study-specific template, extracted brains in
native space were registered with the extracted brain template in MNI space. This
registration used a combination of 12-linear affine transformations and a linear
combination of smooth spatial basis functions to account for the non-linear global
shape differences. The original T1 images were then normalised into stereotactic
space by application of the same combination of linear and non-linear transformation
parameters obtained for the extracted brains.
Successful spatial normalisation was determined by visual comparison of
homologous regions of the template and normalised images using the 'check
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registration' option in SPM; this function allows simultaneous visual inspection of
anatomical regions on 2 or more images. Two images did not normalise correctly and
so were not included in the analysis. This meant that, in the case of cannabis for
example, the contrast was 68 people with a substantial cannabis use history against 72
who had had no/minimal exposure to the drug.
The GM optimally normalised images were then segmented into GM, WM
and CSF using the study-specific templates and the same modified cluster analysis
function, and the extracerebral voxels removed as previously described. Each of the




SPM5 was used for the statistical analysis as it was the latest version available.
In all VBM analyses the statistical analysis was performed on a voxel by voxel basis,
based on the general linear model. Analysis of grey and white matter was conducted
separately. In each case a tissue appropriate mask was applied.
Voxel-wise statistical analysis performed on spatially normalised segmented
images results in statistical parametric maps showing areas where tissue concentration
differs significantly between groups. The hypothesis being investigated was that use
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of each of these substances was associated with tissue loss. The reverse investigation
(that use was associated with tissue gain) was not investigated. This was important in
limiting the number of analyses. Additionally, as can be seen from Section 4.1.3, there
is no significant evidence to suggest that use of cannabis, alcohol or tobacco is
associated with tissue gain.
For the reasons discussed in Section 8.2.2 the contrasts of interest were
between the high and low exposure groups to each substance. These groups were
compared using a t-test comparison, both with and without inclusion of relevant
covariates. All of the covariates which emerged from the volumetric regression
analyses as being predictive of any structure volumes were included as covariates in
these analyses. Covariates included were thus: (1) use of substances other than the
specific substance under investigation (i.e four of past use of cannabis, alcohol,
tobacco, amphetamines and ecstasy, each expressed as a binary measure); (2) age; (3)
gender. IQ was not included as a covariate as it did not emerge from the volumetric
regression analyses as a significant predictor of any structure volumes. Similarly, past
use of LSD was not included as it did not predict any brain regional volumes in the
volumetric regression analysis. Whole brain volume was not included as a covariate
due to the inherent correction for brain volume provided by spatial normalisation.617
The statistical parametric maps are displayed on a 'glass brain' allowing
visualisation of clusters in 3 orthogonal planes - axial, coronal and sagittal. For all
analyses, significance was assessed using uncorrected height thresholds of PO.OOl,
and reported at PO.05 corrected for multiple comparisons. This threshold has
previously been used in VBM analysis.618"620
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8.2.6.2 Statistical models for investigating imaging associations ofspecific drugs
Cannabis
For the cannabis analysis, the three highest cannabis exposure groups of high
risk subjects, (those subjects who had used cannabis 'occasionally', 'frequently' or
'most days'), were compared to those who had either never used the drug, or used it
only on isolated occasions (<3 times in their life). The two latter groups were
combined as it seemed highly unlikely that such minimal historic use of the drug
would be associated with any identifiable sequelae; including these subjects in the
'substantially exposed' group would thus dilute any effects that were present. This
choice of cut off could be regarded as somewhat at odds with the inclusion of people
with any level of use of cannabis use in the inter-scan period in the 'exposed' group in
the longitudinal analyses (see Section 6.2.1). I believe however that this slight
difference in categorisation is justified for a number of reasons: (1) longitudinal
analyses may be expected to be more sensitive to subtle interactions; (2) case-control
comparisons undertaken by other groups have excluded subjects with a history of
537minimal use of cannabis from the exposure group; and (3) the model chosen for the
longitudinal analysis also has precedent. In reality, (given that a dose response
relationship between cannabis use and brain structural abnormalities is suggested by
the volumetric analyses above), the consumption cut-off point chosen in determining
exposed and unexposed groups should not make any fundamental difference to the
results obtained.
By employing the approach outlined above the inclusion of all subjects was
achieved and thus power maximised. Given the two images that did not normalise
correctly, 140 scans were available; of these 72 subjects were in the non/minimally
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exposed group, and 68 in the group with considerable cannabis exposure. It was thus
the case that the two groups were numerically well balanced. Demographic and other
relevant characteristics of these two groups are compared in Table 8.5.
Never used Consumed cannabis P
cannabis/used on <3 on >3 occasions
occasions n = 68
N = 72
Gender M:F 30:42 43:25 .011*
Age at tl (SD) 21.2(3.1) 21.2 (2.7) .993
RISC at tl (SD) 28.53 29.75 .511
Cigarette smoker Y:N 21:49 53:12 <.001*
History excessive alcohol 14:58 30:36 .001*
use3 Y:N
Past use ecstasy3 Y:N 4:68 27:41 <.001*
Past use amphetamines 6:66 39:29 <.001*
Y:N
Table 8.5
Demographic and drug use characteristics of the two groups with and without a
significant history of cannabis exposure at point of entry in to the study.
P = independent t test, except * = chi squared
As discussed above, initial comparison was made without the addition of any
covariates and at whole brain level. This was justified as a primary aim of this initial
analysis was exploratory, to identify any brain regions not targeted with the ROI
analysis but demonstrating structural abnormalities in association with cannabis use.
As mentioned above, VBM is known to be a conservative method of analysis,
meaning that addition of covariates would result in substantial loss of degrees of
freedom. In this context this could result in the non-detection of important areas of
tissue loss.
Supplementary analyses were also run with the inclusion of relevant SVCs; in
the case of the cannabis analyses these were SVCs for the AHC, frontal lobes and a
12mm diameter sphere centred on the central point of the third ventricle. The volume
of the sphere employed is comparable to those used in previous analyses of these
data.490 These analyses were run without the inclusion of any covariates in the initial
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analysis. Given that these analyses had pre-decided areas of interest, exclusion of
these covariates is more difficult to justify on the basis of it being an exploratory
analysis and these findings must be interpreted with caution. It is the case however
that the initial ROI regression analysis found that only cannabis consumption, gender
and age were significant predictors of third ventricular volume; other variables were
not predictive of volume of this structure. As when applying the third ventricular
centred SVC we were particularly interested in changes in this region, it seemed
reasonable to re-run the analysis covarying only for these relevant factors. This was
particularly important in the case of gender, as this variable was unbalanced between
the two groups.
Additionally, all the above analyses were re-run including all the covariates
incorporated in to the logistic regression model (with the exception of whole brain
volume). Given the substantial loss of degrees of freedom associated with this, it was
viewed as unlikely to yield significant findings. It did however seem important to
attempt as close a reproduction as possible of the ROI analysis.
Alcohol
The alcohol analyses were run in a manner comparable to those for cannabis,
though with some important differences. In this analysis only the two highest alcohol
exposure groups, (those subjects with a history of consuming greater than government
recommendations or frank dependence) were combined to form the potentially risk
associated group. They were contrasted against the 'occasional use' group, rather than
'teetotal' group. As discussed in Section 6.2.1, this was because of concerns that the
'teetotal' group may be atypical. The group consuming alcohol regularly but not
reporting that they exceeded government recommendations were not included in these
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analyses. This was because I did not believe it appropriate to include them in either
the putative risk associated or control groups. Inclusion in the latter group was
inappropriate as they had not consumed alcohol at a level generally believed to be
associated with risk. Conversely, the fact that I suspected the genetically high risk
group may have a particular susceptibility to the structural consequences of substance
use, combined with concern that some within this group may actually have exceeded
government recommendations (discussed in Section 6.2.1), meant it was not
appropriate to include them in the comparator group. I believed the benefits of
excluding these subjects outweighed the consequent loss of power. This meant that 28
individuals with a history of occasional use of alcohol were compared to 44
individuals with a history of alcohol use exceeding government recommendations.











Gender M:F 14:14 24:20 .71*
Age at tl (SD) 19.80 (3.19) 21.87 (2.69) .004
RISC at tl (SD) 26.57(11.27) 29.73 (11.72) .262









Comparison of demographic and relevant clinical details of high risk subjects with
and without a history of hazardous or harmful alcohol consumption.
Past smoking history was not available for one subject from each category.
P = independent t test, except * = chi squared
Similarly to the cannabis VBM analysis, the initial analysis was run without
any covariates. The analysis was also run including all potential covariates of interest,
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again to try and replicate as much as possible the region of interest analysis. As
before, the loss of degrees of freedom meant I believed it unlikely that this would
yield significant findings.
Given that alcohol consumption emerged from the regression analysis as a
significant predictor of frontal lobe volume, contrasts were also repeated including a
frontal lobe SVC. Alcohol did not emerge from the regression analysis as a significant
predictor of third ventricular volume; thus a thalamic/third-ventricular based SVC was
not employed in the alcohol analyses. Again, given overwhelming evidence for
amygdalohippocampal abnormalities as being important in the development of
schizophrenia, an AHC SVC was included.
Other substances
There was no evidence of dose response relationships between tobacco
consumption and volumes of any of the regions investigated in the ROI analyses.
Consumption of greater than 20 cigarettes a day did however emerge from the
regression analysis as predictive of right frontal lobe volume. This positive finding
from the regression analysis justified using the frontal lobe SVC, and as in all drug
contrasts the AHC SVC was also included. As there was no clear rationale for it,
analyses were not repeated utilising the thalamic SVC.
In the VBM analyses smokers/former smokers were contrasted against those
who had never smoked. In deciding on this cut off point I was aware that including
those who had only ever been light smokers/were now non-smokers in the smoking
group did risk diluting abnormalities only associated with heavier use. I did however
believe this to be justified for two reasons: (1) given the young ages of the subjects,
even those who were currently none smokers would have been unlikely to be
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abstinent for long; (2) there is no obvious level of tobacco consumption which can be
regarded as a cut off between harmful and non-harmful use. Demographic and other
relevant characteristics of these two groups are compared in Table 8.6.
Never smoked Smoker P
N = 61 n = 74
Gender M:F 31:30 41:33 .595*
Age at tl (SD) 21.34 (3.11) 21.02 (2.75) .525
RISC at tl (SD) 27.77 (11.13) 30.31 (10.79) .182
History of greater than
isolated cannabis use Y:N
12:49 53:21 <.001*
History excessive alcohol 12:49 31:41 .004*
usea Y:N





Comparison of demographic and relevant clinical details of high risk subjects with
and without a history of smoking.
P = independent t test, except * = chi squared
As in previous analyses, the initial analysis was undertaken without inclusion
of any covariates. The contrast was repeated including all covariates of interest. These
analyses were then repeated utilising the frontal lobe and AHC SVCs.
Relatively small numbers of subjects had used ecstasy and amphetamines at a
level exceeding isolated use; only 21 and 25 subjects respectively. Considering the
relatively small numbers together with the relatively low power of VBM to detect
differences, it did not seem feasible to undertake VBM contrasts for these variables.
These analyses were therefore not undertaken.
8.2.7 Identifying Talairach Regions
The VBM whole brain and SVC analyses were implemented in MNI space.
The voxel co-ordinates of the results are extracted from MNI standard space and I
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also report the Talairach co-ordinates using the Matlab function mni2tal.621 The
anatomic location of significant results was manually checked using the Talairach
atlas,614 supplemented by use of Tailarach Daemon
(http://ric.uthscsa.edu/projects/talairachdaemon.html). Talairach Daemon is a
622





Demographic details for the 140 subjects included in the initial analysis are
detailed in Table 7.4. Sixty eight subjects who had used cannabis on more than three
occasions were compared to 72 who had either never used the drug or used it on a
maximum of three occasions. As information on past use of all drugs of interest was
not available for a small number of subjects (see Section 5.2.3; complete data were
available for 135), these subjects had to be excluded from analyses including these
covariates.
VBM analysis
On the initial grey matter contrast, without application of a SVC, no
significant regions of grey matter loss were observed. This was also the case on
application of the AHC and frontal lobe SVCs. On applying the SVC encompassing
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regions surrounding the third ventricle however, a region of density loss was
identified in the medial thalamus and hypothalamus, with three single significant
maximal voxel locations. One, at P_corrected = .005 (t contrast value = 4.12) was
found at MNI coordinate [-6, -8, -2], The second, at P_corrected = .008 (t contrast
value = 3.85) was found at MNI coordinate [-6, -11, -5]. Finally, the third, at
Pcorrected = .017 (t contrast value = 3.72) was found at MNI coordinate [-2, 12, 5].
These were converted into Tailarach coordinates (detailed in Table 8.7) and are
shown both on a 'glass brain' and overlayed on a structural image in Figure 8.4.
When gender and age were included as covariates a significant result remained in this
brain region, encompassing an area including the hypothalamus and inferior
dorsomedial thalamic nucleus. There were two maximal voxel locations; one at
P_corrected = .035 (t contrast value = 3.41) was found at MNI coordinate [-6, -8, -2],
while the second, at /^corrected = .049 (t contrast value = 3.85) was found at MNI
coordinate [-8, -12, -4],
Figure 8.4.
SPM superimposed on a 'glass brain' showing voxels reduced density in cannabis
exposed compared to non or minimally exposed subjects (left).
SPM overlay on a structural image demonstrating the region of density loss in the left
thalamus (right).
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also report the Talairach co-ordinates using the Matlab function mni2tal.621 The
anatomic location of significant results was manually checked using the Talairach
atlas,614 supplemented by use of Tailarach Daemon
(http://ric.uthscsa.edu/projects/talairachdaemon.html). Talairach Daemon is a
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When all the covariates incorporated into the ROI multiple regression analysis
were included in the analysis both the above results became non-significant. In this
analysis however a region of grey matter loss emerged in the right prefrontal lobe, in
the region of the medial prefrontal gyrus (MNI coordinate 22, 33, -12). On application
of the frontal lobe small volume correction this fell just short of significance,





Point of maximal change
.005 -5.9 -8.7 -1.3 Left hypothalamus
.008 -5.9 -10.9 -3.7 Below left anterior thalamic nucleus
.017 -2.0 -11.4 5.2 Left dorsomedial thalamic nucleus
Table 8.8
Contrast of high risk subjects with >3 exposures to cannabis against those with
minimal history of use of the drug. SVC for region around third ventricle has been
applied.
The observed thalamic/hypothalamic result was robust to inclusion of all covariates
found in the ROI regression analysis to predict third ventricular volume. It is the case
however that on inclusion of additional covariates the finding became non-significant.
Given this, I wished to try and confirm that this did represent a genuine effect. It is
generally accepted that an observed effect such as this is regarded as more robust if
the areas of maximal reduction are anatomically plausible when overlayed on the
original scans included in the analysis.624 With this aim, a random selection of scans
were observed, with the location of maximum difference on the statistical maps (after
application of the spherical SVC surrounding the third ventricle) being identified. A
clear pattern emerged. In exposed subjects this point is on the thalamic/third ventricle
boundary, whereas in controls it is in body of thalamus. This does seem to suggest
that volume is being lost by the thalamus (in a fairly specific region that encompasses
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the anterior and dorsomedial thalamic nuclei), and that this is resulting in the third
ventricle result.
The white matter contrast revealed no significant areas of tissue density loss.
This was also the case on inclusion of the relevant covariates.
Discussion
The findings outlined above suggest that the third ventricular enlargement
observed on the ROI analysis in association with cannabis is due to loss of thalamic
(and possibly hypothalamic) volume. Though not robust to inclusion of all covariates
included in the ROI regression analysis (this likely being attributable to the
consequent loss of degrees of freedom), it is robust to the inclusion of all covariates
found to be predictive of third ventricular volume in the baseline regression analysis.
These findings suggest that in this high risk population cannabis consumption may
have a particularly thalamotoxic effect. Indeed, it even suggests that this effect may
be specific to particular, paraventricular thalamic nuclei (namely the anterior and
mediodorsal thalamic nuclei)
If thalamic volume loss has genuinely occurred in association with cannabis
use, then why is this not seen on volumetric analysis? Though on first consideration
this lack of consistency between the two methods seems contradictory, on reflection
however it may not be entirely unexpected, a potential explanation arising from the
intrinsic differences between the two techniques. Importantly, as discussed in Section
7.2.1, it is well recognised that volumetric and VBM techniques have different
sensitivities; while VBM is less sensitive than volumetric techniques in some regions,
it can be more sensitive to localised tissue loss.604'606'613 The thalamic tissue loss
observed by VBM has occurred in a small, relatively localised region within this
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structure. Given that the thalamus is a relatively large structure, this will constitute
only a small percentage of total volume, and thus the volume loss would be expected
to be within the bounds of measurement error inherent in semi-automated hand-
tracing techniques. It would thus be missed by the volumetric approach, even if
detected by VBM. The resulting increase of volume of the third ventricle however,
given that this is a smaller structure, will constitute a greater proportion of the total
volume of this structure potentially lying out-with the boundaries of measurement
error. It will thus stand a greater chance ofbeing detected by hand-tracing.
These speculations are attractive, and do confer some coherence to the ROI
and VBM results. Given the borderline significance of the result however, this
explanation is certainly for from conclusive. What it does provide however is a
hypothesis to guide analysis of the longitudinal data, suggesting that thalamic volume
loss over time may be observed in association with cannabis exposure.
8.2.8.2 Alcohol
Demographics
Demographic details for the 72 individuals included in the analysis are
detailed in Table 8.5. Twenty eight individuals with a history of occasional use of




On the initial alcohol analysis (without any covariates), the strongest grey
matter finding was loss of a region of grey matter in the left superior parietal lobe.
This did not however reach significance; Pcorrected = .580 (t contrast value = 4.22)
was found at MNI coordinate [-32, -50, 63]. A frontal lobe SVC was applied, but even
with this no significant regions of grey matter density loss were observed. This was
also the case after application of an AHC SVC. No significant findings were observed
after inclusion of all relevant covariates.
White matter findings were more striking. On the initial analysis (with no
covariates), density loss was observed in a diffuse region extending in to much of the
corpus callosum. Density loss was particularly pronounced in the splenium, the voxel
location of maximum change being found at MNI coordinate [18, -25, 18 ], though
this still fell short of significance; ^corrected = .291 (t contrast value = 4.36). This
probability map is shown both on a 'glass brain' and overlayed on a structural image
in Figure 8.5. This finding remained non-significant after inclusion of all relevant
covariates. Even with application of a frontal lobe SVC no significant areas of white




SPM superimposed on a 'glass brain' showing voxels demonstrating reduced white
matter density in subjects with a history of excessive alcohol consumption compared
to occasional drinkers (left).
SPM overlay on a structural image demonstrating the region of density loss in the
corpus collosum (right).
Discussion
Abnormalities observed in association with excessive use of alcohol were seen
predominantly in white matter. This is as we would have expected; the weight of
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evidence is that this tissue type is particularly vulnerable to the effects of alcohol.
Though it fell short of significance, the strongest grey matter result was in the left
parietal lobe. There is in fact a body of evidence suggesting that the parietal lobe is
particularly vulnerable to the effects of this drug.397'625 Indeed, this was a region
demonstrated to be particularly vulnerable to volume loss in Mathalon et al. 's study of




For the 135 people for whom smoking history was known, those with any
history of smoking were compared to those who had never smoked. Demographic and
relevant clinical details of these subjects are outlined in Table 8.6.
Results
On the initial tobacco analysis (without any covariates), the strongest grey
matter finding was loss of a region of grey matter in the superior temporal gyrus, at
MNI coordinate [41, -37, 15]. This did not however approach significance;
/-■ corrected = .412 (t contrast value = 4.22). No significant regions of grey matter
density loss were observed on applying either a frontal lobe or AHC SVC.
Additionally, no significant findings were observed after inclusion of all of the
covariates included in the ROI regression analysis.
White matter findings were more striking. On the initial analysis (with no
covariates), a significant area of density loss was observed in the right cerebellum,
maximal at MNI coordinate [24, -60, -43], Pcorrected = .036 (t contrast value =
4.83). This probability map is shown both on a 'glass brain' and overlayed on a
structural image in Figure 7.6. This finding remained significant after inclusion of all
relevant covariates, P_corrected = .049 (t contrast value = 4.77). Even with
application of a frontal lobe SVC no significant areas ofwhite matter density
reduction were seen in this region.
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Figure 8.6
SPM superimposed on a 'glass brain' showing voxels demonstrating reduced grey
matter density in subjects with a history of cigarette smoking compared to those
without (left).
SPM overlay on a structural image demonstrating the region of density loss in the
right cerebellum (right).
Discussion
Tobacco use was associated with reduced white matter density in the right
cerebellum. This has not been reported in previous studies investigating brain
structural abnormalities associated with tobacco use 4.1.3.3. The cerebellum was not
an area which had been identified a priori as a brain region to be investigated in this
study. There has been considerable interest in recent years however in the possibility
that cerebellar abnormalities may be important in the pathophysiology of
schizophrenia. Clearly this finding does raise intriguing possibilities that an
interaction between tobacco use and cerebellar structure does exists in those at high
risk for schizophrenia. As this was a brain region which was not a primary focus of
this study however (and for which volumetric analysis was not undertaken), it will not
be specifically investigated further; it is of course feasible however that longitudinal
changes may be apparent in subsequent automated analyses (see next Chapter).
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8.3 Summary of findings from baseline analyses
As had been expected, there were some differences between findings from the
semi-automated volumetric analyses and from VBM. These seem to be explicable by
the differing sensitivities of the two methodologies however, and it is the case that
results of the two methodologies are overall generally reasonably compatible.
Findings from these two methodologies will now be synthesised, with the aim of
providing the most accurate picture possible of the structural abnormalities associated
with substance by this at-risk group. The structural abnormalities associated with
alcohol, cannabis, tobacco and the other drugs of interest will be discussed in turn.
8.3.1 Cannabis
Among the strongest findings from the volumetric analyses of the high risk
group was that of third ventricular enlargement in association with cannabis
consumption. A dose response relationship was observed between level of cannabis
consumption and volume of this structure, and frequent use of cannabis emerged from
the regression analysis as a predictor of third ventricular volume. In contrast, there
was no suggestion of third ventricular enlargement in association with cannabis
consumption in the controls. The thalamus surrounds the third ventricle, and would be
the most obvious structure from which tissue was lost to give rise to this third
ventricular enlargement. In keeping with this, VBM analysis identified a region of
tissue density loss localised to the anterior and mediodorsal nuclei of the left
thalamus. Though this result was not robust to the inclusion of all the covariates
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included in the ROI analysis, it does indeed suggest that the third ventricular
enlargement observed in association with cannabis consumption is attributable, (at
least in part), to thalamic volume loss. Such an effect seems to be specific to
individuals at genetically high risk of schizophrenia.
8.3.2 Alcohol
Alcohol use history exhibited a dose response relationship both with
ventricular enlargement and frontal lobe volume loss in those individuals at high
genetic risk of schizophrenia. Once again, a comparable relationship was not apparent
in controls. Alcohol use exceeding government recommendations also emerged from
the regression analysis as predictive of lateral ventricular volume and left frontal lobe
volume reduction in high risk subjects. As discussed in Section 4.1.3.2, brain
structural abnormalities associated with alcohol use would be expected to be diffuse;
as outlined in Section 6.2.1, this would make them difficult to detect at a significant
level using VBM. This was indeed the case, VBM indicating loss of grey matter in the
prefrontal lobes and loss of white matter in the corpus callosum, but neither of these
findings approaching significance.
8.3.3 Tobacco
Though tobacco use did not demonstrate a dose response relationship with
volume of any of the brain regions investigated, consumption of greater than 20
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cigarettes a day did emerge from the regression analysis as predictive of right frontal
lobe volume. There was no suggestion of tissue loss in this region in association with
tobacco use on VBM analysis. VBM comparisons did however reveal an area of
reduced white mater density in association with a history of tobacco use in the right
cerebellum.
8.3.4 Other drugs
It is of substantial interest that when entered in to the regression model as
additional factors, amphetamine and ecstasy use were predictors of either left or right
lateral ventricular volume. Unfortunately, users with substantial histories of use of
these drugs were too few to justify running VBM analyses to further elucidate any
structural imaging abnormalities associated with their use in schizophrenia. In the
case of amphetamines at least, there is considerable evidence that substantial use of
these substances is associated with structural brain abnormalities (see Section 4.1.3.4).
The possibility that people at risk of, (or even with), schizophrenia are particularly
vulnerable to brain structural sequelae on using these drugs, (in addition to alcohol
and cannabis), is an important consideration for future research.
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Chapter 9
Analysis of longitudinal data
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9.1 Planning of longitudinal analyses
9.1.1 Integration ofbaselinefindings in to planning of longitudinal analyses
At the outset of this study it was hoped that the longitudinal analysis could be
guided by baseline findings. Given this, consideration of the data presented in Chapter
7 will be important in planning which brain regions on which to focus investigation in
the longitudinal analyses.
Findings from the baseline analyses were summarised in Section 8.3. As
discussed in this section, synthesis of the volumetric and VBM analyses suggested
that thalamic volume loss was associated with cannabis consumption. Other structural
abnormalities observed in association with cannabis use, particularly lateral
ventricular volume loss, are suggestive of diffuse change rather than implicating a
particular structure. It is the case however that although no dose response relationship
was observed, VBM analysis (on inclusion of all relevant covariates employed in the
volumetric regression analysis) did reveal a near significant region of grey matter
density loss in the right medial frontal gyrus.
In the case of alcohol, a dose response relationship was seen between frontal
lobe volume loss and use of this drug. The association also emerged as significant in
the regression analysis. No significant regions of density loss were seen in association
with alcohol use on VBM analysis, a fact likely attributable to the nature of this
change being diffuse. Synthesis of the baseline analyses did not suggest that thalamic
volume loss had occurred in association with this drug.
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Associations between tobacco use and brain structural abnormalities were
generally less obvious than was the case with cannabis and alcohol. An exception was
the identification of an area of white matter density loss in the right cerebellum with
VBM.
Though it is important to incorporate baseline findings in to the planning of
longitudinal analyses, this should not be relied on exclusively. It is possible that
genuine associations between use of a particular substance and specific brain regional
volume loss could be undetectable by a case-control study design, but detectable
within a longitudinal study design. Thus, if there is strong reason to suspect that a
particular brain region may be vulnerable to the effects of a particular substance, it
may be reasonable to investigate this putative association even in the absence of data
from the baseline analyses suggesting such a relationship.
Given the above considerations, a number of putative effects will be of
particular interest in the longitudinal analysis. Firstly, given the data outlined above, it
will be important to investigate if thalamic volume loss occurs in association with
cannabis use. Additionally, investigation of frontal lobe volume loss in association
with either cannabis or alcohol will also be a priority. No associations were observed
between use of any of the substances investigated and hippocampal volume loss in the
baseline analysis. It is the case however that hippocampal volume loss is one of the
most robust findings in schizophrenia (see Section 4.2.1); as a consequence, and
despite the paucity of findings involving this structure on baseline analysis, I believe
it is appropriate that this structure is also singled out a priori for investigation of any
longitudinal changes occurring in it in association with use of either cannabis or
alcohol.
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As discussed above, the only significant association observed between tobacco
use and structural imaging abnormalities in the baseline analysis was the finding of an
area of reduced white matter density in the right cerebellum in association with
smoking seen on VBM. The cerebellum was not a region subject to hand tracing
analysis; given this, longitudinal changes in this structure can not be investigated by
ROI methodology. Given the absence of any findings from baseline analyses strongly
suggestive of structural abnormalities in association with tobacco use in any of the
brain regions actually subject to volumetric analysis, volumetric techniques were not
used to investigate if longitudinal structure volume loss occurred in association with
tobacco use. Any grey or white matter loss over time in association with smoking will
however be investigated with TBM.
Relatively few subjects used ecstasy or amphetamines between scanning
points. Given the small number of subjects with this exposure, and to limit the total
number of comparisons, abnormalities associated with these drugs will also not be
directly investigated. They will however be included as covariates in other analyses.
9.1.2 The biological rationale forfocusing on these structures in the longitudinal
analysis
Utilising findings from the baseline analyses to guide the longitudinal analyses
has numerous advantages. It provides coherence to the study design, reduces the total
number of comparisons undertaken and can hopefully facilitate the detection of
abnormalities where they exist. As alluded to above however, it is also important that
the choice of regions being investigated is underpinned by a clear biological rationale.
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This should reflect the existing evidence base, with there being good reason to suspect
(in this population at least), that any abnormalities observed could reasonably be
attributable to substance use. With this in mind, I will now examine how each of the
potential interactions between substance misuse and brain structure being singled out
for investigation in the longitudinal analyses could be conceptualised as biologically
feasible.
9.1.2.1 Regions in which the effects ofcannabis will be specifically investigated
Thalamus
As reviewed in Section 4.2.1, thalamic volume reduction is in fact one of the
627 628
most consistently demonstrated structural abnormalities in schizophrenia. ' The
point in illness development at which this abnormality arises has however been more
difficult to ascertain. Previous reports from the EHRS have indicated that people who
are clinically well but at genetically high risk of schizophrenia have reduced thalamic
volume compared to controls, (see Section 4.2.2.1 and Lawrie et al,629) and replicated
studies have established this reduction as a measure of genetic liability to
psychosis.630'631 In contrast however, a VBM-based meta-analysis of high risk studies
failed to detect thalamic deficits on combining eight (admittedly heterogeneous)
reports; conversely, the same meta-analysis detected left thalamic deficits in first
episode compared to high risk subjects, and bilateral deficits in those with chronic
schizophrenia compared to controls. As discussed in Section 4.2, synthesis of the
available data suggests that, though some thalamic abnormalities may indeed exist
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long before the development of schizophrenia, it is likely that further structural
change does occur during transition to illness.
Central to the stress-diathesis model of schizophrenia is the belief that the
condition arises when a vulnerable individual is exposed to environmental stressors
that increase the risk of transition from vulnerability phenotype to frank psychosis.633
As discussed in Section 3.2.2.1.1, cannabis is an environmental factor with
considerable evidence of risk modifying effect. The findings from our baseline
analysis may thus suggest that cannabis exposure could provide one potential
mechanism by which thalamic structural changes arise during the process of
development of schizophrenia.
Independent of our earlier findings, there are data suggesting the thalamus is
directly influenced by exposure to cannabis. Though CB1 receptors are not as densely
expressed in this brain region as some others, they are present. Indeed, highest levels
ofbinding are found in the mediodorsal and anterior complex nuclei,634 regions that
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connect to cortical association areas consistently implicated in schizophrenia.
Changes in thalamic regional cerebral blood flow secondary to cannabis consumption
have also been reported, though these findings have been inconsistent and not all
studies have reported effects.636' 637 Interestingly, this is despite animal studies finding
robust and reproducible effects of cannabis consumption on the function of several
zr-jo f.'iQ
thalamic subregions. ' Structural imaging studies have not reported thalamic
volume loss secondary to cannabis consumption in cannabis users. Indeed, as
reviewed in Section 4.1.3.1, in the non-schizophrenic population there have been no
consistent reports of any structural abnormalities in association with use of this drug.
In contrast, a number of studies have reported grey matter loss in association with
cannabis use in people with established schizophrenia (see Section 4.3.1.1). In the
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longitudinal study of Rais et al. this occurred in the context of third ventricular
1 539
enlargement.
Considering the above it does therefore seem biologically plausible that
cannabis could be associated with thalamic abnormalities. If such abnormalities did
occur, we would expect them most likely to be detectable in a longitudinal study of
vulnerable individuals, such as those in the EHRS. It does thus seem that investigation
of longitudinal thalamic volume change in association with cannabis consumption is
clearly justifiable.
Frontal lobes
As reviewed in Section 4.2.1, frontal lobe volume loss is again one of the most
robust findings in schizophrenia. Very subtle deficits in the region may be present
even prior to the onset of illness, but it seems likely that the transition from at risk
state to frank psychosis is associated with significant prefrontal grey matter loss.
Identification of environmental exposures associated with prefrontal loss in at-risk
individuals is thus of paramount importance.
As discussed above and in Section 4.1.3.1, in the 'normal' population cannabis
consumption is not associated with any robust structural imaging abnormalities. It is
the case however that expression of the CB1 receptor, the principle cannabinoid
receptor in the brain, is particularly pronounced in the prefrontal cortex.640 Thus, if
cannabis consumption was to have brain structural consequences, this would be one
of the prime candidate regions. The finding of a near significant region of tissue
density reduction in the right prefrontal lobe in association with cannabis on baseline
VBM analysis must also be considered in this context. This, together with the
accumulated data outlined above, does suggest that further exploration of the
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possibility that cannabis use is associated with longitudinal loss of frontal lobe grey
matter in individuals at genetically high risk of schizophrenia is warranted. Thus, this
possibility will also be specifically investigated in the longitudinal analyses.
Amygdalo-hippocampal complex
The AHC is also a region consistently identified as being reduced in volume in
people with chronic schizophrenia (see Section 4.2.1.1). It is also the structure most
consistently reported as reduced in first episode subjects. Evidence that more subtle
hippocampal abnormalities are present in people at high risk of schizophrenia are
particularly robust, and it does seem that further reductions of hippocampal volume
may occur in individuals who are at particularly elevated risk of making the transition
to psychosis (see Section 4.2.3).
As discussed above, no structural brain abnormalities are consistently
identified in 'normal' cannabis using subjects. It is the case however that the limited
data available do suggest that people with schizophrenia who have used cannabis
exhibit additional grey matter reductions in left hippocampus (see Section 4.3.1.1). It
is also the case that, together with the frontal lobes, CB1 receptor expression is
particularly dense in the hippocampus.640 On considering these data it does thus seem
that this is a further structure in which the possibility of longitudinal structural
changes in association with cannabis should be specifically explored.
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9.1.2.2 Regions in which the effects ofalcohol will be specifically investigated
Frontal lobes and AHC
The structural abnormalities seen at baseline in association with cannabis
consumption appear to be predominantly localised around the third ventricle. In
contrast, the abnormalities associated with alcohol seem to be more diffuse,
manifesting as lateral ventricular enlargement and frontal lobe volume loss. As
discussed in sections 4.1.3.2.1 and 4.2.1, frontal lobe volume loss is strongly
associated with both alcohol use and schizophrenia. As discussed in Section 4.1.3.2.3,
if alcohol-associated abnormalities are detectably anywhere in young alcohol abusers
it is likely either here or in the hippocampi. There is thus a strong rationale for
investigating if further frontal lobe volume loss is observed in association with
excessive alcohol use between scans.
Aside from the frontal lobe effects, there was little suggestion from baseline
analyses that specific brain regions were predominantly affected by alcohol
consumption. As however hippocampal volume loss is one of the most robust findings
in schizophrenia (see Section 4.2.1), as well as possibly being associated with alcohol
use in young people, (see above), it is important to investigate if heavy alcohol
consumption by this group is associated with progressive structural abnormalities of
this structure. Longitudinal analyses investigating changes overt time in association
with use of alcohol in the high risk subjects will thus be limited to these two regions.
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9.1.2.3 Regions in which the effects oftobacco will be specifically investigated
Aside from cerebellar white matter loss there was little evidence from baseline
analyses that tobacco use was associated with brain structural abnormalities in
schizophrenia. Similarly (in the absence of either concurrent alcohol absue or
cerebrovascular disease at least), there was little evidence of smoking being
associated with substantial brain structural abnormalities in the general popualties (see
Section 4.1.3.3). In the single longitudinal study investigating the brain structural
consequences of smoking in schizophrenia, it was reported that smoking could not
explain the brain structural changes observed (see Section 4.3.1.3).
Given the above data the association of smoking with brain structure volume
loss in those at high risk of schizophrenia will not be investigated for any specific
brain regions. It will however be investigated with automated whole brain
methodology, in an exploratory manner.
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9.2 Volumetric analysis
9.2.1 Semi-automated volumetric methodology
This was as described for the baseline analyses (see Section 8.1.2). The same
tracing protocols were employed, and tracing was undertaken by the same operators.
Follow up scans were obtained using the same scanner, scanning protocol and tracing
protocol as the baseline images.
All thalamic nuclei were grouped together, as MRI resolution makes
distinction between the individual thalamic nuclei difficult.641 The intraclass
correlation coefficient between raters was 0.84 for the thalami, 0.82 for the amygdalo-
hippocampal complex, and 0.98 for the prefrontal lobes.
9.2.2 Statistical analysis ofvolumetric data
Statistical testing was conducted with the SPSS 14. Demographic and clinical
variables were compared between high risk subgroups in the two exposure groups for
both cannabis and alcohol, as previously outlined in Section 5.2.2.4 (Tables 5.10, 5.11
and 5.12). These data are reproduced in the tables below together with baseline
volumes both of the whole brain and specific brain regions being compared in the
analyses undertaken for each substance. Volumes were compared between exposure
groups using the independent t-test.
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Mean absolute change in regional volumes was calculated as the mean
difference between the two scans (scan 2 - scan 1), such that a negative value
indicates volume reduction. Rate of change in volume was determined by dividing
this value by the time (in days) between the two scans.
No cannabis use Cannabis use P
N = 32 N = 25
Mean age at first assessment
(SD)
21.11 (2.87) 21.76 (2.52) .38
Gender (male/female) 15:17 15:10 .33 (a)
Handedness (R:L:both) 28:4:0 21:2:2 .24 (a)
IQ (SD) 100.59 100.12 .90
Exceed recommended max 4 7 .18 (b)
alcohol consumption
Smoke tobacco 8 18 <.001 (a)
Use ecstasy 0 9 <.001 (b)
Use amphetamines 0 10 <.001 (b)
Days between assessments (SD) 648.38 (128.06) 679.12 (206.85) .49
Rate of change in whole brain
volume
-13.49 (43.74) -0.27 (68.20) .40
Baseline whole brain volume 1349.13 (127.07) 1362.85 (138.86) .70
(cm3)







Baseline left prefrontal lobe 75.36 74.93 .90
volume (cm3) (13.41) (10.22)
Baseline right AHC volume 4.74 48.54 .52
(cm3) (0.68) (0.97)
Baseline left AHC volume 4.60 4.60 .98
(cm3) (0.52) (0.63)
Baseline right thalamic volume 6.01 (0.77) 6.23 (0.87) .29
(cm3)
Baseline left thalamic volume 6.15 (0.79) 6.29 (0.91) .55
(cm3)
Rust Inventory of Schizotypal
Cognitions baseline score
25.44 (9.94) 27.92(11.70) .39
Table 9.1
Demographic and clinical characteristics of high risk subjects who did and did not
consume cannabis between timepoints 1 and 2.




limits N = 46 limits N = 11
Mean age at first assessment 21.31 21.73 .650
(SD)
Gender (male/female) 5:6 25:21 .596 (a)
Handedness (R:L:both) 39:5:2 10:1:0 .762 (a)
IQ (SD) 101.93 (13.52) 93.91 (11.04) .008
Use cannabis 18:28 7:4 .184 (a)
Smoke tobacco Y:N 17:29 9:2 .007 (a)
Use ecstasy Y:N 6:40 3:8 .354 (b)
Use amphetamines Y:N 7:39 3:8 .387 (b)
Days between assessments (SD) 656.09 (144.05) 686.00 (246.35) .597
Rate of change in whole brain
volume
-10.11 (58.48) 2.42 (42.51) .507
Baseline whole brain volume 1359.62 (125.61) 1336.42 (158.48) .603
(cm3)
Baseline right frontal lobe (cm3) 78.49(12.32) 72.07(10.63) .773
Baseline left frontal lobe 75.91 (12.32) 72.07(10.63) .346
volume (cm3)
Baseline right AHC volume
(cm3)
4.74 (0.68) 4.99 (0.63) .264
Baseline left AHC volume 4.59(0.75) 4.66 (0.55) .712
(cm3)
Rust Inventory of Schizotypal
Cognitions baseline score
24.80(10.12) 33.73 (10.60) .012
Table 9.2
Demographic and clinical characteristics of high risk subjects who do and do not
report hazardous or harmful levels alcohol consumption between timepoints 1 and 2.
P = independent t test, except (a) = chi squared and (b) = Fisher's exact test
9.2.2.1 Longitudinal changes associated with cannabis consumption
Any differential volume change in high risk subjects exposed and not exposed
to cannabis in the interim period was examined for right and left thalami, amygdalo-
hippocampal complexes and frontal lobes separately, using repeated measures
analysis of variance and looking for cannabis exposure x time interactions. Structure
volume at tl and t2 were entered as the dependent variable, gender and exposure
status to cannabis, alcohol, tobacco, ecstasy and amphetamines were included as fixed
factors, and age at first assessment and days between assessments 1 and 2 were
entered as covariates. A small number of subjects had used illicit drugs other than
those listed above. Repeated measures analysis was therefore rerun excluding any
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individuals with a history of use of any substance other than alcohol, cannabis,
tobacco, ecstasy and amphetamines. None of the subjects who did not consume
cannabis between the two timepoints had used either ecstasy or amphetamines,
whereas substantial numbers of cannabis using subjects had used one of these drugs.
Given this imbalance of variables, and the evidence that ecstasy in particular may be
specifically thalamotoxic,642 repeated measures analyses was also run excluding any
subjects who had used either of these two drugs in the inter-scan period.
It was conceivable that any volume change observed to occur in the structures
investigated in association with cannabis consumption was simply part of a more
generalised effect. To ascertain if any volume changes were specific to these
structures, repeated measures analyses was re-run with addition of rate of change of
whole brain volume ([WBV2-WBVl]/time between assessments) included as an
additional covariate.
9.2.2.2 Longitudinal changes associated with alcohol consumption
This employed the same methodology as above, with the exception that only
associations with the prefrontal lobes and AHC were investigated. Thalamic volume
changes were not investigated as it was important to limit the total number of
analyses, and there was no reason to suspect from baseline analyses that alcohol
consumption was associated with thalamic volume abnormalities in this population.
As alcohol consumption was the variable of interest, it was obviously not included as




As can be seen in Table 9.1, at baseline there was no significant difference in
whole brain, thalamic, AHC complex or frontal lobe volumes between people who did
and did not subsequently use cannabis. Additionally, the two groups were reasonably
balanced at baseline in terms of age, gender and scores on the Rust Inventory of
Schizotypal Cognitions.643
The mean raw absolute volume change in the thalami, AHCs and frontal lobes
together with mean rate of volume change ([volume at t2 - volume at tl]/time
between scans) in both the cannabis exposed and non-exposed groups is shown in
Table 8.3. Cannabis exposure x time interactions are also shown, after inclusion of
the covariates detailed in the accompanying text. As can be seen, cannabis exposure is
associated with bilateral thalamic volume loss, this effect being significant on the left
(F = 4.47,p = .04) and highly significant on the right (F = 7.66,p = .008). This effect
was not observed in the frontal lobes or AHC.
Analysis was repeated with the 7 subjects who consumed illicit drugs other
than cannabis, ecstasy or amphetamines in the period of interest excluded; the
cannabis exposure x time interaction remained significant on both the right and left
side. It was also re-run excluding the 14 people who had used either ecstasy or
amphetamine in the period of interest; again the cannabis exposure x time interaction
remained significant bilaterally. Additionally, the primary analysis was also re-run
with the inclusion of rate of change of whole brain volume as an additional covariate.
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Once again, the cannabis exposure x time interaction remained significant on both
sides, the p value increasing marginally (p = .01 on the right side and p = .046 on the
left).
Absolute change Rate of change Exposure x time*
(scan 2 - scan 1) ([scan 2 - scan l|/time)
Mean (SD) Mean (SD)
No cannabis Cannabis No cannabis Cannabis
exposure exposure exposure exposure
(mm3) (mm3) (mm3/day) (mm3/day)
Right frontal 136.36 1947.12 0.13 2.70 F = 0.07, p = .79
lobe (5717.37) (6978.63) (9.63) (10.97)
Left frontal -1284.44 564.15 -1.74 -0.05 F = 0.08, p = .77
lobe (4633.68) (6237.21) (7.42) (11.37)
Right AHC 147.77 175.31 0.18 0.19 F = 0.71,/? = .40
(563.94) (432.19) (0.95) (0.66)
Left AHC -121.37 -4.43 -0.23 -0.03 II © o II kO K>
(488.70) (384.77) (0.81) (0.59)
Right 32.84 (509.35) -264.48 0.06 -0.36 F = 7.66, p = <.01
thalamus (621.70) (0.80) (0.92)
Left thalamus 26.66 (667.58) -181.39 0.07 -0.22 F = 4.47, p = .04
(621.70) (1.00) (1.01)
Table 9.3
Comparison of specific structure volume changes over time in cannabis exposed and
non-exposed high risk individuals.
investigation of exposure x time interaction has been undertaken with inclusion of the following
covariates: gender, age at first assessment, time between scans and use of other substances in inter-scan
period (alcohol exceeding government recommendations, tobacco use, use of ecstasy and use of
amphetamines each being included as separate factors).
9.2.3.2 Alcohol
As can be seen in Table 9.2, at baseline there was no significant difference in
baseline whole brain, thalamic, AHC complex or frontal lobe volumes on comparing
people who did and did not subsequently use cannabis. Additionally, the two groups
were reasonably balanced at baseline in terms of age and gender. The two groups did
differ substantially in scores on the Rust Inventory of Schizotypal Cognitions 643
however, an observation which will be further investigated in Section 9.4.
Those who consumed alcohol in excess of governemt recommended limits
were more likely than those who did not to smoke in the inter-scan period. They were
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however no more likely to use cannabis, amphetamines or cannabis. In addition to the
substances detailed in Table 9.2, two subjects used opiates, two cocaine and six LSD
in the period between scans. The LSD and cocaine using subjects were in the 'within
recommended limits' group, while those who used opiates were in the
hazardous/harmful drinking group.
Rate of change of frontal lobe and AHC volumes between tl and t2 scans were
compared in those whose alcohol consumption exceeded government
recommendations to those whose did not. The covarites included in this anlaysis were
gender, age at first assessment, time between scans and use of other substances in
inter-scan period (cannabis use, tobacco use, use of ecstasy and use of amphetamines
each being included as separate factors) In neither structure and on neither side was
the alcohol exposure x time interaction significant.
9.3.4 Discussion
It is thus the case that the only significant finding to arise from the volumetric
analyses investigating longitudinal changes in association with substance misuse in
the high risk individuals is thalamic volume loss in association with cannabis use.
Such a finding is clearly compatible with the baseline analyses which were discussed
in Section 9.1.2. Notably, baseline volumetric analysis identified third ventricular
enlargement in association with cannabis use, and VBM analysis localised tissue
density reductions associated with use of the drug to the thalamic dorsomedial and
anterior nuclei. The longitudinal findings add substantially to this, confirming that
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thalamic volume loss is a dynamic process, occurring in association with exposure to
cannabis in this vulnerable group.
These longitudinal findings do seem robust, but a number of potential
limitations must be considered. Firstly, given the diffuse boundaries of the thalamus,
it is a structure which is generally accepted as challenging to trace. Despite this
however, inter-rater reliabilities for thalamic volume were acceptable (0.84). The
possibility of 'rater drift' could be proposed to explain the apparent volume loss; it is
the case however that rate of change was compared in two subgroups (i.e. thalami in
the two groups contrasted were both measured at the two timepoints), thus negating
this as a possible explanation for the findings. Equally, the possibility of the cannabis
effect arising due to confounding by use of other substances was addressed by
inclusion of use of other substances as covariates. Indeed, this latter possibility is
further undermined by the fact that the effect was actually robust to the exclusion of
all subjects who had used illicit drugs other than cannabis in the between-scan period.
It is thus the case that there is no obvious explanation for the thalamic volume loss
obsereved other than it being attributable to the effects of cannabis.
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9.3 Tensor-based morphometric analysis
As discussed earlier, in addition to semi-automated ROI techniques, fully
automated VBM was applied to baseline scans of subjects recruited to the EHRS.
Subjects with the highest degree of exposure to alcohol and cannabis were compared
to those with the lowest, and those with a history of tobacco smoking were compared
to non-smokers.
Given the potential advantages of automated techniques (Section 7.2.1), it
would seem optimal to also apply an automated technique to the analysis of the
longitudinal data. Conventional VBM studies have been used in schizophrenia to
study changes over time.644 Concerns have been raised about this approach however,
it being unable to distinguish the effects that are due to imperfect image realignment
from changes in tissue density.6'5 A refinement to VBM is Tensor-Based
Morphometry (TBM), which uses the deformation field created when warping a
subjects' follow-up brain scan to their baseline scan. Unlike VBM, this technique is
able to distinguish intrinsic changes in brain anatomy from translational shifts caused
by imperfect image registration.61" This is essentially the basis of TBM; by
application of a high dimensional warp it corrects for slice misalignment between
timepoints, and thus ensures that the same voxels are being compared in successive
scans from the same subject. This opens up the possibility of applying an automated
image analysis technique more suited to the analysis of longitudinal data than VBM.
As it can be applied to standard, T1 weighted images, it is feasible to employ this
methodology in the analysis of longitudinal data from the EHRS.
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In a manner comparable to VBM, TBM is more sensitive to localised tissue
loss than region of interest techniques. Thus, while diffuse changes may not be
detected by it (but maybe by ROI), for localised tissue loss the converse is true.604'606
As discussed in relation to the ROI analysis, a subset of subjects were
rescanned at time 2. Further scanning points were undertaken, but as the first two
scans used the same scanner, these two scan points are ofparticular interest. The
difficulties posed by a change of scanner would make the application of TBM to
elucidation of longitudinal changes substantially more complicated, if not completely
unfeasible; it would thus be outwith the scope of this study.
When running TBM analyses, similarly to VBM, corrections are made for
multiple comparisons at whole brain level. In the context of TBM it is common
practice to restrict the analysis to regions which have been determined a priori to be
of particular interest. As discussed previously, in relation to VBM analyses, this is
achieved by using the small volume correction function in SPM, significance being
correcting for the voxels included in this restricted analysis rather than the whole
brain. As with the VBM baseline analyses, the regions in which use of a SVC will be
justified in the TBM contrasts will be determined by combination of literature review
and findings from previous analyses in this study. These considerations were
discussed in Section 9.1.2, and the regions for which an SVC will be applied in the
TBM analysis will be the same as those regions investigated with hand-traced ROI
techniques. Thus, thalamic, AHC and frontal lobe SVCs will be applied in the
cannabis analysis, and AHC and frontal lobe SVCs in the alcohol analysis. The case
for employing a thalamic SVC is clearly strengthened by the finding of thalamic




MR image acquisition was as discussed previously. Contrasts made were as
undertaken for the analyses of volumetric data, described above (Section 9.2). As will
be discussed below however, two fewer scans were available for the automated
longitudinal analyses.
9.3.2 Scan preprocessing
We implemented the TBM protocol released for the Statistical Parametric
Mapping (SPM2) application by John Ashburner (http://www.fil.ion.ucl.ac.uk/spm/).
This protocol was implemented by and discussed in Kipps et al.645 and implemented
by Whitford et a/.646 We implemented this staged protocol as described below and in
Moorhead et al. 's 2007 publication.615
1. The SPM brain extract function was used to recover the first- and second-round
native space brains from the participants' T1 scans and the SPM2 default T1-weighted
single subject using raw space segmentations. These extractions were used to exclude
non-brain tissue from the analysis.
2. The SPM coregister function was used to register the first- and second-round
extracted brains with the extracted brain from the SPM single subject, without
rescaling. This provided a coregistration mapping of the brain tissue for each subject
and with alignment along the MNI template anterior-posterior commissure axis. The
mappings to obtain these anterior-posterior commissure axis registrations were then
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applied to the T1 raw images (non-brain-extracted) to obtain coregistered native space
T1 images. The SPM segment function was then used to extract gray matter (GM)
segments for the native space coregistered first- and second-round scans.
3. The SPM deformations toolbox was used to implement a high-dimensional (HD)
warp between the second- and first-round coregistered brains given by step 2. The
resultant warp was then used to implement a HD registration of the second-round GM
segment with the first-round GM segment. This HD warp is used to minimize local
registration differences between the first- and second-round tissue segments. We
subtracted the first-round GM segment from the second-round HD warped GM
segment to give a native space GM difference image. The Jacobian determinants for
the HD warp were then evaluated.
4. In a procedure analogous to modulated-VBM, localized tissue change is recovered
in the form of a GM and WM modulated difference images. In this the Jacobian
determinants from HD deformation between the 1st and 2nd rounds are used to ensure
that the assessments of tissue changes over time are corrected for MRI sampling
noise.
5. To obtain subject-to-subject coregistration, we applied nonlinear warping to
normalize the first-round extracted brain from step 2 with the SPM2 single-subject
T1-extracted brain acquired from step 1. The normalization warp was then applied to
the modulated difference image from step 4. Steps 1-5 were also repeated for white
matter.
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Unfortunatley scans from two subjects could not be successfully preprocessed for the
TBM analysis. This was the reason why the total number of subjects available for the
automated longitudinal analyses was 55 rather than 57. Both of these individuals were
in the cannabis consuming group.
9.3.3 Statistical analysis
9.3.3.1 Statistical design for cannabis contrast
As the two subjects whose scans could not be successfully preprocessed for
the TBM analysis were both in the cannabis using group, in the automated analyses
23 subjects who consumed cannabis between scan points were contrasted against 32
who did not. Demographic and relevant clinical details of these two groups are
compared in Table 9.4.
Differences in the modulated difference images (from step 5) between high
risk subjects who did and did not consume cannabis between timepoints 1 and 2 were
compared in SPM5 using the general linear model. A grey matter mask was included.
Age, interscan interval, sex, and use of alcohol, cigarettes, ecstasy and amphetamines
were included in the model as covariates. As these were not exploratory analyses, but
guided by findings from earlier analyses, I did not feel that running the analysis
without the inclusion of appropriate covariates was justified. T-contrasts were
thresholded at T = 0.0001 (uncorrected). Whole brain analysis was supplemented with
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a small volume correction for the thalamus, frotal lobes and amygdala and
hippocampus combined (the AHC). These SVCs were the same as those used in the
baseline VBM analysis (see Section 8.2.4). As was the case with the VBM analyses,
the TBM whole brain and SVC analyses were implemented in MNI space. Again as
before, the voxel co-ordinates of the results are extracted from MNI standard space
f\~) 1
and I also report the Talairach co-ordinates using the Matlab function mni2tal. The
anatomic location of significant results was manually checked using the Talairach
atlas,614 supplemented by use of Tailarach Daemon
(http://ric.uthscsa.edu/projects/talairachdaemon.html).
Two additional steps were taken to confirm that results were genuine and
exclude possibilities such as that, for example, they were due to the presence of an
artefact. Firstly, statistical parametric maps were superimposed on scans from the
study to ensure that regions of maximal difference were indeed arising in
anatomically feasible locations. Additionally, the identical analysis was run on
expansion images to investigate volume gain in association with cannabis
consumption. This would only be expected to be seen in the presence of an artefact.
9.3.3.2 Statistical design for alcohol contrast
This was undertaken as for the cannabis analysis, but with the 11
hazardous/dependent drinkers contrasted against the 44 who did not exceed
government recommendations. Demographic and relevant clinical details of these two
groups are compared in Table 9.5. Obviously alcohol consumption was not included
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as a covariate, with use of cannabis in the inter-scan period being substituted instead.
The alcohol analyses did not include a thalamic SVC, but did include frontal lobe and
AHC SVCs. As in the cannabis analysis, (as a safeguard against any possibility that
results arose from artefacts), in the event of any positive findings the same analysis
was run on the expanded images.
9.3.4 Results
9.3.4.1 Cannabis
Demographic and relevant clinical details for the 55 subjects included in the
TBM analysis are detailed in Table 9.4. Participants who used and did not use
cannabis between the scan points did not differ significantly in terms of gender, age at
time of initial scan, rating on the RISC at scan timepoint 1, or the proportion who
exceeding government recommended maximum weekly alcohol consumption
between scanning points. Significantly more of the cannabis using group did however
smoke cigarettes and consume ecstasy and amphetamines in the inter-scan period. All
the aforementioned variables, including those not significantly different between the
groups, were included as covariates in the TBM analysis.
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No cannabis between Consumed cannabis P
scans between scans
<NIIZ N = 23
Gender M:F 15:17 15:8 .18
Age at tl (SD) 21.1 (2.9) 21.8(2.6) .34
IQ (SD) 100.59 (14.73) 100.09(12.10) .89
Days between scans
(SD)
648.4 (128.1) 679.6 (214.9) .50
RISC at tl (SD) 25.4 (9.9) 27.9(11.4) .40
Cigarette smoker Y:N 6 17 <.01
Excessive alcohol Y:N 4 7 .10(a)
Ecstasy 0 9 <.01 (a)
Amphetamines 0 9 <.01
Table 9.4
Comparison of demographic details and other substance use in inter-scan period in
those who did and did not consume cannabis between timepoints 1 and 2.
The t test was used for comparison of age, RISC and time lapse between scans. For all other
comparisons chi squared was used, aside from (a) which used Fischer's exact test.
The initial analysis, conducted at whole brain level, compared grey matter loss
in cannabis consumers versus non-consumers between timepoints 1 and 2. Though
they did not reach statistical significance at the level of whole brain analysis, three
regions of prominent grey matter loss were observed in the former compared to latter
group. These were located left prefrontal lobe, left caudate and right anterior
hippocampus. The caudate was not part of our initial hypothesis, and thus this area of
grey matter loss was not investigated any further. The analysis was however rerun
with the inclusion of both amygdala-hippocampal and frontal lobe SVCs.
Using the bilateral amygdala-hippocampal complex SVC, greater GM tissue
loss was found in the cannabis using group compared to the cannabis non-using
group. The group differences in tissue change over time were estimated using t-
contrasts; the df in these contrasts was 46. A single significant maximal voxel location
at ^corrected = .029 (t contrast value = 3.88) was found at MNI coordinate [-35, -
8.0, -24], This was converted into Tailarach coordinates, detailed in Table 8.5, and is






Point of maximal change
.029 -34.7 -8.8 -20.6 Right anterior hippocampus
Table 9.5
Maximum voxel results for contrast of cannabis consumers versus cannabis non-
consumers between timel and time2. The amygdala-hippocampal complex SVC has
been applied.
Figure 9.1
SPM superimposed on a 'glass brain' showing voxels of reduced density in those
exposed to cannabis in the interim period when compared to those not exposed (left).
SPM overlay on a structural image demonstrating the region of density loss in the
right anterior hippocampus (right).
When a bilateral frontal lobe SVC was applied, greater GM tissue loss was
again found in the cannabis using group compared to the cannabis non-using group.
As before, the group differences in tissue change over time were estimated using t-
contrasts, the df in these contrasts being 46. A single significant maximal voxel
location at ^corrected = .026 (t contrast value = 4.68) was found at MNI coordinate
[-18.0, 55.0, 42], This was again converted into Talairach coordinates (detailed in







Point of maximal change
.026 -17.8 55.2 35.9 Left superior frontal gyrus
Table 9.6
Maximum voxel results for contrast of cannabis consumers versus cannabis non-
consumers between timel and time2. The frontal lobe SVC has been applied.








SPM superimposed on a 'glass brain' showing voxels of reduced density in those
exposed to cannabis in the interim period when compared to those not exposed (left).
SPM overlay on a structural image demonstrating the region of density loss in the left
superior frontal gyrus (right).
It is notable that none of the subjects who did not consume cannabis in the inter-scan
period consumed ecstasy or amphetamine, while substantial numbers of the cannabis
consuming subjects did. This raises concerns that structural abnormalities associated
with use of these substances could potentially confound the results outlined above.
This emphasises the importance of having included these variables as covariates.
Additionally however, given that this imbalance of variables was so marked across
the comparator groups, I felt it important to take further steps to confirm that this
imbalance was not resulting in a spurious finding. I thus repeated the above analyses
excluding the 11 subjects who consumed either amphetamine, ecstasy or both drugs in
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the inter-scan period. The analysis included all the other covariates in the previous
analyses.
On repeating this analysis an area of significantly greater grey matter loss was
again seen in the region of the anterior hippocampus. This was again statistically
significant on applying an amygdala-hippocampal SVC (P_corrected = .039, t
contrast value = 3.90, Talairach coordinates 31.7, -10.7, -19.7). The region of grey
matter loss observed in the left prefrontal lobe did not remain significant after
removal of these subjects. Given the persistence of the hippocampal result however,
this seems most likely to be due to loss of power rather than the initial finding being
spurious.
9.3.4.2 Alcohol
Demographic and relevant clinical details for the 55 subjects included in the
TBM analysis are detailed in Table 9.7. Participants who did and did not exceed
government alcohol recommendations did not differ significantly in terms of gender,
age at time of initial scan, or level of use of the illicit drugs of interest. They did
however differ on levels of tobacco use and, as was previously noted in the
volumetric analyses, rating on the Rust Inventory of Schizotypal Cognitions (RISC).
As before, all the aforementioned variables, including those not significantly different
between the groups, were included as covariates in the TBM analysis.
The initial analysis, conducted at whole brain level, compared grey matter loss
in the 11 subjects whose alcohol consumption exceeded government
recommendations in the inter-scan period again those whose consumption did not. A
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region of increased grey matter loss was identified at MNI coordinate [1, -52, -4], but
this fell far short of significance [^corrected = .812 (t contrast value = 3.82)]. This
was located in the anterior lobe of the right cerebellum. On rerunning the analysis
with the frontal lobe and AHC SVCs no significant regions of density loss were
identified.
Did not exceed Did exceed P
recommendations recommendations
between scans between scans
N = 44 n= 11
Gender M:F 25:19 5:6 .498
Age at tl (SD) 21.33 (2.79) 21.72 (2.73) .676
IQ (SD) 102.00(13.77) 93.91 (11.04) .077
Days between scans 655.27(146.41) 686.00 (246.35) .594
(SD)
RISC at tl (SD) 24.64 (9.83) 33.73 (10.60) .009
Cigarette smoker Y:N 16:28 9:2 .007
Cannabis Y:N 16:28 7:4 .170 (a)
Ecstasy 6:38 3:8 .362 (a)
Amphetamines 6:38 3:8 .362 (a)
Table 9.7
Comparison of demographic details and other substance use in inter-scan period in
those who did and did not consume alcohol at levels exceeding government
reccomendations between timepoints 1 and 2.
The t test was used for comparison of age, RISC and time lapse between scans. For all other
comparisons chi squared was used, aside from (a) which used Fischer's exact test.
9.3.4.3 Tobacco
This was undertaken as for the above analyses, but with the 25 subjects who
smoked between scans contrasted against the 30 who did not. Levels of use of other
substances were included as covariates. Given the lack of evidence for effects in any
specific brain regions, only an AHC SVC was included. As in the other analyses,
(with the aim of guarding against any possibility that results arose from artefacts), in
the event of any positive findings the same analysis was run on the expanded images.
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Non-smoker between Smoker between P
scans scans
N = 30 n = 25
Gender M:F 16:14 14:11 .843
Age at tl (SD) 21.53 21.27 .735
IQ (SD) 101.23 (15.34) 99.36(11.32) .61
Days between scans 659.97 663.16 .945
(SD)
RISC at tl (SD) 23.27 30.28 .013
Excess alcohol Y:N 2:28 9:16 .015
Cannabis Y:N 6:24 17:8 <.001
Ecstasy Y:N 1:29 8:17 .008 (a)
Amphetamines Y:N 2:28 7:18 .064 (a)
Table 9.8
Comparison of demographic details and other substance use in inter-scan period in
those who did and did not smoke between timepoints 1 and 2.
The t test was used for comparison of age, RISC and time lapse between scans. For all other
comparisons chi squared was used, aside froma which used Fischer's exact test.
The initial analysis, conducted at whole brain level, compared grey matter loss
in the 30 subjects who did not smoke in the inter-scan period against the 25 who did.
A region of increased grey matter loss was identified at MNI coordinate [-41, 23, 49],
but this fell far short of significance [^corrected = .868 (t contrast value = 3.74)].
This was located in the left middle frontal gyrus. On rerunning the comparison with
the AHC SVC no significant regions of density loss were identified. Though not a
planned contrast, given the location of the identified region of grey matter density
loss, the comparison was also repeated with the frontal lobe SVC; it remained non¬
significant even after application of this SVC.
9.3.5 Discussion
As was the case with the volumetric analysis, the automated approach did not
identify any areas of significant structural change associated with alcohol use by the
high risk subjects. Similarly, there was no evidence of significant structural change in
association with smoking. By contrast however, significant areas of tissue loss were
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identified in the right anterior hippocampus and left superior frontal gyrus in
association with cannabis use. As discussed in Section 9.1.2.1, both structures exhibit
a high density of CB1 receptors; they are thus structures which, if a cannabis/risk
interaction was to occur anywhere in the brain of this group of high risk individuals,
would be regarded as a definite candidate regions in which to observe such an effect.
The case for the hippocampus is particularly strong in this regard, there being
previous evidence of this structure being vulnerable to the effects of cannabis in
people with schizophrenia.
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9.4 RISC rating as a predictor of substance use
As discussed in Section 6.2.3 and above, a higher RISC rating at point of entry
in to the study was associated with greater use of both tobacco and alcohol between
scan points 1 and 2. This was despite RISC rating not being significantly different on
comparing groups with different historic levels of exposure to alcohol and tobacco at
entry in to the study (see Table 6.6). As discussed in Section 6.2.3, to ascertain if
RISC rating independently predicted use of either or indeed both drugs, a logistic
regression analysis was planned.
Logistic regression was first undertaken in separate analyses to establish if
RISC rating predicted use of alcohol or tobacco. In the alcohol analysis level of use of
alcohol between scanning points (either exceeded or did not exceed government
recommendations) was entered as the categorical outcome variable. Age and gender
were included as covariates. This was repeated for the tobacco analysis, with whether
or not the person was a smoker at the second assessment replacing alcohol use as the
categorical outcome variable. Results are shown in Table 9.8.
Dependent
variable
Significance of RISC as a predictor of substance use
B (SE) Wald P Exp(B) (CI)
Alcohol 0.094 (0.041) 5.256 .022 1.10(1.01-1.19)
Tobacco 0.077 (0.030) 6.839 .009 1.08 (1.02-1.15)
Table 9.9
RISC rating as a predictor of alcohol and tobacco use between scan points
When both alcohol and tobacco use were simultaneously entered in to the analysis,
only tobacco use emerged as significantly predicted by RISC rating (Wald statistic
3.49, P = .040). These results were unaltered by the inclusion of IQ as an additional
covariate.
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On the basis of the above it does thus seem that, in a population at genetically
increased risk of developing schizophrenia at least, a greater weight of schizotypal
symptoms is associated with an increased tendency to either continue or begin using
tobacco. It may also be associated with an increased tendency to use alcohol, though
some of this association may be explained by the overlap between tobacco and
alcohol use.
These findings are particularly interesting when considered with the baseline
data investigating the association between historic levels of substance use and rating
on the RISC. Though RISC ratings were higher in cannabis consumers in this baseline
data, excessive alcohol consumption and smoking were not associated with higher
RISC ratings. This dichotomy may have implications for understanding the
association between schizophrenia and smoking, but first I must explore the actual
changes in substance use which brought it about.
The fact that higher RISC ratings are associated with subsequent but not
current excessive alcohol use and tobacco smoking clearly implies that the prevalence
of these behaviours changes over time in the subset of high risk subjects for whom
longitudinal data are available. Specifically, those high risk subjects with higher RISC
ratings are either less likely to cease the activities of excessive drinking and smoking
tobacco and/or are more likely to take up these behaviours. Conversely, people with
higher RISC ratings at baseline do not seem more likely to consume cannabis in the
follow-up period. The extent of these behavioural changes, and how they relate to
RISC ratings are detailed in Table 9.9.
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Substance Subjects commencing











Alcohol 4 34.3 (3.2) 10 26.1 (10.3) .154
Tobacco 4 23.8(7.1) 4 18.5 (10.0) .425
Table 9.10
Comparison of baseline RISC ratings in those who do and do not commence
substance use between scans.
Comparisons are made using the independent t-test.
As can be seen from the table, it is only in relatively few cases that a subject's
substance using behaviour between the scan points differs from their pattern of use up
to the point of inclusion in to the study. This makes the comparisons of RISC ratings
in the starting/stopping use groups very low powered, a fact that likely explains the
fact that the RISC rating comparisons detailed above are not significant. These data
do however suggest that, in the case ofboth smoking and excessive alcohol
consumption, higher RISC ratings are indeed associated with subsequent use of these
substances, and lower ratings with cessation of use. It does thus seem to be the case
that a change in substance use patterns between scan points does indeed contribute to
higher RISC ratings at baseline being associated with subsequent use of tobacco and,
(though the relationship seems weaker), with excessive use of alcohol. This would
seem to provide evidence that the experience of psychotic-type symptoms may
predispose to use of these substances, this association being particularly strong for
tobacco. This suggests that self-medication is indeed a relevant consideration in
explaining the association between tobacco smoking and schizophrenia; it can also
not be discounted as contributing to the association between alcohol use and
schizophrneia.
379
9.5 Substance misuse at point of entry in to the study and the subsequent
development of schizophrenia
The analyses outlined above investigate the association between the
experience of psychotic-type symptoms and subsequent substance use. Given the
nature of the current study however, it is of course also important to explore if a
history of drug use is associated with the subsequent development of schizophrenia.
Outcome (i.e. whether or not an individual developed schizophrenia during the
course of the study), is known for all high risk subjects recruited. Additionally, level
of use of various substances up to the point of recruitment is known for the vast
majority of partipants; specifically, cannabis history is known for 145 individuals,
alcohol history for 143, and tobacco use for 137. A total of 19 of the subjects for
whom these data are available developed schizophrenia during the duration of the
study. By contrast, none of the control subjects developed schizophrenia. As
described in Section 6.3, availability of these data means that the association between
a history of use of each of these substances and the subsequent development of
schizophrenia can be explored. The contrasts chosen were previously discussed in
Section 6.3.
Results of these contrasts are detailed in Table 8.10. When the proportion of
high risk subjects with a history of cannabis exposure greater than isolated use were
compared to those whose use history was below this cut off, the former individuals
had an elevated rate of developing schizophrenia (P = .029, OR 3.18; 95% CI 1.08-
9.36). A similar result was obtained when subjects with a history of alcohol
dependence were compared to all individuals with lesser histories of use. Again, those
with a history of heavy use of the substance were at elevated risk of developing
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schizophrenia {P = .017, OR = 6.35; 95% CI 1.53-26.26). In contrast, when smokers
were compared to non-smokers, the rate of development of schizophrenia was not




Levels of use being contrasted Develop
schizophrenia
N (% of subjects with
that level of use)
Chi squared test
Yes No
Cannabis Nil/isolated 5 (6.9) 67 (93.1) X2(1,7V=115)= 4.76
p = .029Occasional/frequently/most days 14(19.2) 59 (80.8)
Alcohol Non-dependent use 15 (11.2) 119(88.8) X2(l ,N = 143)= 5.74a
p = .017Dependent 4 (44.4) 5 (55.6)
Table 9.11
Comparison of proportion of subjects developing schizophrenia at different levels of
exposure to cannabis and alcohol.






The main findings from the image analysis sections are summarised in Tabe
10.1 below. On considering the totality of the imaging data in this study, there is
support for the contention that certain brain structural abnormalities are associated
with the use of specific substances by people at genetically high risk of schizophrenia.
It must be acknowledged however that some findings do initially present as
contradictory. Themes and contradictions that emerge from the synthesis of these
findings will be discussed below. Where there do seem to be inconsistencies, potential
explanations for these will be postulated. This will be followed by integration of these
findings into the wider literature base, and consideration of what they may tell us




Main findings in high risk individuals
Baseline ROI Dose response relationship between levels of alcohol use and (increased)
volume of lateral ventricles and (decreased) volume of frontal lobes. Heavy
alcohol use emerges from regression analysis as a significant predictor of
(increased) lateral ventricular volumes and (decreased) left frontal lobe
volume.
Dose response relationship between level of cannabis use and (increased)
third ventricular volume and frequent cannabis use emerges from regression
analysis as a significant predictor of (increased) third ventricular volume.
Voxel-based Cannabis use associated with reduced grey matter density in the left anterior
and dorsomedial thalamus and left hypothalamus
Longitudinal ROI Cannabis use in the inter-scan period associated with bilateral thalamic
volume loss
Voxel-based Cannabis use in the inter-scan period associated with grey matter loss in the
right anterior hippocampus and left superior frontal gyrus
Table 10.1.
Summary of findings from image-analysis section.
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10.1.1 Cannabis use is associated with thalamic volume loss
This is strongly supported by baseline findings. Specifically, a dose response
relationship exists between level of cannabis use and third ventricular volume, and
regions of tissue loss are identified in association with a history of significant
cannabis consumption in the anterior and mediodorsal thalamic nuclei by VBM (see
Sections 8.1.3 and 8.2.8.1). Furthermore, longitudinal ROI methodology demonstrates
progressive thalamic volume loss in association with ongoing cannabis consumption
(see Section 9.3.4.1). It is the case however that volumetric analysis does not identify
reduced thalamic volume on the baseline analysis, and TBM does not identify regions
of thalamic grey matter loss over time in association with cannabis use (see Sections
8.1.3 and 9.3.4.1).
As discussed in Section 7.2.1 the sensitivities of the semi-automated
volumetric and automated techniques do differ; the former methodology has greater
sensitivity for the detection of diffuse change, while the latter is more likely to detect
localised abnormalities. Given these considerations it is not entirely surprising that
findings of the two approaches do not exactly tally, the differing sensitivities of the
two techniques conceivably going some way to explaining the apparent
inconsistencies seen. It may be, for example, that cannabis use by a high risk
population at a younger age is associated with effects localised to the anterior and
mediodorsal thalamic nuclei; such localised change will be apparent at the time of the
baseline scans, and is most likely to be detected by VBM. Conversely, cannabis use in
older high risk individuals may be associated with more diffuse effects; this effect
would occur between scans 1 and 2 and would be more likely to be detected by a
volumetric rather than voxel-based approach. Hence, a combination of cannabis
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having subtly different effects on thalamic structure at different stages of development
and the different sensitivities of volumetric and voxel-based approaches offers a
viable explanation for the findings obtained.
10.1.2 Cannabis use is associated with right anterior hippocampus and left superior
frontal gyrus grey matter loss
Both of these effects were seen only on the longitudinal TBM analysis (see
Secion 9.3.4.1). It is the case however that a region of grey matter loss which
approached significance was also seen in association with a history of substantial
cannabis use in the baseline VBM analysis (in the right medial prefrontal gyrus, see
Section 8.2.8.1). As discussed above, the sensitivity of the automated image analysis
methodologies is greater for localised abnormalities. The fact that frontal lobe deficits
are observed only with these methodologies (and not volumetric approaches) could
thus be explained by the frontal lobe abnormalities that occur in association with
cannabis use being very localised. Given that the frontal lobes are relatively large
structures, this will constitute only a small percentage of total volume, and thus the
volume loss would be expected to be within the bounds of the measurement error
inherent in semi-automated hand-tracing techniques. It would thus be missed by
volumetric approaches, even if detected by voxel-based techniques.
A similar explanation may of course be relevant when considering that
longitudinal anterior hippocampal grey matter loss was seen in association with
cannabis use with TBM but not volumetry (see Sections 9.3.4.1 and 8.2.8.1). In
explaining why such an effect was not seen in the baseline VBM analysis however,
386
the influence of age may once again be important. That hippocampal volume loss
precedes transition to schizophrenia is one of the most robustly supported dynamic
changes believed to occur in those destined to develop the condition (see Sections
4.2.3 and 9.1.2.1). It may be that the period between scans 1 and 2 captured the
window in which individuals are vulnerable to cannabis exposure influencing these
changes, whereas the majority of those assessed in the baseline analyses had not yet
passed through this risk period; consequently the effect is only observed on the
longitudinal analyses.
10.1.3 Substantial alcohol use is associated with lateral ventricle enlargement and
frontal lobe volume loss
The effects of alcohol on brain structure in high risk individuals were only
apparent in the baseline volumetric analyses. They were however very marked. A
strong dose response relationship was apparent bilaterally relating historic alcohol
consumption to lateral ventricular enlargement and frontal lobe volume loss;
additionally, volumes of both the lateral ventricles and the left frontal lobe emerging
from the regression analysis as predicted by a history of heavy alcohol use.
As discussed in Section 4.1.3.2 brain structural abnormalities associated with
alcohol use would be expected to be diffuse. As discussed above and in Sections 7.2.1
and 8.3.2 this would make them difficult to detect as significant findings using voxel-
based approaches; thus a tenable explanation as to why comparable effects were not
detected with VBM and TBM is provided.
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On considering why effects of alcohol were not observed on volumetric
analysis of longitudinal data, age may again be important. It is conceivable that the
effects of alcohol on brain structure in those at high risk of schizophrenia are most
apparent at earlier ages; hence, they would be detected on the baseline but not
longitudinal analysis. It is the case however, that in contrast to the findings with
cannabis, there were no significant longitudinal brain structural changes observed in
association with heavy alcohol use. Given that only 11 subjects on whom longitudinal
data were available drank at levels exceeding government recommendation this may
of course be explained by a lack ofpower; other potential implications for this finding
will however be discussed further below.
10.2 Implications of these findings for our understanding of the relationship
between drug use and schizophrenia
These are the first findings to demonstrate that within a population at high risk
of schizophrenia for familial reasons, but clinically well, those who abuse alcohol
and/or cannabis have structural imaging findings distinguishing them from those who
do not. In contrast, use of these substances by people not at elevated risk of
schizophrenia was not associated with comparable imaging findings. Furthermore,
within the high risk group both alcohol dependence and regular cannabis use were
associated with the subsequent development of schizophrenia (see Section 9.5). We
believe that the most likely explanation for these findings is that people at high risk of
schizophrenia are more vulnerable to the effects of these substances on the brain, and
that these brain structural consequences influence subsequent risk of schizophrenia.
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This, together with alternative explanations for the findings of this study will be
considered below. In examining these possibilities different substances of abuse will
be considered separately; this is essential as it is of course the case that the nature of
the relationship between drug use and schizophrenia may differ for different
substances.
10.2.1 The relationship between structural imaging abnormalities and substance
use is driven by selfmedication
The self-medication hypothesis was discussed in Section 3.2.1. On reviewing
these data it was clear that the hypothesis that people with schizophrenia use
substances to relieve psychotic symptoms had negligible support. Nonetheless, it was
conceivable that some features of the broader syndrome could be transiently relieved
by specific substances; specifically stimulants and tobacco may alleviate cognitive
deficits, and alcohol may elevate mood and relieve anxiety. For self-medication to be
a feasible explanation for the current findings, it would require that those with greater
structural abnormalities were more unwell and consumed more substances. This
possibility will be explored for those two substances to which the majority of findings
from this study relate; specifically cannabis and alcohol. In undertaking this
discussion it is important to emphasise that the high risk individuals who took part in
this study were all well at the time of assessment/s, none actually having
schizophrenia. It is the case however that some individuals did experience subclinical
psychotic-type symptoms, the tendency towards this being encapsulated by scores on
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the RISC. As higher scores on the RISC would be expected to represent a greater need
for self medication, consideration of the relationship between RISC scores and
subsequent substance use will be useful in exploring the feasibility of the self-
medication hypothesis in this population.
Cannabis
As discussed in Section 3.2.2.1.1, evidence for self medication driving the
relationship between cannabis and either schizophrenia or the extended phenotype of
the condition is particularly weak. This is further supported by the present study.
Specifically, if self-medication was a viable explanation for the association, then
those with a greater weight of subsyndromal psychopathology at the baseline
assessment would be expected to be more likely to use cannabis in the subsequent
follow up period. As can be seen from Section 9.4 however, such as association is not
seen; those with higher RISC scores at baseline are in fact no more likely to
subsequently use cannabis than those with lower scores on this measure. Also relevant
to this discussion is a previous analysis of this sample, which has demonstrated that
partial or transient psychotic symptoms were not related to the brain structural
abnormalities.491 Those with greater partial or transient psychotic symptoms at
baseline do not have more pronounced brain structural abnormalities, and thus self
medication is clearly not a tenable explanation for the associations seen in this study.
Alcohol
The finding that partial or transient psychotic symptoms were not related to
brain structural abnormalities is equally relevant when considering the alcohol results.
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Clearly this finding also undermines any suggestion that the structural abnormalities
that were associated with alcohol use in the baseline analyses are explicable by self
medication. It is the case however that the suggestion that some of the association
between alcohol use and schizophrenia is mediated by self medication is more
credible than is the case for cannabis. Firstly, as outlined in Section 3.2.1.2, though
alcohol use may also worsen psychotic symptoms it may genuinely provide transient
relief from anxiety and dysphoria. Furthermore, (though admittedly the association
was rendered non-significant on controlling for tobacco use), high RISC scores at
baseline were associated with subsequent heavy use of alcohol by the high risk
subjects. This provides prospective support for the supposition that those with a
greater weight of subsyndromal psycopathology are indeed more likely to use alcohol
to excess. Thus, though it clearly has limited utility in explaining the structural
associations observed in this study, that self medication mediates some of the
association between schizophrenia and alcohol use cannot be completely dismissed.
10.2.2 Brain structural abnormalities predispose to substance misuse
A potential explanation for the observed association between brain structural
abnormalities and substance misuse is that, independent of any associations with
schizophrenia, these abnormalities predispose to alcohol and cannabis use. The
compatibility of this explanation with Chambers' theory that cortical and hippocampal
dysfunctions in schizophrenia are responsible for the greater reinforcing properties of
drugs of misuse (and hence development of drug problems) in this population is
evident (see Section 3.2.3.1).
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Cannabis
As demonstrated in Chapter9, it is the case that cannabis use is associated with
progressive grey matter loss in several brain regions in people at high genetic risk of
schizophrenia. Given the progressive nature of these strutural abnormalities it is
clearly the case that their association with cannabis use is not explicable by such
abnormalities simply predisposing to use of the drug.
Alcohol
When data from this study are considered alone, the above possibility is
however difficult to refute in relation to alcohol use; specifically, though baseline
associations between alcohol use and structural abnormalities were robust, significant
progressive changes attributable to the drug were not demonstrated in the longitudinal
analyses (see Chapter 9). Potential explanations for the absence of such findings are
discussed in Section 10.1.3. It is the case however that previous longitudinal studies
have demonstrated the progressive nature ofbrain structural abnormalities with
ongoing alcohol use (see Section 4.1.3.2.1). Additionally, data that pre-existing brain
structural abnormalities predispose to alcohol use are not very convincing (see
Section 4.1.1) Thus, though the possibility that structural abnormalities predispose to
alcohol misuse cannot be discounted on the basis of the data presented in this study
alone, this is clearly not the whole story; the evidence is strong that (in a high risk
population such as this at least), both alcohol and cannabis use do impact on brain
structure.
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10.2.3 The observedfindings are an expected consequence ofsubstance misuse
This hinges on the structural abnormalities observed being a "normal"
consequence of the reported levels of drug use. Two sources of information are
relevant in ascertaining if this is the case. The first and most direct of these are the
comparisons made between the brain structural associations of substance use observed
in the high risk populations and those observed in the controls. As discussed in
Section 8.1.3.2, there was no suggestion that associations comparable to those
observed in the high risk group were present in controls even at trend level. It could
be argued that is potentially attributable to the small size of the control group. It is the
case however that Fischer Z test (which accounts for the relative size of each group)
demonstrated a significant difference between high-risk and control subjects in the
effect of alcohol on the right prefrontal lobe and cannabis on the third ventricle.
The second important source of information in assessing if the effects
observed are a 'normal' consequence of drug use are studies investigating the brain
structural consequences of such behaviours in individuals without (and not at
particularly elevated risk of) mental illness. This will now be considered for both
alcohol and cannabis.
Cannabis
The brain structural abnormalities associated with heavy cannabis use were
reviewed in Section 4.1.3.1. As was apparent from this and previous reviews, in the
normal population there is no consistent evidence ofbrain structural abnormalities
being associated with cannabis use. It is thus clear that the structural abnormalities
observed in association with cannabis sue in this study are not a 'normal'
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consequence of this exposure.
Alcohol
The brain structural abnormalities identified in chronic alcoholics were
reviewed in Section 4.1.3.2, the extent of these abnormalities in individuals under 40
being the subject of a systematic review. Though abnormalities where identified in
some of these studies, these were subtle, inconsistent, and certainly not of the
magnitude identified in the present study. If present they were most commonly
localized to the frontal cortex and hippocampi. In all of these studies individuals
included had diagnoses of alcohol abuse or dependence, and all of the non-adolescent
subjects were recruited from treatment groups. Reflecting the more pronounced
drinking histories of the individuals in these studies, when quantified (e.g. Fein et al,
TTO TOI
Pfefferbaum et al ' ) lifetime alcohol intake was greatly in excess of even the
heaviest drinking high risk subjects. It does thus seem to be the case that although
subtle structural changes, possibly including a degree of frontal lobe volume loss, may
be observable in "uncomplicated" alcoholism in this age range, the gross structural
abnormalities we observed would not be expected in a healthy population.
10.2.4 People at elevatedfamilial risk ofschizophrenia are particularly vulnerable to
the structural imaging consequences ofsubstance use
As discussed above, the brain structural abnormalities observed in this
population in association with use of alcohol and cannabis, (and indeed amphetamine
and ecstasy), are all of greater magnitude than would be expected in healthy
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individuals with a comparable level of exposure. This is in keeping with previous
evidence that brain volume loss is more pronounced in individuals with established
schizophrenia who use either cannabis or alcohol, (reviewed in Sections 4.3.1.1 and
4.3.1.2 respectively), findings which suggested that individuals with schizophrenia
have a particular sensitivity to brain volume loss on exposure to these substances. The
current study builds on this work, being the first to provide structural imaging
evidence that such a process may occur in a population at high risk of schizophrenia
but currently clinically well. This provides biologically plausible evidence of how use
of these substances may be contributing to the aetiology of schizophrenia and clearly
underlines the potential hazards of a high-risk population using them.
Cannabis
That people at high risk of schizophrenia for familial reasons are particularly
vulnerable to the brain structural consequences of cannabis use is a particularly robust
finding of this study. As well as a dose response relationship between cannabis use
and structural brain abnormalities being demonstrated in baseline data, (which is not
present in controls), longitudinal data provide evidence of progressive changes in
association with use of the drug. The findings presented in this report thus
demonstrate for the first time the structural brain changes that occur when people
vulnerable to schizophrenia use this drug. This has important implicatios for the
ongoing debate as to whether or not cannabis use can increase the risk of an
individual subsequently developing schizophrenia. For the first time evidence is
provided of cannabis having effects on brain structure which are specific to those at
high risk of the condition. When this is combined with data from cohort studies
implicating cannabis as a risk factor for schizophrenia (reviewed in Section 3.2.2.1.1),
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the case for cannabis use playing a role in the aetiology of the psychosis seems
remarkably robust. The current findings have implications which go beyond this
however. By identifying the brain regions in which cannabis potentiates the
development ofbrain structural abnormalities, the data presented in this report yield
insights in to how cannabis mediates its risk modifying effects. Specifically, it seems
that cannabis use by this population promotes grey matter loss in the thalami, anterior
hippocampus and regions of the frontal lobes. As reviewed in Section 4.2, these are
precisely those regions in which changes are believed to occur during the transition
from at risk state to psychosis.
Alcohol
In contrast to the data relating to cannabis, only cross-sectional findings
confirmed an association in those at high risk of schizophrenia between brain
structural abnormalities and heavy use of alcohol. Consequently inferences about
direction of causality do remain speculative. Nonetheless, and as discussed above, it is
the case that the most likely explanation for these associations is that, in a manner
comparable to the effects of cannabis, those at elevated risk of schizophrenia are
particularly susceptible the brain structural consequences of alcohol use. When taken
together with the markedly elevated rate of schizophrenia in subjects with a history of
alcohol dependence, this does raise the rather controversial possibility that alcohol
consumption could itself be interacting with vulnerability factors for schizophrenia to
increase some individuals' risk of developing the condition. As discussed in Section
3.2.2.1.2, a role for alcohol in the development of schizophrenia can be
conceptualized within the framework of the stress vulnerability theory of
schizophrenia. The findings outlined in this report thus raise the intriguing possibility
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that not only cannabis, but also alcohol may, in a vulnerable population at least,
contribute to the aetiology of schizophrenia. Though the structural abnormalities
associated with alcohol do seem rather more diffuse than is the case with cannabis,
the available evidence does suggest that effects on the frontal lobes may be
particularly important (see Section 8.1.3.1).
10.3 Limitations
Though the findings detailed above do seem robust, a number of limitations
must nonetheless be acknowledged. Firstly, it is the case that ascertainment of drug
use did rely entirely on self report. Though this may be regarded as some as a
weakness, it is our opinion that the nature of the exposures that were ascertained
means that drug testing would in fact have added little to the study. Additionally, and
as discussed in Section 6.4.2, self report has been shown to be a reliable measure of
drug use in the research context. A more important limitation is the small number of
controls available for the baseline analyses, and absence of a normal control
comparator group in the longitudinal analyses. It is notable however that despite the
relatively small numbers of controls, a significant difference in the effect of both
cannabis and alcohol on high risk and control subjects was nonetheless demonstrated
in the baseline analyses (see Section 8.1.3.2). It is my belief that the weakness of not
having a control group available for the longitudinal analyses is substantially obviated
by the comprehensive review ofbrain structural imaging findings in 'normal' drug
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and alcohol users which is reported in Section 4.1. Thus, though longitudinal
comparator data in normal controls are not available from the study itself, data from
studies undertaken by multiple other groups can be considered when interpreting the
longitudinal findings.
A further limitation of the study is the fact that it was not feasible to explore
the possibility of specific gene-drug interactions impacting on brain structure. As
discussed in Section 4.2.4, it is unfortunately the case that the cohort was simply not
large enough to enable this. Furthermore, the nature of the study also means that it can
offer little insight into the processes occurring at a cellular or receptor level that result
in the observed brain structural consequences. Nonetheless it is the case, (as was
discussed above), that by localizing the structures on which the effects of these
substances are mediated, the current findings can direct future research designed to
elucidate this information. The particular impact of cannabis on thalamic structure, for
example, may offer some clues as to the circuits involved in mediating the
propsychotic effects of this drug.
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